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Abstract 
Introduction: Cancer-associated fibroblasts (CAFs) constitute the most abundant 
mesenchymal cell type present within the tumour microenvironment. Recent evidence 
suggests that nutrient deprived cancer cells survive as a result of their ability to undergo 
extensive metabolic reprogramming exploiting the metabolic capacities of surrounding 
CAFs. Additionally, it has been proposed that CAFs also play a role in enhancing 
tumourigenicity and the metastatic capability of cancer cells. However, the mechanisms 
underlying the interactions between epithelial cancer cells and surrounding stromal 
fibroblasts remain to be elucidated. We therefore hypothesize, that nutrient deprived 
breast cancer epithelial cells could influence cancer-associated fibroblasts (CAF’s), to 
produce metabolites which may be utilized by cancer cells for survival, chemo-resistance 
and enhanced migration.  
Methods: E0771 cancer cells were subjected to glucose starvation after which cell 
viability, oxidative stress analysis and cell death was assessed. E0771 conditioned media 
was then generated and proteomic analysis on conditioned media was performed. This 
media was also used to treat mouse embryonic fibroblast (MEF) cells. The activation of a 
CAF phenotype was assessed by means of Western blotting and confocal microscopy. 
Furthermore, cell viability assays, oxidative stress, glucose uptake and GLUT4 
translocation were assessed. MEF conditioned media was then generated and again 
proteomic analyses were performed. MEF conditioned media was then used to treat 
glucose deprived E0771 cells. Where after cell viability, cell death and migration were 
assessed. The effects of CAFs on chemotherapy resistance and metastasis was 
assessed by treating E0771 cells with doxorubicin and MEF conditioned media, following 
which, cell viability, apoptosis and migration assays were performed. An in vivo tumour 
bearing mouse model was established using female C57/BL6 mice treated with 
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doxorubicin. Primary epithelial organoids were isolated from tumours and a 3D branching 
morphogenesis assay was performed.  
Results: 12 hours of glucose deprivation resulted in no significant changes in 
mitochondrial reductive capacity or markers of apoptosis, however, a significant increase 
in mitochondrial oxidative stress was observed. Proteomic analysis of glucose deprived 
E0771 conditioned media revealed an increase in proteins associated with exosome-like 
vesicles and an increased clustering of proteins involved in epithelial-to-mesenchymal 
transition and glucose metabolism. 2-NBDG glucose uptake was significantly increased 
in conjunction with an increase in the fluorescent intensity of the HA-GLUT4-GFP 
construct following exposure to E0771 conditioned media, indicating the increase in 
glucose uptake is in part mediated by GLUT4 translocation. Furthermore the treatment of 
E0771s with MEF conditioned media lead to a significant increase the speed of migration 
and EMT. Furthermore, increased invasiveness of epithelial organoids was observed 
following exposure to MEF-CM in Dox treated animals, with an increase in a more 
epithelial-like phenotype.  
Conclusion: Our data suggest that glucose deprivation induces a state of oxidative stress 
in the E0771 cells which is transferred to MEFs leading to the “activation” of a CAF-like 
phenotype, and that this “activated” phenotype contributes significantly to the pro-survival 
and pro-metastatic abilities of breast cancer cells. Furthermore, our results contribute 
significantly to the understanding of the molecular mechanisms underlying the interaction 
between epithelial cancer cells and fibroblasts within the tumour microenvironment.  
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Opsomming 
Inleiding: Kanker-geassosieërde fibroblaste (KGFe) maak die grootste deel uit van die 
mesenkiemale selle wat in die tumor mikro-omgewing voorkom. Onlangse bewyse stel 
voor dat nutriënt-ontneemde kankerselle oorleef as gevolg van hul vermoë om 
omvattende metaboliese herprogrammering te ondergaan en die metabolise kapasiteit 
van omliggende KGFe te benut. Daar word ook verder voorgestel dat KGFe ‘n rol speel 
om die tumorigenisiteit en die metastatiese kapasitiet van kankerselle te verhoog. Die 
meganismes onderliggend aan hierdie interaksie tussen die epiteliale kankerselle en die 
omliggende fibroblaste moet egter nog ontrafel word. Ons hipotese is dus dat nutriënt-
ontneemde borskanker epiteelselle KGFe beïnvloed om metaboliete te produseer wat 
deur die kankerselle vir oorlewing, chemo-weerstand en verhoogde migrasie benut kan 
word.  
Metodes: E0771 borskankerselle is blootgestel aan media wat van glukose ontneem is, 
waarna sellewensvatbaarheid, oksidatiewe stres en merkers van seldood is geanaliseer. 
Gekondisioneeerde media uit E0771 selle gegenereer waarna proteomiese analises 
daarop uitgevoer is. Hierdie media is ook gebruik om muis embrioniese fibroblaste (MEFe) 
te behandel. Die aktivering van die KGF fenotipe is bepaal deur middel van westelike 
kladtegniek en konfokale mikroskopie. Verder is sel-lewensvatbaarheid, oksidatiewe 
stres, glukose opname en GLUT4 translokering, geasseseer. MEF-gekondisioneerde 
media is daarna gegenereer waarop daar ook proteomiese analises uitgevoer is. MEF-
gekondisioneerde media is ook gebruik om glukose-ontneemde E0771 kankerselle te 
behandel waarna sellewensvatbaarheid, L-laktaat konsentrasies, ATP produksie en 
seldood gemeet is. Die effek van KGFe op chemoterapie weerstand en metastase is 
geasseseer deur E0771 kankerselle met doxorubicin in kombinasie met MEF 
gekondisioneerde media te behandel, waarna sellewensvatbaarheidsanalise, apoptose 
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asook ‘n migrasie bepalings uitgevoer is. Verder is daar ook ‘n in vivo tumor-draende 
muismodel gebruik waar C57/BL6 muise met doxorubicin behandel is. Primêre epiteel 
organoïede is vanuit tumore geïsoleer waarop daar ‘n 3D vertakkingsmorfogenese 
gedoen is.  
Resultate: 12 ure van glukose-ontneming het geen veranderinge in mitokondriale 
reduktiewe kapasitiet of in merkers van apoptose teweeggebring nie, alhoewel ‘n 
insiggewende verhoging in mitokondriale oksidatiewe stress op daardie tydspunt 
waargeneem is. Proteomiese analise van glukose-ontneemde E0771-gekondisioneerde 
media toon ‘n toename in proteïene aan wat geassosieer word met eksosoom vesikels; 
proteïene wat betrokke is by epiteel-tot-mesenkiemale oorgang asook proteïene betrokke 
by glukose metabolisme. 2-NBDG glukose opname is ook insiggewend verhoog tesame 
met ‘n toename in fluoriserende intensiteit van die HA-GLUT4-GFP fragment na 
blootstelling aan E0771-gekondisioneerde media, wat aandui dat glukose opname 
gedeeltelik bemiddel is deur GLUT4 translokering. Die behandeling van E0771 selle met 
MEF-gekondisioneerde media het tot ‘n insiggewende verhoging in die spoed van 
migrasie gelei, asook ‘n toename in EMO. Daar is ook ‘n toename in ‘n epiteelfenotipe en 
indringing in die epiteel-organoiede waargeneem na blootstelling aan MEF-
gekondisioneerde media in Dox-behandelde muise.  
Gevolgtrekking: Ons data bewys dat glukose-ontneming oksidatiewe stress in E0771 
kankerselle teweegbring wat dan veroorsaak dat die omliggende MEFe geaktiveer word 
om na ‘n KGF fenotipe te verander. Hierdie geaktiveerde fenotipe dra dan op hulle beurt 
insiggewend by tot die oorlewing en pro-metastatiese vermoë van nutriënt-ontneemde 
borskankerselle. Ons resultate maak ‘n insiggewende bydrae tot die verstaan van die 
molekulêre meganismes betrokke by die interaksie tussen kankerselle en fibroblaste in 
die tumor mikro-omgewing. 
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Chapter 1:  Literature Review 
1.1. Introduction 
The majority of human tumours are comprised of cancerous epithelial cells that coexist 
with a multitude of different cell types (particularly, fibroblasts, adipocytes, immune and 
endothelial cells) and extracellular matrix components (McAllister et al., 2010) together 
creating what is termed the cancer microenvironment (stroma). Recent evidence suggests 
that the different cell types comprising the tumour stroma form a complex signalling 
network which plays an essential role in the survival, growth and metastatic capabilities of 
the cancerous epithelial cells within solid tumours (Quail et al., 2013).  
During the initial process of tumour invasion, remodelling of the tumour stroma, both 
molecularly and architecturally, results in the invasion of these cells into the neighbouring 
tissue. Invasion has been shown to rely heavily on immune cells, endothelial cells and 
most notably, proliferating “activated” fibroblasts (Tuxhorn et al., 2002). These “activated” 
fibroblasts within the tumour stroma have been identified as mesenchymal cells with 
characteristic signs of smooth muscle differentiation, and have thus been termed 
“myofibroblasts” (De Wever et al., 2002).  Myofibroblasts and their interactions with the 
surrounding environment have been extensively studied for the critical role they play in 
both wound healing and chronic inflammation (Li et al., 2015). Due to their ability to 
promote angiogenesis, stimulate epithelial cell growth, migration and contraction during 
wound healing (Orimo et al., 2006), it has been postulated that these cells may play a 
similar role within the tumour microenvironment, thereby facilitating the growth and 
progression of invasive cancers.  
Olumi and colleagues (Olumi et al., 1999) demonstrated that stromal fibroblasts isolated 
from human prostate carcinomas, display potent tumour-promoting properties when 
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injected in combination with non-tumourigenic prostate epithelial cells into immune-
deficient mice, whereas normal prostate fibroblasts failed to initiate the same response. In 
cancer, myofibroblasts termed cancer associated fibroblasts (CAFs), are characterized by 
their concurrent production of α-smooth muscle actin (α-SMA) and vimentin (Sugimoto et 
al., 2006), and are found to be one of the most abundant mesenchymal cell types present 
within most human carcinomas. Morphologically CAFs are characterized by large spindle-
shaped cells with stress fibres and highly developed fibronexi (transmembrane complex 
with extracellular fibronectin, integrins and intracellular actin) (Xing et al., 2010).   
Resident fibroblasts in the surrounding stroma are an immediate source for the recruitment 
of CAFs. However, CAFs have been shown also to originate from three other 
compartments (Figure 1.1). Firstly, the recruitment of CAFs from distant sites into the 
tumour can occur. Evidence suggests that bone marrow derived mesenchymal stem cells 
and precursor cells are a source of CAFs (Karnoub et al., 2007). Additionally, within the 
tumour stroma various other cell types including endothelial, immune and epithelial cells 
can undergo lineage reprogramming (known as trans-differentiation) to transform into 
mesenchymal cells. Furthermore, other mesenchymal cells within the stroma, such as 
adipocytes and vascular smooth muscle cells could also potentially trans-differentiate and 
give rise to CAFs. Evidence suggests that the ability of CAFs to be recruited from a range 
of sources leads to a heterogeneous population of CAFs displaying common tumour 
growth promoting functions within the tumour microenvironment (Busch et al., 2017). 
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1.2. Cancer-associated fibroblasts and cancer progression 
The role of these “activated” fibroblasts in tumour progression appears to be multifaceted. 
The initial stages of tumour progression have been shown to be repressed by the action 
of fibroblasts, predominantly due to the formation of gap junctions between adjacent 
“activated” fibroblasts thereby exerting contact inhibitory effects on epithelial cancer cells 
(Hinz et al., 2007). Subsequent to the degradation of the basement membrane and the 
infiltration of fibroblasts into direct contact with epithelial cancer cells, the resulting 
activation of CAFs leads to the remodelling of the extracellular matrix (ECM) (Ao et al., 
2015 and Neri et al., 2016). CAFs are predominantly responsible for the production of 
Figure 1.1: Origins of cancer-associated fibroblasts (CAFs) within the tumour stroma. CAFs are 
considered to be recruited from various cell types. The most immediate source of CAF recruitment 
comes from the “activation” of resident fibroblasts (through the process of mesenchymal-to-
mesenchymal transition; MMT), from epithelial and adipocyte cells (via the process of epithelial-to-
mesenchymal transition: EMT), or endothelial cells (endothelial-to-mesenchymal transition; EndMT). 
Finally, bone marrow derived mesenchymal stem cells can be recruited into the tumour stroma where 
they are thought to also undergo MMT, giving rise to CAFs. Adapted from Shiga et al., 2015. 
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essential ECM proteins (such as fibronectin and collagens) and proteases, including 
fibroblast activated protein (FAP) and matrix metalloproteases (MMPs) (Catteau et al., 
2016).  
In solid tumours, progressive stiffening of the ECM with a concurrent increase in matrix 
deposition is frequently observed, as such CAFs play a pivotal role in the remodelling of 
the ECM during tumour progression. Additionally, numerous cancer types show an 
increase in desmoplasia (increased fibrosis), characterized by an increase in collagen 
type I and III with a decrease in collagen type IV, which is often associated with a poor 
cancer prognosis (Kauppila et al., 1998). Interestingly, peritumoural CAFs have been 
implicated in the initiation of desmoplasia, through their ability to secrete a fibrillar network 
identical to that seen during wound healing.  
A consequence of this increased desmoplasia is that the tumour stromal environment 
becomes more rigid, which stimulates the expression of integrins, which mediate cell-cell 
and cell-ECM interactions and signalling across the plasma membrane, making integrins 
important cell adhesion molecules (Campbell et al., 2011 and Lӧhr et al., 2001). In addition 
to ECM modulatory capabilities, integrins have also been shown to be key regulators in 
tumour angiogenesis. Integrins in conjunction with various pro-angiogenic factors directly 
influence the migratory, adhesion and proliferative abilities of endothelial cells during the 
formation of mature blood vessels (Cai et al., 2009). In terms of tumour angiogenesis the 
αvβ3 and αvβ5 integrins are of specific importance, as both are highly expressed in a variety 
of tumour cells as well as in neovascular endothelial cells (Camenisch et al., 2002). 
However, on mature endothelial cells in normal tissue, these integrins are not expressed 
to the same degree, making them a promising target for anti-angiogenic therapies.  
It is widely accepted that cell shape and adhesion are governed by integrin signalling, and 
as anchorage dependence is an essential requirement for cell viability, integrins are 
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essential regulators in cellular responses to survival. The response of integrins to 
intracellular stress can occur through a range of mechanisms, as they are known to 
regulate both the expression and activity of several Bcl-2 protein members. Increased 
resistance to serum starvation in both HT29 colon carcinoma cells (O’Brien et al., 1996) 
and Chinese hamster ovary (CHO) cells (Zhang et al., 1995) for example is mediated by 
the ligation of the integrin α5β1 which has a protective effect against apoptosis. 
Additionally, the binding of the integrin α6β1 to its ligand, laminin, has been shown to be 
protective against apoptosis in mammary epithelial cells (Farrelly et al., 1999).  
Furthermore, the invasiveness of gastric cancer cells has been shown to be promoted by 
the secretion of the chemokine CXCL12 (stromal-derived factor 1) through its ability to 
increase integrin β1 clustering (Izumi et al., 2016). In patients with chronic lymphocytic 
leukaemia, the tissue localization and trafficking of B cells was initially identified to be 
regulated by CXCL12 and its associated receptor CXCR4 (Mӧhle et al., 1999). 
Subsequently, it was proposed that the invasion of breast cancer cells to distant metastatic 
sites is also under the regulation of CXCR4. CXCR4 has been shown to be highly 
expressed in over 23 different tumour types, including those of the brain (Burger et al., 
2000), prostate (Akashi et al., 2008), and breast (Salmaggi et al., 2009), whereas in 
normal tissue its expression level is absent or very low. Additionally, CXCL12 is also highly 
expressed in lymph nodes, lungs and bone marrow - organ sites where breast cancer cells 
most frequently metastasize (Mϋller et al., 2001). As such, the CXCL12/CXCR4 
chemotactic pathway has been implicated as a critical determinant in the destination of 
tumour metastasis.  
Increased expression of hypoxia inducible factor 1α (HIF1α) in response to a lack of 
oxygen availability, results in the HIF1α-dependent gene expression of both CXCL12 and 
CXCR4 (Hill et al., 2009). Recently, CXCR4 has been identified as a CAF-associated 
gene, signifying the existence of an autocrine feedback loop. The secretion of CXCL12 by 
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CAFs has been shown to increase CXCL12/CXCR4 signalling, thereby promoting 
angiogenesis and tumour growth in both non-small lung cancer (Wald et al., 2011) and 
breast cancer (Orimo et al., 2006). Furthermore, enhanced CXCL12/CXCR4 signalling in 
CAFs, has also been implicated in chemotherapeutic resistance in a variety of cancer 
types. In pancreatic cancer, CXCR4 is often overexpressed and activation of these cells 
by CXCL12 induces a cascade of downstream effects resulting in an increased resistance 
of pancreatic cancer cells to the chemotherapeutic drug, gemcitabine (Singh et al., 2010). 
Additionally, high basal CXCR4 expression and CXCL12 mRNA expression in patients 
with colorectal cancer is associated with poor prognosis and distant cancer recurrence 
(Saigusa et al., 2010). 
Additionally, CAFs have been shown to play a critical role in mediating tumour-promoting 
inflammation through enhanced secretion of inflammatory factors including tumour 
necrosis factor α (TNFα), cyclooxygenase 2 (COX-2) and interleukin 6 (IL-6) leading to 
tumour cell invasion (Erez et al., 2013, Erez et al., 2010 and Toullec et al., 2010).  In 
particular, the secretion of IL-6 and monocyte chemoattractant protein 1 (MCP-1) leads to 
the trans-differentiation of macrophages to a tumour-associated macrophage (TAM) 
phenotype. Recently, enhanced reactivity between CAFs and TAMs has been identified, 
the interplay of which promotes cancer cell motility and invasion (Hashimoto et al., 2016). 
In contrast, oestrogen receptor α positive CAFs have also been implicated in the 
suppression of prostate cancer cell invasion through a decrease in IL-6 expression and 
TAM infiltration into the tumour microenvironment (Yeh et al., 2016). Furthermore, the 
promotion of tumour progression and metastasis through the recruitment of TAMs is 
enhanced with the loss of transforming growth factor-beta (TGF-β) receptor type 2 in CAFs 
(Hembruff et al., 2010). Increased TGF-β as well as TNF-α secretion by mammary CAFs 
has been shown to increase matrix metalloproteinase 9 (MMP-9) expression via the 
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mothers against decapentaplegic homolog (SMAD), ras and PI3K signalling (Stuelten et 
al., 2005).   
 
1.3. Contribution of CAFs to the “Hallmarks of Cancer” 
In 2000, Douglas Hanahan and Robert Weinberg described six principle cellular 
physiological aspects, referred to as the ‘hallmarks of cancer’, which are obligate for 
cancer formation and progression (Hanahan et al., 2000). More recently, increasing 
evidence suggests that the evasion of cancer cells from immune destruction, and the 
ability to reprogram cellular metabolism are two additional hallmarks of cancer cells 
(Hanahan et al., 2011) (Figure 1.2). Although there is plenty of evidence to support their 
involvement in neoplastic progression of some cancer cell types, neither capability has 
been fully validated and as such they are referred to as emerging hallmarks. Furthermore, 
genomic instability and the ensuing mutations as well as tumour-promoting inflammation, 
are involved in the acquisition of both the emerging and principle hallmarks and as such 
have been characterized as consequential or enabling characteristics (Figure 1.2).  
During cancer development it is thought that normal cells progressively evolve, through 
the acquisition of these hallmarks, to their ultimate neoplastic state. More recently, the 
understanding of the biology of tumours has been extended to include the effects of the 
tumour microenvironment in the tumourigenic process. As such the contribution of stromal 
cells to the “hallmarks of cancer” such as, sustaining proliferative signalling, deregulating 
cellular energetics, resisting cell death, inducing angiogenesis and activating invasion and 
metastasis, has become an intriguing area of research, which will be highlighted in the 
next section.   
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1.3.1. Sustaining Proliferative Signalling (PI3K/Akt Signalling and 
Cancer) 
The phosphatidylinositol-3-kinase (PI3K) signalling pathway plays a critical role in various 
aspects of cell survival and growth. The activation of PI3K/Akt signalling through both the 
inflammatory and chemotactic signalling cascades plays a central role in both cancer 
progression and metastasis (Figure 1.3). Additionally, the proliferation of fibroblasts has 
been shown to be promoted by the interaction between integrins and the ECM via the 
activation of the PI3K/Akt signalling pathway (Lu et al., 2010). In the context of cancer 
PI3K/Akt signalling is of particular importance as numerous hallmarks of cancer are 
regulated by Akt signalling, which highlights the importance of this signalling cascade as 
a potential therapeutic target for the treatment of cancer. 
Figure 1.2: The Hallmarks of Cancer. Eight functional (six principle and two emerging) hallmarks 
in addition to two enabling characteristics originally described by Hanahan and Weinberg are 
obligate for cancer formation and progression. Hanahan and Weinberg, 2011. 
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Activation of the PI3K pathway in response to a range of regulators, including integrin and 
chemokine signalling results in disturbances in both cell growth and survival. In fact, 
mutations arising within the PI3K/Akt signalling pathway (e.g. Ras, PTEN, or PI3K) are 
commonly encountered in various cancer types, including many breast cancers (Stemke--
Hale et al., 2008). These mutations contribute to both the metastatic ability of cancer cells 
as well as to therapeutic resistance. Akt exerts direct effects on cell survival through the 
phosphorylation and inhibition of Bad (Ser136), a pro-apoptotic BH3 protein, which results 
in the inhibition of apoptosis (Datta et al., 1997).  
Figure 1.3: Activation of the PI3K/Akt signalling pathway through both integrin and chemotactic 
CXCL12/CXCR4 signalling is critical to various aspects of cancer progression.  The activation of 
Akt downstream of PI3K results in alterations in glucose metabolism through the recruitment of GLUT 
transporters to the cell surface as well as increasing hexokinase (HK) and phosphofructokinase (PFK) 
activity. The inhibition of FOXO by Akt leads to alterations in cell cycle progression and the induction of 
autophagy. Furthermore, the phosphorylation and inhibition of Bad through Akt promotes cancer cell 
survival. Akt also promotes angiogenesis and metastasis though direct effects on the transcription factor 
NF-κβ. 
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In addition to Bad (Ser136) phosphorylation, Akt also inhibits the pro-apoptotic effects of 
the forkhead box O (FoxO) transcription factors through their phosphorylation, thereby 
promoting cell survival. FoxOs have also been shown to regulate DNA repair and cell cycle 
progression in addition to apoptosis (Nakamura et al., 2000). Thus, the phosphorylation 
and inactivation of FoxOs by Akt, results in its cytoplasmic accumulation and altered 
expression of cell cycle regulators such as CDKI p27Kip1 (Medema et al., 2000), 
retinoblastoma-related protein p130 (Kops et al., 2002) and cyclin D (Schmidt et al., 2002). 
Furthermore, cell survival is additionally enhanced through the inhibition of FoxOs by Akt, 
as FoxOs are also direct regulators of the pro-apoptotic protein TNF-related apoptosis 
inducing ligand (TRAIL) (Modur et al., 2002).  
Overexpression of FoxOs has been implicated in the reduction of tumour size in vivo and 
the inhibition of tumour growth in an in vitro setting. Additionally, the cytoplasmic 
localization of FoxO correlates with a poorer prognosis in breast cancer patients, whereas 
FoxOs nuclear localization results in the suspension of cell cycle progression (Nakamura 
et al., 2000), and angiogenesis (Poente et al., 2005) as well as the induction of apoptosis 
(Urbich et al., 2005). Cumulatively, this evidence suggests that the signalling mechanisms 
of both the PI3K/Akt/FoxO signalling pathways and the CXCL12/CXCR4 chemotactic 
pathway warrant further investigation in the context of CAF-induced tumour metastasis 
and doxorubicin resistance in breast cancer. 
In addition to its role in cell survival, stimulation of Akt through the insulin receptor is also 
involved in the regulation of glucose metabolism. The increased ability of tumour cells to 
utilize external nutrients occurs as a result of Akt-induced localization of glucose 
transporters, specifically GLUT-1 and GLUT-3, to the cell surface (Wieman et al., 2007, 
Rathmell et al., 2003 and Sommermann et al., 2011). As many cancer cell types are highly 
dependent on glucose metabolism for cell survival, this increased dependence on 
glycolysis has been shown to fuel apoptosis resistance in cancer cells.  
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1.3.2. Resisting Cell Death  
The progression of tumour development and growth involves the evasion of cell death in 
cancer cells in addition to their sustained proliferative signalling. Therefore, in order to 
safeguard their proliferative capacity and survive, these cells must develop survival 
strategies to resist both intrinsic and extrinsic death signals. In part, pro-survival signals 
supplied from the tumour stroma allow for the effective evasion of cancer cells to apoptotic 
cell death. Insulin-like growth factor (IGF) -1 and -2 secreted by surrounding stromal CAFs, 
imparts critical survival signals promoting tumour growth (Strnad et al., 2009, LeBedis et 
al., 2002). Additionally, the ECM stiffening induced by CAFs plays a critical role in the 
process of malignant transformation and invasion (Leventhal et al., 2009). 
The release of IGF1/2 as well as other growth factors, including hepatocyte growth factor 
(HGF), fibroblast growth factor (FGF) and platelet derived growth factor (PDGF), from 
CAFs (Nakagawa et al., 2004, Peddareddigari et al., 2010 and De Boeck et al., 2013), act 
via the mitogen-activated protein kinase (MAPK) and PI3K/Akt signalling pathways to 
induce cell proliferation, anti-apoptotic signalling and invasion (Valenciano et al., 2012). 
The activation of the PI3K/Akt and MAPK signalling pathways through the phosphorylation 
of human epidermal growth factor receptor 2/3 (HER2/3) and the receptor tyrosine kinase, 
c-Met, in colorectal cancer cells occurs as a result of HGF and neuregulin-1 found in the 
supernatant of CAFs (De Wever et al., 2004, De Boeck et al., 2012).  
On the other hand, a less supportive microenvironment towards cancer cells is induced 
through tumour suppression proteins, such as p53 and retinoblastoma (RB). In response 
to oncogenic stress signals, the p53 gene (TP53) acts as a tumour suppressor. Upon its 
activation, p53-induced apoptosis or replicative senescence ensues in order to prevent 
enhanced proliferation of malignant cells (Childs et al., 2014). Therefore, protein secretion 
from CAFs is altered following the induction of p53, resulting in a microenvironment which 
is less supportive. The tumour suppressive role of p53 in CAFs is further supported by the 
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fact that the suppression of the chemokine CXCL12 can be repressed by the activation of 
p53.  Furthermore, independent of direct cell-to-cell contact, p53 induction in CAFs is 
suppressed in lung cancer cells (Bar et al., 2009). 
The retinoblastoma (RB) protein, another tumour suppressor, is often hyper-
phosphorylated in differentiated or quiescent cells and functions to repress the 
transcription of essential cell cycle genes. Phosphorylation of RB, as seen in isolated 
human breast CAFs, leads to its inactivation and the subsequent progression of cells 
through the cell cycle (Mercier et al., 2008). Moreover, the depletion of RB in CAFs leads 
to the enhanced invasiveness of cancer cells. This occurs through the increased 
production of keratinocyte growth factor (KGF or FGF7) from CAFs, regulating invasion 
via an Akt-E-twenty-six (Ets)-MMP1 dependent pathway (Pickard et al., 2012). However, 
further research is needed in order to fully elucidate the role of both RB and p53 inhibition 
in CAFs and their involvement in cancer progression. 
 
1.3.3. Induction of Angiogenesis  
In addition to the secretion of pro-survival signals, CAFs also provide pro-angiogenic 
factors. The release of pro-angiogenic factors, including VEGF-A, from CAFs into the 
tumour stroma has been shown to be released in much higher quantities than that 
released by overt tumour cells (Thijssen et al., 2004). Fukumura and colleagues 
demonstrated that the induction of VEGF promotor activity in stromal cells is dramatically 
increased in mouse models of spontaneous mammary or orthotopic tumours expressing 
GFP-VEGF promotors (Fukumura et al., 1998). VEGF secreted by CAFs has been shown 
to be induced by bradykinin B2 receptor signalling and prostaglandin E2 produced by 
cyclooxygenase-2 (COX-2) (Amano et al., 2003, Williams et al., 2000 and Ikeda et al., 
2000). Furthermore, the expression of fibroblast growth factor (FGF) 2 in CAFs is induced 
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by both the autocrine signalling of the cytokine, CXCL14 and paracrine activation by PDGF 
receptor signalling (Anderberg et al., 2009, Pietras et al., 2008 and Augsten et al., 2009).  
Finally, the recruitment of endothelial progenitor cells into the tumour neo-vasculature is 
enhanced by the secretion of stromal-derived factor (SDF) 1α from CAFs, resulting in the 
promotion of angiogenesis in the tumours of MCF-7-ras human breast carcinoma 
xenografts (Orimo et al., 2005).  
Pericytes are essential regulators of endothelial cell function and are required for the 
stability of blood vessels. Signalling via PDGF receptor β is essential for the recruitment 
of pericytes into the blood vessels of tumours (Furuhashi et al., 2004). As such, 
perturbations in PDGFβ expression have been utilized to elucidate the role of pericytes in 
tumour growth and angiogenesis.  A classic example of this can be seen in mouse B16 
melanoma cells, where the ectopic expression of PDGFβ leads to enhanced pericyte 
recruitment and stabilization of the neo-vasculature (Robinson et al., 2008). However, in 
pancreatic and colon carcinoma cell lines the transfection of PDGFβ resulted in pericyte-
mediated angiostatic effects and growth inhibition (McCarty et al., 2007). Additionally, the 
complex diversity of pericyte recruitment into the newly formed blood vessels of tumours 
is dependent on the cellular source of PDGFβ. Furthermore, a disordered and 
haemorrhagic vasculature, with pericytes detached from the endothelium, is seen in 
mouse tumours engineered to express a deletion variant of PDGFβ which is not retained 
near the producing cell (Abramsson et al., 2003). It is therefore plausible that in order to 
attain a balance between ideal blood vessel formation and function during angiogenesis, 
different subsets of pericytes need to be maintained. 
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1.3.4. Activating Invasion and Metastasis  
During the acquisition of malignancy cancer cells attain the ability to invade into the 
surrounding tissue and metastasize through either the lymphatic or blood vessels. 
Essential to this process is the acquisition of a migratory phenotype of tumour cells and 
the extensive remodelling of the ECM. Sung and colleagues suggested that the exposure 
of epithelial cells to stromal cells results in these epithelial cells undergoing permanent 
pro-invasive changes (Sung et al., 2008).   
Several pro-invasive factors such as HGF, TGFβ, secreted protein acidic and rich in 
cysteine (SPARC), cathepsins and matrix metalloproteases (MMPs) are secreted by 
CAFs. The secretion of HGF and TGFβ by CAFs contributes to enhanced invasion and 
metastatic capabilities of tumour cells (Bhowmick et al., 2004). Additionally, the prognosis 
of patients with resectable pancreatic cancer can be predicted by the expression of 
SPARC by CAFs (Infante et al., 2007). Furthermore, CAFs are also a key source of 
protease activity, including cathepsins, plasminogen activators and MMPs (Joyce et al., 
2009). The release of these proteases into the tumour microenvironment plays a crucial 
role during ECM remodelling, as they lead to a loss of adhesion between adjacent tumour 
cells, resulting in enhanced tumour invasion and migration.  
MMP-induced ECM remodelling is considered as one of the most crucial steps for tumour 
progression and the formation of the tumour microenvironment. Under normal 
physiological conditions the balance between MMPs and their inhibitors is essential in 
maintaining the organized structure of the ECM. However, during tumour progression the 
increased secretion of various MMPs in addition to their activators (such as urokinase 
plasminogen activator, uPAR) by CAFs play a major role in tumour cell invasion (Camps 
et al., 1990). The cleavage and subsequent upregulation of MMP activity by uPAR results 
in the significant degradation of the ECM and contributes to enhanced angiogenesis and 
metastasis (Egeblad et al., 2002). A wide variety of MMPs are known to contribute to 
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metastasis. Abnormal mammary gland branching and epithelial cell hyperplasia is 
stimulated by MMP3 overexpression in CAFs (Thomasset et al., 1998). In gliomas, 
pathological angiogenesis and tumour growth requires high levels of MMP2 production in 
stromal cells (Takahashi et al., 2002), and increased levels of the interstitial collagenase 
MMP1 has been seen in peritumoural fibroblasts isolated from melanomas (Wandel et al., 
2000). The upregulation of MMP1 leads to the cleavage of protease-activated receptor-1 
(PAR1) on the surface of cancer cells, stimulating both invasion and growth signalling. As 
such, MMP1 is now recognized as a putative breast cancer predictive marker (Poola et 
al., 2005). Increased MMP and uPAR activity is observed in a range of different cancer 
cells, indicating that fibroblasts are not the only source of MMPs. Due to the mutual 
interaction between tumour and stromal cells, soluble factors secreted by cancer cells also 
affect the expression of MMPs. For example, the direct contact of CAFs with malignant 
epithelial cells is essential for the expression of MMP9. Furthermore, paracrine stimulatory 
signals enhance the expression of MMP2 in the tumour stroma (Singer et al., 2002). 
Collectively, several in vivo experiments demonstrate the significance of CAFs in cancer 
cell invasion, through the secretion of pro-invasive factors and the loss of cell-to-cell 
adhesion (Chen et al., 2009, Calvo et al., 2011). As CAFs are a major source of MMP 
production, which plays a critical role in metastasis, the development of novel anti-cancer 
treatment strategies, targeting MMP secretion from CAFs is a promising area of research. 
 
1.3.5. Deregulating Cellular Energetics 
In the presence of abundant oxygen (O2), most non-proliferating cells in differentiated 
tissue rely primarily on the oxidation of glucose to carbon dioxide (CO2) through the 
oxidation of glycolytic pyruvate in the tricarboxylic acid (TCA) cycle within the mitochondria 
(Van der Heiden et al., 2009). During the metabolism of glucose to CO2 reduced 
nicotinamide adenine dinucleotide (NADH) is produced. NADH then behaves as a 
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reducing equivalent in the electron transport chain, thereby maximizing the production of 
adenosine triphosphate (ATP) whilst minimizing lactate production. Louis Pasteur first 
demonstrated that in the presence of O2, glucose flux is reduced (termed the ‘Pasteur 
effect’), this allows for the preservation of ATP production over a wide range of O2 
concentrations.  
However, the conversion of glucose into lactate despite an abundance of O2 (aerobic 
glycolysis) is seen in cancer cells. This observation, termed the ‘Warburg effect’, was first 
described by Otto Warburg in the 1920’s. Warburg proposed that this altered metabolism 
in cancer cells, occurs as a result of defective mitochondria, thereby inhibiting their ability 
to effectively oxidize glucose to CO2 (Warburg et al., 1926). However, evidence now 
suggests that mitochondria of cancer cells are not defective in their ability to carry out 
oxidative phosphorylation, instead they reprogram mitochondrial metabolism to cope with 
macromolecular synthesis (Ward et al., 2012).  
It has been proposed that depending on the surrounding stromal conditions, epithelial 
cancer cells may have the propensity to preferentially produce energy via oxidative 
phosphorylation as opposed to increased glycolysis (Lee and Yoon, 2015). In this theory 
(termed the ‘reverse Warburg effect’), nutrient/oxygen deprived epithelial cancer cells are 
thought to “educate” surrounding stromal cells to increase aerobic glycolysis, resulting in 
an increased production of metabolites such as lactate, which can then be converted to 
pyruvate and utilized by oxidative phosphorylation in epithelial cancer cells (Figure 1.4). 
This suggests that nutrient/oxygen deprived epithelial cancer cells present within solid 
tumours are able to survive these conditions, as a result of their ability to undergo 
extensive metabolic reprogramming (Carrer et al., 2015) to exploit the metabolic 
capacities of stromal cells within the surrounding microenvironment.   
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Figure 1.4: Proposed mechanism of action underlying metabolic reprogramming of cancer-
associated fibroblasts promoting epithelial cancer cell survival. The induction of reactive oxygen 
species (ROS) in epithelial cancer cells in response to glucose deprivation results in the transcription and 
packaging of essential genes (mRNA and miRNA) involved in glycolysis and autophagy induction into 
exosomes. Additionally, ROS are directly transferred to cancer-associated fibroblasts (CAFs), the resulting 
increase in oxidative stress leads to the transcription and translation of hypoxia inducible factor 1α (HIF-1α). 
HIF-1α expression in CAFs results in an increased transcription of glucose transporters, glycolysis and 
autophagy and the direct inhibition of pyruvate dehydrogenase (PDH) (normally responsible for the 
conversion of pyruvate to acetyl-CoA) leading to the conversion of pyruvate to lactate. Intracellular build-up 
of lactate results in its export out of CAFs, where epithelial cancer cells are able to import and utilize lactate 
as a fuel source to promote cell survival. (Mitchell and Engelbrecht, 2017) 
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1.4. Metabolic Reprogramming and the “Reverse Warburg 
Effect”  
The question of how epithelial cancer cells “educate” surrounding CAFs under nutrient 
deprived / hypoxic conditions remains to be fully elucidated. However, it has been 
proposed that in addition to directly increasing aerobic glycolysis, an increased production 
of reactive oxygen species (ROS) within epithelial cancer cells, leads to an activation of 
key transcription factors (HIF-1α and NFκβ) (Giannoni et al., 2011), and the subsequent 
induction of oxidative stress and autophagy in neighbouring CAFs (Pavlides et al., 2012). 
An explanation for this transfer of oxidative stress, is that the secretion of hydrogen 
peroxide (H2O2) by epithelial cancer cells into the tumour stroma acts as the driving force, 
leading to the induction of oxidative stress and the subsequent activation of autophagy 
within surrounding CAFs (Capparelli et al., 2011) (Figure 1.4).  
Increased production of reactive oxygen species (ROS), including free radicals such as 
superoxide (O2-) and H2O2 induce cellular damage and ultimately cell death (Chen et al., 
2008).  Increased generation of mitochondrial ROS has been implicated in the progression 
of cancer as well as alterations in chemotherapy sensitivity. In addition to the release of 
H2O2 by epithelial cancer cells in response to nutrient deprivation, the removal of damaged 
proteins and organelles, under certain cellular conditions, can occur via the release of 
exosomes into the surrounding extracellular microenvironment (Okon et al., 2016).  
Exosomes are small vesicles, typically between 30 and 100 nm in diameter that carry 
biological molecules, such as activated growth factor receptors, microRNA (miRNA) and 
mRNAs, which can be transferred to recipient cells (Figure 1.4)  Exosomes have been 
shown to be secreted into the extracellular matrix by almost every human cell type and 
their cargo exhibits functionality within recipient cells (Valadi et al., 2007 and Kosaka et 
al., 2010), thereby highlighting their importance as intercellular signalling shuttles within 
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the extracellular matrix. The formation of exosomes occurs through the inward budding of 
the membrane of late endosomes or multi-vesicular bodies (MVBs), and their secretion 
into the extracellular matrix occurs predominantly through highly constitutive signalling 
processes (Février et al., 2004). However, their secretion can additionally be modulated 
by increased cellular stress, resulting in changes to their protein and RNA content (De 
Jong et al., 2012). The ability of cells to alter the protein and RNA content of exosomes in 
response to intracellular stressors, suggests that exosomes may play a significant role in 
cell survival as their cargo can be tailored to the specific metabolic needs of the cell. 
 
1.5. Exosomes in cancer progression, metastasis and 
chemotherapy resistance 
In the context of the tumour microenvironment, epithelial cancer cells have been shown 
to secrete exosomes which are transferred to surrounding CAFs, leading to the activation 
of key signalling pathways involved in both autophagy and glycolysis. Furthermore, CAFs 
have recently themselves also been shown to secrete exosomes in response to nutrient 
deprivation and increased oxidative stress (Luga et al., 2013). In cancer, exosomes 
secreted from both tumour cells and CAFs function in both a paracrine and an autocrine 
fashion resulting in the promotion of angiogenesis (Orimo et al., 2005), inflammation (Erez 
et al., 2013) and pre-metastatic niche formation (Hoffman et al., 2013), further highlighting 
them as essential intercellular signalling vesicles within the tumour stroma. 
The tetraspanin molecule, CD81, has been shown to be an abundantly expressed plasma 
membrane protein on the surface of exosomes. The expression of CD81 on CAF-secreted 
exosomes has been shown to enhance the metastatic potential of breast cancer cells, 
specifically to the lungs (Luga et al., 2012). More recently, Hoshino and colleagues 
demonstrated that the specific integrin expression profile of circulating tumour-derived 
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exosomes determines the organ site of future metastasis and that these exosomes also 
prime the tissue site for the arrival of circulating epithelial cancer cells, thereby rendering 
the organ permissive to the growth of these metastatic cells. For example they have 
demonstrated that exosomes derived from the MDA-MB-231 sub-line which colonizes to 
the lung (4175-LuT), expresses the integrins α6β4 and α6β1 and co-localizes with S100A4+ 
cells within the laminin-rich microenvironment of the lung (Hoshino et al., 2015).  
In addition to enhancing cancer metastasis, exosomes have also been implicated in the 
development of chemotherapy resistance (Hu et al., 2015). Tumours are comprised of a 
heterogeneous population of epithelial cancer cells with varying degrees of susceptibility 
to chemotherapeutic drugs. Following chemotherapeutic treatment the majority of 
malignant epithelial cells undergo cell death. However, a small population of these 
cancerous epithelial cells remain unaffected by the cytotoxic effects of the 
chemotherapeutic drug. These drug-resistant cells, have the ability of transferring these 
resistance traits through exosomes to neighbouring cells (Chen et al., 2014 and Xiao et 
al., 2014).  Additionally, exosomes have been shown to interfere with the binding of 
chemotherapeutic drugs to tumour cells, for example the binding of trastuzumab to Her2 
receptors, is inhibited by exosomes secreted from Her2-overexpressing breast cancer 
cells (Ciravolo et al., 2011). Furthermore, the sequestration and export of 
chemotherapeutic drugs as well as their metabolites by exosomes suggests that they also 
mediate drug efflux.  
Clinically the discovery that these highly stable, cell-free exosomes are found to be 
circulating in the bodily fluids of cancer patients, means that they may be utilized as 
biomarkers in novel diagnostic and prognostic tools. Furthermore, the premise that 
tumour-derived exosomes act as intercellular shuttles utilized by cancerous epithelial cells 
to “educate” surrounding CAFs under conditions of nutrient deprivation, unlocks an 
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exciting new avenue of research in order to elucidate the molecular mechanisms 
underlying this complex interaction.  
Recently, Ao and colleagues demonstrated that CAFs can be found circulating in the blood 
of patients with metastatic breast cancer. They showed that these circulating CAFs 
(cCAFs) could be detected in 88.2% of stage IV breast cancer patients with overt 
metastasis compared to a 23.1% in stage I breast cancer patients treated with curative 
therapy (Ao et al., 2015), suggesting that cCAFs play a direct role in facilitating breast 
cancer metastasis. Additionally, the discovery that cCAFs accompanied by circulating 
tumour cells (CTC) allows for the evasion of these cells to cell death and promotes pre-
metastatic niche formation (Duda et al., 2010), further supports the notion that CAFs are 
critical role players in cancer metastasis. Based on the ‘seed and soil hypothesis’ 
described by Stephen Paget in 1889, tumour cells detached from primary tumours 
(‘seeds’) preferentially metastasize to select organs with suitable microenvironments 
(‘soil’) (Paget et al., 1889), therefore it is conceivable that the metabolic status of cCAFs 
could potentially serve as a novel tool for the assessment of primary tumour status and 
metastatic risk. 
 
1.6. Autophagy and Tumour Progression 
Exosome induced signalling (Baixauli et al., 2014) and increased reactive oxygen species 
(ROS) production can induce autophagy in CAFs (Karna et al., 2010), which is thought to 
be critical for the metabolic reprogramming of CAFs. Autophagy is a highly dynamic, 
evolutionary conserved self-degradative process (Kondo et al., 2005), which plays a 
critical role in maintaining cellular homeostasis and promoting cell survival (Hippert et al., 
2006). Currently there are three well defined types of autophagy, namely; chaperone-
mediated, micro- and macro-autophagy (Morselli et al., 2009). Macro-autophagy 
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(hereafter referred to as autophagy) constitutes the most abundant form of autophagy and 
involves the delivery of cytosolic cargo to lysosomes by means of a double membrane 
bound vesicle, called an autophagosome (Rabinowitz et al., 2010).  
Under normal physiological conditions, low level basal autophagy serves as a 
housekeeping function, whereby old and redundant cellular constituents are degraded and 
utilized as additional energy sources for various metabolic processes (Levine, 2007). 
Basal autophagy serves a particularly indispensable role in quiescent and terminally 
differentiated cells where the aggregation of defective components may become cytotoxic, 
as they are not diluted through the process of cell division (Rabinowitz et al., 2010). Under 
conditions where autophagy is activated in response to cellular stressors, such as nutrient 
deprivation and hypoxia, the process of autophagy becomes somewhat “double-edged” 
(Shintani et al., 2004) as increased levels of autophagy, serve as a protective mechanism, 
whereby non-essential cellular constituents may be broken down to refuel essential 
cellular processes (Hippert et al., 2006). However, unregulated autophagy in these 
conditions may result in the excessive “self-cannibalization” of intracellular organelles 
thereby resulting in cell death (Mizushima et al., 2008). 
Autophagosome formation is mediated by a group of autophagy-specific genes (ATG) 
whose products are categorized  into four classes, namely; (i) an upstream autophagy 
regulatory complex, which responds to nutrient availability, (ii) a vesicle nucleation lipid 
kinase group, (iii) two ubiquitin-like protein systems, responsible for the production of 
modified autophagy regulatory complexes (Atg8-PE and Atg5-Atg12-Atg16) essential for 
autophagosome assembly and size determination (Hanada et al., 2007), and (iv) a group 
of complexes responsible for the degradation of ATG complexes (Hippert et al., 2006) 
(Figure 1.5).  
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The autophagy receptor p62/SQSTM1 recognises and binds to proteins tagged by 
ubiquitin targeting them for degradation (Komatsu et al., 2007). During the process of 
autophagosome formation, LC3 I is converted to LC3 II via a lipidation step. LC3 II is then 
sequestered to the inner surface of the phagophore, where it associates with p62 
(Mizushima et al., 2008). Autophagosomal cargo is subsequently delivered to lysosomes 
(Rabinowitz et al., 2010) where the release of lysosomal digestive enzymes into the lumen 
of the autophagolysosome results in the degradation of p62 as well as sequestered 
cellular constituents, ultimately resulting in the release of free fatty acids, amino acids, 
nucleotides and sugars (Levine, 2007).  
mTOR the predominant regulator of the autophagic process, is a sensor of intracellular 
nutrient status and master regulator of cell growth. mTOR serves as a negative regulator 
of autophagy through its ability to phosphorylate and thus inactivate Unc-51-like kinase 
(ULK1) and Atg13, two of the main ULK1 components, thus inhibiting the initiation of 
phagophore synthesis (Mathew et al., 2011). mTOR exists in two biologically functional 
signalling complexes namely, mTORC1 and mTORC2. Pharmacological administration of 
Rapamycin results in the detachment of RAPTOR from mTOR. RAPTOR acts as a 
scaffold for the recruitment and activation of mTOR substrates and thus the inhibition of 
mTORC1. Additionally, the mTORC1 substrates S6-kinase and eIF4E-binding protein 
(4E-BP1) interact with various mRNAs regulating the initiation of translation and thus 
controlling protein synthesis rates (Belda-Iniesta et al., 2011). Furthermore, mTORC1 
governs the translation of regulators of cell growth, such as cyclin-D1, HIF1α and c-myc, 
thus promoting cellular processes such as cell cycle progression, cell growth and 
angiogenesis, all of which become deregulated during tumorigenesis. 
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Figure 1.5: Schematic representation of the molecular pathways involved in the regulation of autophagy in mammalian cells. Adapted from: Mathew et al., 2011.
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Enhanced tumour cell invasion and metastasis in hypoxic tumour regions is widely 
accepted to occur in response to the induction of the transcription factor HIF1α (Gilkes et 
al., 2013, Eisinger-Mathason et al., 2013). As described previously, autophagic induction 
in response to hypoxia favours tumour cell growth and survival, through the production of 
essential cellular metabolites. However, in recent years the relationship between 
autophagy and glycolysis has gained increasing attention following reports that increased 
sensitivity to reduced glucose availability is seen in cells with competent autophagy (Lock 
et al., 2010). Therefore, the induction of autophagy in CAFs during the process of 
metabolic reprogramming is proposed to play a critical role in enhancing glycolysis (Wang 
et al., 2017), leading to the increased production of glycolytic intermediates, such as 
lactate. 
 
1.7. Lactate in the tumour microenvironment 
The monocarboxylate, lactate (2-hydroxypropanoic acid), exists predominantly as the 
physiological enantiomer L-lactate, however, it may also exist as the stereoisomer D-
lactate. Most tissues in the body produce lactate with high levels of production being found 
in muscle. Under normal physiological conditions, lactate is cleared predominantly by the 
liver and to a lesser extent by the kidneys. Systemically, lactic acid (CH3CH(OH)CO2H) is 
transported to the liver where it is reconverted to glucose via the Cori cycle, and thus 
serves as an additional energy source (Waterhouse et al., 1969).  
The metabolism of glucose by glycolysis results in the production of pyruvate as a final 
product. Under normoxic conditions, the enzyme pyruvate dehydrogenase (PDH) converts 
pyruvate to acetyl-CoA which enters the TCA cycle. As the conversion of pyruvate to 
acetyl-CoA requires the presence of O2, under conditions of limited oxygen availability, 
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pyruvate is converted to lactic acid by the enzymatic action of lactate dehydrogenase 
(Phypers et al., 2006).  
A variety of tumour suppressor genes and oncogenes, including myc, Akt/protein kinase 
B, PI3K, mTOR and HIF-1α (Levine et al., 2010, DeBerardinis, 2008) are frequently 
mutated in many human cancers. Many of which have been shown to lead to the 
stimulation of genes encoding for glycolysis and glutaminolysis mediated proteins. The 
transcription factor HIF-1α, usually controlled by cellular O2 conditions, can be stabilized 
(even under normoxic conditions) by both lactate and pyruvate, leading to its intracellular 
accumulation (Lu et al., 2002). Expression of genes regulated by HIF-1 has been shown 
to lead to enhanced glycolytic flux in tumour cells which is independent of oxygen 
concentrations, suggesting that lactate accumulation in tumours is not a direct result of 
hypoxia (Yaromina et al., 2009). In order to ensure the adequate delivery of glucose into 
the cell in addition to secretion of accumulated lactate out of the cell, HIF-1 targets include 
both glucose (GLUT-1) and lactate (MCT-4) membrane transporters. In addition to 
enhanced GLUT-1 translocation, glycolysis and ATP production are permitted as a result 
of the production of the reducing equivalent NAD+, a direct consequence of enhanced 
lactate dehydrogenase A (LDH-A) expression. Moreover, the inactivation of the PDH 
complex, a result of HIF-1 dependent inhibition of pyruvate dehydrogenase kinase (PDK) 
I, contributes to the decreased flux through oxidative phosphorylation (Zimmer et al., 
2016).  
Recent evidence suggests that this metabolic switch to dysregulated glycolysis is 
fundamental to the tumourigenic process and may be an early event. Schafer et al (2009) 
demonstrated that enhanced glycolysis in Her2/neu+ ductal breast carcinoma cells 
maintain PI3K activation, thus providing a survival advantage to these cells.  
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As described above, even under normoxic conditions, tumour cells preferentially convert 
pyruvate into lactate instead of utilizing the TCA cycle for energy production. A 
consequence of this Warburg effect is that increased glycolysis in cancer cells results in 
the secretion of large quantities of lactate into the extracellular matrix, leading to an 
acidification of the tumour microenvironment (pH 6.0 – 6.5) (Xie et al., 2014). This 
acidification serves as a potent signal for enhanced angiogenesis (Végran et al., 2011, 
Sonveaux et al., 2012) and induced immunosuppression (Husain et al., 2013, Fischer et 
al., 2007, Mendler et al., 2012).  
Additionally, exogenous lactate, at relevant in vivo solid tumour concentrations (0 – 40 
mmol/L) led to concentration-dependent increases in random migration in a variety of 
cancer cell lines, as demonstrated in classic Boyden chamber experiments. This 
increased lactate-dependent motility of tumour cells has also been observed by means of 
time-lapse microscopy for enforced bulk migration (Goetze et al., 2011). Several lactate-
dependent changes in protein activation and signalling events (including that of β1-
integrins) have been demonstrated, however, the molecular mechanisms underlying the 
involvement of lactate in cell motility remain to be fully elucidated. Recently, signalling of 
the TGF-β2 pathway has been shown to play a role in mediating lactate-associated cancer 
cell migration (Baumann et al., 2009).  
The proton-linked transport of lactate (as well as other monocarboxylates, such as ketones 
and pyruvate) across the plasma membrane is catalysed by the transmembrane 
monocarboxylate transporters (MCTs) (Palmieri et al., 1996, Price et al., 1998 and Cheeti 
et al., 2006). A wide variety of cell types including tumour cells (Carpenter et al., 1994) 
have MCT transporters located on their plasma membranes. Cell types which rely on 
lactate as an oxidative metabolite (such as the heart and skeletal muscle) or as a substrate 
for gluconeogenesis (liver), are dependent on the presence of MCTs. To date four MCT 
isoforms (MCT 1-4) have been identified, each of which have distinctive substrate 
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affinities. Low level expression of MCT1 is seen in most tissues, whereas MCT2 and 
MCT3 expression is limited to specific tissue types namely; the liver, neurons and kidneys 
which primarily express MCT2 where MCT3 expression occurs in the choroid plexus and 
in the basolateral retinal pigment epithelium. MCT4 is highly expressed in the fibres of 
white skeletal muscle and low level expression is seen in other tissues, such as the 
placenta, testis and lung (Petrides et al., 2016). Furthermore, MCT4 is also expressed in 
specific cell types such as astrocytes (Pierre et al., 2007), chondrocytes (Meredith et al., 
2002) and leukocytes (Merezhinskaya et al., 2006).  
The different lactate affinities observed by MCTs allows for the directed influx and efflux 
of lactate across the plasma membrane (Brooks, 2009, Gladden, 2008). The co-transport 
of both lactate and protons out of the cell prevents the deleterious effects that would be 
observed following the accumulation of lactate and the subsequent acidification of the 
intercellular environment. More specifically, the intra- versus extracellular concentrations 
of lactate and other substrates transported by MCTs as well as the pH govern the 
directionality of lactate transport across the plasma membrane (Dimmer et al., 2000, 
Doherty et al., 2013).  
The export of lactate out of glycolytic cells, such as astrocytes, can be utilized by other 
cell types, like neurons, as a metabolic substrate for oxidative phosphorylation (Hall et al., 
2012). This directed transport of lactate by cell-specific MCTs (also known as the “lactate 
shuttle”), has been proposed to occur as a similar phenomenon in certain cancer types, 
and is often referred to as metabolic symbiosis (Sonveaux et al., 2008).  
Generally, it has been suggested that lactate is exported out of cancer cells (via MCT-4) 
leading to tumour microenvironment acidification thereby affecting surrounding stromal 
cells. However, lactate has been shown to play a fundamental role in the symbiotic 
relationship between hypoxic and surrounding oxygenated tumour cells (Sonveaux et al., 
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2008). Under hypoxic conditions tumour cells have been shown to increase GLUT-1 
expression and enhanced glucose uptake leading to increased glycolytic flux and lactate 
accumulation. Lactate export via MCT-4 from these hypoxic tumour cells can then be 
utilized as a metabolic substrate by aerobic tumour cells, where lactate is then converted 
by lactate dehydrogenase to pyruvate. Pyruvate then enters the TCA cycle resulting in 
enhanced energy production (Guillaumond et al., 2013).  
The notion that tumour cells utilize metabolic symbiosis implies that the net flux of lactate 
occurs from hypoxic cells to oxygenated cells, and is directly related to the distance that 
these cells are from blood vessels within the tumour stroma (Sotgia et al., 2012). However, 
the current understanding of metabolic symbiosis in tumours fails to accurately take into 
account the dynamic nature of tumour progression, for instance, as a result of 
neovascularization, regions of perfusion are under constant modification. Furthermore, 
substrate and oxygen availability are not static and are also subjected to dynamic 
changes. As a result, tumour cells may at times be forced to alternate between available 
energy sources in order to survive. Taking this into account, the combined effects of 
metabolic symbiosis and the “reverse Warburg effect” (as described previously) may 
orchestrate the metabolic survival strategies utilized by tumour cells, which warrants 
further research attention in order to fully elucidate the molecular mechanisms governing 
these interactions.  
Additionally, it has long been established that enhanced lactate production in tumours and 
subsequently increased plasma lactate levels are strongly associated with poor clinical 
outcomes of patients’ with metastatic cancer. In recent years, it has been demonstrated 
that lactate plays a causative role in the progression of breast cancer metastasis 
(Bonuccelli et al., 2010). However, the molecular mechanisms underlying the induction of 
metastasis by lactate still remains to be fully elucidated.  
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1.8.  Cancer Metastasis 
Tumour metastasis can be depicted as a multistep invasion-metastasis cascade in which 
the end-product involves the effective dissemination of cancer cells to distant organ sites 
and their subsequent adaptation to the foreign tissue microenvironment (Sossey-Alaoui et 
al., 2011). For successful dissemination, cancer cells from the primary tumour need to first 
invade through the local tissue parenchyma into nearby microvessels (known as 
intravasation), where they are able to undergo haematogenous dissemination and 
subsequent niche colonisation (McAllister et al., 2014, Nguyen et al., 2009, Redig et al., 
2013, Valastyan et al., 2011).   
The simplistic classification of metastasis as an orderly sequence of basic cellular events 
namely; local invasion, intravasation, haematogenous dissemination, extravasation and 
colonization (Figure 1.6), has helped to better understand and rationalize the complexity 
of the signalling processes that need to be acquired in order for the successful progression 
towards overt metastasis. Over recent years, the biological events contributing to the 
metastatic process have been extensively studied and many of the genetic and epigenetic 
events have been identified (Kanda et al., 2015). Initially, oncogenic transformation is an 
essential event which allows for cells to sustain proliferation despite having an unstable 
genome. However, oncogenic transformation alone is not sufficient to maintain metastatic 
competence as, despite tumour cell dissemination, some patients never develop clinical 
metastatic disease (Klein, 2003).  
Additionally, the establishment of distant metastasis does not automatically develop as 
seen in several oncogene-driven murine models of cancer (Moasser et al., 2007). As such, 
transformed cells require the acquisition of additional capabilities in order to overcome 
physiological barriers preventing metastatic dissemination (Thiery et al., 2006). 
Regardless of the method, it is clear that in order to surmount the biological challenges 
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which prevent cancer cell dissemination, the acquisition of a metastatic phenotype 
involves several complex signalling pathways which enable migration and invasion 
(Spano et al., 2012). One of the most widely understood and extensively studied 
processes involved in metastasis is that of epithelial-to-mesenchymal transition (EMT).   
 
1.9. Epithelial-to-Mesenchymal Transition (EMT) 
EMT, a biological process not only unique to cancer metastasis, is essential during 
embryonic development, where morphogenic movements underlie the formation of organs 
such as the peripheral nervous system, heart, muscular system and neural crest (Huber 
Figure 1.6: Sequential processes involved in metastatic tumour dissemination and colonization. 
The pre-colonization phase of metastasis comprises a series of events that occur on a timescale of 
minutes to hours. Local invasion of the primary tumour by cancer cells is followed by their intravasation 
into the tumour vasculature. The cancer cells then enter the circulatory system as single cells or clusters 
that are coated with platelets. On their arrest in capillaries at distant sites, the cancer cells extravasate 
into the parenchyma of target organs to commence colonization. Reymond et al., 2013. 
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et al., 2005). Additionally, during tissue inflammation and wound healing enhanced EMT 
leads to the stimulation of new fibroblasts. However, this not only provides positive tissue 
healing effects, but new fibroblasts formed by EMT have the propensity to retain their 
mesenchymal state permanently. This is associated with increased connective tissue 
formation which may disrupt the underlying epithelium, ultimately invading into the 
surrounding stroma and leading to tissue fibrosis (Grünert et al., 2003, Nawshad et al., 
2004, Balkwill, 2006, Eger et al., 2005).  
Polarized epithelial cells usually interact with the basement membrane via their basal 
surface. This interaction is essential for the maintenance of their biological function, which 
includes endocytosis, vesicle transport and exocytosis. Regularly spaced membrane-
associated junctions and keratin filaments are seen on the basolateral surface of epithelial 
cells; as such they closely associate with adjacent cells. This protective barrier plays a 
critical role to inhibit the movement of individual cells which allows for the preservation of 
both rigidity and structure (Denef et al., 2009).  
Characteristic of the induction of mesenchymal cells (via the process of EMT), is the 
acquisition of front-rear end polarization with a loss of baso-apical polarization, thus 
allowing for the distinctive migratory capacity of these cells. Additionally, the acquisition of 
a mesenchymal phenotype is associated with elevated resistance to apoptotic cell death 
and increased ECM deposition (Kalluri et al., 2009). The initiation of EMT is characterized 
by the degradation of the basement membrane and the formation of a mesenchymal cell 
which has the ability to migrate away from its’ original epithelial layer. Upon the successful 
establishment of secondary colonies at distant sites, EMT-derived metastatic cancer cells 
shed their mesenchymal phenotype through the process of mesenchymal-to-epithelial 
transition (MET) (Zeisberg and Kalluri, 2013).  
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The ability of disseminated tumour cells to undergo MET hinges on the resident 
microenvironment encountered after extravasation. It has been suggested that this 
dissemination could be as a result of the lack of heterotypic signals exposed to within the 
primary tumour site that lead to the initiation of EMT (Bissell et al., 2002, Jechlinger et al., 
2002, Thiery et al., 2009). The entire repertoire of signalling mediators involved in the 
metastatic dissemination (including both EMT and MET) of cancer cells remain unclear 
and still require experimental validation. 
The initiation and completion of EMT requires the engagement of several distinctive and 
highly co-ordinated molecular processes. In many cancer types, the induction and 
activation of a series of EMT- inducing transcription factors, which include Snail, Slug, 
Twist, zinc finger E-box binding homobox 1 (ZEB1), FOXC2 and Goosecoid appear to be 
as a direct result of EMT-inducing signals such as PDGF, HGF, EGF and TGF-β, 
originating from the surrounding tumour stroma (Shi and Massagué, 2003, Niessen et al., 
2008, Medici et al., 2008, Kokudo et al., 2008). Upon the activation of these transcription 
factors they are able to act pleiotropically and in unison to co-ordinate the execution of the 
EMT cascade. 
The activation of EMT involves the loss of intercellular cohesion, enzymatic ECM 
degradation, and enhanced motility and invasion (Hartwell et al., 2006 and Taki et al., 
2006). In mesenchymal cells the loss of intercellular cohesion results predominantly due 
to alterations in mechanical attachment sites (comprised of desmosomal, adherens and 
tight junctions) responsible for the regulation of the entire junctional complex (Miyoshi et 
al., 2008). Moreover, the execution of EMT depends on a sequence of intracellular 
signalling pathways involving MAPK, ERK, PI3K/Akt, Smads, and β-catenin, in addition to 
the activation of many β4 integrin cell surface proteins, including α5β1 and αvβ6 (Tse and 
Kalluri, 2007). 
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TGF-β signalling plays a critical role in the inhibition of epithelial cell proliferation and 
subsequently also inhibits the induction of tumourigenesis, however, there is ample 
evidence supporting its involvement in the advancement of tumour progression and 
metastasis (Bierie et al., 2006, Oft et al., 1998 and Derynck et al., 2001) as well as the 
induction of EMT (Song, 2007). Two possible signalling pathways have been implicated 
in the induction of EMT by TGF-β. The first involves a RhoA and p38 MAPK mediated 
autocrine TGF-β-induced EMT of mammary epithelial cells in NMuMG mice (Bhowmick et 
al., 2001a and Bhowmick et al., 2001b). The activation of the PI3K signalling pathway 
through Ras activation results in the inhibition of TGF-β-induced apoptosis in addition to 
the induction of EMT in Ras-transformed hepatocytes (Gotzmann et al., 2002, Oft et al., 
1996, Janda et al., 2002). Additionally, the integrin αvβ6 leads to the activation of latent 
TGF-β, serving as an essential mediator in this signalling process (Bhowmick et al., 2001a 
and Bhowmick et al., 2001b). Furthermore, Ras mutant-induced EMT is mediated by both 
PI3K/Akt and ERK/MAPK signalling pathways, and the addition of either MAPK kinase 1 
(MEK1) inhibitors or wild-type Ras results in the reversal of this EMT process (Janda et 
al., 2002).  
The second signalling pathway implicated in TGF-β-induced EMT involves mothers 
against decapentaplegic homolog (Smad) mediated signalling (Zeisberg et al., 2003), 
wherein EMT is amplified and reinforced by the modulatory effects of inhibitory Smads 
and its autocrine production of TGF-β (Miyazono, 2000, Dernyck et al., 2001, Bhowmick 
et al., 2001a and Saika et al., 2004). Additionally, signalling pathways which mediate 
lymphoid enhancer-binding factor (LEF) and β-catenin activity cooperate with Smads 
inducing EMT (Eger et al., 2004), demonstrating the involvement of the TGF-
β/Smad/LEF/PDGF signalling axis in the induction of an EMT phenotype in cancer.  
The role of TGF-β-induced EMT in promoting cancer cell invasiveness has been widely 
explored and the absence of the TGF-β receptor expression has been shown to result in 
Stellenbosch University  https://scholar.sun.ac.za
35 
 
a better cancer prognosis in mouse models of skin cancer (Cui et al., 1996) and in human 
colon cancer (Watanabe et al., 2001). Furthermore, TGF-β-induced EMT may be 
enhanced by changes in the expression of essential cell polarity proteins, for example the 
loss of E-cadherin in cancer cells promotes their passage through EMT (Gheldof and Berx, 
2013).   
 
1.10. E-cadherin and Epithelial-to-Mesenchymal Transition 
The transmembrane glycoprotein E-cadherin (type I cadherin superfamily) is the 
predominant molecule in the adherent junctions of epithelial cells (Pećina-Šlaus, 2003, Li 
et al., 2012). Structurally E-cadherin is made up of an extracellular and an intracellular 
domain. The extracellular domain consists of 5 repeat moieties which form the E-cadherin 
dimers. The E-cadherin dimers of neighbouring cells interact with each other to stabilize 
epithelial cell adherent junctions (Stemmler, 2008). Linked to the intracellular domain is a 
beta- alpha- and p120-catenin containing protein complex, which interacts with actin 
filament networks. As such, the interactions of both E-cadherin domains creates a 
communication pathway, which serves as an essential integration point for both intra- and 
intercellular signalling pathways, including that which govern cell-to-cell contact, 
transcription signalling and nuclear function (Birchmeier and Behrens, 1994, Conacci-
Sorrell et al., 2002) (Figure 1.7).  
The translocation and accumulation of β-catenin in the nucleus is associated with the 
induction of EMT and thus the subsequent acquisition of a mesenchymal phenotype. With 
its nuclear translocation, β-catenin associates with the Tcf/LEF complexes (Stockinger et 
al., 2001, Gottardi et al., 2001). Therefore, the sequestration of β-catenin by E-cadherin 
maintains its cytoplasmic localization, thus maintaining an epithelial phenotype. The loss 
of E-cadherin in cancer cells therefore correlates with the nuclear accumulation of β-
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catenin, and enhanced susceptibility of these cells to enter the EMT process to acquire a 
more invasive phenotype (Kim et al., 2002, Thiery et al., 2009). The importance of E-
cadherin and β-catenin/LEF activity in the establishment of metastatic potential has been 
demonstrated in several studies (Muta et al., 1996, Saito et al., 1999).  
 
In studies of different human cancer types, E-cadherin expression levels vary greatly, and 
mutations in the E-Cadherin gene has been identified in cancer cell types which are more 
susceptible to EMT and metastatic transformation (Muta et al., 1996, Saito et al., 1999). 
Figure 1.7: E-Cadherin/Catenin membrane complex.  Structurally, E-cadherin is made up of an 
extracellular and an intracellular domain. The extracellular domain consists of 5 repeat moieties which 
form the E-cadherin dimers. Linked to the intracellular domain is a beta- alpha- and p120-catenin 
containing protein complex, which interacts with intracellular actin filament networks. 
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When transferred to immunodeficient mice, cell lines which lack E-cadherin demonstrated 
enhanced tumourigenicity and metastatic potential (Birchmeier et al., 1994). A more in 
depth analysis of the mechanistic role that loss of E-cadherin plays in the metastatic 
progression of cancer is still required, however, it is clear that its central role in the 
acquisition of a mesenchymal phenotype is facilitated by the action of several other 
transcription factors, including that of Slug and Snail. The expression of these TGF-β-
induced transcription factors result in the repression of E-cadherin expression (Medici et 
al., 2008). In mice, Snail has additionally been shown to facilitate cancer cell invasiveness 
(Nieto, 2002), and increased nuclear levels of Snail is associated with enhanced Wnt 
signalling induced by the loss of E-cadherin (Blanco et al., 2002). Furthermore, nuclear 
Snail, along with survival of motor neuron protein interacting protein 1 (SIP1), binds in an 
overlapping fashion to the promotor region of E-cadherin, repressing its expression 
(Comijn et al., 2001, Yokoyama et al., 2001).  
Recently, non-coding micro-RNAs (miRNAs) have been shown to be critical components 
in the EMT regulatory signalling network. miR-200 and miR-205 have both been shown to 
inhibit ZEB1 and ZEB2, repressors of E-cadherin expression, and as such function to 
maintain an epithelial phenotype (Korpal et al., 2008, Park et al., 2008). Increased 
expression of the mesenchymal marker vimentin and decreased E-cadherin expression is 
correlated with the loss of miR-200 in breast carcinoma (Gregory et al., 2008, and 
Paterson et al., 2008), whereas, miR21 facilitates TGF-β-induced EMT and is often 
upregulated in many cancer types (Zavadil et al., 2007). Moreover, human cancer cells 
exhibit enhanced metastatic potential and stem cell-like properties when induced to 
undergo EMT (Mani et al., 2008). 
Taken together, the generation of highly invasive cancer cells with stem cell-like properties 
(including that of self-renewal) and the ability to disseminate and form secondary tumours 
may be facilitated by EMT. However, additional direct evidence of this still remains to be 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
demonstrated, specifically with regards to the  EMT-inducing properties of the tumour 
microenvironment and the role that both resident and circulating CAFs play in rendering 
cancerous epithelial cells permissive to EMT.   
Adjuvant therapy and surgical resection remains the most effective therapeutic strategies 
for the treatment of well-confined primary tumours. However, this strategy remains largely 
ineffective in the treatment of metastatic cancer due to its enhanced chemotherapeutic 
resistance coupled with the systemic nature of the disease (McAllister et al., 2014). 
Clinically, over 90% of all cancer-associated deaths are as a direct result of the effective 
dissemination and metastatic spread of primary tumours to additional sites (Spano et al., 
2012). As a result, extensive focus is being placed not only on elucidating the mechanisms 
involved in tumour dissemination, but also on understanding the role that the tumour 
microenvironment plays in both cancer progression and metastatic dissemination.  
 
1.11. Clinical Implications - Overcoming cancer resistance 
through metabolic manipulation of CAFs 
Anthracyclines, such as doxorubicin (Dox), are considered as some of the most effective 
chemotherapeutic agents for the treatment of various solid cancers, including those 
arising in the breast (Barrett-Lee et al., 2009). Unfortunately, anthracyclines are also 
cytotoxic and affect a wide variety of systems. Aside from these severe cumulative dose-
dependent side effects, resistance of cancer cells to chemotherapeutic strategies has 
become an ongoing complex issue faced by many cancer patients and oncologists alike. 
Currently it is believed that chemoresistance accounts for over 90% of the failure rate seen 
with the treatment of metastatic breast cancer (Coley et al., 2008). Furthermore, the 
majority of patients diagnosed with breast cancer will at some point have a recurrence of 
the disease, resulting in poorer clinical outcomes. Due to the highly variable responses 
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seen with the treatment of breast cancer in particular, a critical need for new strategies 
aimed at overcoming these issues and improving cancer cell susceptibility has arisen. The 
failure of current chemotherapeutic strategies may partially be attributed to an 
underestimation of the stromal influence exerted on epithelial cancer cells. Furthermore, 
many preclinical models fail to accurately represent the influence of the tumour 
microenvironment (Singh et al., 2010). Therefore, one approach to increase tumour 
susceptibility and overcome chemotherapeutic resistance, involves the development of 
novel treatment strategies which interfere with the metabolic capacity of the surrounding 
tumour microenvironment. 
Exposure of CAFs to chemotherapeutic drugs has been shown to result in changes in the 
expression of metabolic enzymes, myofibroblastic differentiation markers, and key 
proteins involved in autophagy (Peiris-Pagès et al., 2015). Additionally, increased 
accumulation of CAFs in colon cancer xenograft tumours occur in response to exposure 
to the chemotherapeutic drug oxaliplatin (Li et al., 2016). Increased production of 
cytokines (such as TGF-β, osteopontin and FGF-2) is induced by chemotherapy. This 
leads to HIF-1α expression which has been shown to promote cancer cell growth and 
metastasis (Yang et al., 2008, Wei et al., 2013 and Schioppa et al., 2003), and could also 
account for the increased recruitment of CAFs seen in tumours following chemotherapy 
treatment (Kojima et al., 2010). In pancreatic cancer models chemoresistance has been 
shown to be enhanced by myofibroblasts through the induction of CpG DNA-
hypermethylation and DNA methyltransferase 1 expression, leading to a reduction in 
caspase expression (Caspase-8, -9, -7 and -3) as well as the epigenetic inhibition of 
STAT1 (Mϋerkӧster et al., 2008).  Due to their abundance within the tumour stroma 
coupled with the profound effects they exert on tumour growth, progression, metastasis 
and chemoresistance, CAFs have become an attractive target for novel chemotherapeutic 
strategies.  
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Recently, pharmacological inhibition of the protein synthesis (mTOR/4E-BP1) pathway in 
CAFs has been shown to abolish the resistance of pancreatic cancer cells to gemcitabine 
(Duluc et al., 2015). Additionally, the in vivo use of targeted fibroblast activated protein 
(FAP) inhibition with PT-100 (a small-molecule dipeptidyl peptidase inhibitor) in 
combination with oxaliplatin was shown to reduce tumour angiogenesis, CAF-associated 
cytokine levels and significantly repressed tumour growth (Li et al., 2016). Furthermore, 
the use of a DNA-based vaccine against the tumour-stromal FAP antigen in combination 
with doxorubicin treatment results in enhanced chemotherapy uptake, increased survival 
and reduced tumour growth in an in vivo model of breast cancer metastasis (Loeffler et 
al., 2006).  
Due to encouraging pre-clinical evidence, several clinical trials are in progress to assess 
the effects of various metabolic therapies for the treatment of cancer. Based on the fact 
that oxidative stress and autophagy play a central role in the metabolic “education” of 
CAFs, modulators of both may be attractive anti-CAF targets. The anti-malarial drug 
chloroquine, a potent inhibitor of autophagy, significantly reduces tumour growth in both 
human tumours and in in vivo xenograft models by targeting fibroblasts (Hiraki et al., 1963, 
Hiraki et al., 1964a and Hiraki et al., 1964b). As such the inhibition of autophagy by 
chloroquine prevents the production of high energy metabolites, thereby disrupting the 
ability of epithelial cancer cells to “activate” CAFs (Martinez-Outschoorn et al., 2010). 
However, in cancer the autophagic process becomes somewhat of a “double-edged 
sword” (Shintani et al., 2004), as it can serve as both a pro-death (Mizushima et al., 2008) 
and a pro-survival (Degenhardt et al., 2006) process depending on cellular conditions. As 
such the paradoxical nature of autophagy makes this treatment strategy quite challenging. 
It is therefore conceivable that the inhibitory effect of chloroquine on autophagy could in 
fact promote cancer growth and progression.  
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Autophagic induction within the stromal compartment has been shown to promote the 
resistance of carcinoma cells to cell death. In particular, the loss of caveolin-1 expression 
in CAFs results in the upregulation of both autophagy and p53-induced glycolysis in 
cancer cells (Martinez-Outschoorn et al., 2010), which is associated with poor clinical 
outcomes in cancer patients (Wietkiewicz et al., 2009, Wu et al., 2011 and Qian et al., 
2011). Additionally, stromal expression of the autophagy-associated marker beclin-1 
(BECN1) in tumours is associated with increased cancer cell proliferation and is 
associated with poor pathological and clinical outcomes in patients with invasive breast 
cancer (Ueno et al., 2016).  Therefore, the assessment of stromal caveolin-1 and beclin-
1 expression in CAFs could potentially serve as markers for the prediction of patient 
outcome. However, extensive research is still needed to fully elucidate the significance of 
both autophagy and CAF involvement in the clinical outcome of cancer patients.   
Additionally, therapeutic strategies aimed at interfering with the ability of epithelial cancer 
cells to utilize the metabolites provided by surrounding CAFs could prove to be effective 
in overcoming CAF-induced chemoresistance. The use of L-asparaginase as an anti-
cancer agent for the treatment of paediatric acute lymphoblastic leukaemia (ALL), exerts 
its cytotoxic effects by depriving ALL cancer cells of the amino acids asparagine and 
glutamine. However, due to its toxic side effects at higher doses the use of L-asparaginase 
in adults is limited (Oettgen et al., 1970), making this therapeutic strategy severely 
restricting. As cancer cells are highly reliant on the presence of exogenous glutamine as 
a fuel source to replenish intermediates of the tricarboxylic acid (TCA) cycle (anaplerosis) 
(Eagle et al., 2001) the use of sodium phenylbutyrate could prove to be a viable strategy 
as it decreases plasma glutamine levels, and thereby exploits the “addiction” of cancer 
cells to glutamine. Currently the efficacy of sodium phenylbutyrate is awaiting clinical 
approval for its use in the treatment of solid tumour malignancies (Gilbert et al., 2001 and 
Phuphanich et al., 2005). A major aspect of the ‘reverse Warburg effect’ involves the 
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transfer of CAF-produced lactate to the epithelial cancer cell. Therefore, the use of an 
inhibitor of either lactates’ export from CAFs or its import into cancer cells could prove 
effective. Currently, a phase I clinical trial (NCT01791595) to assess the safety and 
potential side effects of AZD3965, a monocarboxylate 1/2 inhibitor) in patients with 
advanced cancer is underway. 
Collectively, current pre-clinical and clinical trials show promising results in overcoming 
tumour progression and chemoresistance through targeted CAF-based therapies. 
However, several key mechanisms still remain to be elucidated in order to fully understand 
the role that CAFs play in cancer progression and chemoresistance. Once answered, the 
understanding of the complex signalling network that exists between cancer cells and 
CAFs will open an exciting new avenue in cancer drug discovery.   
 
1.12. Problem Statement 
The highly complex nature of the tumour microenvironment in conjunction with an 
underestimation of the influence that stromal cells, particularly cancer-associated 
fibroblasts (CAFs), exert on the metabolic and migratory ability of cancerous epithelial 
cells, results in an increase in the failure of current chemotherapeutic strategies. As such, 
there is a critical need for the development of novel pre-clinical models which effectively 
recapitulate the metabolic and metastatic influences of stromal cells on epithelial cancer 
cells within the tumour microenvironment.  
 
1.13. Hypothesis 
Based on this collective evidence, we hypothesize that nutrient deprived breast cancer 
epithelial cells influence cancer-associated fibroblasts (CAF’s), leading to the production 
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of metabolites which may be utilized by these cancer cells for survival, chemo-resistance 
and enhanced migration. Furthermore, we hypothesize that the manipulation of autophagy 
in CAFs could inhibit the migratory capacity of these nutrient deprived epithelial breast 
cancer cells. 
 
1.14. Aims 
In vitro 
 To induce oxidative stress in E0771 breast cancer cells without significant cell 
death (simulating the tumour microenvironment where cancer cells are deprived of 
nutrients and oxygen) in order to generate conditioned media to treat CAFs.  
 To determine changes in the metabolic profile of CAF’s treated with conditioned 
media (CM) derived from cancer cells. 
 To determine the metabolic response of E0771 cancer cells exposed to CAF 
derived conditioned media (CM). 
 To assess whether CAFs contribute to doxorubicin resistance and enhanced 
metastatic capabilities of E0771 cancer cells. 
 To determine whether autophagy in CAFs plays a role in mediating epithelial-to-
mesenchymal transition (EMT) and migration of E0771 cancer cells.  
 
In vivo 
 To establish a physiologically relevant tumour-bearing mouse model. 
 To determine if any ultrastructural changes occur in tumours and mammary fat 
pads in response to systemic doxorubicin administration.  
Stellenbosch University  https://scholar.sun.ac.za
44 
 
 To determine the extent of collagen deposition in tumours following doxorubicin 
administration. 
 To determine the degree of CAF infiltration in tumours in response to doxorubicin 
exposure.  
 To establish a primary epithelial organoid model which accurately recapitulates the 
3D environment of tumour epithelial cells. 
 To determine if differences exist between in vitro and in vivo models of cancer cell 
migration and epithelial-to-mesenchymal transition (EMT). 
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Chapter 2: Materials and Methods 
2.1. Cell Culture 
For this study the E0771 murine breast cancer (CH3 BioSystems) and the mouse embryonic 
fibroblast (MEF) (ATCC #SCRC-1008) cell lines were utilized. Both E0771 and MEF cells were 
cultured in Dulbecco’s Modified Eagles Medium (DMEM) (Life Technologies) that was 
supplemented with 10% Foetal Bovine Serum (Scientific Group) and 1% Penicillin 
Streptomycin (PenStrep) (Life Technologies) collectively known as growth medium. Cells were 
cultured as a monolayer and maintained at an atmosphere of 37 ºC and 5% CO2 humidity. 
Growth media was refreshed every 2 days and cells were regularly sub-cultured once a 
confluency 70 - 80% was reached.  Upon reaching confluency, cells were split and seeded 
with fresh media for experiments. Seeding was accomplished by washing the cell monolayer 
with warmed Phosphate Buffered Saline (PBS) before incubation in 4 ml 0.25% Trypsin EDTA 
(1X) (Life Technologies) until all cells had loosened from the surface of the flask.  
 
2.2. Treatment Strategies 
2.2.1. Glucose Deprivation 
Prior to treatment, media was aspirated and cell monolayers were washed twice with warm 
PBS to ensure all cell debris was removed. In order to determine optimal treatment times, 
time responses were carried out for treatment periods of 4, 8, 12, 24, 48 and 72 hours 
using glucose free DMEM (Life Technologies, #A1443001). Treatment time was then 
selected based on cell viability and oxidative stress analysis, with the treatment time 
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producing the least toxic effect while still increasing oxidative stress levels in the E0771 
cancer cells being used.  
 
2.2.2. Doxorubicin 
Prior to treatment, media was aspirated and the cell monolayer was washed twice with 
warm PBS to ensure all cell debris was removed. In order to determine optimal 
concentrations, concentration curves were done for a treatment period of 24 hours for 
doxorubicin (LKT Laboratories, #D5794) with the following concentrations: 0.1, 1.0, 2.5, 
5.0 and 10.0 μM. The concentration of doxorubicin was determined based on cell viability, 
with the lowest concentration that lead to a significant decrease in mitochondrial reductive 
capacity in the E0771 cancer cells being selected.  
 
2.3. MTT Assay 
A MTT cell viability assay was conducted to assess the percentage of metabolically viable 
cells. The principle of this assay is based on the reduction of MTT to yield purple formazan 
crystals by various reduction enzymes present within the mitochondria.  Under conditions 
whereby cells have undergone or are in the process of apoptosis MTT will not be reduced. 
Cells from each cell line where arbitrarily divided into four treatment groups and seeded 
at a cell density of 5 x 105  cells per well into 24 well plates (Cellstar, Greiner bio-one). 
Cells were left for 24 hours to attach and proliferate in 1 ml of growth media after which 
media was refreshed and treatments administered as described above. Subsequent to 
treatments, all media was aspirated (Mini-vac power, PeqLab biotechnologie GmbH) and 
500 µl of MTT working solution (0.001 g MTT/ml PBS) was added to each well. As MTT is 
a light sensitive compound this experiment was conducted in the dark and 24 well plates 
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were covered in tin foil. After the addition of MTT working solution to wells, cells were 
incubated for 1.5 hours at a 37ºC, 5% CO2 humidified environment (C01901R, Snijders 
Scientific). Subsequent to incubation, 500 µl Isopropanol:HCl/ Triton-X-100 solution was 
added to each well, and the tinfoil wrapped plate was placed on a heated shaker (37ºC, 
200 RPM) for a period of ± 5 min until formazan crystals generated by healthy cells had 
dissolved. Plates were then analysed using KCjunior software on a universal micro plate 
reader (EL800, Bio-Tek Instruments Inc.) where absorbance values were determined at a 
wavelength of 595 nm. All groups were analysed in triplicate and three independent 
experiments (biological replicates) were conducted. Absorbance values were all 
expressed as a percentage of MTT reduction versus the untreated control.  
 
2.4. Oxidative Stress Analysis  
Oxidative stress analysis was performed using flow cytometry by staining cells with DCF 
(2’.7’-Dichlorofluorescein) (Sigma Aldrich, #35848) or MitoSOX™ Red Mitochondrial 
Superoxide Indicator (Life Technologies, #M36008).  Prior to treatments E0771 and MEF 
cells were seeded into T25 flasks at a density of 4 x 105 cells. Media was discarded and 
the cell monolayer was washed twice with warm PBS, cells were trypsinized and 
centrifuged at room temperature for 5 min at 300 x g. Supernatant was discarded and the 
pellet gently re-suspended in 1 ml of the PBS, and DCF or MitoSox was added to unfixed 
cells to obtain final concentrations of 50 µM and 5 µM respectively. Cells were incubated 
in the dark at 37 ºC for 10 min. Hydrogen peroxide (H2O2) was used as a positive control. 
Samples were analysed on the flow cytometer (BD FACSAria I) and a minimum of 10 000 
live cell events were acquired for each sample using a 488 nm laser and 610 LP, 616/23 
BP emission filters. Mean percentages from three separate experiments were used to 
perform statistical comparisons.  
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2.5. Western Blot Analysis  
In order to carry out western blot analysis cells were seeded into T25 flasks (25 cm2, 
NEST) with 4 ml of growth media per flask. Flasks were all incubated in a 37 ºC, 5% CO2 
environment for 24 hours to allow cells to attach and proliferate.  
 
2.5.1. Protein Extraction and Quantification 
After treatment, media was aspirated from T25 flasks and cells were immediately placed 
on ice. The cell monolayer was washed with 1 ml cold PBS, which was repeated twice 
more. 100 µl modified radioprecipitation (RIPA) buffer comprising of 2.5 mM Tris-HCL, 1 
mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
benzamidine, 50 mM NaF, 4 mg/ml SBTI, 10 mg/ml leupeptin, 0.1% SDS 0.5%, Na 
deoxycholate and 1% NP40, calibrated to pH 7.4, was added to each petri dish and 
allowed to stand for 5 min on ice in order to extract total cell protein. Cells were then 
detached from the flask surface with the use of a cell scraper that was cleaned using EtOH 
between samples. Whole cell lysates were sonicated on ice at 3 Hz for 8 seconds and 
centrifuged at 8000 RPM for 30 seconds. The supernatant was then decanted into 
Eppendorf tubes and stored at -80 ºC ready for protein quantification. A Direct Detect® 
infrared spectrometer (DDHW00010-WW, Merck) was used to determine the protein 
content of samples from each cell line.  
 
2.5.2. Sample Preparation 
Samples used for western blots were prepared following protein determination. Aliquots 
were prepared containing 20 µg protein content and diluted with sample buffer. Prepared 
samples were then stored at -80 ºC for further western blot analysis.  
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2.5.3. SDS-PAGE and Western Blot Analysis 
Cell lysates were subsequently separated on 4-15% polyacrylamide precast gels (mini-
PROTEAN® TGX™ Gels, Bio-Rad) by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). 5 µl of a protein marker ladder (PeqGold) was loaded into 
the first well of each gel run; this is used for orientation of gels as well as for determination 
of molecular weights of separated proteins.  Prepared cell lysates were heated to a 
temperature of 95 ºC for 5 minutes in order to denature proteins and pulse centrifuged, 
after which 50 µg of protein was added to each lane following the ladder. 
Gels were run at 100 V (constant) and 400 mA for a period of more or less 90 minutes 
(Power Pac 300, BioRad). On completion of SDS-PAGE, proteins were transferred to 
prepared polyvinylidine fluoride (PVDF) membranes using a semi-dry electrotransfer 
system (TransBlot® Turbo™ v1.02, BioRad) for 30 minutes at 25 V and 1.0 A. Membranes 
were visualized using the stain free blot protocol provided on a Chemi-Doc™ MP (BioRad) 
system in order to visualize that proteins transferred correctly. Membranes were 
subsequently washed in 0.1% Tris Buffered Saline-Tween20 (TBS-T) and blocked for 2 
hours in 5% (w/v) non-fat milk and TBS-T, whilst being gently agitated at room 
temperature, this prevents non-specific binding of the antibody. Membranes were then 
incubated at 4 ºC overnight in TBS-T diluted primary antibodies (1:1000). The following 
day membranes were removed from the primary antibody and washed with TBS-T before 
being incubated in anti-rabbit IgG horseradish peroxidase conjugated secondary antibody 
(1:10000) (from donkey) (Cell Signalling Technologies) with gently agitation at room 
temperature for 1 hour. Subsequent to the incubation period membranes were washed in 
TBS-T before antibodies were detected with the use of an ECL western blotting substrate 
detection kit  (Pierce®, Thermo Scientific) and protein bands visualised with the use of 
ImageLab 4.0 software on a Chemi-Doc™ MP (BioRad) imaging system. Exposed bands 
were visualized and quantification was done with the use of BioRad ImageLab software 
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where samples were normalized to total protein present on the same membrane. Bands 
for each specific protein were quantified as normalized readings comparative to the control 
sample present on the same blot.  
 
2.6. Generation of Conditioned media 
E0771 and MEF cells were seeded into T75 flasks at a density of 1 x 105 cells. After the 
treatment period, media was collected and centrifuged at 5000 RPM for 10 min at a 
temperature of 4 ⁰C. The pellet was discarded and centrifuged conditioned media was 
filtered using a 0.2 µm filter. Conditioned media was then snap frozen in liquid nitrogen 
and stored at -80 ⁰C for no longer than 4 weeks until further use / analysis. For analysis 
purposes conditioned media was collected from three flasks and pooled to provide a single 
technical replicate. In order to account for variance conditioned media was collected from 
four separate cultures for analysis. 
 
2.6.1. Conditioned Media Treatment Strategies 
Prior to treatment, media was aspirated and cell monolayers were washed twice with warm 
PBS to ensure all cell debris was removed. Conditioned media was thawed and allowed 
to reach a temperature of 37 ⁰C.  Following this, cells were treated for 24 hours with 
conditioned media that was diluted with fresh DMEM (50:50) in order to maintain cellular 
viability whilst still eliciting a desired response. Treatment groups were established as 
described in table 2.1 below. 
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Table 2.1: This study was divided into two main experimental groups utilizing conditioned media which consisted of the 
following treatment groups: 
 
2.7. Proteomics Analysis of Conditioned Media  
E0771 and MEF cells were seeded individually into T75 flasks at a density of 1.5 x 106 
cells per flask. After 2 days, DMEM media was discarded and the cell monolayer washed 
twice using 1 x DPBS (Life Technologies). Following this, 15 ml of chemically defined 
Chinese hamster ovary (CD-CHO) serum-free media (Invitrogen) supplemented with 8 
mM glutamine (Invitrogen) was added to each flask. Flasks were then allowed to incubate 
Experimental 
Group 1 
Control Control 
Conditioned 
Media 
E0771 
Untreated 
Conditioned 
Media 
E0771 
Conditioned 
Media 
 (Control-CM) (E0771-UTCM) (E0771-CM) 
Untreated NO cells untreated E0771 
12 hr  glucose 
deprived E0771 
Experimental 
Group 2 
Control Control 
Conditioned 
Media 
MEF Untreated 
Conditioned 
Media 
MEF 
Conditioned 
Media 
 (Control-CM) (MEF-UTCM) (MEF-CM) 
Untreated NO cells 
Untreated 
MEF 
E0771-CM 
treated MEF 
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at a 37ºC, 5% CO2 humidified environment (C01901R, Snijders Scientific) for the required 
treatment times. Conditioned media generated was collected as previously described and 
media from four T75 flasks were pooled to obtain a total volume of 60 ml conditioned 
media per sample, and a total of four biological replicates per treatment group for each 
cell line were generated for proteomics analysis. Proteins present in the conditioned media 
were concentrated and liquid chromatography mass spectrometry (LC-MS) was 
performed by the Centre for Proteomic & Genomic Research (CPGR), an ISO 9001:2008 
accredited facility. 
 
2.7.1. Sample Purification and Concentration 
Overnight passivation of spin filters was achieved using 5% TWEEN-20 (Sigma, #9005-
64-5). Spin columns were then three times washed for 30 minutes each using water prior 
to use. Columns were then placed inside collection tubes and 500 μl of Millipore water 
was spun through. Following which, columns were conditioned using 500 μl of 50 mM 
ammonium bicarbonate (Sigma, #40867) spun for 15 minutes at 12 000 x g at 4˚C. Five 
hundred μl from each sample was then added to the spin filters and spun through at the 
same settings as above. This was repeated three times so that a final volume of 1.5 ml of 
sample was concentrated to less than 50 μl. Samples were then washed three times with 
500 μl of 50 mM ammonium bicarbonate leaving a residual volume of less than 40 μl. 
Samples were then transferred to protein LoBind tubes and a final volume of 60 μl was 
achieved using 50 mM ammonium bicarbonate (final concentration), 2% SDS (Sigma, 
#71736). Protein quantification was achieved using the QuantiPro BCA assay kit (Sigma, 
#QPBCA). 
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2.7.2. On-bead Hydrophilic Interaction Chromatography 
(HILIC) Digestion 
Protein reduction was achieved by incubating samples for 1 hour at 60˚C in 10 mM final 
concentration tris(2-carboxyethyl) phosphine per sample (Sigma, #646547). Once cooled 
to room temperature, samples were alkylated with 10 mM final concentration 
methylmethanethiosulphonate (Sigma, #208795) per sample, where samples were 
allowed to incubate at room temperature for 15 minutes. Prior to HILIC magnetic bead 
workflow, beads were aliquoted into a new tube to remove shipping solution. 
Subsequently, beads were washed twice with 250 μl wash buffer (15% acetonitrile, 100 
mM ammonium acetate (Sigma, #14267) pH 4.5) for one minute. Beads were then re-
suspended in loading buffer (30% acetonitrile, 200 mM ammonium acetate, pH 4.5). For 
digestion, 50 μg of protein or the entire sample was transferred to a protein LoBind plate 
and HILIC magnetic beads were added at an equal volume to that of the sample (at a ratio 
of 5:1 total protein). The plate was then transferred to a shaker at 900 RPM and incubated 
for 30 minutes to allow for binding of protein to beads. After binding, beads were washed 
twice with 500 μl of 95% acetonitrile for one minute. For digestion, 200 μl trypsin 
(Promega, #PRV5111), made up in 50 mM triethylammonium bicarbonate (Sigma,# 
T7408) was added at a ratio of 1:10 total protein and the plate was incubated at 37˚C on 
a shaker for 4 hours. After digestion, the supernatant containing peptides was removed 
and dried down, after which samples were re-suspended in LC loading buffer (0.1% formic 
acid, 2.5% acetonitrile). 
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2.7.3. Liquid Chromatography Mass Spectrometry (LC-MS) 
LCMS analysis was conducted with a Q-Exactive quadrupole-Orbitrap mass spectrometer 
(Thermo Fisher Scientific, USA) coupled with a Dionex Ultimate 3000 nano-HPLC system. 
Peptides were dissolved in 0.1% formic acid (Sigma, #56302), 2% acetonitrile (Burdick & 
Jackson, #BJLC015CS) and loaded on a C18 trap column (300 μm × 5 mm × 5 μm). 
Chromatographic separation was performed using a PepAcclaim C18 column (75 μm × 
25 cm × 2 μm) and LC water (Burdick and Jackson, #BJLC365); 0.1% formic acid (solvent 
A) and acetonitrile, 0.1% formic acid (solvent B) was employed as the solvent system. The 
multi-step gradient for peptide separation was generated at 300 nL / min as follows: time 
change 6 min, gradient change: 3.5 – 9% solvent B, time change 45.5 min, gradient 
change 9 – 24.6% solvent B, time change 2 min, gradient change 24.6 – 38.7% solvent 
B, time change 2.1 min, gradient change 38.7 – 52.8% solvent B. The mass spectrometer 
was operated in positive ion mode with a capillary temperature of 320°C, and an 
electrospray voltage of 1.95 kV was applied.  
 
2.7.4. Data Analysis 
Progenesis QI (Nonlinear, UK) was used in order to determine the relative quantification 
of protein abundance in each sample. Data processing included peak picking, run 
alignment and normalisation and relative quantification was based on four biological 
replicates per condition using non-conflicting peptides. Proteins, containing at least two 
unique peptides that were above the first false positive protein identified for each sample, 
were reported. A protein with a fold change greater than or equal to two with a 
corresponding p-value <0.05 was considered regulated. Identified peptides were then 
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matched to proteins using a human database source from UniProt (www.uniprot.org) 
dated 23/03/2017 by means of Byonic Software (Protein Metrics, USA). 
 
2.7.5. Gene Ontology (GO) Approach 
Data generated using ‘omics’ platforms are in themselves not very informative as the 
share scale of the data generated renders any direct insight into biological significance 
inaccessible.  In this regard, a number of techniques have been developed to ‘condense’ 
a data set into a meaningful description of the information generated. Often, these 
approaches involve grouping genes or proteins into categories, such as their shared 
involvement in a metabolic or signalling pathway. 
In this study, the Gene Ontology (GO) approach was implemented. A heuristic way of 
understanding the GO approach can be provided by analogy to the central dogma of life; 
similarly to the way in which DNA is transcribed to RNA and subsequently translated to 
protein, the protein itself can in turn be ‘assigned’ a particular relevance (i.e. protein be 
‘translated’ into a function or activity). These ‘assigned relevance’ or GO terms describe 
gene products in terms of three ontologies; molecular function, biological process and 
cellular component. For example, ‘molecular function’ includes “iron-binding”, whereas 
‘biological process’ describes the process in which the molecular function is implemented 
(e.g. iron sequestration as a host response during an infection). Structure denotes the 
physical location of the gene product (e.g. nucleus or cytosolic) or the structure into which 
the component is incorporated (e.g. a subunit of the apoptosome).  
A second feature of GO terms is that they are hierarchically arranged, that is to say that a 
more descriptive GO term is nested in a less descriptive GO term. As an example, the GO 
term “response to gamma radiation” is contained in the less descriptive (i.e. more generic) 
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term “response to ionizing radiation”. The interaction between GO terms are via ‘controlled 
vocabularies’. For example, the GO term ‘protein kinase activity’ is related to ‘protein 
phosphorylation’ by the fact that ‘protein kinase activity’ is part of the biological process 
‘protein phosphorylation’. These main aspects give rise to a hierarchal network of 
descriptive terms that can be used to identify proteins with the same functionality or 
involvement in the same process as well as the location of these proteins (Figure 2.1). 
 
Figure 2.1: A graphical representation of the GO term “protein kinase activity” 
(GO:0004672) generated in AmiGO 2. 
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2.7.6. Bioinformatics Analysis 
From the list of regulated proteins provided by CPGR, a list of UniProt accession numbers 
of all regulated proteins where extracted. Protein sets for each treatment condition were 
then grouped according to proteins which were upregulated and those that were 
downregulated. A basic descriptive overview of differentially regulated proteins between 
groups where visualised by generating Venn diagrams using Venny 2.1 
(http://bioinfogp.cnb.csic.es/tools/venny/). Next, GO terms were assigned by submitting 
the list of regulated proteins into DAVID (Database for Annotation, Visualization and 
Integrated Discovery) version 6.8 [Systematic and integrative analysis of large gene lists 
using DAVID bioinformatics resources]. The list of GO terms and their associated P-values 
(Benjamini–Hochberg procedure to control for multiple testing) was subsequently 
submitted to REVIGO (which summarizes and visualizes long lists of gene ontology terms) 
in order to visualise GO terms and their associations. REVIGO provides a number of 
graph-based tools to visualise and inspect the association between GO terms, allowing 
for the identification of protein clusters as well as the identification of interactions occurring 
between clusters. 
Interesting associations between GO terms were followed up with more detailed analysis 
using various tool suits provided in DAVID. For example, DAVID allows for the quick 
access to KEGG (Kyoto Encyclopaedia of Genes and Genomes), where regulated 
proteins in a pathway can be visualised. In this manner, the ‘condensed’ information in a 
GO term can be revisited to gain a more refined view of the proteins’ biological relevance 
within a metabolic pathway.  DAVID also provides a 2D-viewer (Figure 2.2), wherein a set 
of proteins involved in common processes or pathways (“Annotation Cluster”) can be 
visualized more informatively.  
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To summarize, the interrogation of the list of regulated proteins between groups provided 
by CPGR, followed a three phase process (Figure 2.3). Firstly, data sets were cleaned 
and prepared for subsequent analysis by extracting Uniprot accession numbers. Next, GO 
terms were extracted and visualised in REVIGO. After which, interesting GO terms as well 
as their interactions observed were followed up by more detailed investigations using 
DAVID tool suits, which included functional annotation clustering (2D-graph viewer) as 
well as pathway analysis (KEGG). 
 
 
Figure 2.2: A representative 2D-graph of proteins (‘y-axes’) and their annotation terms (‘x-axes). 
Green blocks indicate shared annotation clustering between proteins, whereas black indicates the lack 
of shared association between proteins. 
Stellenbosch University  https://scholar.sun.ac.za
59 
 
 
2.8. Immunocytochemistry  
MEF cells were grown in 8-well chamber slides (Lab-Tek, Thermoscientific) at a density 
of 1.2 x 104 cells cells/well. After the treatment period, growth medium was removed and 
cells were washed with PBS. Cells were fixed with ice-cold methanol and acetone (1:1) 
and left to incubate on ice for 10 min. The fixative mixture was then removed and cells 
were allowed to air-dry for 20 min. After being rinsed twice with PBS, non-specific binding 
was prevented by incubating cells in a 1% BSA/PBS blocking solution for 30 min at RT. 
After this time period, the blocking solution was drained off and primary monoclonal 
antibodies against alpha smooth muscle actin (α-SMA) (Abcam, #ab7817) and vimentin 
(Cell Signalling Technologies, #D21H3) diluted in PBS (1:50 and 1:100 respectively) were 
added to cells and allowed to incubate overnight at 4°C. Cells were then rinsed three times 
Figure 2.3: A brief outline of the procedures followed to explore proteomic data sets. 
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with PBS and allowed to incubate with the appropriate secondary antibody for 30 min at 
room temperature. In this case an Alexa Fluor 488 conjugated donkey anti-mouse 
secondary antibody (Life Technologies, #A-21206) and an Alexa Fluor 647 conjugated 
goat anti-rabbit secondary antibody (Life Technologies, #A-21244) was used. After 
incubation, Hoechst 33342 dye (1:200) was additionally added and kept in contact with 
cells for a further 10 min incubation period. Next, cells were rinsed and mounted with 
DAKO fluorescent mounting medium (DAKO Inc., CA, USA). Chambers were kept 
wrapped in foil at -20 °C until image acquisition was performed using the Zen imaging 
software on a Carl Zeiss LSM780 confocal microscope (Carl Zeiss, Germany) using a 60x 
oil immersion objective.  
 
2.9. Glucose Uptake Assay 
MEF cells were seeded into 6-well plates at a density of 2.5 x 105 cells/well. After the 
treatment period, media was discarded and the cell monolayer was washed twice with 
warm PBS, after which 2 ml 0.25% Trypsin EDTA (Life Technologies) was added to each 
well for 3-4 min until all cells had detached. The cell suspension was then added to 15 ml 
Falcon tubes (BD Biosciences) and centrifuged at 1500 RPM for 3 min. The supernatant 
was removed and the pellet re-suspended in 1 ml PBS. 2-NBDG (2-(N-(7-Nitrobenz-2-
oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose) (Life Technologies, #N13195) and 
Propidium Iodide (PI) (Sigma-Aldrich, # P4170) was added to the unfixed cells to obtain 
final concentrations of 100 µM and 1 mg/ml respectively, and incubated for 10 min before 
being analysed on the flow cytometer (BD FACSAria I). A minimum of 10 000 live cell 
events were collected and analysed. As PI has an emission spectrum of 550 – 720 nm a 
bandpass filter of 585/42 was employed to detect light emitted between 564 and 606 nm 
by stained cells. PI inclusion signified loss in membrane integrity and cell death as such 
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only live cells (signified by PI exclusion) were evaluated for glucose uptake. Values were 
represented as a percentage of the control and mean percentages from three separate 
experiments were used to perform statistical comparisons.  
 
2.10. GLUT4 Translocation Assay 
Translocation of GLUT4 to the cell membrane was determined through the expression of 
the HA-GLUT4-GFP fusion protein (A kind gift from Prof. M.F. Essop and Dr D. Joseph, 
Stellenbosch University, RSA). Transfection of HA-GLUT4-GFP was achieved by 
electroporation using the Neon® transfection system (Invitrogen, Carlsbad, CA, USA). 
Prior to seeding, MEF cells were washed with warm PBS and centrifuged at 400 x g for 5 
min at room temperature. Supernatant was discarded and the pellet gently re-suspended 
in the supplied re-suspension buffer R to a final density of 1 x 107 cells/ml and gently 
pipetted to obtain a single cell suspension. A Neon® tube containing 3 ml Electrolytic buffer 
was placed into the Neon® pipette station. 500 ng of the HA-GLUT4-GFP construct was 
added to a cell suspension at a density of 5 x 106 cells/ml and cells were pulsed once at a 
voltage of 1350 and pulse width of 30 ms using a 10 µl tip. Transfected cells were then 
seeded onto 8-well chamber slides (Lab-Tek, Thermoscientific) at a density of 12 000 
cells/well and plates were gently swirled and incubated at an atmosphere of 37 ºC and 5% 
CO2 humidity for 24 hours. GLUT4 expression was confirmed following transfection in cells 
demonstrating positive GFP fluorescence. After the treatment period, growth medium was 
removed and cells were washed twice with warm PBS. Cells were fixed using a 4% 
paraformaldehyde solution and incubated for 15 min at RT. The fixative solution was then 
removed and cells were allowed to air-dry for 20 min. After being rinsed twice with PBS, 
non-specific binding was prevented by incubating cells in a 1% BSA/PBS blocking solution 
for 30 min at RT. After this time period, the blocking solution was drained off and an anti-
Stellenbosch University  https://scholar.sun.ac.za
62 
 
HA Alexa Fluor 647 conjugated antibody diluted in PBS (1:100) was added to cells and 
allowed to incubate overnight at 4°C. Cells were then rinsed three times with PBS and 
mounted with DAKO fluorescent mounting medium (DAKO Inc., CA, USA). Chambers 
were kept wrapped in foil at -20°C until image acquisition was performed using the Zen 
imaging software on a Carl Zeiss LSM780 confocal microscope (Carl Zeiss, Germany) 
using a 60x oil immersion objective. 
 
2.11. Pyruvate dehydrogenase (PDH) Assay  
Assessment of intracellular pyruvate dehydrogenase activity was achieved by means of a 
commercially available pyruvate dehydrogenase (PDH) Combo (Activity + Profiling) 
Microplate Assay Kit (Abcam, ab110671). This assay combines two independent kits to 
assess relative PDH protein concentration and activity as well as relative specific activity 
(activity / protein concentration).  
 
2.11.1. Sample Preparation 
MEF cells were seeded into T75 flasks at a density of 1.5 x 106 cells/flask. Following 
treatment, cell monolayers were washed with warm PBS, and 4 ml 0.25% Trypsin EDTA 
(Life Technologies) was added to each well for 3-4 min until all cells had detached. The 
cell suspension was then added to 15 ml Falcon tubes (BD Biosciences) and centrifuged 
at 1500 RPM for 3 min. The supernatant was removed and the pellet re-suspended in 
PBS. Prior to sample solubilisation the protein concentration of each sample was 
measured and adjusted using PBS to obtain a concentration of 15 mg/ml.  Intact, 
functional PDH was solubilized with the addition of an appropriate volume of the supplied 
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detergent solution in order to produce a final protein concentration of 13.5 mg/ml. Samples 
were then incubated on ice for 10 min and centrifuged at 1 000 x g for 10 min at 4 ⁰C.  
 
2.11.2. PDH Enzyme Activity Assay  
The colorimetric PDH enzyme activity assay relies on the immunocapture of the PDH enzyme 
within the wells and the subsequent reduction of NAD+ to NADH, coupled to the reduction of 
a reporter dye producing a change in colour (λmax = 450 nm) which can be then be detected 
spectrophotometrically. 
 
2.11.2.1. Assay Procedure 
A 1 x buffer solution was prepared by diluting the supplied 20 x buffer with dH2O, and 
samples were diluted appropriately in order to obtain a concentration of 500 µg / 200 
µl/well (which falls within the linear working range of 100 – 1000 µg / 200 µl/well). 200 µl 
of each sample was then added to each well of the microplate, additionally two positive 
control samples (100 µg / 200 µl/well and 1000 µg / 200 µl/well) in addition to the negative 
buffer control was included and the microplate was then allowed to incubate at room 
temperature for 3 hours. A working stabilizer solution was prepared by diluting the 5 x 
stock stabilizer solution provided in the kit with freshly prepared 1 x buffer solution. 
Following incubation the wells of the microplate were emptied and 300 µl of the 1 x 
stabilizer solution was added to each well, this was then repeated for a second time. 
Finally the wells were emptied and 200 µl of prepared assay solution was added to each 
well and absorbance was then measured at 450 nm at room temperature using a universal 
micro plate reader (EL800, Bio-Tek Instruments Inc.) set to kinetic program for 30 minutes 
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with readings being taken every 42 seconds. PDH activity was then expressed as the 
initial rate of reaction, determined by the slopes of the generated curves.  
 
2.11.3. PDH Protein Profiling Microplate Assay  
This “sandwich” ELISA assay relies on the purification and immobilization of the PDH 
enzyme by an anti-PDH capture antibody pre-coated in the wells of a microplate. The 
amount of PDH which is captured is determined with the addition of a second anti-PDH 
antibody which binds to captured PDH. Once bound the addition of a HRP conjugated 
anti-mouse secondary antibody results in a change in colour (colourless to blue) of the 
HRP development solution. This colour change (absorbance) is directly proportional to the 
amount of captured PDH. 
 
2.11.3.1. Assay Procedure 
200 µl of previously prepared samples was added to each well of the supplied microplate. 
The same two positive control samples in addition to the negative buffer control was 
included and the microplate was then allowed to incubate at room temperature for 3 hours. 
1 x buffer solution was freshly prepared by diluting the supplied 20 x buffer with supplied 
incubation buffer. The wells of the microplate were then emptied by inverting the plate 
over a receptacle and firmly shaking out the well contents in a single rapid downward 
motion. Wells were washed twice by rapidly adding 300 µl of 1 x stabilizer solution to each 
well and then removing the solution. Following the second wash the plate was inverted 
onto a paper towel in order to remove excess liquid. 200 µl of 1 x detector antibody was 
added to each well and plates were covered and incubated at room temperature for 1 
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hour. Following incubation, wells were washed twice using 1 x buffer solution (without 
stabilizer). 200 µl of the provided 1 x HRP label was then added to each well and plates 
were covered and incubated for a further 1 hour at room temperature. Plates were then 
washed for a total of three times before 200 µl of the provided HRP development solution 
was added to each well. Absorbance was then measured at 600 nm at room temperature 
using a universal micro plate reader (EL800, Bio-Tek Instruments Inc.) set to a kinetic 
program for 30 minutes with readings being taken every 42 seconds. PDH activity was 
then expressed as the initial rate of reaction, determined by the slopes of the generated 
curves.  
 
2.12. L-Lactate Assay 
Assessment of intracellular L-Lactate levels was achieved by means of a commercial 
colorimetric L-Lactate assay kit (Abcam, ab65331). This assay relies on the oxidation of 
lactate by lactate dehydrogenase. The resulting product interacts with the provided probe 
to produce a change in colour (λmax = 450 nm) which can be then be detected.   
 
2.12.1. Sample Preparation 
MEF and E0771 cells were seeded into T25 flasks at a density of 4 x 105 and 8 x 105 cells 
respectively. Following treatment, cell monolayers were washed with warm PBS and 2 ml 
0.25% Trypsin EDTA (Life Technologies) was added to each well for 3 - 4 min until all 
cells had detached. The cell suspension was then added to 15 ml Falcon tubes (BD 
Biosciences) and centrifuged at 1500 RPM for 3 min. The supernatant was removed and 
the pellet washed with cold PBS. The cells were centrifuged again at the same 
specifications and the supernatant was removed as before. 500 µl of lactate assay buffer 
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provided in the kit was added to re-suspend each pellet. Cells were then homogenized by 
quickly pipetting up and down a few times. Insoluble debris was then removed by means 
of centrifugation at top speed (5 min at 4 ⁰C). The supernatant was then kept and a 
deproteinization step was performed in order to remove endogenous lactate 
dehydrogenase which could lead to lactate degradation. Deproteinization was achieved 
by adding ice cold perchloric acid (PCA) to each sample at a final concentration of 1 M. 
Samples were then incubated on ice for 5 min and centrifuged at 13 000 x g for 2 min at 
4⁰C. Supernatants were then transferred to clean tubes and excess PCA was precipitated 
out by adding ice cold 2 M potassium hydroxide (KOH) to equal 34% of the supernatant 
volume. pH was assessed (testing 1 µl on litmus paper) and each sample was adjusted 
to a pH of 6 – 8.5. Samples were then centrifuged at 13 000 x g for 2 min at 4 ⁰C and the 
supernatant collected.  
 
2.12.2. Assay Procedure 
Working solutions of lactate standards were prepared using the stock solution provided in 
the kit. Triplicates of serially diluted lactate standards (0 – 10 nmol/well) were pipetted into 
wells of a 96-well microtiter plate. Duplicates of prepared protein samples (50 µl) were 
pipetted, followed by the addition of 50 µl reaction mix (lactate enzyme mix, substrate mix 
and assay buffer) to all wells. Plates were then allowed to incubate at room temperature 
for 30 min where after absorbance was read at 450 nm using KCjunior software on a 
universal micro plate reader (EL800, Bio-Tek Instruments Inc.). Lactate concentrations 
were then calculated by using the sample amount from the standard curve (Lα) in nmol, 
sample volume (Sν) and dilution factor (D) in the following equation: Lactate concentration 
= (Lα/Sν) x D. Values were represented as a percentage of the control.  
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2.13. Cell Death Analysis 
E0771 cells were grown in T25 flasks at a seeding density of 8 x 105 cells/flask. After the 
treatment period, 2 ml 0.25% Trypsin EDTA (Life Technologies) was added to each flask 
for 3 - 4 min until all cells had detached. The cell suspension was then added to 15 ml 
Falcon tubes (BD Biosciences) and centrifuged at 1500 RPM for 3 min. The supernatant 
was removed and the pellet washed with 0.1 M PBS. The cells were centrifuged again at 
the same specifications and the supernatant was removed as before. Propidium Iodide 
(PI) (Sigma-Aldrich) and Hoechst 33342 was added to the unfixed cells to obtain final 
concentrations of 1 mg/ml, incubated for 10 min and analysed on the flow cytometer (BD 
FACSAria I). A minimum of 10 000 events were collected and analysed using a 488 nm 
laser and 610LP, 616/23BP emission filters. PI inclusion signified loss in membrane 
integrity and cell death. Values were represented as a percentage of the control and mean 
percentages from three separate experiments were used to perform statistical 
comparisons.  
 
2.14. ATP Analysis 
Intracellular ATP concentrations were assessed by means of the ENLITEN® ATP 
bioluminescent assay kit (Promega, Madison WI). In this assay, recombinant luciferase is 
utilized to catalyze the reaction:  
ATP + D-Luciferin + O2 → Oxyluciferin + AMP + PPi + Light (560 nm) 
In this ATP dependent reaction the ATP concentration present is directly proportional to 
the light intensity emitted. As such, the measurement of emitted light using a luminometer 
allows for the direct quantification of intracellular ATP concentrations.  
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2.14.1. Sample Preparation 
MEF and E0771 cells were seeded into T25 flasks at a density of 4 x 105 and 8 x 105 cells 
respectively. Subsequent to treatments, media was discarded and the cell monolayer 
washed with sterile PBS. Cells were detached from flasks using 2 ml 0.25% Trypsin EDTA 
(Life Technologies). Detached cells were collected and centrifuged at 1500 RPM for 3 min 
at 4 ⁰C. The supernatant was discarded and cell pellets washed using sterile PBS. 
Following a second centrifugation step, pellets were re-suspended in 50 μl ice cold lysis 
buffer comprising of 100 mM Tris-HCl, and 4 mM EDTA calibrated to pH 7.75 (Essmann 
et al., 2003). Immediately following re-suspension 150 μl of boiling lysis buffer was added 
to each sample and incubated at 99 °C for 2 min. Samples were then centrifuged at 8,000 
x g, for 1 min at 4 ⁰C. The resulting supernatant was then collected for ATP analysis and 
protein determination.  
 
2.14.2. Assay Procedure 
A working solution of ATP standards was prepared using the stock solution provided in 
the kit, and triplicates of serially diluted ATP standards (0 – 100 nmol/well) was pipetted 
into wells of a white 96-well luminometer plate (Glomax Promega, Madison WI). 50 μl of 
prepared samples was then added to wells in triplicate. For this assay an ATP standard 
served as a positive control and ATP-free water as a negative control, which was added 
to triplicate wells (50 μl). The provided luciferase rL/L reagent was reconstituted as per 
manufacturer’s instructions and 50 μl added to samples followed by immediate analysis 
using a Glomax-96 luminometer (Promega, Madison WI). 
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2.15. Migration Assay 
In order to assess cell migration capabilities, cell migration (wound healing) assays were 
performed. This assay involves the introduction of a linear wound (with the use of a sterile 
200 µl tip) to a confluent monolayer and then relies on the ability of these cells to move 
into and fill the gap introduced.  
 
2.15.1. Mitomycin C Preparation  
The cytostatic agent Mitomycin C was used to inhibit cellular proliferation, thus excluding 
any effects that may be as a result of proliferation. Mitomycin C is an antibiotic produced 
from Steptomyces caespitosus which acts as a powerful inhibitor of DNA synthesis (Ueda 
et al., 1984). A 0.4 mg/ml stock solution of Mitomycin C (Sigma Aldrich, #) was prepared 
and aliquots were shielded from light and stored at 4 ⁰C for no longer than one week as a 
toxic precipitate may form if stored longer than prescribed. A dose response assay was 
performed in order to determine the optimal concentration of Mitomycin C needed to 
effectively inhibit cellular proliferation.  Briefly, E0771 cells were seeded onto sterile glass 
coverslips in 6-well plates at a density of 1 x 105 cells/well and plates were gently swirled 
and incubated at an atmosphere of 37 ºC and 5% CO2 humidity for 24 hours. Triplicate 
wells were then treated with a range of Mitomycin C concentrations (1 µg/ml, 2 µg/ml, 5 
µg/ml and 10 µg/ml) for 24 hours. Following treatment, coverslips were removed from 
wells and gently washed twice with warm PBS.  Cells were then fixed with ice-cold 100% 
methanol and left to incubate on ice for 5 min. Methanol fixative was then removed and 
cells were washed three times with PBS. 200 µl of Hoechst 33342 (Sigma Aldrich, #) at a 
final concentration of 10 µg/ml was added to each coverslip and allowed to incubate at 
room temperature for 10 min. Following staining, coverslips were rinsed and mounted onto 
glass slides with DAKO fluorescent mounting medium (DAKO Inc., CA, USA). Slides were 
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then allowed to air dry for 2 hours at RT and kept wrapped in foil at -20 °C. Imaging was 
performed with the use of a Nikon Eclipse E400 microscope equipped with a DS-Fi2 colour 
digital camera (Nikon, Japan) with a DAPI barrier filter (excitation 340 - 380 nm, emission 
435 - 483 nm). A total of nine random fields of view images per slide were acquired, and 
nuclear counts compared to control groups (0 and 24 hours) were performed as an 
indication of cellular proliferation.  
 
2.15.2. Assay Procedure 
E0771 cells were cultured in 6-well plates at a density of 6 x 105 cells/well. Cells were 
allowed to adhere for 24 hours, after which, three linear wounds were made in each well 
using a sterile 200 µl pipette tip. Cell monolayers were then washed with warm PBS to 
remove cell debris and fresh growth medium was added to each well. Control (0 hr) 
images were acquired for each well using an Olympus® Cell^R system and Olympus® 
IX81 inverted fluorescence microscope (Olympus®, GMBH Japan), which is equipped 
with a temperature-controlled incubator system that was set to 37 °C and a motorized 
stage control that allows exact coordinate positions to be saved and accessed at a later 
point in time. For each well, a total of three positions across the three wounds were saved 
and used in all subsequent time-points (6, 12, 18 and 24 hrs). Subsequent to the 
acquisition of the first images, wells were treated with appropriate conditioned media 
supplemented with Mitomycin C and doxorubicin. As both Mitomycin C and doxorubicin 
are light sensitive, treatment proceeded after the acquisition of initial images in order to 
avoid excessive light exposure. Image analysis was performed using ImageJ analysis 
software where wound area was calculated using the software by demarcating the 
migration front on scaled images. Percentage wound closure and rate of wound closure 
(% per hour) was then calculated by using the following equations:  
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 % 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 𝑎𝑡 𝑥 ℎ𝑟 =  
𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑎𝑡 (0 ℎ𝑟) − 𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 (𝑥 ℎ𝑟)
𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 (0 ℎ𝑟)
 × 100 
 
𝑟𝑎𝑡𝑒 𝑜𝑓 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 𝑎𝑡 𝑥 ℎ𝑟 (%. ℎ𝑟−1) =  
% 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 (𝑥 ℎ𝑟)
𝑥
 × 100 
 
2.16. Atg5 Knockdown 
Cells were transfected by means of electroporation using the Neon® transfection system 
(Invitrogen, Carlsbad, CA, USA). Prior to seeding, MEF cells were washed with warm PBS 
and centrifuged at 400 x g for 5 min at room temperature. Supernatant was discarded and 
the pellet gently re-suspended in supplied re-suspension buffer R to a final density of 1 x 
107 cells/ml and gently pipetted to obtain a single cell suspension. A Neon® tube containing 
3 ml Electrolytic buffer was placed into the Neon® pipette station. 500 ng of an 
endoribonuclease-prepared siRNA (esiRNA) targeted against Atg5 (Sigma-Aldrich, 
Mission® esiRNA mouse Atg5 (esiRNA1) # EMU038061) was added to a cell suspension 
at a density of 5 x 106 cells/ml and cells were pulsed once at a voltage of 1350 and pulse 
width of 30 ms. Transfected cells were then seeded either into 6-well plates (Whitehead 
Scientific, #S00023) or into T25 flasks at a seeding density of 1 x 105 cells/well and 4 x 
105 cells/flask respectively. Plates or flasks were gently swirled and incubated at an 
atmosphere of 37 ºC and 5% CO2 humidity for 24 hours. esiRNA against Mouse Kif11 
(Sigma-Aldrich, Mission esiRNA mouse Kiff11 #EMU017691) was used as a positive 
control, and esiRNA against enhanced green fluorescent protein (eGFP) (Sigma-Aldrich, 
Mission esiRNA eGFP #EHU019931) served as a negative control.  
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2.17. In vivo Tumour-bearing Mouse Model 
Ethical approval for the in vivo animal study was obtained from the animal research ethics 
committee (REC) of Stellenbosch University (no. SU-ACUD15-00027). All protocols in this 
study were carried out according to the guidelines for the care and use of laboratory 
animals implemented at Stellenbosch University. Eight week-old female C57BL/6 mice 
were obtained from the University of Stellenbosch Tygerberg breeding facility and housed 
at the Stellenbosch University animal unit under reverse dark/light cycle and temperature 
controlled conditions. For the duration of the study all animals were maintained on a 
standard chow diet and tap water ad lib. A total of 40 mice were utilized for this study. 
Prior to induction of cancer, female mice were randomized (into two groups, n=20 per 
group) and placed into one of two groups. One group was inoculated with tumours (using 
the syngeneic E0771 murine breast cancer cell line) and upon tumour appearance, each 
group was further divided into two sub-groups (n=10) where only one sub-group received 
doxorubicin treatment. Animals were routinely monitored and weighed twice a week prior 
to the initiation of the experiment, after which tumour volume and weight was recorded 
every second day for the duration of the study. 
 
2.17.1. Tumour Inoculation  
Mice were inoculated subcutaneously on the right pad of the fourth mammary gland with 
200 µl of 2.5 x 105 E0771 cells suspended in Hanks Balanced Salt Solution (HBSS) 
(Sigma Chemical Co., St Louis, MO, USA), using a 23-gauge needle. The use of the 
murine E0771 breast cancer cell line in this tumour-bearing mouse model, previously 
established in our lab, is a more physiologically relevant model as it makes use of normal 
(non-immunocompromised) C57BL/6 mice with a syngeneic cancer cell line for tumour 
inoculation. Tumour dimensions were obtained every second day using digital callipers 
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where length (longest dimension) and width (dimension perpendicular to length) was 
recorded. Tumour volume was then calculated using the following equation: 
Tumour volume (𝑚𝑚3) =
𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ2
2
 
 
2.17.2. Doxorubicin Treatment 
Doxorubicin (LKT Laboratories, #D5794) stock solutions for the in vivo animal study were 
prepared in Hanks Balanced Salt Solution (HBSS) and made up to a concentration of 2 
mg/ml. Once tumours became palpable doxorubicin treatment was initiated and was 
administered via intraperitoneal (i.p.) injection using a 25 gauge needle every third day. 
Animals were weighed prior to the preparation of the doxorubicin and further dilutions in 
HBSS were performed to obtain a final injection volume of 100 µl per mouse. Animals 
received three doses of 4 mg/kg doxorubicin (resulting in a cumulative dosage of 12 
mg/kg), whereas, control animals received an isovolumetric i.p. injection of HBSS.  
 
2.17.3. Animal Euthanasia and Tissue Harvesting 
The study was terminated when tumours reached a volume of 400 mm3. Additional 
humane endpoints were established in the event that animals lost more than 10% body 
weight or upon the occurrence of bleeding ulcers at the tumour site. Animals were 
anaesthetised using 3% isofluorane (Isofor, Safeline Pharmaceuticals) and euthanasia 
was achieved by means of exsanguination through cardiac puncture. Tumours were then 
carefully excised and processed appropriately. Tumours from some of the animals (6 
animals per group) were divided into two parts. One part was snap frozen in liquid nitrogen 
and subsequently stored at -80 °C for further analysis by means of Western blot 
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experiments. The second part, was stored in formalin at room temperature for additional 
immunohistochemistry analysis. Tumours from the remaining animals (4 animals per 
group) were placed in a sterile petri dish for 3D culture of isolated epithelial organoids.  
 
2.18. 3D Culture of Isolated Tumour Epithelial Organoids 
Organoids are defined as being miniaturized and simplified organs which are produced in 
vitro through the dissociation of harvested tissue. When cultured in three dimension (3D) 
they depict a realistic micro-anatomy. Organoids are currently a widely accepted model in 
cancer research due to the fact that they better recapitulate the physiological structure 
and response of tumours in vivo. 
 
2.18.1. Isolation of Mammary Epithelial Organoids  
Under sterile conditions in a tissue culture hood, harvested tumour and mammary fat pad 
samples used for primary 3D cell culture models were minced using a scalpel (25 – 50 
times per sample) until the tissue relaxed. Minced samples were then transferred into a 
sterile 50 ml tube containing 10 ml filtered collagenase solution (DMEM/F12 media 
containing 2 mg/ml collagenase (Sigma-Aldrich, collagenase from Clostridium histolyticum 
#C2139), 2 mg/ml trypsin (Life Technologies, #27250018), 5% FBS (Scientific Group), 5 
µg/ml Insulin (Sigma-Aldrich, #I9278) and 50 µg/ml gentamicin (Life Technologies, 
#15750037)). The suspension was shaken at 110 – 150 RPM for 30 - 40 min in an orbital 
shaker set to 37ºC until the tissue was broken up into smaller pieces and relatively 
dispersed (care was taken to ensure that the samples were not over-digested). Samples 
were then centrifuged at 1500 RPM for 10 min at room temperature. The top opaque fatty 
layer was carefully removed using a sterile pipette coated with a BSA solution and placed 
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into a sterile BSA coated 15 ml tube. At this stage samples have been separated into three 
distinct layers; a top fatty layer, middle aqueous layer and a red epithelial pellet layer at 
the bottom. As the top fatty layer could still contain additional epithelial organoids which 
can be harvested, this layer was removed and placed into a clean BSA coated 15ml 
Falcon tube. The fatty layer was then dispersed by pipetting the solution up and down 
vigorously prior to being centrifuged again. Following the second centrifugation step, the 
pellets from both samples were combined and re-suspended in 10 ml of DMEM/F12. 
Samples were then centrifuged again at the same settings and the resultant pellet was re-
suspended in 4 ml DMEM/F12 media. DNase I (2 U/µl) was then added to each sample 
and gently inverted by hand at room temperature for 2 – 5 min. The addition of DNase I 
to the solution allows for clusters of cells to be broken up, in addition it also allows for the 
detachment of organoids from single cells. Samples were then centrifuged again at 1500 
RPM for 10 min at room temperature. Finally, differential centrifugation was performed in 
order to obtain a pellet containing epithelial cell organoids without single cells. 
 
2.18.2. Organoid Density Determination 
The density of the organoids obtained from each tumour was determined by re-
suspending the final pellet in 10 ml of fresh DMEM/F12 media. Once a homogenous 
solution was obtained, 50 µl was transferred to a sterile 30 mm Petri dish and the number 
of organoids visible counted under a microscope. The total number of organoids collected 
from each tumour sample was calculated using the following equation:  
 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑟𝑔𝑎𝑛𝑜𝑖𝑑𝑠 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑟𝑔𝑎𝑛𝑜𝑖𝑑𝑠 
𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (50 µ𝑙)
 × 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒 (9950 µ𝑙) 
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Samples were then adjusted to 1000 organoids / ml in order to simplify the allocation of 
organoids to ECM gels. The required number of organoids for each experiment was then 
calculated and the appropriate volume of each sample was aliquoted into sterile BSA-
coated 1.5 ml microcentrifuge tubes. Tubes were then centrifuged at 1500 RPM for 5 min 
at room temperature and the appropriate volume of ECM solution was added to each tube 
in order to obtain a final density of 2 organoids / µl.   
 
2.18.3. Plating of Organoids in Matrigel  
Prior to plating, growth factor reduced Matrigel (BD Biosciences, #354230) was allowed 
to thaw at 4 ºC for 3 – 4 hours. In the meantime, a 24-well black glass bottomed plate was 
pre-incubated at 37 ºC for 5 min before being placed directly onto a heating block set to 
37 ºC inside a tissue culture hood. The appropriate volume of liquid Matrigel needed was 
then placed into the sterile microcentrifuge tube containing the organoid pellet. The 
organoid pellet was re-suspended by gently pipetting the Matrigel solution up and down 
on ice. The appropriate volume of Matrigel / organoid solution was then plated into each 
well. The plate was then placed on the heating block set to 37 ºC for several minutes in 
order to allow for further gelation before being incubated at 37 ºC, 5% CO2 for 30 – 60 
minutes. Pre-warmed organoid medium (DMEM/F12 containing 1% PenStrep and 1% 
insulin-transferrin-selenium X (ITS) (Life Technologies, #51500) and 2.5 nM EGF (Sigma 
Aldrich, #F0291) was added to each well. In order to prevent dehydration of samples, 
sterile PBS was added to empty wells. Plates were then incubated for 24 hours before 
treatment commenced.  
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2.18.4. Branching Morphogenesis and Invasion Assays  
Subsequent to plating, isolated organoids were allowed to equilibrate at 37 ºC, 5% CO2 for 
24 hours. Control (0 hr) images were acquired using an Olympus® Cell^R system and 
Olympus® IX81 inverted fluorescence microscope (Olympus®, GMBH Japan), which is 
equipped with a temperature-controlled incubator system that was set to 37 °C and a 
motorized stage control that allows exact coordinate positions to be saved and accessed 
at a later point in time. For each animal two separate wells were imaged for each treatment 
group and a total of 12 organoids across each group were imaged and used in all 
subsequent time-points (0, 12, 24, 36, and 48 hours). Subsequent to the acquisition of the 
first images, organoids were treated with freshly collected MEF conditioned media. Across 
the imaging time points, organoids were refreshed with new media every 24 hours. Image 
analysis was performed using ImageJ analysis software where branching morphogenesis 
and the rate of invasion was calculated using the software by demarcating the leader cell 
migration front on scaled images and then calculating the distance travelled over time as 
a ratio of organoid surface area.  
 
2.19. Western Blotting Analysis of Whole Tumour Samples 
In order to carry out western blot analysis snap frozen tumour and mammary fat pad 
samples were divided into two smaller sections. One section was then processed for 
Western blot analysis and the other section was frozen and stored at -80 °C and utilized.  
 
2.19.1. Protein Extraction and Quantification 
Samples were immediately placed on ice and allowed to thaw at 4 °C. 300 µl of ice cold 
modified radioprecipitation (RIPA) buffer comprising of 2.5 mM Tris-HCL, 1 mM EDTA, 1 
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mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine, 50 
mM NaF, 4 mg/ml SBTI, 10 mg/ml leupeptin, 0.1% SDS 0.5%, Na deoxycholate and 1% 
NP40, calibrated to pH 7.4, was added to each sample and allowed to stand for 5 min on 
ice in order to extract total cell protein. Samples were then homogenized on ice, with the 
blades of the homogeniser being cleaned using EtOH between each sample in order to 
prevent cross contamination of proteins. Upon the formation of a homogenous liquid which 
contained no lumps of whole tissue, samples were centrifuged at 14 000 RPM for 1 hour 
at 4 °C. At this stage, samples had been separated into four distinct layers, two top fat 
layers, a middle supernatant layer and a bottom pellet.  In order to prevent the oily fat layer 
from mixing into the supernatant and causing smudges to form during SDS-PAGE, sterile 
23-guage needles were used to remove the supernatant from the sides of Eppendorf 
tubes. The supernatant was then placed into clean Eppendorf tubes and samples were 
centrifuged again at 14 000 RPM for 30 minutes at 4 °C. The process of removing the 
supernatant was repeated and samples were stored at -80 ºC ready for protein 
quantification. A Direct Detect® infrared spectrometer (DDHW00010-WW, Merck) was 
used to determine the protein content of each sample and aliquots were prepared 
containing 20 µg protein content diluted with sample buffer. SDS-PAGE was performed 
for each sample as previously described (Section 2.7.3). 
 
2.20. Tissue Processing and Sectioning 
Formalin fixed tissue samples were placed into individually labelled cassettes and 
underwent (i) dehydration, (ii) “clearing” and (iii) impregnation with paraffin wax using an 
automated tissue processor (Leica Biosystems, #TP1020) set to follow a 20 hour pre-
programmed time-schedule. Dehydration of samples was achieved by soaking samples 
in an increasing concentration series of ethanol solutions, namely; 2 rounds of 70% 
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ethanol for 90 minutes each, 90% ethanol for 90 minutes, 2 rounds of 95% ethanol for 90 
minutes each, 2 rounds of 100% ethanol for 90 minutes each and then a final 100% 
ethanol solution for 120 minutes. Clearing of tissues was then achieved through a 90 
minute xylene incubation step followed by a second xylene incubation for 120 minutes. 
Finally, wax impregnation was achieved with two 120 minute paraffin wax incubation 
steps. Following the automated tissue processing protocol, samples were placed into 
clean individually labelled cassettes, where samples were orientated in such a way as to 
achieve a longitudinal section through the sample. Cassettes were then filled with hot 
paraffin wax and allowed to cool on a cold block, before being sectioned into 5 µm sections 
using a microtome (Leica Biosystems, #RM2235). Three sections of each sample was 
placed onto a slide and slides were placed to on a pre-warmed heating plate to dry. Prior 
to any staining procedures samples were deparaffinised and rehydrated using an 
automated stainer (Leica Biosystems, # ST4020), where samples were dipped in xylene 
twice, 100% ethanol, 90% ethanol, 70% ethanol and 50% ethanol, samples remained in 
each solution for a period of 2 minutes before being placed into distilled water (dH20), 
ready for subsequent staining steps.  
 
2.20.1. Histological Staining  
Following sectioning, deparaffinization and rehydration, tissue samples were stained for 
ultrastructure changes (haemotoxylin and eosin (H&E) staining) as well as for fibrosis 
(picrosirius red staining). H&E staining of tissue samples was achieved using an 
automated tissue stainer (Leica Biosystems, # ST4020), where slides where dipped into 
a haemotoxylin solution, followed by dH2O, scott’s tap water, dH2O, eosin and dH2O. 
Samples remained in each solution for a period of 2 minutes before coverslips were 
mounted using DPX mounting media. Picrosirius red staining for fibrosis was achieved by 
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staining sections for 1 hour at room temperature using a 0.1% Sirius red solution dissolved 
in aqueous picric acid. Samples were then washed twice using 0.5% hydrogen chloride 
(acidified) water, dehydrated and then mounted with DPX mounting media.   
 
2.20.2. Immunofluorescent Staining of Tumour Samples 
Following sectioning onto poly-L-lysine coated glass slides, tumour samples were 
deparaffinised and rehydrated. Tumour sections were then fixed for 8 minutes at room 
temperature with a 0.25% Triton-x-100 solution made up in DPBS. The fixative mixture 
was then removed and sections were placed back into Coplin jars containing dH20. During 
the process of formalin fixation, methylene bridges form causing the cross-linking of 
proteins, and thus allowing for the preservation of cellular and subcellular structure. 
Protein cross-linking results in the antigenicity of some cell structures to be reduced, 
causing the obstruction of antibody binding. In order to overcome this cross-linking, heat-
induced antigen retrieval was performed by boiling a Coplin jar containing a 10 mM sodium 
citrate, 0.05% Tween 20 (pH 6.0) solution in a 95 °C water bath and then placing samples 
into the solution for 20 minutes. Coplin jars containing samples were removed from the 
water bath and allowed to cool to room temperature before samples were removed and 
blocked using 5% donkey serum for 1 hour. Samples were then incubated overnight at 4 
ºC in primary antibodies against alpha smooth muscle actin (α-SMA) (Abcam, #ab7817) 
and vimentin (Cell Signalling Technologies, #D21H3) diluted in PBS containing 3% BSA 
(1:250). Samples were then rinsed three times with PBS and allowed to incubate with the 
appropriate secondary antibody for 1 hour at room temperature. In this case Alexa Fluor 
488 conjugated donkey anti-mouse secondary antibody (Life Technologies, #A-21206) 
and Alexa Fluor 564 conjugated donkey anti-rabbit secondary antibody (Life 
Technologies, #A-21244) were used. Tumour samples were rinsed and mounted with 
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DAKO fluorescent mounting medium (DAKO Inc., CA, USA). All samples were kept 
wrapped in foil at -20 °C until analysis on a Zeiss confocal microscope. In each condition, 
three images across two different sections were obtained. 
 
2.21. Statistical Analysis  
All statistical analyses was carried out using GraphPad Prism 5. All data was assessed 
using mean ± standard error of the mean (SEM). All In vitro experiments made use of both 
technical (three separate wells or flasks) and biological (three separate experiments) 
replicates One-way or two-way analysis of variance (ANOVA) with Bonferroni post hoc 
test as well as t-tests were conducted where appropriate. A p-value ≤0.05 was considered 
statistically significant. 
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Chapter 3: Results 
3.1. Induction of Oxidative Stress without Cell Death in E0771 
Breast Cancer Cells 
3.1.1. Time-Dependent Changes in Viability Following Glucose 
Deprivation  
In order to establish a time course of glucose deprivation that elicits the least cytotoxic 
effect in E0771 cancer cells, while still producing a significant increase in oxidative stress, 
E0771 murine breast cancer cells were treated for various time points with glucose free 
DMEM. MTT cell viability assays were carried out to determine the relative percentage 
cell death at different treatment time points.  
Figure 3.1: The effects of short (A) and long (B) term glucose deprivation on the viability of 
E0771 murine breast cancer cells. E0771 cells were incubated in 25 mM glucose containing DMEM 
(Control), or glucose free (0 mM) DMEM for 4, 8 and 12 hours or for 24, 48 and 72 hours. Cell viability 
was assessed using the MTT assay. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). *** = p<0.001 vs control. 
*** *** *** 
*** *** 
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When compared to control, a significant decrease in MTT reductive capacity was observed 
in E0771 murine breast cancer cells following 4, 8, 24, 48 and 72 hours of glucose 
deprivation (4 hours: 80.42% ± 1.687% vs 100% ± 1.011%, p<0.001; 8 hours: 80.75% ± 
2.197% vs 100% ± 1.011%, p<0.05; 24 hours: 45.90% ± 3.321% vs 100% ± 2.475%, 
p<0.0001; 48 hours: 42.76% ± 3.476% vs 100% ± 2.475%, p<0.0001 and 72 hours: 
47.069% ± 4.149% vs 100% ± 2.475%, p<0.0001).  However when subjected to 12 hours 
of glucose deprivation no significant change in reductive capacity was observed (90.67% 
± 3.959% vs 100% ± 1.011%, p=0.1445) when compared to control.  
In order to determine if the increased mitochondrial reductive capacity observed after 12 
hours of glucose deprivation is a cell line specific compensation, we carried out time 
responses for glucose deprivation in four other human triple negative cancer cell lines. A 
significant reduction in MTT reductive capacity was observed in the MDA-MB-23 human 
breast cancer cell line across all time points following glucose deprivation (4 hours: 
66.44% ± 2.410% vs 100% ± 3.600%, p<0.0001; 8 hours: 73.32% ± 1.248% vs 100% ± 
3.600%, p<0.0001; 12 hours: 81.52% ± 3.511% vs 100% ± 3.600%, p<0.0001; 24 hours: 
71.80% ± 2.033% vs 100% ± 3.408%, p<0.0001; 48 hours: 63.22% ± 1.566% vs 100% ± 
3.408%, p<0.0001 and 72 hours: 61.30% ± 2.111% vs 100% ± 2.475%, p<0.0001).  
However, an increase in MTT reductive capacity was seen following 12 hours of glucose 
deprivation in MDA-MB-231 cells when compared to the 8 hour time point (81.52% ± 
3.511% vs 73.90% ± 1.248%, p<0.0001 
In comparison to control, a significant reduction in MTT reductive capacity was observed 
in HCC-70 human breast cancer cells following 4, 24, 48 and 72 hours of glucose 
deprivation (4 hours: 86.81% ± 2.269% vs 100% ± 2.269%, p<0.0001; 24 hours: 73.71% 
± 4.052% vs 100% ± 1.465%, p<0.0001; 48 hours: 77.37% ± 5.202% vs 100% ± 3.408%, 
p<0.0001 and 72 hours: 80.24% ± 6.110% vs 100% ± 1.465%, p<0.0029).  
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Assessment of mitochondrial reductive capacity in BT-549 human breast cancer cells 
showed a significant reduction in MTT reduction following 8, 24, 48 and 72 hours of 
glucose deprivation when compared to control (79.80% ± 2.104% vs 100% ± 3.612%, 
p<0.0001, 24 hours: 73.55% ± 4.756% vs 100% ± 1.401%, p<0.0001; 48 hours: 77.03% 
± 5.438% vs 100% ± 1.401%, p=0.0002 and 72 hours: 77.10% ± 5.099% vs 100% ± 
1.401%, p<0.0001). However, when BT-549 cells were subjected to both 4 and 12 hours 
of glucose deprivation no significant reduction in MTT reductive capacity was observed. 
*** *** *** *** *** 
*** 
*** ** * ** 
Figure 3.2: The effects of short (A) and long (B) term glucose deprivation on the viability of 
human MDA-MB-231 and HCC-70 breast carcinoma cells. MDA-MB-231 and HCC-70 cells were 
incubated in 25 mM glucose containing DMEM (Control), or glucose free (0 mM) DMEM for 4, 8 and 12 
hours or for 24, 48 and 72 hours. Cell viability was assessed using the MTT assay. Statistical analysis: 
One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). 
* = p<0.05 vs control, ** = p<0.001 vs control and *** = p<0.001 vs control. 
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Finally, the subjection of the non-adherent DU4475 human breast cancer cells to glucose 
deprivation resulted in a significant reduction in mitochondrial reductive capacity following 
8, 24, 48 and 72 hours (8 hours: 90.18% ± 1.867% vs 100% ± 1.552%, p=0.0005, 24 
hours: 83.61% ± 2.038% vs 100% ± 2.734%, p<0.0001; 48 hours: 74.38% ± 2.773% vs 
100% ± 2.734%, p<0.0001 and 72 hours: 75.58% ± 3.302% vs 100% ± 2.734%, p<0.0001) 
when compared to control. In comparison to the 8 hour glucose deprivation time point in 
DU4475 cells a significant increase in MTT reduction was observed following 12 hours of 
glucose deprivation (96.43% ± 1.920% vs 90.18% ± 1.730%, p=0.0264). 
** *** ** ** 
*** *** *** 
** 
Figure 3.3: The effects of short (A) and long (B) term glucose deprivation on the viability of 
human BT-549 and DU4475 breast carcinoma cells. BT-549 and DU4475 cells were incubated in 25 
mM glucose containing DMEM (Control), or glucose free (0 mM) DMEM for 4, 8 and 12 hours or for 24, 
48 and 72 hours. Cell viability was assessed using the MTT assay. Statistical analysis: One way ANOVA 
with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). ** = p<0.001 vs 
control and *** = p<0.001 vs control. 
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Based on initial time responses and cell death analyses, long term (24 – 72 hours) glucose 
deprivation in the E0771 murine breast cancer cells lead to a significant reduction in MTT 
reductive capacity with a significant increase in the protein expression of key cell death 
markers, therefore these time points were disregarded for all subsequent experiments. 
 
3.1.2. Effect of Glucose Deprivation on Cell Death Induction 
3.1.2.1. PARP-cleavage 
Poly (ADP-ribose) Polymerase (PARP) is a 116 kDa nuclear protein that plays a critical 
role in DNA damage repair mechanisms (Grasso et al., 2012). PARP is synthesized upon 
the fragmentation of DNA in the presence of nuclear poly-ADP ribosylated proteins. Its 
activation then occurs when PARP binds to broken DNA strands. Through the poly (ADP-
ribosylation of various nuclear proteins, PARP utilizes nicotinamide adenine dinucleotide 
(NAD+) as a substrate. Therefore, it was originally thought that PARP contributes to 
apoptotic cell death via cellular depletion of NAD+ and ATP. However, PARP has been 
shown to be cleaved by caspase-3 during the initial stages of apoptosis into 24- and 89 
kDa fragments respectively containing the enzymatic DNA –binding domains and active 
sites (Boulares et al, 1999). Once cleaved the smaller 24 kDa fragment binds to 
fragmented DNA ends, inhibiting the access of DNA repair enzymes, and thus ensuring 
the cells’ commitment to apoptosis (Grasso et al., 2012).  
Therefore, PARP expression was assessed as a marker of nuclear damage and apoptosis 
induction in the E0771 cancer cells in response to glucose deprivation. Although Western 
blots show a trend towards an increase in PARP expression following 8 hours of glucose 
deprivation no statistically significance was seen across all treatment groups when 
compared to control. 
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3.1.2.2. Ratio of Cleaved Caspase-3 to Caspase-3 
Caspase-3 is an executioner caspase which leads to the induction of apoptotic cell death 
upon its cleavage by upstream initiator caspases. Western blot analysis for both caspase-
3 and cleaved caspase-3 was used to assess apoptotic activity in E0771 cells following 
glucose deprivation. A significant increase in cleaved caspase-3 was seen following 8 
hours of glucose deprivation (144.5 ± 18.19% vs 100% ± 6.186%, p=0.0432) when 
compared to control. However, when total caspase-3 protein expression was compared 
to control no significant differences were observed across all three treatment groups. As 
the cleavage of caspase-3 is required for the initiation of apoptosis the ratio of cleaved 
caspase-3 to total caspase-3 protein expression, could provide a better understanding of 
the initiation of cell death in E0771 cells following glucose deprivation. 
Figure 3.4: Western Blot analysis of PARP in E0771 mouse breast cancer cells following glucose 
deprivation. E0771 cells were subjected to (1) Control, (2) 4, (3) 8 and (4) 12 hours of glucose 
deprivation. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are 
presented as mean ± SEM (n=6). 
Total 
Protein  
PARP 
116 kDa 
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When compared to control, a significant increase in the ratio of cleaved caspase-3 to 
caspase-3 was seen in both the 4 hour and 8 hour glucose deprived treatment groups (4 
hours: 161.0 ± 17.58% vs 100% ± 10.58%, p=0.0138 and 8 hours: 150.2 ± 18.11% vs 
100% ± 10.58%, p=0.0404). 
 
3.1.3. Effects of Glucose Deprivation on Oxidative Stress 
In order to determine the effects of glucose deprivation on oxidative stress, E0771 cells 
were stained with either DCF (cytosolic H2O2) or MitoSOX (mitochondrial O2-) and the 
mean fluorescent intensity was measured by means of flow cytometry. No significant 
increases in the ability of glucose deprivation to generate cytoplasmic hydrogen peroxide 
Figure 3.5: Western Blot analysis of the ratio of cleaved caspase-3 to total caspase-3 in E0771 
mouse breast cancer cells following glucose deprivation. E0771 cells were subjected to (1) Control, 
(2) 4, (3) 8 and (4) 12 hours of glucose deprivation. Statistical analysis: One way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=6). * = p<0.05 vs control. 
c-Caspase 3 
17 kDa 
Total 
Protein  
Caspase 3 
35kDa 
* * 
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were observed across all three time points. However, a significant increase in 
mitochondrial superoxide was observed following 12 hours of glucose deprivation alone 
in comparison to control (146.1 ± 8.938% vs 100 ± 1.586%, p=0.0001). 
 
Based on initial time responses for glucose deprivation, a treatment time of 12 hours did 
not lead to a significant reduction in cell viability, however, an increase in oxidative stress 
in the E0771 murine breast cancer cells was observed. Therefore this time point was 
chosen for all subsequent experiments. 
 
 
 
 
Figure 3.6: The effects of short term glucose deprivation on cytosolic H2O2 (A) and mitochondrial 
O2- (B) production in E0771 murine breast cancer cells. E0771 cells were incubated in 25 mM 
glucose containing DMEM (Control), or glucose free (0 mM) DMEM for 4, 8 and 12 hours. Oxidative 
stress was assessed by means of flow cytometry. Statistical analysis: One way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=3). *** = p<0.001 vs control. 
*** 
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3.2: Proteomics Analysis of E0771  
Conditioned Media 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
91 
 
3.2. Proteomic Analysis of E0771 Conditioned Media 
In order to determine the protein composition present in conditioned media generated from 
E0771 murine breast cancer cells following glucose deprivation proteomic analysis was 
performed, wherein protein abundance of regulated proteins adhering to the 
predetermined selection criteria (see section 2.4.4), were normalized to control (for list of 
regulated proteins refer to section 7.1.1).  Briefly, a total of 62 protein elements were found 
exclusively in the glucose deprived E0771 conditioned media, whereas a total of 41 protein 
elements were displayed exclusively in control conditioned media. A total of 3 protein 
elements were found to be present in both conditions.  
 
3.2.1. Biological Processes Downregulated in the Glucose Deprived Group 
GO terms obtained from the list of proteins found to be downregulated in conditioned 
media derived from E0771 breast cancer cells were submitted into REVIGO and proteins 
Figure 3.7: Broad overview of protein elements differentially regulated between control and 
glucose deprived conditioned media generated from E0771 breast cancer cells. E0771 cells were 
incubated in 25 mM glucose containing DMEM (E0771_C), or glucose free (0 mM) DMEM (E0771_GD) 
for 12 hours. Diagram generated by CPGR using Venny freeware. 
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were clustered according to biological processes. Although a number of GO terms were 
identified to be downregulated in response to glucose deprivation, REVIGO collapsed all 
of these terms into a single biological process. The size of “bubbles” (nodes) generated 
by REVIGO is indicative of the number of specific GO terms collapsed into it. Therefore 
larger nodes imply a lower specificity. Although all nodes displayed are significant (p<0.05 
translates to a –log[p-value] >1.3) the colour of the node is representative of the 
significance of terms collapsed into it. Based on the fact that REVIGO clustered our list of 
downregulated proteins into a single biological process with a low significance, these were 
not interrogated further using DAVID.   
 
 
 
 
 
 
 
 
3.2.2. Biological Processes Upregulated in the Glucose Deprived Group 
Again as mentioned above, GO terms obtained for proteins upregulated in response to 
glucose deprivation were submitted into REVIGO, and a scatterplot view of protein 
clusters for biological processes which are upregulated was generated. A large number of 
biological processes were found to be upregulated in the conditioned media of glucose 
deprived E0771 breast cancer cells, many of which were observed to be involved in cell 
migration and metabolism. In terms of cell migration, a significant upregulation in the Wnt 
signalling pathway, ephrin receptor signalling pathway, ARP2/3 complex-mediated actin 
nucleation as well cell-cell adhesion was observed. An upregulation of both canonical 
Figure 3.8: Scatterplot view of biological processes downregulated in E0771 cancer cells 
following 12 hours of glucose deprivation. Graph generated in REVIGO using GO terms.  
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glycolysis and gluconeogenesis was also observed. Of additional interest, we also 
observed a significant upregulation in the cellular response to reactive oxygen species as 
well as processes involved in protein polyubiquitination. 
 
Based on the interesting biological processes we observed to be upregulated in REVIGO, 
we further interrogated the protein list for similar clustering using Functional Annotation 
Clustering (FAC) in DAVID. Clustering of common processes in both REVIGO and DAVID 
can be interpreted as highly significant, as different clustering algorithms are used by the 
two software programs. Interrogation of functional clustering in DAVID also revealed a 
significant upregulation in cell-cell adhesion processes with a large number of proteins 
found to be clustered together.  
Figure 3.9: Scatterplot view of biological processes upregulated in E0771 cancer cells following 
12 hours of glucose deprivation. Graph generated in REVIGO using GO terms.  
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Proteins involved in cell-cell adhesion of most interest, within the context of this study, 
were found to be the upregulation of vinculin (VCL), AHNAK nucleoprotein (AHNAK), 
profilin 1 (PFN1) and heat shock proteins (HSP) 70 and 90. 
 
A significant clustering of proteins involved in glycolysis, gluconeogenesis and a variety of 
metabolic pathways were also observed in DAVID. Again proteins, of interest in the context of 
Figure 3.10: 2D viewer of functional annotation clustering of upregulated proteins involved in 
cell-cell adhesion in E0771 cancer cells following 12 hours of glucose deprivation. Graph 
generated in DAVID using UniProt accession numbers.  
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this study, involved in cellular metabolism were identified to be glucose-6-phosphate 
dehydrogenase (G6PD), lactate dehydrogenase A (LDHA), pyruvate kinase, muscle (PKM), 
enolase -1 (ENO1) and -3 (ENO3).   
 
Additionally, significant clustering of proteins involved in PI3K/Akt signalling was observed 
in glucose deprived E0771 conditioned media. Of particular interest for this study is the 
Figure 3.11: 2D viewer of functional annotation clustering of upregulated proteins involved in 
glycolytic, gluconeogenesis and metabolic pathways in E0771 cancer cells following 12 hours of 
glucose deprivation. Graph generated in DAVID using UniProt accession numbers. Proteins are 
displayed horizontally and their functional relationship is displayed vertically. 
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upregulation of the proteins, collagen type IV alpha 2 chain (COL4A2), laminin subunit 
gamma I (LAMC1), heat shock protein 90 (HSP90) and insulin like growth factor 1 (IGF1).  
Figure 3.12: 2D viewer of functional annotation clustering of upregulated proteins involved in 
PI3K/Akt signalling in E0771 cancer cells following 12 hours of glucose deprivation. Graph 
generated in DAVID using UniProt accession numbers.  
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Figure 3.13: 2D viewer of functional annotation clustering of upregulated proteins involved in Wnt 
signalling, protein catabolism and protein polyubiquitination in E0771 cancer cells following 12 hours of 
glucose deprivation. Graph generated in DAVID using UniProt accession numbers. Proteins are displayed 
horizontally and their functional relationship is displayed vertically. 
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Finally, the functional clustering of proteins involved in the Wnt signalling pathway, protein 
polyubiquitination and protein catabolism using DAVID revealed an upregulation in the 
proteasome subunits alpha (PSMA) 1, 2, 3, 5, 6 and 7, involved in Wnt signalling, protein 
catabolism and polyubiquitination. Additionally, an upregulation was seen in the proteasome 
subunits beta (PSMB) 1, 2, 3 and 4 and ubiquitin C (UBC), all of which are linked to both Wnt 
signalling and protein polyubiquitination.  
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3.3. Effects of E0771 Conditioned Media on Cancer-Associated 
Fibroblasts Metabolism 
3.3.1.  Verifying the “Activation” of Cancer-Associated Fibroblast  
Currently, there is not one unique marker that identifies a cancer-associated fibroblast, 
currently the concurrent expression of several protein markers are rather used to define 
CAFs within the tumour microenvironment (Giannoni et al., 2010, Erez et al., 2010). 
Therefore, in order to determine whether mouse embryonic fibroblasts were able to 
“activate” a cancer-associated fibroblast phenotype in response to treatment with glucose 
deprived E0771 conditioned media, MEF cells were cultured under standard cellular 
conditions and following treatment, confocal microscopy and Western blot analysis was 
performed to assess the relative expression of the protein markers;  α-smooth muscle 
actin (α-SMA), platelet derived growth factor receptor α (PDGFRα), vimentin and E-
cadherin. 
 
3.3.1.1. Confocal Microscopy  
To assess the “activation” of MEFs to a cancer-associated phenotype in response to 
treatment with glucose deprived E0771 conditioned media, MEF cells were cultured under 
standard cellular conditions until reaching confluency; following treatment, cells were 
immunostained with α-SMA:AlexaFluor 488, vimentin: AlexaFluor 595 and Hoechst 33342 
and visualized using confocal fluorescent microscopy. Visually a distinct increase in 
fluorescent intensity was observed in both the mesenchymal markers α-smooth muscle 
actin (α-SMA) and vimentin in MEF cells that were treated with either untreated E0771 
conditioned media or glucose deprived E0771 conditioned media.  
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Figure 3.14: Characterization of cancer-associated fibroblast “activation” of mouse embryonic 
fibroblasts (MEF) cells. MEF cells were cultured under standard control cellular conditions in 8-well chamber 
plates. MEF cells were then subjected to (1) Control, (2) Control conditioned media, (3) E0771 untreated 
conditioned media and (4) glucose deprived E0771 conditioned media for 24 hours. Cells were immunostained 
for α-SMA (Green), vimentin (Red) and Hoechst 33342 (Blue) and visualized using fluorescent confocal 
microscopy. Images acquired at 60x magnification. 
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3.3.1.2. Western blot Analysis of CAF Markers 
3.3.1.2.1. α-SMA and PDGFRα 
The mouse embryonic fibroblast (MEF) cells showed a significant increase in α-smooth 
muscle actin (α-SMA) protein levels following treatment with E0771-CM in comparison to 
control (166.8% ± 21.71% vs 100% ± 11.67%, p=0.0133) and Control-CM (166.8% ± 
21.71% vs 103.3% ± 13.07%, p=0.0214). Although α-SMA levels were increased following 
treatment with E0771-UTCM they were not significant, when compared to either control 
(131.0 ± 16.39% vs 100% ± 11.67%, p=0.1460) or control-CM (131.0 ± 16.39% vs 103.3% 
± 13.07%, p=0.2075). Furthermore, no statistically significant differences in PDGFRα 
across all treatment groups were observed when compared to control. 
α-SMA 
37 kDa 
Total 
Protein  
Total 
Protein  
PDGFRα 
190 kDa 
* 
# 
Figure 3.15: Western blot analysis of α-SMA and PDGFRα in mouse embryonic fibroblast (MEF) 
cells following E0771 conditioned media treatment. MEF cells were subjected to (1) Control, (2) 
Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) 
glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=6). * = p<0.05 
vs control, # = p<0.05 vs control-CM. 
Stellenbosch University  https://scholar.sun.ac.za
 103 
 
3.3.1.2.2. Vimentin and E-cadherin 
Examination of vimentin protein expression revealed a significant increase in protein 
levels with E0771-CM treatment when compared to control (253.5% ± 39.91% vs 100% ± 
16.85%, p<0.0001) and control-CM (253.5% ± 39.91% vs 122.6% ± 16.67%, p=0.0073). 
Additionally, an increase vimentin expression was seen with E0771-UTCM treatment 
(173.4% ± 20.92% vs 100% ± 16.85%, p=0.0172) when compared to control.  
 
We also observed a significant decrease in the protein expression of the epithelial marker, 
E-cadherin, in MEF cells following E0771-CM treatment when compared to control 
(29.13% ± 7.375% vs 100% ± 21.29%, p=0.0071) and control-CM (69.38% ± 11.76% vs 
83.62% ± 22.14%, p=0.0350). However, no statistical differences in E-cadherin 
Figure 3.16: Western blot analysis of vimentin and E-cadherin in mouse embryonic fibroblast 
(MEF) cells following E0771 conditioned media treatment. MEF cells were subjected to (1) Control, 
(2) Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and 
(4) glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=6). * = p<0.05 
vs control, *** = p<0.0001 vs control, # = p<0.05 vs control-CM, ## = p<0.01 vs control-CM. 
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expression were seen following E0771-UTCM treatment when compared to either the 
control (69.38% ± 11.76% vs 100% ± 21.29%, p=0.2286) or control-CM (69.38% ± 11.96% 
vs 83.62% ± 22.14%, p=0.5792) groups. 
 
3.3.2. Cell Viability 
Subsequent to the verification of CAF “activation”, MTT cell viability assays were carried 
out to assess the effects of E0771 conditioned media on mitochondrial reductive capacity. 
No significant changes in reductive capacity were observed following treatment with either 
control-CM or E0771-UTCM in comparison to control. However, a significant increase in 
MTT reductive capacity was seen following treatment with glucose deprived E0771-CM 
when compared to control (118.4 ± 2.899% vs 100% ± 2.976%, p<0.0001) as well as when 
compared to control-CM (118.4 ± 2.899% vs 97.36 ± 2.932%, p<0.0001).  
Figure 3.17: Determination of the effects of E0771 conditioned media on the viability of mouse 
embryonic fibroblast (MEF) cells. MEF cells were subjected to (1) Control, (2) Control conditioned 
media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived 
E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). *** = p<0.0001 vs 
control and ### = p<0.0001 vs control-CM. 
*** 
### 
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3.3.3. Oxidative Stress Analysis 
Oxidative stress was assessed based on the understanding that the secretion of hydrogen 
peroxide (H2O2) by epithelial cancer cells in response to either hypoxia and nutrient 
deprivation acts as the driving force for the induction of oxidative stress and the 
subsequent activation of autophagy within surrounding CAFs (Capparelli et al., 2011).  
 
Oxidative stress was assessed following treatment with E0771 conditioned media by 
staining MEF cells with either DCF (cytosolic H2O2) or MitoSOX (mitochondrial O2-) and 
measuring mean fluorescent intensity using flow cytometry. Significant increases in both 
DCF (148.1% ± 5.719% vs 100% ± 9.960%, p=0.0138) and MitoSOX (201.4% ± 13.58% 
vs 100% ± 10.88%, p=0.0135) mean fluorescent intensity were observed following 
treatment with glucose deprived E0771-CM. However, no significant differences were 
observed across all treatment groups when compared to control-CM. 
 
Figure 3.18: Determination of the effects of E0771 conditioned media on oxidative stress in 
mouse embryonic fibroblast (MEF) cells. MEF cells were subjected to (1) Control, (2) Control 
conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) 
glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Oxidative stress was assessed 
by means of flow cytometry following staining with either DCF or MitoSOX. Statistical analysis: One 
way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). * = 
p<0.05 vs control and ** = p<0.001 vs control. 
** * 
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3.3.4. HIF-1α Protein Expression 
ROS induced stabilization of HIF-1α has been shown to occur under hypoxic as well as 
normoxic conditions. Based on the significant induction of both cytosolic and mitochondrial 
ROS we observed in MEF cells subjected to 24 hour treatment with E0771 conditioned 
media, we aimed to assess the relative protein expression levels of HIF-1α to determine 
if ROS-induced HIF-1α expression plays a role in the metabolic reprogramming of CAFs. 
A significant increase in HIF-1α expression was seen following E0771-CM treatment when 
compared to both control (175.8% ± 14.31% vs 100% ± 15.28%, p=0.0223) and control-
CM (175.8% ± 14.31% vs 71.02% ± 8.745%, p=0.0033). 
Figure 3.19: Western blot analysis of HIF-1α protein expression in MEF cells treated with E0771 
conditioned media. MEF cells were subjected to (1) Control, (2) Control conditioned media (Control-
CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived E0771 conditioned 
media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control and ## = p<0.01 vs 
control-CM 
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3.3.5. Autophagy Assessment 
In order to determine whether treatment of MEF cells with E0771 conditioned media 
results in the induction of the autophagic process, Western blot analysis was carried out 
using recognised markers of autophagy, namely; mTOR, p62 and LC3.  
 
3.3.5.1. p-mTOR (Ser2448) and mTOR 
In comparison to the control group, a significant decrease in mTOR phosphorylation 
(Ser2448) was observed following  E0771-UTCM (62.56% ± 7.071% vs 100% ± 7.699%, 
p=0.0231) and E0771-CM (45.02% ± 17.44% vs 100% ± 7.699%, p=0.0448) treatment.  
Figure 3.20: Western blot analysis of p-mTOR and total mTOR protein expression in MEF cells 
treated with E0771 conditioned media. MEF cells were subjected to (1) Control, (2) Control conditioned 
media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived 
E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control, and # = p<0.05 
vs control-CM. 
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Total mTOR assessment revealed a significant decrease in mTOR protein expression 
following E0771-UTCM (65.02% ± 9.242% vs 100% ± 4.529%, p=0.0273) and E0771-CM 
(48.88% ± 10.44% vs 100% ± 4.529%, p=0.0109) treatment in comparison to control. 
When compared to control-CM a significant decrease in total mTOR protein expression 
was only observed in the E0771-CM (48.88% ± 10.44% vs 100.4% ± 12.65%, p=0.0349) 
treated group. 
 
3.3.5.2. LC3 II and p62 
Assessment of LC3 II protein expression showed no significant differences across all 
treatment groups when compared to both control and control-CM.  
Figure 3.21: Western blot analysis of LC3 II and p62 protein expression in MEF cells treated with 
E0771 conditioned media. MEF cells were subjected to (1) Control, (2) Control conditioned media 
(Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived E0771 
conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post 
hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control, ** = P<0.01 vs 
control and ## = p<0.01 vs control-CM. 
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A significant increase in p62 protein expression was seen in MEF cells following treatment 
with both E0771-UTCM (168.7% ± 14.90% vs 100% ± 7.353%, p=0.0061) and E0771-CM 
(192.6% ± 14.61% vs 100% ± 7.353%, p=0.0013) when compared to control. Furthermore, 
when compared to control-CM a significant increase in p62 expression was also observed 
in the E0771-CM (192.6% ± 14.61% vs 115.1% ± 13.38%, p=0.0079). 
 
3.3.6. Glucose Uptake Assay 
The effects of glucose deprived E0771 conditioned media on glucose uptake in MEFs was 
achieved by means of flow cytometry with the utilization of 2-NBDG, a fluorescently 
labelled deoxyglucose analog.  A significant increase in 2-NBDG mean fluorescent 
intensity was observed in MEF cells following treatment with glucose deprived E0771-CM 
when compared to control (132.1% ± 10.95% vs 100% ± 3.722%, p=0.0107) and when 
compared to control-CM (132.1% ± 10.95% vs 105.8% ± 6.120%, p=0.0475). 
* 
Figure 3.22: Determination of the effects of E0771 conditioned media on glucose uptake in mouse 
embryonic fibroblast (MEF) cells. MEF cells were subjected to (1) Control, (2) Control conditioned 
media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived 
E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control. 
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3.3.7. GLUT4 Translocation 
In order to determine whether the increase in glucose uptake observed in MEF cells 
following treatment with glucose deprived E0771-CM is in part mediated by the 
translocation of the GLUT4 transporter to the plasma membrane, MEF cells were first 
transfected with a HA-GLUT4-GFP expressing plasmid and then visualized using confocal 
microscopy.  
Figure 3.23: Assessment of GLUT4 translocation in MEF cells following treatment with E0771 
conditioned media. MEF cells were subjected to (1) Control, (2) Control conditioned media (Control-
CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived E0771 
conditioned media (E0771-CM) for 24 hours. Cells were then immunostained for the HA tag using an 
Alexa Fluor 647 secondary antibody (Red). GFP and HA expression were visualized using fluorescent 
confocal microscopy. Images acquired at 60x magnification 
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As the translocation of the GLUT4 transporter to the plasma membrane results in the 
extracellular expression of the bound HA tag, staining of the HA-tag using an Alexa Fluor 
647 specific antibody indicates total GLUT4 translocation. Thus the ratio between 
cytosolic - (GFP fluorescent intensity) and translocated GLUT4 (HA:Alexa Fluor 647 
fluorescent intensity) can be determined, and used as an indicator of glucose uptake via 
GLUT4 (Zeigerer et al., 2002, Martin et al., 2005). Visually GFP fluorescent intensity (total 
GLUT4) remained fairly constant across all treatment groups. However, HA:Alexa Fluor 
647 fluorescent intensity (translocated GLUT4) appeared to be increased in MEF cells in 
response to treatment with either untreated E0771 conditioned media (EUM) or glucose 
deprived E0771 conditioned media (ECM) in comparison to both the control and control 
conditioned media treated cells (CCM).   
 
3.3.8. Pyruvate dehydrogenase (PDH) Assay 
The catabolism of glucose via glycolysis in cells, under normal oxygen tension, results in 
the generation of pyruvate, which is converted to acetyl-CoA and further catabolized within 
the mitochondria to produce energy via oxidative phosphorylation (Randle, 1986). 
Pyruvate dehydrogenase catalyzes the irreversible conversion of pyruvate to acetyl-CoA, 
and therefore serves as the rate-limiting connection between glycolysis and oxidative 
phosphorylation (Koukourakis et al., 2005). However, under conditions of hypoxia the 
activation of HIF-1α results in the inhibition of PDH, through the activation of the PDH 
antagonizer pyruvate dehydrogenase kinase (PDK), leading to decreased energy 
production via oxidative phosphorylation (Kim et al., 2006). Additionally, decreased 
oxidative phosphorylation resulting in enhanced lactate production is a key metabolic 
feature of the “reverse Warburg effect”. Therefore, in order to determine whether the 
E0771 conditioned media results in the induction of the “reverse Warburg effect” in MEF 
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cells, we assessed the protein profile of PDH in MEF cells following 24 hour treatment 
with E0771 conditioned media.    
 
Our results show a significant increase in total amount of PDH present in MEF cells that 
had been treated with glucose deprived E0771 conditioned media (E0771-CM) at the 1008 
second time point (131.4% % ± 6.554% vs 100% % ± 3.898%, p<0.05), which steadily 
increased over the remaining time course of the assay when compared to control. A similar 
statistical result was obtained when compared to the control-CM group. However, the 
amount of PDH increased significantly from the 672 second time point (121.2% ± 6.414% 
Figure 3.24: Determining the effect of E0771 conditioned media on the protein profile of PDH in 
mouse embryonic fibroblasts (MEF) cells. MMEF cells were subjected to (1) Control, (2) Control 
conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) 
glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: Two-way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 
vs control, ** = p<0.01 vs control, *** = p<0.0001 vs control, * = p<0.05 vs control-CM, ** = p<0.01 vs 
control-CM, *** = p<0.0001 vs control-CM, * = p<0.05 vs E0771-UTCM, ** = p<0.01 vs E0771-UTCM, 
*** = p<0.0001 vs E0771-UTCM. 
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vs 87.88% % ± 2.185%, p<0.05) onwards. Furthermore, when compared to the E0771-
UTCM treatment group a statistically significant increase was only seen from the 1176 
second time point (140.3% ± 8.718% vs 103.1% % ± 11.04%, p<0.01). 
 
3.3.9. PDH Enzyme Activity Assay  
As the enzymatic activity of PDH is a determinant of the metabolic conversion of pyruvate 
to acetyl-CoA, assessment of PDH activity provides partial insight into the flux of pyruvate 
into oxidative phosphorylation. No statistically significant differences in the enzymatic 
activity of PDH was observed across all treatment groups when compared to control.  
Figure 3.25: Determining the effect of E0771 conditioned media on the enzymatic activity of PDH 
in mouse embryonic fibroblasts (MEF) cells. MEF cells were subjected to (1) Control, (2) Control 
conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) 
glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). 
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3.3.10. L-Lactate Assay 
As the activation of HIF-1α results in the inhibition of pyruvate dehydrogenase and a 
shunting of pyruvate away from oxidative phosphorylation, leading to the increased 
production of lactate (Kim et al., 2006, Papandreou et al., 2006), L-lactate concentrations 
were therefore assessed by means of a commercially available colorimetric assay. A 
significant increase in L-lactate production was observed following the treatment of MEF 
cells with glucose deprived E0771-CM in comparison to both control (340.2% ± 50.13% 
vs 100% ± 11.70%, p=0.0009) and control-CM (340.2% ± 50.13% vs 128.0% ± 21.35%, 
p=0.0030). Treatment of MEF cells with E0771-UTCM resulted in a significant increase in 
L-lactate concentrations in comparison to control (214.4% ± 38.34% vs 100% ± 11.70%, 
p=0.0172) alone.  
Figure 3.26: Determination of the effects of E0771 conditioned media on L-lactate 
concentrations in mouse embryonic fibroblast (MEF) cells. MEF cells were subjected to (1) 
Control, (2) Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-
UTCM) and (4) glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± 
SEM (n=3). * = p<0.05 vs control, *** = p<0.0001 vs control and ## = p<0.01 vs control-CM. 
*** 
## 
* 
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3.3.11. Lactate Transporter Expression  
Assessment of the relative protein expression levels of the monocarboxylate transporters 
(MCT) 1 and 4, allows for the inference of the transport of monocarboxylates, such as L-
lactate, across the plasma membrane. Our results revealed a significant decrease in MCT-
1 protein expression levels in MEF cells treated with E0771-CM (49.78% ± 12.28% vs 
100% ± 10.98%, p=0.0381) when compared to control. No significant differences in MCT-
4 protein expression levels were observed across all treatment groups when compared to 
control. 
 
Figure 3.27: Western blot analysis of MCT-1 and MCT-4 protein expression in MEF cells treated 
with E0771 conditioned media. MEF cells were subjected to (1) Control, (2) Control conditioned media 
(Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) glucose deprived E0771 
conditioned media (E0771-CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post 
hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control. 
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3.4. Proteomics Analysis of MEF Conditioned Media 
Assessment of the protein composition of conditioned media generated from MEF cells 
that had been treated with E0771 conditioned media for 24 hours was achieved as 
previously described (see section 3.2) (refer to section 7.1.2 for the list of regulated 
proteins). In this section, a total of 23 protein elements were found exclusively in the 
conditioned media generated from MEF cells treated with glucose deprived E0771 CM 
(MEF_ECM), and a total of 7 protein elements found exclusively in the conditioned media 
generated from MEF cells treated with untreated E0771 CM (MEF_EUM), whereas a total 
of 32 protein elements were displayed exclusively in conditioned media generated from 
control MEF cells. A total of 9 elements were found common to both MEF_C and 
MEF_ECM, 17 common elements to MEF_C and MEF_EUM, and a total of 24 protein 
elements were found to be present in all three conditions.  
Figure 3.28: Broad overview of the total number of protein elements identified between control, 
MEF_EUM and MEF_ECM conditioned media groups. MEF cells were incubated in either control 
DMEM (MEF_C), untreated E0771 conditioned media (MEF_EUM) or glucose deprived E0771 
conditioned media (MEF_ECM) for 24 hours. Diagram generated by CPGR using Venny freeware. 
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3.4.1. Biological Processes Downregulated in MEF_EUM Conditioned Media 
As described previously, GO terms obtained from the list of proteins found to be 
downregulated in conditioned media generated from MEF cells treated with untreated 
E0771 conditioned media (MEF_EUM) were submitted into REVIGO and proteins 
clustered according to their involvement in various biological processes.  
 
A variety of biological processes involved in cell migration and metabolism were found to 
be significantly downregulated in MEF_EUM conditioned media. Again, within the context 
of this study, a downregulation in the Wnt signalling pathway, cell-cell adhesion, glycolysis, 
gluconeogenesis and protein polyubiquitination was observed. Of additional interest, we 
also observed a significant downregulation in tumour necrosis factor (TNF) mediated 
signalling. 
Figure 3.29: Scatterplot view of biological processes downregulated in MEF conditioned media 
following 24 hours of treatment with untreated E0771 conditioned media (MEF_EUM). Graph 
generated in REVIGO using GO terms.  
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To gain a better understanding of the interactions between interesting biological 
processes identified in REVIGO, additional interactive graphs were assessed. Interactive 
graphs generated in REVIGO, also display both the specificity of the terms (larger nodes 
indicate more GO terms which have been collapsed and as such indicates a lower 
specificity) as well as the significance of the term (deeper-red nodes show greater 
significance). Furthermore, interconnections between nodes represent the hierarchical 
relationship between collapsed GO terms.  
 
From the interactive graphs generated in REVIGO for the downregulation of biological 
processes involved in cell migration, a distinct hierarchical interaction between the Wnt 
signalling pathway and tumour necrosis factor mediated signalling is observed, both of 
which being highly specific.  
Figure 3.30: Interactive graph of downregulated biological processes involved in cell migration 
in MEF conditioned media following 24 hours of treatment with untreated E0771 conditioned 
media (MEF_EUM). Graph generated in REVIGO using GO terms.  
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Assessment of the interactive graph containing a wide variety of metabolic processes, 
revealed a hierarchical interaction between protein catabolism and glycolysis. Additionally, 
interactions between protein polyubiquitination and MAPK signalling as well as NK/NF-
kappaB signalling and MAPK signalling were observed. This is of particular interest as 
MAPK signalling is seen to have further interactions with both glycolysis and proteolysis 
involved in cellular protein catabolism. 
Figure 3.31: Interactive graph of downregulated biological processes involved in cellular 
metabolism in MEF conditioned media following 24 hours of treatment with untreated E0771 
conditioned media (MEF_EUM). Graph generated in REVIGO using GO terms. 
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Furthermore, submission of UnitProt accession numbers generated from downregulated 
proteins in MEF_EUM conditioned media into DAVID also showed significant clustering of 
proteins involved in cell-cell adhesion and metabolism. Interrogation of proteins clustered 
into cell-cell adhesion pathways, showed a significant downregulation of enolase I 
(ENO1), annexin I (ANXA1), profilin 1 (PFN1) and charged multivesicular body protein 4B 
(CHMP4B). 
Figure 3.32: 2D viewer of functional annotation clustering of downregulated proteins involved in 
cell-cell adhesion processes in MEF_EUM conditioned media. Graph generated in DAVID using 
UniProt accession numbers. Proteins are displayed horizontally and their functional relationship is 
displayed vertically. 
Stellenbosch University  https://scholar.sun.ac.za
122 
 
 
In depth assessment of protein clustering involved in glycolysis, gluconeogenesis and/or 
carbon metabolism in MEF_EUM, showed a downregulation of lactate dehydrogenase A 
(LDHA), malate dehydrogenase (MDH) -1 and -2, pyruvate kinase, muscle (PKM) and 
enolase (ENO) -1 and -3.  
Figure 3.33: 2D viewer of functional annotation clustering of downregulated proteins involved in 
metabolic processes in MEF_EUM conditioned media. Graph generated in DAVID using UniProt 
accession numbers. Proteins are displayed horizontally and their functional relationship is displayed 
vertically. 
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3.4.2. Biological Processes Upregulated in MEF_EUM Conditioned Media 
Upregulated GO terms for MEF_EUM conditioned media, when submitted into REVIGO, 
resulted in a collapse of these terms into only a few clusters associated with cellular 
components. No biological processes were shown to be upregulated in MEF_EUM 
conditioned media. The scatterplot view generated for clusters associated with cellular 
components in REVIGO proved to not to be very informative, therefore, only the interactive 
graph is displayed as the hierarchical interactions between the extracellular space, 
extracellular region and cytoplasm as well as their significance can be easily interpreted. 
Again based on the fact that very few clusters were generated in REVIGO, none of which 
were found to be involved in any biological processes, these were not submitted into 
DAVID for further analysis in this study. 
 
 
 
 
 
 
 
 
3.4.3. Biological Processes Downregulated in MEF_ECM Conditioned Media 
Bioinformatic analysis of MEF_ECM was conducted using the same pipeline as described 
above. Interestingly, we noted an opposite effect in MEF_ECM as to that seen in the 
analysis of MEF_EUM conditioned media, where REVIGO showed that no biological 
Figure 3.34: Interactive graph of upregulated cellular components in MEF conditioned media 
following 24 hours of treatment with untreated E0771 conditioned media (MEF_EUM). Graph 
generated in REVIGO using GO terms.  
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processes were downregulated in MEF_ECM, and GO terms were clustered into very few 
nodes involved in cellular components. Again, for the purpose of this study, these were 
not analysed further using DAVID and only the interactive graph of downregulated cellular 
components, showing the interaction between the extracellular region and extracellular 
space, is displayed below. 
 
 
 
 
 
 
 
 
 
3.4.4. Biological Processes Upregulated in MEF_ECM Conditioned Media 
Protein clustering analysis for biological processes upregulated in MEF_ECM conditioned 
media using REVIGO, showed significant clustering of processes heavily involved in cell 
migration and metastasis, namely; the Wnt signalling pathway, ephrin signalling pathway, 
ARP2/3 complex-mediated actin nucleation, movement of cell or subcellular component 
and cell-cell adhesion. Additionally, significant clustering was also observed in processes 
involved in cell metabolism, including; glycolysis, gluconeogenesis and protein 
polyubiquitination. 
Figure 3.35: Interactive graph of downregulated cellular components in MEF conditioned media 
following 24 hours of treatment with glucose deprived E0771 conditioned media (MEF_ECM). 
Graph generated in REVIGO using GO terms.  
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As described in the previous section, interactive graphs were generated in REVIGO in order 
to assess the hierarchical interactions between nodes of upregulated biological processes in 
MEF_ECM conditioned media. Assessment of the REVIGO interactive graph, which displays 
the interactions of several biological processes involved in cell migration, demonstrates a 
hierarchical association between ephrin signalling and Wnt signalling. Tumour necrosis 
factor-mediated signalling was observed to interact with both ephrin and Wnt signalling 
pathways, in addition to the response to unfolded proteins.  
Significant interactions were also observed between nodes of upregulated biological 
processes involved in cell metabolism. In MEF_ECM conditioned media we observed 
hierarchical interactions between glycolysis, gluconeogenesis and protein catabolism. 
Interactions between protein polyubiquitination - MAPK signalling and NK/NF-kappaB 
signalling - MAPK signalling were also observed.  
Figure 3.36: Scatterplot view of biological processes upregulated in MEF conditioned media 
following 24 hours of treatment with glucose deprived E0771 conditioned media (MEF_ECM). 
Graph generated in REVIGO using GO terms.  
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Figure 3.37: Interactive graph of upregulated biological processes involved in cell migration in 
MEF conditioned media following 24 hours of treatment with glucose deprived E0771 conditioned 
media (MEF_ECM). Graph generated in REVIGO using GO terms.  
Figure 3.38: Interactive graph of upregulated biological processes involved in metabolic 
processes in MEF conditioned media following 24 hours of treatment with glucose deprived 
E0771 conditioned media (MEF_ECM). Graph generated in REVIGO using GO terms.  
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Significant clustering of proteins involved in cell-cell adhesion and cadherin binding involved 
in cell adhesion were observed. Upregulated proteins of interest involved in cell adhesion in 
MEF_CM, within the context of this study, were identified and include; annexin A1 (ANXA1), 
charged multivessicular body protein 4B (CHMP4B), heat shock protein family A (HSP70) 
member -5 (HSPA5) and -8 (HSPA8), heat shock protein 90 alpha family class B member 1 
(HSP90AB1), lactate dehydrogenase A (LDHA), S100 calcium binding protein A11 (S100A11) 
and enolase 1 (ENO1). 
Figure 3.39: 2D viewer of functional annotation clustering of upregulated proteins involved in 
cell-cell adhesion processes in MEF_ECM conditioned media. Graph generated in DAVID using 
UniProt accession numbers. Proteins are displayed horizontally and their functional relationship is 
displayed vertically. 
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Upregulated proteins of interest clustering in processes involved in cell metabolism in 
MEF_CM were also assessed. Proteins of interest found to be positively associated with 
glycolysis and gluconeogenesis were identified as, glucose-6-phosphate isomerase (GPI), 
enolase -1 (ENO1) and -3 (ENO3), lactate dehydrogenase A (LDHA) and aldo-keto reductase 
family 1 member A1 (AKR1A1).  
Figure 3.40: 2D viewer of functional annotation clustering of upregulated proteins involved in 
metabolic processes in MEF_ECM conditioned media. Graph generated in DAVID using UniProt 
accession numbers. Proteins are displayed horizontally and their functional relationship is displayed 
vertically. 
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We also observed a significant clustering of proteins involved in PI3K/Akt signalling in 
MEF_ECM conditioned media. An upregulation of the proteins, laminin subunit gamma I 
(LAMC1), collagen type IV alpha 2 chain (COL4A2), insulin like growth factor 1 (IGF1) and 
heat shock protein 90 (HSP90) were observed.  
Figure 3.41: 2D viewer of functional annotation clustering of upregulated proteins involved in 
PI3K/Akt signalling in MEF_ECM conditioned media. Graph generated in DAVID using UniProt 
accession numbers. Proteins are displayed horizontally and their functional relationship is displayed 
vertically. 
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Figure 3.42: 2D viewer of functional annotation clustering of upregulated proteins involved in 
Wnt signalling, protein catabolism and protein polyubiquitination in MEF_ECM conditioned 
media. Graph generated in DAVID using UniProt accession numbers. Proteins are displayed horizontally 
and their functional relationship is displayed vertically. 
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Finally, the functional clustering of proteins involved in the Wnt signalling pathway, protein 
polyubiquitination and protein catabolism using DAVID were identified. As observed previously 
(see section 3.2) an upregulation in the proteasome subunits alpha (PSMA) 1, 2, 5, 6 and 7, 
known to play a role in the Wnt signalling pathway, protein catabolism and protein 
polyubiquitination were also seen in MEF_ECM conditioned media. Additionally, an 
upregulation was seen in the proteasome subunits beta (PSMB) 1, 2, 3 and 4, which are linked 
to both Wnt signalling and protein polyubiquitination. Of additional interest, DAVID also 
identified an upregulation in ubiquitin conjugating enzyme E2 K (UBE2K) which is critically 
involved in both the processes of proteasome-mediated ubiquitin-dependent protein 
catabolism and ubiquitin-dependent protein catabolism.  
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3.5. Effects of MEF Conditioned Media on E0771 Breast Cancer Cell 
Metabolism 
Based on the interesting results we obtained for the proteomics analysis of MEF_ECM 
conditioned media, we therefore set out to determine the effects of MEF derived 
conditioned media on both the metabolic profile and the migratory capacity of glucose 
deprived E0771 breast cancer cells. 
 
3.5.1. Cell Viability  
In order to determine the effects of MEF conditioned media on the metabolic capabilities 
of glucose deprived E0771 cancer cells, MTT cell viability assays were performed 
following treatments.  
Figure 3.43: Determination of the effects of MEF conditioned media on the viability of glucose 
deprived E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM 
glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-
CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned 
media (MEF-CM) for 24 hours. Cell viability was assessed using the MTT assay. Statistical analysis: 
One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). 
# = p<0.05 vs control-CM and ## = p<0.01 vs control-CM. 
## # 
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No significant differences in mitochondrial reductive capacity was seen when E0771 
breast cancer cells were treated with control conditioned media for 24 hours following 12 
hours of glucose deprivation. However, when glucose deprived E0771 cells were treated 
with MEF-CM a significant increase in MTT reductive capacity was observed when 
compared to control-CM (108.9% ± 3.957% vs 93.68% ± 2.644%, p=0.0016) as well as 
when these cells were treated with MEF-UTCM when compared to control-CM (104.7% ± 
3.786% vs 93.68% ± 2.644%, p=0.0170) alone.  
 
3.5.2. Cell Death Assessment (Hoechst + PI) 
In order to validate the data obtained from the MTT cell viability assay, cell death was 
assessed further by means of flow cytometry by staining E0771 cells with Hoechst 33342 and 
propidium iodide (PI) following all treatments. Our results showed no significant differences in 
either the live or dead cell populations across all treatment groups.  
Figure 3.44: Determination of the effects of MEF conditioned media on cell death in glucose 
deprived E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM 
glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-
CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned 
media (MEF-CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3).  
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3.5.3. MCT-1/4 Protein Expression 
As previously described, changes in the relative expression levels of the monocarboxylate 
transporters (MCT) of E0771 breast cancer cells can provide insight into the degree to 
which monocarboxylates, including L-lactate, are transported across the plasma 
membrane. We observed a significant increase in the relative protein expression levels of 
the importer MCT-1 following both MEF_UTCM (232.9% ± 28.95% vs 100% ± 27.56%, 
p=0.0292) and MEF_CM (227.7% ± 9.004% vs 100% ± 27.56%, p=0.0116) treatment 
when compared to the control group.  
 
Figure 3.45: Western blot analysis of MCT-1 and MCT-4 protein expression in E0771 breast cancer 
cells treated with MEF conditioned media. Subsequent to 12 hours of glucose deprivation (0 mM 
glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), 
(3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media (MEF-
CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). **= p<0.01 vs control and ## = p<0.01 vs control-CM 
* 
* 
MCT-1 
48 kDa 
Total 
Protein  
MCT-4 
43 kDa 
Total 
Protein  
** 
## 
** 
* 
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Additionally, we observed a concomitant decrease in the expression levels of the exporter 
MCT-4 following MEF-CM (48.34% ± 4.006% vs 100% ± 8.812%, p=0.0059) treatment 
alone when compared to control and control-CM (48.34% ± 4.006% vs 104.4% ± 7.962%, 
p=0.0033). 
 
3.5.4. L-Lactate Assay 
As described previously, in the “reverse Warburg effect” lactate generated and exported 
from CAFs can be utilized by either oxygen or nutrient deprived cancer cells as an energy 
source to promoting cancer cell survival (Lee et al., 2015), L-lactate concentrations were 
therefore assessed following treatment of glucose deprived E0771 cells with MEF 
conditioned media by means of a commercially available colorimetric assay.  
** 
Figure 3.46: Determination of the effects of MEF conditioned media on L-lactate 
concentrations in E0771 murine breast cancer cells. Subsequent to 12 hours of glucose 
deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control 
conditioned media (Control-CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 
treated MEF conditioned media (MEF-CM) for 24 hours. Statistical analysis: One way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). ** = p<0.01 vs 
control. 
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A significant increase in L-lactate production was observed following the treatment of 
glucose deprived E0771 cells with MEF-CM (211.5% ± 13.49% vs 100% ± 4.706%, 
p=0.0083) in comparison to control. However, no significant differences were observed 
when MEF-CM treated E0771 cells were compared to those treated with control-CM. 
 
3.5.5. ATP Production Assay 
Following the treatment of E0771 murine breast cancer cells with MEF conditioned media, 
ATP production was assessed by means of a commercially available bioluminescent 
assay kit. A significant increase in ATP concentrations were observed in glucose deprived 
E0771 cancer cells following 24 hour treatment with MEF-CM in comparison to both the 
control (28.37 ± 1.008 % vs 10.50 ± 0.4346 %, p<0.0001) and the control-CM (28.37 ± 
1.008 % vs 17.76 ± 2.874 %, p<0.001) groups. 
Figure 3.47: Determining the effects of MEF conditioned media on ATP production in E0771 
murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM glucose DMEM), 
E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), (3) Untreated 
MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media (MEF-CM) for 24 
hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are 
presented as mean ± SEM (n=3). *** = p<0.0001 vs control and ## = p<0.01 vs control-CM. 
*** 
## 
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3.5.6. Pyruvate dehydrogenase (PDH) Assay 
In order to determine the relative substrate availability for oxidative phosphorylation in 
E0771 breast cancer cells in response to treatment with MEF-derived conditioned media, 
the total PDH protein profile was assessed using a commercially available “sandwich” 
ELISA assay. Analysis of the protein profile of PDH in glucose deprived E0771 cells 
subjected to treatment with conditioned media derived from “activated” MEF cells, showed 
no significant differences in the amount of PDH present in E0771 breast cancer cells 
across all treatment groups and analysis time points when compared to both the control 
and control-CM groups. 
 
Figure 3.48: Determination of the effects of MEF conditioned media on the protein profile of 
PDH in E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM 
glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-
CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned 
media (MEF-CM) for 24 hours. Statistical analysis: Two-way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). 
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3.5.7. PDH Enzyme Activity Assay  
Assessment of the relative enzymatic activity of PDH in E0771 breast cancer cells 
following MEF conditioned media treatment was achieved using a commercially available 
kinetic assay. Our results showed no statistically significant differences in the enzymatic 
activity of PDH in E0771 cancer cells across all treatment groups for the entire duration of 
the assay when compared to control and control-CM. 
 
 
Figure 3.49: Determination of the effects of MEF conditioned media on the enzymatic activity 
of PDH in E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 
mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media 
(Control-CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF 
conditioned media (MEF-CM) for 24 hours. Statistical analysis: Two-way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=3).  
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3.5.8. Mitomycin C Concentration Response 
In order to establish a concentration of Mitomycin C that results in the effective inhibition 
of proliferation, E0771 cells were treated with various concentrations of Mitomycin C for a 
period of 24 hours. Nuclear counts were performed by manually counting intact nuclei 
following Hoechst 33342 staining. When compared to control (0 hr), a significant increase 
in the number of nuclei present was observed after 24 hours of no treatment (Control 24 
hrs) (251.5 ± 21.79 vs 147.9 ± 7.161, p<0.0001), this was taken as the total proliferative 
capacity of E0771 cells in a 24 hour period. Treatment with both 5.0 µg/ml (167.5 ± 12.58 
vs 251.5 ± 21.79, p<0.01) and 10 µg/ml (143.5 ± 8.738 vs 251.5 ± 21.79, p<0.0001) of 
Mitomycin C resulted in a significant decrease in the number of nuclei after 24 hours when 
compared to Control (24 hrs).  
Figure 3.50: Determining the effects of Mitomycin C on the proliferative capabilities of E0771 
murine breast cancer cells. Under standard cellular conditions nuclear counts were performed on 
E0771 cells subjected to (1) Control (0 hrs), (2) Control (24 hrs), (3) 1.0 µg/ml (4) 2.0 µg/ml (5) 1.0 
µg/ml, and (6) 10 µg/ml Mitomycin C for 24 hours. Nuclear counts were assessed following Hoechst 
33342 staining by manually counting intact nuclei. Statistical analysis: One way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=3). ** = p<0.01 vs control and *** = 
p<0.0001 vs control (24 hrs). 
*** 
** 
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Based on the Mitomycin C concentration response obtained, treatment with 10 µg/ml 
Mitomycin C for a period of 24 hours lead to a significant reduction in the nuclear count of 
the E0771 murine breast cancer cells compared to the 24 hour control. The reduction 
observed was comparable to the nuclear counts obtained for the baseline control (0 hrs), 
therefore this concentration was chosen for all subsequent experiments. 
 
3.5.9. Migration (Scratch) Assay 
Migration (scratch) assays were performed in E0771 cancer cells following MEF-CM 
treatment for 24 hrs. Images of wound areas were acquired at time points 6, 12, 18 and 
24 hours during the 24 hour MEF-CM treatment period. Statistical analyses by means of 
two-way ANOVAs (with Bonferroni post hoc) were performed separately for each time 
point. Collective graphs showing the statistical results and representative images for each 
separate time point are included below. Proliferation control groups (cells not treated with 
Mitomycin C) showed significantly greater wound closure when compared to other 
treatment groups. This is as expected, as wound closure can be attributed to the fact that 
both cellular migration and proliferation contribute to wound closure.  
When compared to control groups, a significant reduction in the percentage of wound 
closure was observed at the 6 hour and 12 hour time points in control-CM (6 hr: 7.871% 
± 1.181% vs 26.430% ± 4.523%, p<0.0001 and 12 hr: 31.806% ± 3.695% vs 45.289% ± 
3.596%, p<0.01), MEF-UTCM (6 hr: 8.712% ± 2.151% vs 26.430% ± 4.523%, p<0.0001  
and 12 hr: 21.399% ± 1.675% vs 45.289% ± 3.596%, p<0.0001), and MEF-CM (6 hr: 
8.340% ± 2.013% vs 26.430% ± 4.523%, p<0.0001 and 12 hr: 30.576% ± 4.498% vs 
45.289% ± 3.596%, p<0.0001) groups.  No significant differences were observed for any 
of the groups at the 18 hour time points. At the 24 hour time point only the MEF-UTCM 
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treatment group showed a significant reduction in percentage wound closure when 
compared to the control group (72.892% ± 2.540% vs 83.422% ± 2.104%, p<0.05).  
However, when compared to the control-CM groups no significant changes in the 
percentage of wound closure was observed for either the MEF-UTCM or MEF-CM groups 
across all time points.  
 
 
Figure 3.51: Determining the effects of MEF conditioned media on the migratory capacity of 
E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM glucose 
DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), (3) 
Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media (MEF-
CM) for 24 hours. Migratory capacity following treatment was assessed by means of a wound healing 
(Scratch) assay. Statistical analysis: Two-way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=9). * = p<0.05 vs control, ** = p<0.01 vs control and *** = p<0.0001 
vs control. 
*** 
** 
*** 
*** 
* 
*** 
*** 
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Figure 3.52: Representative time point images of the migration (scratch) assay performed on E0771 
murine breast cancer cells following MEF conditioned media treatment. Subsequent to 12 hours of 
glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned 
media, (3) Untreated MEF conditioned media and (3) E0771 treated MEF conditioned media for 24 hours. 
Image analysis performed in ImageJ using an MRI_wound_healing plugin, and images displayed are for the 
0, 12 and 24 hour time points only. 
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Based on the fact that no statistical differences were obtained with the analysis of the 
percentage wound closure at the 18 hour time point, the slopes of the regression lines 
(Figure 3.49) for each separate time point were analysed to determine whether treatment 
with MEF-CM has an effect on the rate of change at which E0771 cells migrate into the 
wound area between each time point.  Significantly lower slopes were seen in control-CM 
(1.312 ± 0.1968% vs 4.405% ± 0.7538%, p<0.01), MEF-UTCM (1.452% ± 0.3584% vs 
4.405% ± 0.7538%, p<0.01) and MEF-CM (1.390% ± 0.3355% vs 4.405% ± 0.7538%, 
p<0.01) treatment groups in comparison to control between the 0-6 hr time points. A 
significant increase in the slope was seen following MEF-CM treatment in comparison to 
control (7.476 ± 0.8522% vs 3.983% ± 0.7789%, p<0.05) between the 12-18 hr time 
points. 
 
 
*p-values indicate slopes which are significantly non-zero 
 
Furthermore, in order to determine whether treatment with MEF-CM has an effect on 
migratory rate of E0771 cancer cells, the rate of wound closure was assessed by 
determining the percentage wound closure over time. A significant reduction in the rate of 
wound closure was seen at both the 6 hour and 12 hour time points for the control-CM (6 
hr: 131.191% ± 19.675% vs 440.498% ± 75.379%, p<0.0001 and 12 hr: 265.049 ± 
Proliferation Control Control Control-CM MEF-UTCM MEF-CM
Slope 7.605 ± 0.3984 4.405 ± 0.7538 1.312 ± 0.1968 1.452 ± 0.3584 1.390 ± 0.3355
p-value < 0.0001 < 0.0001 < 0.0001 0.0009 0.0008
Slope 3.510 ± 0.7022 3.143 ± 0.9630 3.989 ± 0.6464 2.114 ± 0.4543 3.706 ± 0.8213
p-value 0.0001 0.0049 < 0.0001 0.0003 0.0004
Slope 2.717 ± 0.7010 3.983 ± 0.7789 6.116 ± 0.9433 6.689 ± 0.5344 7.476 ± 0.8522
p-value 0.0013 0.0001 < 0.0001 < 0.0001 < 0.0001
Slope 1.775 ± 0.4680 2.372 ± 0.6085 1.487 ± 0.9333 1.893 ± 0.6219 0.7352 ± 0.4980
p-value 0.0016 0.0013 0.1306 0.0077 0.1593
0-6 hrs
6-12 hrs
12-18 hrs
18-24 hrs
Table 3.1: Determining the effects of MEF conditioned media on the rate of change (slope) of 
migration of E0771 murine breast cancer cells.  
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30.788% vs 377.409% ± 29.969%, p<0.05), MEF-UTCM (6 hr: 145.202% ± 35.843% vs 
440.498% ± 75.379%, p<0.0001 and 12 hr: 178.323 ± 13.958% vs 377.409% ± 29.969%, 
p<0.0001) and MEF-CM (6 hr: 138.995% ± 33.546% vs 440.498% ± 75.379%, p<0.0001 
and 12 hr: 254.798% ± 37.482% vs 377.409% ± 29.969%, p<0.01) treatment groups when 
compared to control. However, only the MEF-UTCM (512.781% ± 22.784% vs 380.561% 
± 23.820%, p<0.01) showed a significant increase in the rate of E0771 cell migration at 
the 18 hour time point when compared to control.  
 
Again, in order to determine if MEF-CM affects the change in the rate of wound closure of 
E0771 cancer cells between each time point, the slopes of the regression lines (Figure 
Figure 3.53: Determining the effects of MEF conditioned media on the rate of migration of 
E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM glucose 
DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), (3) 
Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media 
(MEF-CM) for 24 hours. Rate of wound closure (% / hr) was calculated by dividing the % wound 
closure at each time point by the number of hours passed. Statistical analysis: Two-way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=9). * = p<0.05 vs control, 
** = p<0.01 vs control and *** = p<0.0001 vs control. 
*** 
* 
*** 
*** 
** 
*** 
** 
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3.51) between each time point were analysed separately. Significantly lower slopes were 
seen in control-CM (21.87% ± 3.279% vs 73.42% ± 12.56%, p<0.0001), MEF-UTCM 
(24.20% ± 5.974% vs 73.42% ± 12.56%, p<0.0001) and MEF-CM (23.17% ± 5.591% vs 
73.42% ± 12.56%, p<0.0001) treatment groups in comparison to control between the 0-6 
hr time points. Of interest to note is that the rate of migration decreases rapidly 
(represented by a change from a positive to negative slope) as early as the 6-12 hour time 
points in both the proliferation control (-34.12% ± 8.205%) and the control groups (-10.51% 
± 13.52%). However, the rate of migration is only seen to decrease between 18-24 hour 
time points in the control-CM (-9.660% ± 4.692%), MEF-UTCM (-34.84% ± 4.187%) and 
MEF-CM (-14.40% ± 2.554%).  
 
 *p-values indicate slopes which are significantly non-zero 
 
3.5.10. EMT Assessment 
In order to determine whether epithelial-to-mesenchymal transition plays a role in the 
migratory capacity of E0771 following treatment with MEF-CM. Western blotting analysis 
was employed to assess the relative protein expression of the mesenchymal markers; α-
smooth muscle actin (α-SMA), platelet derived growth factor receptor α (PDGFRα) and 
vimentin as well as the epithelial cell surface marker E-cadherin.  
Proliferation Control Control Control-CM MEF-UTCM MEF-CM
Slope 126.7 ± 6.640 73.42 ± 12.56 21.87 ± 3.279 24.20 ± 5.974 23.17 ± 5.591
p-value < 0.0001 < 0.0001 < 0.0001 0,0009 0,0008
Slope -34.12 ± 8.205 -10.51 ± 13.52 22.31 ± 6.090 5.520 ± 6.411 19.30 ± 8.384
p-value 0,0007 0,4481 0,0021 0,4019 0,0351
Slope -15.78 ± 5.298 1.161 ± 5.708 19.25 ± 6.488 55.74 ± 4.453 27.38 ± 6.641
p-value 0,0089 0,8414 0,0091 < 0.0001 0,0008
Slope -11.82 ± 2.433 -6.131 ± 3.126 -9.660 ± 4.692 -34.84 ± 4.187 -14.40 ± 2.554
p-value 0,0002 0,0675 0,0562 < 0.0001 < 0.0001
12-18 hrs
18-24 hrs
0-6 hrs
6-12 hrs
Table 3.2: Determining the effects of MEF conditioned media on the change in the rate (slope) 
of wound closure of E0771 cancer cells. 
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3.5.10.1. α-SMA and PDGFRα 
When compared to the control group, we observed a significant increase in the relative 
protein expression levels of α-SMA in E0771 breast cancer cells that had been treated 
with MEF-CM (141.1% ± 9.479% vs 100% ± 11.42%, p=0.0323). However, when PDGFRα 
protein expression levels were assessed no statistically significant differences were 
observed across all treatment groups when compared to control.  
 
Total 
Protein  
PDGFRα 
190 kDa 
α-SMA 
37 kDa 
Total 
Protein  
* 
Figure 3.54: Western blot analysis of α-SMA and PDGFRα in E0771 breast cancer cells following 
MEF conditioned media treatment. Subsequent to 12 hours of glucose deprivation (0 mM glucose 
DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), (3) 
Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media (MEF-
CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). * = p<0.05 vs control. 
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3.5.10.2. Vimentin and E-cadherin 
Assessment of vimentin showed a significant increase in relative protein expression levels 
in E0771 breast cancer cells following treatment with MEF-CM (188.0% ± 5.651% vs 
100% ± 13.12%, p=0.0010) in comparison to the control group. We also observed a 
significant decrease in the protein expression of the epithelial marker E-cadherin following 
treatment with both MEF-UTCM (55.79% ± 9.842% vs 100% ± 11.09%, p=0.0098) and 
MEF-CM (38.06% ± 9.317% vs 100% ± 11.09%, p=0.0006) in comparison to the control 
group. 
Figure 3.55: Western blot analysis of vimentin and E-cadherin in E0771 breast cancer cells 
following MEF conditioned media treatment. Subsequent to 12 hours of glucose deprivation (0 mM 
glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media (Control-CM), 
(3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF conditioned media (MEF-
CM) for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). * = p<0.05 vs control, ** = p<0.01 vs control and *** = p<0.0001 vs 
control. 
E-cadherin 
135 kDa 
Total 
Protein  
Total 
Protein  
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3.6. Effects of MEF Conditioned Media on Doxorubicin Resistance 
and Cell Migration in E0771 Breast Cancer Cells 
In addition to the role that CAFs play in mediating cell migration and cancer metastasis, it 
has become increasingly evident that CAFs also play a role in the chemotherapeutic 
resistance of tumours (Kojima et al., 2010, Yang et al., 2010, Mϋerkӧster et al., 2008). 
Based on this, the next section of this study focuses on elucidating the influences that the 
combination of MEF conditioned media and doxorubicin treatment have on E0771 breast 
cancer cell metabolism and cell migration. 
 
3.6.1. Doxorubicin Dose Response 
In order to establish a dose of doxorubicin that produces the least significant percentage 
of cell death in the doxorubicin resistant E0771 murine breast cancer cells. E0771 cells 
were treated with various concentrations of doxorubicin for a period of 24 hours. MTT cell 
viability assays were carried out to determine the relative percentage cell death. When 
compared to control, neither 0.1, or 1.0 μM doxorubicin resulted in a decrease in the MTT 
reductive capacity (0.1 μM:98.52% ± 2.802% vs 100% ± 3.434% and 1.0 μM: 92.60% ± 
2.698% vs 100% ± 3.434%), however when subjected to either 2.5, 5.0, or 10.0 μM of 
doxorubicin for a period of 24 hours a significant reduction in MTT reductive capacity (2.5 
μM: 73.31% ± 2.588% vs 100% ± 3.434%, p<0.0001. 5.0 μM: 69.13% ± 2.442% vs 100% 
± 3.434%, p<0.0001 and 10.0 μM: 68.46% ± 3.104% vs 100% ± 3.434%, p<0.0001) when 
compared to control. 
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Based on initial doxorubicin dose responses, treatment with 2.5 µM doxorubicin over a 
period of 24 hours lead to a significant reduction in cell viability of the E0771 murine breast 
cancer cells, therefore this concentration was chosen for all further experiments. As we 
aimed to assess the effects of MEF conditioned media on doxorubicin resistance, E0771 
cells were first glucose starved for 12 hours as previously described and then treated with 
MEF-CM in combination with 2.5 µM doxorubicin for 24 hours. Therefore, the following 
treatment groups were used for this section of the study (1) control; (2) control conditioned 
media (Control-CM); (3) MEF untreated conditioned media (MEF-UTCM), (4) MEF 
conditioned media (MEF-CM),  (5) 2.5 µM Doxorubicin, (6) 2.5 µM Doxorubicin + control 
conditioned media (Dox + Control-CM), (7) 2.5 µM Doxorubicin + MEF untreated 
conditioned media (Dox + MEF-UTCM) and (8) 2.5 µM Doxorubicin + MEF conditioned 
media (Dox + MEF-CM). 
Figure 3.56: The effect of various concentrations of Doxorubicin on the viability of E0771 murine 
breast cancer cells. E0771 cells were incubated in 0 (Control), 0.1, 1.0 2.5, 5.0 and 10.0 µM doxorubicin 
for 24 hours. Cell viability was assessed using the MTT assay. Values are expressed as a percentage of the 
control and presented as mean ± SEM (n=3). *** = p<0.0001 vs control. 
*** *** *** 
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3.6.2. Cell Viability  
MTT cell viability assays were carried out to assess the viability of E0771 murine cancer 
cells following treatments. E0771 cells showed a significant reduction in MTT reductive 
capacity following 2.5 µM doxorubicin treatment when compared to control (77.21% ± 
1.776% vs 100% ± 2.630%, p<0.0001), However, when glucose deprived E0771 cells 
were treated with doxorubicin in combination with MEF-CM a significant increase in 
mitochondrial reductive capacity was observed when compared to doxorubicin treatment 
alone (91.39% ± 3.870% vs 77.21% ± 1.776%, p<0.05).  
Figure 3.57: Determining the effects of MEF conditioned media in combination with doxorubicin 
on the viability of glucose deprived E0771 murine breast cancer cells. Subsequent to 12 hours of 
glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Doxorubicin, 
(3) Doxorubicin + control conditioned media (Dox + Control-CM), (4) Doxorubicin + MEF untreated 
conditioned media (Dox + MEF-UTCM) and (5) Doxorubicin + MEF conditioned media (Dox + MEF-
CM) for 24 hours. Cell viability was assessed using the MTT assay. Statistical analysis: One way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). *** = 
p<0.0001 vs Control, ### = p<0.0001 vs Doxorubicin. 
### 
*** 
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3.6.3. Cell Death Assessment (Hoechst + PI) 
As previously described, cell death analysis by means of flow cytometry, following 
doxorubicin treatment in conjunction with MEF conditioned media was conducted in order 
to further validate the results obtained for the MTT cell viability assay. A significant 
decrease in E0771 live cell population was observed following MEF-CM treatment in 
combination with 2.5 µM doxorubicin in comparison to the control group (70.03% ± 
0.4356% vs 85.40% ± 1.044%, p<0.0001). A concomitant increase in the dead cell 
population of E0771 cancer cells treated with the combination of MEF-CM and doxorubicin 
was also observed when compared to control (30.18% ± 0.4294% vs 10.40% ± 0.8983%, 
p<0.0001).  
Figure 3.58: Determination of the effects of MEF conditioned media in combination with 
doxorubicin on cell death in glucose deprived E0771 murine breast cancer cells. Subsequent to 
12 hours of glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) 
Doxorubicin, (3) Doxorubicin + Control conditioned media, (4) Doxorubicin + Untreated MEF 
conditioned media (Dox + MEF-UTCM) and (5) Doxorubicin + E0771 treated MEF conditioned media 
(Dox + MEF-CM) for 24 hours. Live / Dead cell populations were determined by means of flow cytometry 
following Hoechst 33342 and PI staining. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). *** = p<0.0001 vs Doxorubicin. 
*** 
*** 
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3.6.4. MCT1/4 transporter expression 
When compared to both doxorubicin (Dox) and Dox + control-CM, no significant 
differences in either MCT-1 (monocarboxylate importer) or MCT-4 (monocarboxylate 
exporter) protein expression levels were observed across all treatment groups.  
 
3.6.5. L-Lactate Assay 
As previously described, L-lactate concentrations were assessed following treatment of 
glucose deprived E0771 cells with MEF conditioned media in combination with 2.5 µM 
Figure 3.59: Western Blot analysis of MCT-1 and MCT-4 protein expression in E0771 breast cancer 
cells treated with doxorubicin and MEF conditioned media. Subsequent to 12 hours of glucose 
deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin (Dox), (2) Dox + 
Control conditioned media, (3) Dox + Untreated MEF conditioned media (MEF-UTCM) and (3) Dox + 
E0771 treated MEF conditioned media (MEF-CM) for 24 hours. Statistical analysis: One way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3).  
MCT-1 
48 kDa 
Total 
Protein  
MCT-4 
43 kDa 
Total 
Protein  
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doxorubicin by means of a commercially available colorimetric assay. A significant 
increase in L-lactate concentration was observed in E0771 breast cancer cells following 
doxorubicin treatment in combination with MEF-CM (211.1% ± 21.75% vs 111.5% ± 
13.49%, p=0.0176) when compared to doxorubicin alone. 
 
3.6.6. ATP Production Assay 
Determination of relative ATP production in glucose deprived E0771 breast cancer cells 
treated with Doxorubicin in combination with MEF conditioned media, demonstrated a 
significant increase in ATP production following Dox + MEF-UTCM (30.03 ± 1.420 vs 
17.79 ± 0.7905, p=0.0079) and Dox + MEF-CM (42.54 ± 2.188 vs 17.79 ± 0.7905, 
p=0.0087) when compared to doxorubicin alone. Additionally, when compared to Dox + 
Figure 3.60: Determination of the effects of MEF conditioned media on L-lactate concentrations 
in E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM glucose 
DMEM), E0771 cells were subjected to (1) Control, (2) Doxorubicin, (3) Doxorubicin + Control 
conditioned media, (4) Doxorubicin + Untreated MEF conditioned media (Dox + MEF-UTCM) and (5) 
Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 hours. Statistical analysis: 
One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). 
* = p<0.05 vs Doxorubicin. 
* 
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control-CM, a significant increase in ATP production was also observed following 
doxorubicin treatment in combination with MEF-UTCM (30.03 ± 1.420 vs 16.32 ± 3.004, 
p=0.0145) and MEF-CM (42.54 ± 2.188 vs 16.32 ± 3.004%, p=0.0083). 
 
3.6.7. Pyruvate dehydrogenase (PDH) Assay 
We observed a significant increase in total amount of PDH present in E0771 cells that had 
been treated with doxorubicin in combination with MEF-CM at the 1680 second time point 
(129.5% ± 8.204% vs 97.29% ± 6.791%, p<0.05) alone when compared to the doxorubicin 
group. Additionally, when compared to the dox + control-CM group a significant increase 
Figure 3.61: Determining the effects of MEF conditioned media in combination with doxorubicin 
on ATP production in E0771 murine breast cancer cells. Subsequent to 12 hours of glucose 
deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Doxorubicin, (3) 
Doxorubicin + Control conditioned media, (4) Doxorubicin + Untreated MEF conditioned media (Dox + 
MEF-UTCM) and (5) Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 
hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are 
presented as mean ± SEM (n=3). ** = p<0.01 vs Doxorubicin, # = p<0.05 vs Dox + control-CM and ## 
= p<0.01 vs Dox + control-CM. 
** 
## 
* 
# 
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in PDH, from the 840 second time point (111.0% ± 2.282% vs 79.58% ± 9.696%, p<0.05) 
onwards was observed in the following dox + MEF-CM treatment.  
 
Furthermore, when compared to the dox + MEF-UTCM treatment group a statistically 
significant increase was seen from the 504 second time point (112.8% ± 5.327% vs 
79.87% ± 6.402%, p<0.05). Of interest to note is that while the total PDH amount 
significantly increases over time in the dox + MEF-CM group when compared to control, 
significant decreases over time in the total PDH amount is seen in the dox + MEF-UTCM 
Figure 3.62: Determination of the effects of doxorubicin in combination with MEF conditioned 
media on the protein profile of PDH in E0771 murine breast cancer cells. Subsequent to 12 
hours of glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) 
Doxorubicin, (3) Doxorubicin + Control conditioned media, (4) Doxorubicin + Untreated MEF 
conditioned media (Dox + MEF-UTCM) and (5) Doxorubicin + E0771 treated MEF conditioned 
media (Dox + MEF-CM) for 24 hours. Statistical analysis: Two-way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). * represent statistically significant results 
for the dox + MEF-CM group and # represent statistically significant results for the dox + MEF-UTCM 
group. The colour of the symbol denotes the comparison group. 
*** 
* * ** 
*** 
*** 
* 
*** 
* * ** 
*** 
*** 
* 
# # 
# # # # 
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group, from the 672 second time point (75.44% ± 6.326% vs 107.6% ± 4.094%, p<0.05) 
up to the 1680 second time point in comparison to control. 
 
3.6.8. PDH Enzyme Activity Assay  
Again, when the enzymatic activity of PDH was assessed over time, no significant 
differences were observed for all treatment groups across all time points when compared 
to the doxorubicin only group. 
 
Figure 3.63: Determination of the effects of doxorubicin in combination with MEF conditioned 
media on the enzymatic activity of PDH in E0771 murine breast cancer cells. Subsequent to 
12 hours of glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Control, 
(2) Doxorubicin, (3) Doxorubicin + Control conditioned media, (4) Doxorubicin + Untreated MEF 
conditioned media (Dox + MEF-UTCM) and (5) Doxorubicin + E0771 treated MEF conditioned 
media (Dox + MEF-CM) for 24 hours. Statistical analysis: Two-way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3).  
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3.6.9. Migration (Scratch) Assay 
Subsequent to metabolic assessment of E0771 breast cancer cells following combined 
treatment with doxorubicin and MEF-CM, cell migration was assessed with the use of a 
migration (scratch) assay, as previously described (see section 3.5.9). A significant 
reduction in wound closure was observed at the 6 hour time point in the Dox + control-CM 
(14.99% ± 1.964% vs 34.18% ± 5.720%, p<0.01), Dox + MEF-UTCM (6.043% ± 7.048% 
vs 34.18% ± 5.720%, p<0.0001), and Dox + MEF-CM (13.00% ± 6.647% vs 34.18% ± 
5.720%, p<0.0001) groups, compared to doxorubicin. Furthermore, a significant reduction 
in % wound closure was seen at the 12, 18 and 24 hour time points only for the dox + 
MEF-UTCM (12 hour: 19.97% ± 5.918% vs 43.22% ± 5.160%, p<0.0001, 18 hour: 41.32% 
± 6.128% vs 61.33% ± 4.519%, p<0.01 and 24 hour: 48.78% ± 4.939% vs 68.13% ± 
3.044%, p<0.01) group when compared to doxorubicin alone. 
Figure 3.64: Determining the effects of MEF conditioned media in combination with doxorubicin 
on the migratory capacity of E0771 murine breast cancer cells. Subsequent to 12 hours of glucose 
deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, (2) Doxorubicin  + 
Control conditioned media, (3) Doxorubicin  + Untreated MEF conditioned media (MEF-UTCM) and (4) 
Doxorubicin + E0771 treated MEF conditioned media (MEF-CM) for 24 hours. Statistical analysis: Two-
way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=9). ** = 
p<0.01 vs Doxorubicin and *** = p<0.0001 vs Doxorubicin 
** 
*** 
*** 
** 
** 
** 
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Figure 3.65: Representative time point images of the migration (scratch) assay performed on E0771 
murine breast cancer cells following doxorubicin and MEF conditioned media treatment. Subsequent 
to 12 hours of glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, (2) 
Dox + Control conditioned media, (3) Dox + Untreated MEF conditioned media and (4) Dox +  E0771 treated 
MEF conditioned media for 24 hours. Image analysis performed in ImageJ using an MRI_wound_healing 
plugin, and images displayed are for the 0, 12 and 24 hour time points only. 
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Again, the slopes of the regression lines (Figure 3.64) for each separate time point were 
analysed to determine whether treatment with the combined effects of doxorubicin and 
MEF-CM have an effect on the rate of change of migration of E0771 cancer cells. 
Significantly lower slopes were seen following doxorubicin + control-CM (2.498 ± 0.3274% 
vs 5.697% ± 0.9533%, p<0.01) in comparison to control between the 0-6 hr time points. 
However, no statistically significant differences in the slopes, for any of the treatment 
groups, were observed between the 6-12 hr, 12-18 hr and 18-24 hr time points. 
 
*p-values indicate slopes which are significantly non-zero 
As previously described, the rate of wound closure was assessed by determining the 
percentage wound closure over time. Again, significant reduction in the rate of wound 
closure was seen only at the 6 hour for the dox + control-CM (249.8% ± 32.74% vs 569.7% 
± 95.33%, p<0.0001), dox + MEF-UTCM (234.2% ± 90.63% vs 569.7% ± 95.33%%, 
p<0.0001) and dox + MEF-CM (216.7% ± 110.8% vs 569.7% ± 95.33%%, p<0.0001) 
treatment groups when compared to control. Additionally, only the dox + MEF-UTCM 
group (204.3% ± 25.96% vs 360.2% ± 43.00%, p<0.05) showed a significant decrease in 
the rate of wound closure at the 12 hour time point when compared to doxorubicin alone.  
Table 3.3: Determining the effects of doxorubicin and MEF conditioned media on the rate of 
change (slope) of migration of E0771 murine breast cancer cells.  
Proliferation Control Control Doxorubicin Dox + Control-CM Dox + MEF-UTCM Dox + MEF-CM
Slope 7.605 ± 0.3984 4.405 ± 0.7538 5.697 ± 0.9533 2.498 ± 0.3274 1.007 ± 1.175 2.167 ± 1.108
p-value < 0.0001 <0.0001 < 0.0001 < 0.0001 0.4039 0.0681
Slope 3.510 ± 0.7022 3.143 ± 0.9630 1.506 ± 1.284 2.678 ± 0.6632 2.320 ± 1.534 2.529 ± 1.505
p-value 0.0001 0.0049 0.2579 0.001 0.1499 0.1124
Slope 2.717 ± 0.7010 3.983 ± 0.7789 3.018 ± 1.143 4.211 ± 0.9599 3.559 ± 1.420 5.282 ± 1.148
p-value 0.0013 0.0001 0.0178 0.0005 0.0234 0.0003
Slope 1.775 ± 0.4680 2.372 ± 0.6085 1.134 ± 0.9081 0.8882 ± 1.043 1.243 ± 1.312 0.1122 ± 0.9534
p-value 0.0016 0.0013 0.2298 0.4071 0.3573 0.9078
0-6 hrs
6-12 hrs
12-18 hrs
18-24 hrs
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Assessment of the slopes of the regression lines (Figure 3.66) between each time point 
were again analysed separately. Significantly lower slopes were seen in the Dox + MEF-
UTCM (39.03% ± 15.11% vs 94.95% ± 15.89%, p<0.05) and Dox + MEF-CM (35.12% ± 
18.46% vs 94.95% ± 15.89%, p<0.05) treatment groups in comparison to doxorubicin 
between the 0-6 hr time points. Again, the rate of migration decreases rapidly (represented 
by a change from a positive to negative slope) as early as the 6-12 hour time points in 
both the proliferation control (-34.12% ± 8.205%), doxorubicin only (-34.93% ± 17.43%) 
and the Dox + MEF-UTCM (-4.973% ± 15.71%) groups. However, the rate of migration is 
only seen to decrease between 18-24 hour time points in the Dox + control-CM (-9.336% 
± 5.181%) and the Dox + MEF-CM (-13.39% ± 4.420%) groups. Of interest to note is that 
Figure 3.66: Determining the effects of doxorubicin and MEF conditioned media on the rate 
of migration of E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation 
(0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, (2) Doxorubicin  + Control 
conditioned media, (3) Doxorubicin + Untreated MEF conditioned media (Dox + MEF-UTCM) and (4) 
Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 hours. Rate of wound 
closure (% / hr) was calculated by dividing the % wound closure at each time point by the number of 
hours passed. Statistical analysis: Two-way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=9). * = p<0.05 vs doxorubicin and *** = p<0.0001 vs doxorubicin. 
*** 
*** 
* 
*** 
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the MEF-UTCM experiences a second burst in the rate of migration (evident by a change 
from a negative to a positive slope) between the 12-18 hour time points (4.207% ± 
7.136%) which rapidly decreases again between the 18-24 hour time points.  
 
*p-values indicate slopes which are significantly non-zero 
 
3.6.10. Epithelial-to-Mesenchymal Transition (EMT) Assessment 
In order to determine whether the combined treatment effects of doxorubicin and MEF-CM 
result in the induction of EMT, as well as to determine the role of EMT in E0771 cancer cell 
migration in the presence of both chemotherapy and “activated” fibroblast conditioned media, 
we assessed the relative protein expression of several key markers of EMT, namely; α-SMA, 
PDGFRα, vimentin and E-cadherin by means of Western blot analysis.  
 
3.6.10.1. α-SMA and PDGFRα 
Our results showed a significant decrease in the protein expression of α-SMA following 
both Dox + MEF-UTCM (33.40% ± 3.141% vs 100% ± 5.790%, p<0.0001) and Dox + 
MEF-CM (26.82% ± 6.837% vs 100% ± 5.790%, p=0.0002) treatment in comparison to 
doxorubicin treatment alone. When compared to Dox + control-CM a significant decrease 
in α-SMA expression was also observed for the MEF-UTCM (33.40% ± 3.141% vs 114.5% 
± 16.99%, p=0.0033) and MEF-CM (26.82% ± 6.837% vs 114.5% ± 16.99%, p=0.0030) 
Table 3.4: Determining the effects of doxorubicin and MEF conditioned media on the rate of 
change (slope) of migration of E0771 murine breast cancer cells.  
Proliferation Control Control Doxorubicin Dox + Control-CM Dox + MEF-UTCM Dox + MEF-CM
Slope 126.7 ± 6.640 73.49 ± 12.56 94.95 ± 15.89 41.64 ± 5.456 39.03 ± 15.11 36.12 ± 18.46
p-value < 0.0001 <0.0001 < 0.0001 < 0.0001 0.0200 0.0681
Slope -34.12 ± 8.205 -10.51 ± 13.52 -34.93 ± 17.43 1.493 ± 7.271 -4.973 ± 15.71 3.018 ± 20.32
p-value 0.0007 0.4481 0.0623 0.8399 0.7557 0.8838
Slope -15.78 ± 5.298 1.161 ± 5.708 -3.242 ± 8.298 9.014 ± 6.424 4.207 ± 7.136 16.30 ± 8.985
p-value 0.0089 0.8414 0.7012 0.1797 0.5637 0.0884
Slope -11.82 ± 2.433 -6.131 ± 3.126 -9.472 ± 4.688 -9.336 ± 5.181 -4.384 ± 6.630 -13.39 ± 4.420
p-value 0.0002 0.0675 0.0604 0.0904 0.5178 0.008018-24 hrs
0-6 hrs
6-12 hrs
12-18 hrs
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treatment groups. Additionally, we observed a significant decrease in PDGFRα protein 
expression levels in the Dox + control-CM (42.88% ± 12.47% vs 100% ± 2.904%, 
p=0.0043), Dox + MEF-UTCM (25.67% ± 5.881% vs 100% ± 2.904%, p<0.0001) and Dox 
+ MEF-CM (25.15% ± 4.550% vs 100% ± 2.904%, p<0.0001) treatment groups when 
compared to doxorubicin alone.  
 
Figure 3.67: Western Blot analysis of α-SMA and PDGFRα protein expression in E0771 breast 
cancer cells following combined doxorubicin and MEF conditioned media treatment. Subsequent 
to 12 hours of glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, 
(2) Doxorubicin + Control conditioned media, (3) Doxorubicin + Untreated MEF conditioned media (Dox 
+ MEF-UTCM) and (4) Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 
hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented 
as mean ± SEM (n=3). ** = p<0.01 vs Doxorubicin, *** = p<0.0001 vs Doxorubicin and ## = p<0.01 vs 
Doxorubicin + Control-CM. 
α-SMA 
37 kDa 
Total 
Protein  
PDGFRα 
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3.6.10.2. Vimentin and E-cadherin 
Assessment of vimentin revealed a significant increase in relative protein expression 
levels in E0771 breast cancer cells following treatment with Dox + MEF-UTCM (302.8% ± 
45.03% vs 100% ± 10.62%, p=0.0037) and Dox + MEF-CM (361.7% ± 53.55% vs 100% 
± 10.62%, p=0.0025) when compared to doxorubicin treatment alone. Additionally, we 
observed a significant increase in E-cadherin protein expression following treatment with 
Dox + control-CM (213.1% ± 21.71% vs 100% ± 11.04%, p=0.0035), Dox + MEF-UTCM 
(195.5% ± 17.73% vs 100% ± 11.04%, p=0.0038) and Dox + MEF-CM (191.4% ± 30.43% 
vs 100% ± 11.04%, p=0.0302) in comparison to the doxorubicin only treated group.  
Total 
Protein  
E-cadherin 
135 kDa 
Total 
Protein  
Vimentin 
37 kDa 
** 
** 
** 
** * 
Figure 3.68: Western Blot analysis of α-SMA and PDGFRα protein expression in E0771 breast 
cancer cells following MEF conditioned media treatment. Subsequent to 12 hours of glucose 
deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, (2) Doxorubicin + 
Control conditioned media, (3) Doxorubicin + Untreated MEF conditioned media (Dox + MEF-UTCM) and 
(4) Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 hours. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM 
(n=3). * = p<0.05 vs Doxorubicin and ** = p<0.01 vs Doxorubicin. 
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3.7: The Effects of Autophagic Manipulation in 
CAFs on the Migration Capacity of E0771 
Breast Cancer Cells 
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3.7. The Effects of Autophagic Manipulation in CAFs on the 
Migration Capacity of E0771 Breast Cancer Cells 
The induction of autophagy is thought be a central component of metabolic 
reprogramming in CAFs, and it is thought that the generation of metabolic intermediates 
through autophagy plays a central role in promoting epithelial cancer cell survival and 
metastasis (Wang et al., 2017). Therefore, this section of the study was aimed at partially 
elucidating the role of autophagic manipulation in CAFs on cancer cell migration. 
 
3.7.1. Verification of Atg5 Knockdown in MEF Cells 
Knockdown of Atg5 in MEF cells was confirmed with the use of Western blotting, after 
MEF cells were electroporated using 500 ng of esiRNA targeted against Atg5 for a period 
of 96 hours.  
Figure 3.69: Verification of Atg5 knockdown. MEF cells were electroporated with 500 ng esiRNA and 
the following groups established (1) Control, (2) Mock (no esiRNA), (3) eGFP and (4) Atg5. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM 
(n=3). *** = p<0.0001 vs control and ### = p<0.0001 vs eGFP. 
Total 
Protein  
Atg5 
56 kDa 
*** 
### 
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We observed a significant reduction in Atg5 protein expression levels was observed 
following 96 hours of 500 ng esiRNA treatment when compared to both control (5.890% ± 
1.597% vs 100% ± 6.608%, p<0.0001), and the negative (eGFP) esiRNA control cells 
(5.890% ± 1.597% vs 71.26% ± 6.067%, p<0.0001), indicating an approximate 94% 
silencing efficiency in the MEF cells. 
 
3.7.2. Cell Viability  
Subsequent to the verification of Atg5 knockdown, esiRNA containing media was removed 
and conditioned media was generated (as previously described, see section 2.3) from 
Atg5 knockdown MEFs. E0771 cells were then treated with Atg5 knockdown MEF 
conditioned media (Atg5 MEF-CM) for 24 hours and cell viability assays were performed.  
A significant reduction in MTT reductive capacity of E0771 cancer cells following treatment 
with Atg5 MEF-CM when compared to control (62.42% ± 6.372% vs 100% ± 3.613%, 
**
## 
Figure 3.70: Cell viability of E0771 breast cancer cells following Atg5 MEF-CM treatment. E0771 
cells were subjected to (1) Control, (2) Mock-CM, (3) eGFP-CM and (4) Atg5 MEF-CM. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM 
(n=3). ** = p<0.01 vs control and ## = p<0.01 vs eGFP. 
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p=0.0002) and the negative control eGFP group (62.42% ± 6.372% vs 101.3% ± 8.944%, 
p<0.01) was observed. 
 
3.7.3. Migration (Scratch) Assay  
Following the successful knockdown of Atg5 in “activated” MEFs, conditioned media was 
generated and used to treat E0771 breast cancer cells. Migration (scratch) assays were 
performed in E0771 cancer cells following Atg5 MEF-CM treatment for 24 hrs. Image 
acquisition and analysis was performed as previously described (see section 3.5.9).  
When compared to the control group, a significant reduction in the percentage of wound 
closure was observed at the 12, 18 and 24 hour time points in Mock-CM (12 hr: 15.21% ± 
4.864% vs 36.05% ± 4.514%, p<0.01, 18 hr: 22.24% ± 4.052% vs 52.23% ± 4.578%, 
p<0.0001 and 24 hr: 34.48% ± 3.778% vs 57.67% ± 2.354%, p<0.0001), eGFP-CM (12 
hr: 18.30% ± 2.246% vs 36.05% ± 4.514%, p<0.05, 18 hr: 20.84% ± 1.833% vs 52.23% ± 
4.578%, p<0.0001  and 24 hr: 27.72% ± 2.326% vs 57.67% ± 2.354%, p<0.0001) and 
Atg5 MEF-CM (12 hr: 14.96% ± 8.066% vs 36.05% ± 4.514%, p<0.01, 18 hr: 28.26% ± 
5.813% vs 52.23% ± 4.578%, p<0.0001 and 24 hr: 36.61% ± 7.787% vs 57.67% ± 2.354%, 
p<0.01) groups.  
However, when compared to the Mock-CM group no significant changes in the percentage 
of wound closure were observed for Atg5 MEF-CM group across all time points. 
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Figure 3.71: Representative time point images of the migration (scratch) assay performed on E0771 
murine breast cancer cells following treatment with Atg5 knockdown MEF-CM. E0771 cells were 
subjected to (1) Control (Dox), (2) Mock-CM (no esiRNA), (3) eGFP-CM (- ve control) and (4) Atg5 MEF-CM 
for 24 hours. Image analysis performed in ImageJ using an MRI_wound_healing plugin, and images displayed 
are for the 0, 12 and 24 hour time points only. 
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As we failed to see any statistically significant differences when comparisons against the 
mock-CM group were performed, the slopes of the regression lines (Figure 3.69) for each 
separate time point were again analysed.  However, this provided no new insights into the 
rate of change at which E0771 cells migrate into the wound when subjected to Atg5 
knockdown MEF-CM, as we observed no statistically significant differences in the slopes 
of the regression lines for all treatment groups, across all time points. 
 
Figure 3.72: Determining the effects of MEF conditioned media on the migratory capacity of 
E0771 murine breast cancer cells. Subsequent to 12 hours of glucose deprivation (0 mM glucose 
DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media, (3) Untreated MEF 
conditioned media (MEF-UTCM) and (3) E0771 treated MEF conditioned media (MEF-CM) for 24 
hours. Migratory capacity following treatment was assessed by means of a wound healing (Scratch) 
assay. Statistical analysis: Two-way ANOVA with Bonferroni post hoc correction. All results are 
presented as mean ± SEM (n=9). * = p<0.05 vs control, ** = p<0.01 vs control and *** = p<0.01 vs 
control. 
** 
* 
** 
*** 
*** 
*** ** 
*** 
*** 
Stellenbosch University  https://scholar.sun.ac.za
 172 
 
 
*p-values indicate slopes which are significantly non-zero 
 
Furthermore, the assessment of the rate of wound closure of E0771 breast cancer cells 
following treatment with Atg5 knockdown MEF conditioned media, revealed significantly 
decreased rates of migration at the 12 and 18 hour time points for the mock-CM (12 hr: 
126.8% ± 40.53% vs 300.4% ± 37.62%, p<0.05 and 18 hr: 123.5% ± 22.51% vs 290.2% 
± 25.43%, p<0.05) and eGFP-CM (12 hr: 152.5% ± 18.72% vs 300.4% ± 37.62%, p<0.05 
and 18 hr: 115.8% ± 10.18% vs 290.2% ± 25.43%, p<0.01) treatment groups when 
compared to control. A significantly decreased migration rate in the Atg5 treatment group 
was only observed at the 12 hour time point when compared to control (124.6% ± 67.22% 
vs 300.4% ± 37.62%, p<0.01). Again, when compared to both the mock-CM and eGFP-
CM control groups no statistically significant differences in the rate of E0771 cell migration 
was observed following treatment with Atg5 knockdown MEF-CM across all time points. 
 
 
 
Table 3.5: Determining the effects of Atg5 knockdown MEF conditioned media on the rate of 
change (slope) of migration of E0771 murine breast cancer cells.  
Proliferation Control Control Mock-CM eGFP-CM Atg5 MEF-CM
Slope 2.892 ± 0.7775 3.011 ± 0.7608 2.441 ± 0.8560 2.185 ± 0.5212 2.108 ± 0.5311
p-value 0.0019 0.0011 0.0115 0.0007 0.0011
Slope 3.387 ± 1.151 2.998 ± 1.070 0.09423 ± 1.179 0.8657 ± 0.6418 0.3847 ± 1.445
p-value 0.0096 0.0128 0.9373 0.1961 0.7935
Slope 4.815 ± 1.021 2.697 ± 1.072 1.170 ± 1.055 0.4231 ± 0.4832 2.217 ± 1.657
p-value 0.0002 0.0229 0.2836 0.3942 0.1996
Slope 2.396 ± 0.6966 0.9054 ± 0.8579 2.040 ± 0.9233 1.147 ± 0.4936 1.392 ± 1.620
p-value 0.0034 0.3069 0.0420 0.0336 0.4027
0-6 hrs
6-12 hrs
12-18 hrs
18-24 hrs
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Analysis of the slopes of each regression line for the rate of wound closure (Figure 3.70) 
again revealed no significant differences across all time points for all treatment groups.  
 
 
*p-values indicate slopes which are significantly non-zero 
Table 3.6: Determining the effects of Atg5 knockdown MEF conditioned media on the rate of 
change (slope) of migration of E0771 murine breast cancer cells.  
Proliferation Control Control Mock-CM eGFP-CM Atg5 MEF-CM
Slope 48.20 ± 12.96 50.18 ± 12.68 40.69 ± 14.27 36.41 ± 8.687 35.14 ± 8.851
p-value 0.0019 0.0011 0.0115 0.0007 0.0011
Slope 4.124 ± 14.76 -0.1045 ± 14.15 -19.56 ± 15.78 -10.99 ± 9.230 -14.36 ± 14.28
p-value 0.7835 0.9942 0.2331 0.2511 0.3294
Slope 9.308 ± 7.745 -1.707 ± 7.568 -0.5409 ± 7.727 -6.123 ± 3.552 5.394 ± 12.43
p-value 0.2469 0.8244 0.9451 0.1040 0.6701
Slope -5.426 ± 3.574 -8.318 ± 4.543 3.355 ± 4.578 -0.04404 ± 2.343 -0.7417 ± 7.630
p-value 0.1485 0.0858 0.4743 0.9852 0.9238
0-6 hrs
6-12 hrs
12-18 hrs
18-24 hrs
* 
* 
** 
* 
** 
Figure 3.73: Determining the effects of Atg5 knockdown MEF conditioned media on the rate 
of migration of E0771 murine breast cancer cells. E0771 cells were subjected to (1) Control, (2) 
Mock-CM (no esiRNA), (3) eGFP-CM (negative control) and (4) Atg5 MEF-CM for 24 hours. Rate of 
wound closure (% / hr) was calculated by dividing the % wound closure at each time point by the 
number of hours passed. Statistical analysis: Two-way ANOVA with Bonferroni post hoc correction. 
All results are presented as mean ± SEM (n=9). * = p<0.05 vs control and ** = p<0.01 vs control. 
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3.7.4. Epithelial-to-Mesenchymal Transition Assessment 
In order to determine if the migratory capacity of E0771 breast cancer cells subjected to 
treatment with Atg5 knockdown MEF conditioned media is influenced by a transition of 
these cells away from a metastatic phenotype, several key markers of epithelial-to-
mesenchymal transition were assessed using Western blot analysis. A significant 
reduction in α-SMA protein expression was seen following mock-CM treatment (9.798% ± 
1.144% vs 100% ± 10.39%, p=0.0044) in comparison to the control group. However, 
treatment with Atg5 MEF-CM resulted in a significant increase in α-SMA expression 
(139.0% ± 17.48% vs 9.798% ± 1.144%, p<0.0001) when compared to the mock-CM 
group.  
Figure 3.74: Western blot analysis of α-SMA and PDGFRα protein expression in E0771 breast 
cancer cells following treatment with Atg5 knockdown MEF conditioned media.  E0771 cells were 
subjected to (1) Control, (2) Mock-CM (no esiRNA), (3) eGFP-CM (negative control) and (4) Atg5 MEF-
CM for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). * = p<0.05 vs control, ** = p<0.01 vs control *** = p<0.0001 and ### 
= p<0.0001 vs mock-CM. 
PDGFRα 
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We observed a significant reduction in PDGFRα protein expression was observed in the 
mock-CM (5.034% ± 2.210% vs 100% ± 19.98%, p<0.0001), eGFP-CM (26.57% ± 6.828% 
vs 100% ± 19.98%, p<0.0001), and Atg5 MEF-CM (55.48% ± 4.670% vs 100% ± 19.98%, 
p=0.0477) treatment groups when compared to control. When compared to the mock-CM 
control group a significant increase in PDGFRα protein expression was seen in the Atg5 
MEF-CM group (55.48% ± 4.670% vs 5.034% ± 2.210%, p<0.05). 
 
When assessing vimentin expression in E0771 cancer cells a similar trend was observed, 
where we noted a significant reduction in vimentin expression following treatment with 
mock- CM (26.68% ± 6.932% vs 100% ± 15.79%, p=0.0008) and eGFP-CM (8.726% ± 
5.179% vs 100% ± 15.79%, p<0.0001) when compared to control. Additionally, when 
Figure 3.75: Western blot analysis of vimentin and E-cadherin protein expression in E0771 breast 
cancer cells following treatment with Atg5 knockdown MEF conditioned media. E0771 cells were 
subjected to (1) Control, (2) Mock-CM (no esiRNA), (3) eGFP-CM (negative control) and (4) Atg5 MEF-
CM for 24 hours. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). *** = p<0.0001 and ### = p<0.0001 vs mock-CM. 
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compared to the mock-CM group a significant increase in vimentin protein expression was 
seen following Atg5 MEF-CM treatment (143.3% ± 21.11% vs 26.68% ± 6.932%, 
p=0.0001). However no significant differences in the protein expression levels of the 
epithelial marker E-cadherin were observed across all treatment groups when compared 
to the control.  
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3.8: In vivo tumour-bearing C57BL/6 mouse 
model 
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3.8. In vivo tumour-bearing C57BL/6 mouse model 
While the use of conventional in vitro cell culture models provide valuable insight into a 
wide variety of pathological disease states, the use of these models fall severely short 
when it comes to the study of the tumour microenvironment and cell-cell interactions that 
promote tumour progression, metastasis and chemotherapeutic resistance. We therefore, 
employed a tumour-bearing C57BL/6 mouse model in order to better recapitulate the 
tumour microenvironment. 
 
3.8.1. The Effects of in vivo Doxorubicin Administration on Body 
Weight, Tumour Volume and Survival 
A total of 40 female C57BL/6 mice aged 8-weeks were randomly divided into four groups, 
and following one week of acclimatization, mice were inoculated into the fourth mammary 
fat pad with the syngeneic E0771 breast cancer cell line, whilst control animals received 
HBSS inoculations. Upon the appearance of palpable tumours, doxorubicin administration 
commenced as previously described (see section 2.17) with animals receiving a 
cumulative dose of 12 mg/kg over the course of the study design. Tumours were palpable 
as early as day nine following E0771 cell inoculations and by day fourteen all 20 tumour-
bearing animals had measurable tumours. Body weight and tumour volume 
measurements were recorded every second day.  
Assessment of body weights over the duration of the study showed no significant 
differences (Figure 3.76), although a trend to increase was observed in the tumour control 
and tumour + doxorubicin groups, indicative of an increase in tumour burden.   
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Assessment of tumour volume revealed a rapid increase in tumour burden in both the 
tumour control and tumour + doxorubicin groups (Figure 3.77). Despite the administration 
of doxorubicin, tumour volume increased at a rate comparable to that of control animals 
who did not receive doxorubicin. 
 
 
 
 
 
Figure 3.76: Average body weight of mice throughout the duration of study. Female C57BL/6 mice 
were randomised into four groups (1) Control, (2) Doxorubicin, (3) Tumour Control and (4) Tumour + 
Doxorubicin. All results are presented as mean ± SEM (n=10 per group).  
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Furthermore, a Kaplan-Meier survival analysis was performed in order to determine if any 
significant differences exist in the time taken to reach desired tumour volume (~400 mm3) 
between groups. Due to the development of bleeding ulcers at the site of doxorubicin 
injection humane endpoints were enforced for two mice (one from each the doxorubicin 
control and tumour + doxorubicin groups), and mice were thus sacrificed before the 
required tumour volume / end of the study period was reached. Although a separation of 
the curves of the tumour-bearing groups from non-tumour-bearing groups was observed 
to occur towards the end of the study (Figure 3.78), no statistically significant differences 
were observed between the groups (p=0.7125).  
 
 
Figure 3.77: Average tumour volume of mice throughout the duration of study. Female C57BL/6 
mice were randomised into four groups (1) Control, (2) Doxorubicin, (3) Tumour Control and (4) Tumour 
+ Doxorubicin. Only Tumour control and Tumour + Doxorubicin grouped animals received inoculation 
with carcinogenic E0771 murine breast cancer cells. Control animals received an isovolumetric 
inoculation with HBSS. All results are presented as mean ± SEM (n=10 per group).  
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Upon sacrifice, tumours and mammary fat pads were harvested from mice and processed 
appropriately for further analysis as described previously (see section 2.17.3). Briefly, 
tumours and mammary fat pads were divided into three sections for histological / 
immunofluorescence, Western blotting analysis (n=6 per group) as well as for primary 
epithelial organoid isolation (n=4 per group).  
 
3.8.2. Histology – Ultrastructure and Fibrosis Assessment 
Mammary fat pads were harvested from animals and served as non-carcinogenic control 
samples. Wherever possible, mammary fat pads from all four groups were analysed 
alongside the tumour samples harvested from tumour-bearing mice. Ultrastructure was 
assessed with the use of conventional haematoxylin and eosin (H&E) staining. 
Figure 3.78: Kaplan-Meier survival analysis showing the cumulative survival percentage of 
C57BL/6 mice throughout the course of the study. Female C57BL/6 mice were randomised into four 
groups (1) Control, (2) Doxorubicin, (3) Tumour Control and (4) Tumour + Doxorubicin. All results are 
presented as mean ± SEM (n=10 per group). Ӏ = censored animal (humane endpoint enforced). 
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Ultrastructural Assessment of Mammary Fat Pads 
Qualitative assessment of mammary fat pad ultrastructure showed no major ultrastructural 
changes between any of the groups, although it was noted that mammary fat pads 
harvested from tumour + doxorubicin animals showed more intense H&E staining. 
Figure 3.75: Kaplan-Meier survival analysis showing the cumulative survival percentage of 
C57BL/6 mice throughout the course of the study. Female C57BL/6 mice were randomised into four 
groups (1) Control, (2) Doxorubicin, (3) Tumour Control and (4) Tumour + Doxorubicin. All results are 
presented as mean ± SEM (n=10 per group). Ӏ = censored animal (humane endpoint enforced). 
3.79: Representative ultrastructural (H&E) ima es of mammary fat pads harvested from
. Fourth mammary fat pads (l ft and right) w re harvested from f male C57BL/6 mice.
Repre entative images displayed are from C ntrol (C) and Tumour C ntrol (TC) groups. Magnification 
at 4x and 10x. 
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Ultrastructural Assessment of Tumours 
Ultrastructural assessment of tumours revealed three distinct regions, an outer peripheral 
section which is densely compacted and stains strongly for nuclear material (purple 
staining), a middle region which appears less compact and stains less heavily for nuclear 
Figure 3.80: Representative ultrastructural (H&E) images of mammary fat pads harvested from 
C57BL/6 mice. Fourth mammary fat pads (left and right) were harvested from female C57BL/6 mice. 
Representative images displayed are from Doxorubicin (D) and Tumour + Doxorubicin (TD) groups. 
Magnification at 4x and 10x. 
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material and finally an inner region located towards the centre of the tumour where nuclear 
staining is drastically diminished (pink staining). These regions were observed in both the 
tumour control and tumour + doxorubicin groups.  
Figure 3.81: Representative ultrastructural (H&E) images of tumours harvested from C57BL/6 
mice. Tumours were harvested from female C57BL/6 mice. Representative images displayed are from 
Tumour Control (TC) and Tumour + Doxorubicin (TD) groups. Magnification at 4x and 10x. 
Stellenbosch University  https://scholar.sun.ac.za
 185 
 
Additionally, of interest we noted in both the tumour control and tumour + doxorubicin 
groups an increase in fat cell accumulation into the tumour site as well as the formation of 
neo-angiogenic blood vessels within the tumour mass. 
 
Figure 3.82: Representative ultrastructural (H&E) images of tumours harvested from C57BL/6 
mice. Tumours were harvested from female C57BL/6 mice. Representative images displayed are from 
Tumour Control (TC) and Tumour + Doxorubicin (TD) groups. Magnification at 4x and 10x. 
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Furthermore, as CAFs are known to result in extensive remodelling of the extracellular 
matrix leading to increased collagen deposition, we next assessed the extent of fibrosis in 
both mammary fat pads and tumours in response to tumour burden and doxorubicin 
treatment.  
 
Assessment of Fibrosis in Mammary Fat Pads 
Figure 3.83: Representative Picrosirius Red images of mammary fat pads harvested from C57BL/6 
mice. Fourth mammary fat pads (left and right) were harvested from female C57BL/6 mice. 
Representative images displayed are from Control (C) and Tumour Control (TC) groups. Magnification 
at 4x and 10x. 
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Extensive collagen deposition was observed surrounding blood vessels and between 
lobules. Qualitatively no obvious differences in fibrosis were observed between the 
control, tumour control and doxorubicin samples. However, a clear reduction in collagen 
deposition (signified by decreased red staining) was observed in the mammary fat pads 
of tumour-bearing mice who were treated with doxorubicin (tumour + doxorubicin).  
Figure 3.84: Representative Picrosirius Red images of mammary fat pads harvested from C57BL/6 
mice. Fourth mammary fat pads (left and right) were harvested from female C57BL/6 mice. 
Representative images displayed are from Doxorubicin (D) and Tumour + Doxorubicin (TD) groups. 
Magnification at 4x and 10x. 
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Assessment of Fibrosis in Tumours 
Again, as seen in the mammary fat pads we observed strong collagen staining 
surrounding neo-angiogenic blood vessels within the tumours. However, fibrosis was also 
seen to occur within the tumour itself and a significantly greater staining intensity was 
observed in tumour + doxorubicin in comparison to tumour control samples. 
Figure 3.85: Representative Picrosirius Red images of tumours harvested from C57BL/6 mice. 
Tumours were harvested from female C57BL/6 mice. Representative images displayed are from Tumour 
Control (TC) and Tumour + Doxorubicin (TD) groups. Magnification at 4x and 10x. 
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3.8.3. Assessing the Effects of in vivo Doxorubicin administration 
on Tumour Cell Proliferation and Fibroblast Infiltration 
Based on the observation that tumours display three distinct regions evident in the H&E 
ultrastructure assessment, we aimed to determine if these regions are representative of a 
Figure 3.86: Representative Picrosirius Red images of tumours harvested from C57BL/6 mice. 
Tumours were harvested from female C57BL/6 mice. Representative images displayed are from 
Tumour Control (TC) and Tumour + Doxorubicin (TD) groups. Magnification at 4x and 10x. 
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hypoxic / nutrient deprived gradient present within the tumour core. Therefore, 
immunofluorescence staining for proliferation in tumour samples only was performed 
using Ki67, a marker exclusive to cell proliferation. 
We observed clear regions of cell proliferation, evident by an increase in the mean 
fluorescent intensity, in both the tumour control and tumour + doxorubicin groups. 
However, only the tumour + doxorubicin group showed the distinctive proliferative regions 
corresponding to the H&E staining performed, a radial pattern of cell proliferation was 
observed instead in the tumour control group. Additionally, it was noted that the tumour + 
doxorubicin group also displays a larger region of highly proliferative cells in comparison 
to the tumour control group.   
 
 
 
 
 
 
 
 
Furthermore, as collagen deposition was observed to occur within tumour masses, and 
this was seen to increase with exposure to doxorubicin, we next aimed to determine 
whether an infiltration and “activation” of cancer-associated fibroblasts into the tumour 
stroma could account for the increased fibrosis we observed.  
Figure 3.87: Representative immunofluorescent images of tumours harvested from C57BL/6 mice. 
Tumours were harvested from female C57BL/6 mice and confocal microscopy was performed following 
staining for Ki67. Representative images displayed are from Tumour Control (TC) and Tumour + 
Doxorubicin (TD) groups. Magnification at 10x. 
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Figure 3.88: Representative immunofluorescent images of tumours harvested from C57BL/6 mice. Tumours were harvested from female C57BL/6 mice 
and confocal microscopy was performed following staining for α-SMA and vimentin. Representative images displayed are from Tumour Control (TC) and Tumour 
+ Doxorubicin (TD) groups. Magnification at 10x. 
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Immunofluorescent imaging of α-SMA and vimentin expression in tumours revealed areas 
of co-localization of α-SMA with vimentin in both the tumour control and tumour + 
doxorubicin groups. However, increased regions of co-localization between α-SMA and 
vimentin were observed in the tumour + doxorubicin group when compared to the tumour 
control group. 
 
3.8.4. Determining the Effects of Exogenous MEF-CM on the 
Invasive Capacity of Isolated Primary Epithelial Organoids 
In order to better understand the influences that CAFs have on enhancing the migratory 
and invasive capacity of epithelial cancer cells within the context of an in vivo tumour 
setting, epithelial organoids were isolated from both mammary fat pads and tumours and 
were then subjected to treatment with/out MEF conditioned media (MEF-CM) that was 
generated in the in vitro cell culture model, and subjected to a 3D branching 
morphogenesis assay. Briefly, mammary fat pads and tumours were dissociated and 
isolated epithelial organoids were plated in Matrigel® in order to maintain their 3D structure 
and prevent contact with the cell culture plastic ware. Organoids were then treated with 
MEF-CM and phase-contrast time-lapse images of primary epithelial cell invasion out of 
the organoid mass were acquired every 12 hours for a period of 60 hours.   
Based on the fact that tumours were inoculated into the fourth mammary fat pad, the 
separation of mammary fat pad epithelial organoids from tumour epithelial organoids is 
impossible. Additionally, epithelial cells form one of the smallest cell components of 
mammary fat tissue and only a few viable epithelial organoids can be isolated from a single 
mammary fat pad. As such, mammary fat pad epithelial organoids were only isolated from 
control and doxorubicin animals and utilized as non-cancerous controls.
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Figure 3.89: Representative phase contrast time-lapse images of epithelial organoids harvested from C57BL/6 mice. Primary epithelial organoids were 
isolated from dissociated mammary fat pads. Organoids were plated in Matrigel® and representative images displayed are from the Control (C) group of animals 
where organoids were subjected to treatment with either control media or MEF-CM. Magnification at 4x 
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Figure 3.90: Representative phase contrast time-lapse images of epithelial organoids harvested from C57BL/6 mice. Primary epithelial organoids were 
isolated from dissociated mammary fat pads. Organoids were plated in Matrigel® and representative images displayed are from the Doxorubicin (D) group of 
animals where organoids were subjected to treatment with either control media or MEF-CM. Magnification at 4x 
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Figure 3.91: Representative phase contrast time-lapse images of epithelial organoids harvested from C57BL/6 mice. Primary epithelial organoids were 
isolated from dissociated mammary fat pads. Organoids were plated in Matrigel® and representative images displayed are from the Tumour Control (TC) group 
of animals where organoids were subjected to treatment with either control media or MEF-CM. Magnification at 4x 
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Figure 3.92: Representative phase contrast time-lapse images of epithelial organoids harvested from C57BL/6 mice. Primary epithelial organoids were 
isolated from dissociated mammary fat pads. Organoids were plated in Matrigel® and representative images displayed are from the Tumour + Doxorubicin (TD) 
group of animals where organoids were subjected to treatment with either control media or MEF-CM. Magnification at 4x 
Stellenbosch University  https://scholar.sun.ac.za
 197 
 
Results from our 3D branching morphogenesis assay showed that organoids isolated from 
all groups of mice successfully lead to the invasion of primary epithelial cells into the 
Matrigel®. Enhanced invasion was observed following doxorubicin administration in 
animals, as we observed an increased migratory distance of leader edges from the 
organoid “mass” in the control media group when compared to that of organoids isolated 
from control animals. Furthermore, the treatment of organoids from the control, 
doxorubicin and tumour + doxorubicin groups with MEF-CM resulted in increased 
migration of epithelial cells into the Matrigel®. This was evident by either an increase in 
total “surface area”, seen in the control and doxorubicin groups, or an increase in the 
distance of the leader front (length) from the organoid “mass”. Of interest to note, is that 
in addition to the increased distance leader edges migrated in organoids isolated from the 
tumour + doxorubicin group, treatment with MEF-CM also resulted in epithelial cells 
detaching from their leader edge at the 48 hour time point. A subsequent “catch-up effect” 
of the leader edge was then observed in this group at the 60 hour time point. 
 
3.8.5. Determining the Role of Epithelial-to-Mesenchymal 
Transition in Response to in vivo Doxorubicin 
Administration  
Finally, we aimed to determine whether in vivo doxorubicin administration leads to 
alterations in epithelial-to-mesenchymal transition (EMT) in whole mammary fat pads and 
tumours of C57BL/6 mice. We therefore employed Western blot analysis for several key 
markers of EMT, namely; α-SMA, PDGFRα, vimentin and E-cadherin.  
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3.8.5.1. α-SMA and PDGFRα 
Analysis of α-SMA of mammary fat pads harvested from C57BL/6 mice revealed a 
significant reduction in α-SMA protein expression in the tumour + doxorubicin group when 
compared to control (51.58% ± 12.39% vs 100% ± 7.336%, p=0.0072), doxorubicin 
(51.58% ± 12.39% vs 104.0% ± 9.319%, p=0.0069), and tumour control (51.58% ± 12.39% 
vs 112.3% ± 15.21%, p=0.0113) groups.  
 
Although a trend to increased PDGFRα protein expression was observed in the 
doxorubicin and tumour control groups of the mammary fat pads, this was not statistically 
significant when compared to control. A significant reduction in PDGFRα protein 
Figure 3.93: Western blot analysis of α-SMA and PDGFRα protein expression in mammary fat 
pads of female C57BL/6 mice. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=6). ** = p<0.01 vs Control, ## = p<0.01 vs 
Doxorubicin and @@ = p<0.01 vs Tumour Control. 
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expression was however observed in the tumour + doxorubicin group when compared to 
the tumour control group (90.91% ± 10.49% vs 156.1% ± 18.83%, p=0.0091). 
 
Whole tumour Western blot analysis of α-SMA protein expression showed no significant 
differences in the expression of α-SMA in the tumour + doxorubicin group compared to 
that of the tumour control (p=0.1095). A significant reduction in PDGFRα protein 
expression was however observed in the tumour + doxorubicin group compared to the 
tumour control group (65.63% ± 5.950% vs 100% ± 4.069%, p=0.0008). 
 
Total 
Protein  
α-SMA 
37 kDa 
Total 
Protein  
PDGFRα 
190 kDa 
Figure 3.94: Western blot analysis of α-SMA and PDGFRα protein expression tumours of female 
C57BL/6 mice. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are 
presented as mean ± SEM (n=6). ***= p<0.0001 vs Tumour Control. 
*** 
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3.8.5.2. Vimentin and E-cadherin 
Western blot analysis of vimentin and E-cadherin protein expression in the mammary fat 
pads of mice showed a significant increase in vimentin expression in the tumour control 
group (8068% ± 1903% vs 100% ± 71.80%, p=0.0058) when compared to the control and 
doxorubicin (8068% ± 1903% vs 2441% ± 547.3%, p=0.0295) groups. Additionally, a 
significant decrease in vimentin protein expression was observed in the tumour + 
doxorubicin group (8068% ± 1903% vs 1769% ± 169.1%, p=0.0165) when compared to 
the tumour control group. Furthermore, a significant increase in E-cadherin expression 
levels in the tumour control group (222.5% ± 37.29% vs 100% ± 9.570%, p=0.0191) was 
observed when compared to the control group. 
Figure 3.95: Western blot analysis of vimentin and E-cadherin protein expression in mammary fat 
pads of female C57BL/6 mice. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=6). *** = p<0.0001 vs Control, # = p<0.05 vs 
Doxorubicin, @ = p<0.05 vs Tumour Control and @@ = p<0.01 vs Tumour Control. 
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Tumour analysis of vimentin and E-cadherin protein expression showed a significant 
reduction in vimentin expression in the tumour + doxorubicin group (62.54% ± 6.853% vs 
100% ± 11.04%, p=0.0163) in comparison to the tumour control. Whereas, significantly 
increased in E-cadherin expression was observed in the tumour + doxorubicin group 
(173.0% ± 17.07% vs 100% ± 10.96%, p=0.0048) when compared to the control group.  
 
 
Figure 3.96: Western blot analysis of vimentin and E-cadherin protein expression in tumours of 
female C57BL/6 mice. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All 
results are presented as mean ± SEM (n=6). * = p<0.05 vs Tumour Control, ** = p<0.01 vs Tumour 
Control. 
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Chapter 4: Discussion 
4.1. Introduction 
Tumours are now recognized as being highly complex tissues, with the stromal cell 
compartment (containing most notably, fibroblasts and endothelial cells) contributing 
significantly to the pro-tumourigenic and metastatic capabilities of cancerous epithelial 
cells. Previously, this contribution of stromal cells, in particular cancer-associated 
fibroblasts (CAFs), to the tumourigenic process has been largely underestimated.  
Cancer is a global concern, and the burden of this disease is rapidly on the rise in both 
developed and developing countries. Currently, the resistance of cancer cells to 
chemotherapeutic agents, like doxorubicin, is an ongoing and complex issue faced by 
both oncologists and patients alike. Increasing evidence implicates the molecular 
stromal-tumour interactions in the enhancement and progression of chemo-resistance. 
Furthermore, many preclinical models fail to accurately represent the influence of the 
tumour microenvironment (Singh et al., 2010) on cancer cell survival and progression 
towards a metastatic phenotype. As such there is a critical need for the development of 
novel treatment strategies which interfere with the metabolic capacity of the tumour 
microenvironment. 
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4.2. Induction of Oxidative Stress without Cell Death in E0771 
Breast Cancer Cells 
According to the ‘reverse Warburg effect’, nutrient/oxygen deprived epithelial cancer 
cells have the propensity to “educate” surrounding stromal cells to increase aerobic 
glycolysis and autophagy, resulting in the enhanced production of metabolites which can 
be utilized by epithelial cancer cells to sustain tumour growth and metastasis (Pavlides 
et al., 2009). Therefore, in this part of the study we aimed to establish a time course of 
glucose deprivation in murine E0771 breast cancer cells, which induces significant 
oxidative stress while still maintaining cell viability. We have demonstrated a 
compensatory mechanism in these cells to glucose deprivation, where a significant 
reduction in MTT reductive capacity was observed following 4, 8, 24, 48 and 72 hours of 
glucose deprivation. However, no significant decrease was seen following 12 hours of 
treatment with glucose deprived DMEM (Figure 3.1). These results are in accordance 
with data we obtained for four other human breast cancer cell lines (Figure 3.2 and 
Figure 3.3), as well as other studies where glucose deprivation in PC12 rat 
pheochromocytoma cells resulted in the rapid reduction in MTT reductive capacity 
immediately following glucose deprivation, with a slight increase occurring after 3 hours, 
where after MTT reductive capacity rapidly decreased over time (Liu et al., 2003).  
As glucose is the predominant substrate in neoplastic cells with high glycolytic rates, this 
could account for the rapid decrease in MTT reductive capacity we observed following 4 
and 8 hours of glucose deprivation in the E0771 cancer cells. The increased reductive 
capacity we observed after 12 hours of glucose deprivation could be a result of a 
compensatory mechanism, whereby E0771 cancer cells are able to switch their 
substrate utilization. This has been reported in several studies, whereby other substrates 
(such as amino acids and glutamine) present in culture media can be utilized for survival 
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(Tsun and Possemato, 2015, Tardito et al., 2015) in the absence of glucose. This could 
also explain the significant decrease in reductive capacity we observed with longer 
deprivation times, as the depletion of these utilized substrates would result in a second 
bout of metabolite starvation, and thus a rapid decrease in cell viability ensues. 
The inactivation of tumour suppressors and concomitant hyper-activation of oncogenes, 
has long been associated with the susceptibility of mammalian cells to proliferation 
(Pedraza-Fariña, 2006). Moreover, changes in cellular metabolism has been shown to 
be tightly coupled with cell proliferation (Matoba et al., 2006), and many of the tumour 
suppressor genes and oncogenes governing cell cycle arrest and proliferation are also 
known to regulate glucose uptake and utilization (Schwartzenberg-Bar-Yoseph et al., 
2004, Gao et al., 2009). This is not surprising, as during cellular proliferation cells are 
required to increase the availability of biomolecules and metabolites at a rate which is 
sufficient to meet the increased demand. In order to maintain sustained proliferative 
capabilities, cancer cells are required to fundamentally alter many of the pathways 
involved in nutrient utilization and energy metabolism to cope with the increased 
metabolic demands of proliferation, a “hallmark of cancer” proposed by Hanahan and 
Weinberg (2011). 
As cell proliferation is metabolically demanding, during the initial stages of inadequate 
nutrient supply, cellular metabolism is drastically reduced and cells resort to cell cycle 
arrest, favouring quiescence in order to promote survival. However, under conditions of 
prolonged nutrient deprivation, basal cellular metabolism cannot be maintained and the 
induction of apoptotic cell death ensues (Altman and Rathmell, 2012). Based on this 
knowledge, we assessed key protein markers of DNA damage (PARP) and apoptosis 
induction (caspase-3 and cleaved caspase-3) in parallel with oxidative stress (cytosolic 
H2O2 and mitochondrial O2-), in order to determine a time point where E0771 cancer 
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cells display increased oxidative stress in response to glucose deprivation without 
significantly inducing apoptotic cell death.  
Western blot analysis of the E0771 murine breast cancer cells in response to short term 
(4-12 hours) glucose deprivation, showed a slight, non-significant increase in PARP 
(Figure 3.4) and cleaved caspase-3 (Figure 3.5) expression following 8 hours of 
glucose deprivation. As the cleavage of caspase-3 results in its activation and the 
commitment of cells to apoptotic cell death (Elmore, 2007), the ratio of cleaved caspase-
3 to total caspase-3 expression provides further insight into the commitment of these 
E0771 cancer cells to apoptotic cell death following glucose deprivation. Our results 
showed that the ratio of caspase-3 to total caspase-3 was significantly increased 
following both 4 and 8 hours of glucose deprivation, but returned to control levels at the 
12 hour time point (Figure 3.5). A significant increase in mitochondrial superoxide (O2-) 
levels was also observed after 12 hours of glucose deprivation in the E0771 cancer cells 
(Figure 3.6b). However, no significant changes in cytoplasmic hydrogen peroxide (H2O2) 
levels were observed across all time points (Figure 3.6a). This may be explained by the 
fact that the antioxidant capacity of these cells was able to quickly neutralise any H2O2 
that may have been produced as a result of glucose deprivation induced stress. Taken 
together these results suggest that following complete glucose deprivation, a rapid 
induction of cell death occurs with a concomitant decrease in mitochondrial reductive 
capacity. However, as cancer cells have the propensity to easily switch their substrate 
utilization to suit the availability of metabolites, glucose deprived E0771 cancer cells 
were able to survive despite having increased mitochondrial oxidative stress after 12 
hours of glucose deprivation. 
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4.3. The Effects of Glucose Deprivation on the Proteome Secreted 
from E0771 Breast Cancer Cells 
It is widely accepted that the secretion of proteins plays a role in various aspects of cell 
signalling including cell-cell communication and migration. Over the last decade 
proteomic analysis of secreted proteins has facilitated the understanding of the 
molecular mechanisms underlying cell-cell communication and has fast become a viable 
approach in the identification of possible diagnostic and prognostic biomarkers in cancer 
(Patel, 2014). The understanding of the cellular “language” involved in the metabolic 
reprogramming of CAFs by epithelial cancer cells will thus have profound effects on 
future chemotherapeutic strategies, targeted to the tumour microenvironment. Therefore, 
in this section of the study, we aimed to utilize a bioinformatics approach to assess the 
protein composition of conditioned media generated from E0771 breast cancer cells 
following 12 hours of glucose deprivation, in order to determine possible candidate 
proteins involved in the metabolic reprogramming of MEFs. Our analysis of the proteome 
of E0771 conditioned media revealed a total of 61 protein elements exclusively present 
in glucose deprived E0771 conditioned media (E0771_GD), and a total of 41 protein 
elements were observed exclusively in control E0771 conditioned media (E0771_C) 
(Figure 3.7). Submission of the upregulated GO terms of E0771_GD into REVIGO 
resulted in a collapse of these proteins into several biological processes, many of which 
were shown to be involved in cell migration, cell-cell adhesion and glucose metabolism 
(Figure 3.9). 
We observed a significant clustering of proteins involved in gluconeogenesis and 
glycolysis in glucose deprived E0771 conditioned media (E0771_GD) (Figure 3.11). 
Most notably, we observed the upregulation of the glycolytic enzymes glucose-6-
phosphate dehydrogenase (G6PD), enolase (ENO) 1/3 and pyruvate kinase, muscle 
(PKM), this was initially surprising as glucose deprivation in E0771 breast cancer cells is 
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expected to result in a downregulation in glycolytic flux. However, functional annotation 
clustering (FAC) analysis in DAVID revealed a significant upregulation in in both protein 
catabolism and protein polyubiquitination (Figure 3.13). These data suggest that an 
increase in protein polyubiquitination and catabolism occur in response to glucose 
deprivation in E0771 breast cancer cells. The breakdown of these proteins could provide 
metabolic intermediates, resulting in an upregulation of glycolysis, and thereby serving 
as an essential energy source for E0771 breast cancer cell survival. 
Additionally, exosome-like vesicles isolated from breast and prostate tumour cells have 
been shown to contain proteins including, annexins (A1 and A2), actin, pyruvate kinase 
(M1 and M2), heat shock protein (HSP 90α), AHNAK and histone (H4) (Hosseini-
Beheshti et al., 2012, Kruger et al., 2014). All of which we observed to be significantly 
upregulated in glucose deprived E0771 conditioned media. Recently, the nucleoprotein 
AHNAK was shown to be highly expressed in human breast tumour samples and is 
critical for the production of extracellular vesicles, including exosomes, as well as the 
targeted directionality of these vesicles towards stromal fibroblasts, resulting in 
increased fibroblast migration (Silva et al., 2016). Based on this evidence, we postulate 
that the upregulation of AHNAK and other exosome-associated proteins in glucose 
deprived E0771 conditioned media might be as a result of enhanced exosomal release 
from these nutrient deprived cancer cells, and that this serves as a possible survival 
strategy utilized by epithelial cancer cells in response to decreased nutrient availability. 
Moreover, significant upregulation of the 14-3-3 protein domain was observed to occur in 
glucose deprived E0771 conditioned media (Figure 3.12). Increased 14-3-3 protein 
expression has been shown to contribute to a wide variety of tumour promoting 
processes in metastatic cancers (Wilker and Yaffe, 2004, Morrison, 2009, Aitken, 2011), 
and the overexpression of several 14-3-3 isoforms are associated with poor clinical 
outcomes and increased metastatic risk in patients with hepatocellular carcinoma (Liu et 
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al., 2011, Ko et al., 2011). In recent years the epsilon isoform of the 14-3-3 protein (14-
3-3ε) has been implicated in the regulation of cancer cell epithelial-to-mesenchymal 
transition (EMT), invasion and metastasis (Liu et al., 2013), and the overexpression of 
14-3-3ε contributes to EMT progression in hepatocellular carcinoma, by increasing 
vimentin and N-cadherin expression while also decreasing E-cadherin protein 
expression. Furthermore, the delta isoform 14-3-3δ, heterogeneous nuclear 
ribonucleoprotein K (HNRNPK) (Figure 3.12) and Annexin A1 have all been implicated 
in enhanced EMT and metastatic progression in cancer (Chaundhury et al., 2010, Ge et 
al., 2012, Sobral-Leite et al., 2015, Raychaudhuri et al., 2016), which we have shown 
are also significantly upregulated in glucose deprived E0771 conditioned media (Figure 
3.10 and Figure 3.12). Furthermore, as 14-3-3 has been shown to be secreted on 
extracellular vesicles, like exosomes, it is conceivable that the upregulation of the 14-3-3 
protein domain in glucose deprived E0771 conditioned media is further indicative of the 
presence of exosome release in response to glucose deprivation and that 14-3-3 
positive exosomes could play a role in the activation of EMT.  
Finally, the pro-metastatic and EMT inducing results we obtained were further 
corroborated by the observation that significant clustering of proteins involved in the 
canonical Wnt signalling pathway (Figure 3.9 and Figure 3.13) were seen using both 
REVIGO and DAVID. Classically, canonical Wnt signalling is β-catenin dependent and is 
well characterized for the role it plays in cancer progression and metastasis (Planutis et 
al., 2013, Lemieux et al., 2015). In mammalian cells, Wnt signalling is involved in the 
regulation of cell survival, adhesion, migration and invasion (Chen et al., 2001, 
Kurayoshi et al., 2006), and has also been implicated in EMT induction and progression 
(Vincan and Barker, 2008, Kahlert et al., 2012). The exosomal secretion of active Wnt 
ligands has been shown to exhibit functional signal-inducing activity upon their uptake in 
recipient cells. Furthermore, the recruitment and “activation” of CAFs in the tumour 
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microenvironment by the Wnt ligand Wnt7a is mediated by both canonical Wnt signalling 
as well as TGFβ receptor signalling (Avgustinova et al., 2016). Therefore, we further 
propose that the upregulation of proteins involved in Wnt signalling in glucose deprived 
E0771 conditioned media may additionally be secreted on exosomes and that this will 
exhibit functionality in recipient cells, leading to enhanced EMT and cell migration.  
As CAFs characteristically display signs of smooth muscle differentiation during their 
activation, which entails the acquisition of an enhanced mesenchymal phenotype (Busch 
et al., 2017), our results from the proteomics analysis of glucose deprived E0771 
conditioned media collectively suggest that 14-3-3 and other pro-metastatic proteins are 
secreted in exosomes, in response to 12 hours of glucose deprivation. Indeed, if this is 
the case the secretion of these exosomes, containing pro-EMT and plausibly metabolic 
cargo, could serve as a potential mechanism whereby E0771 breast cancer cells 
“activate” and metabolically reprogram stromal CAFs to promote their own survival. 
However, in order to validate this, conditioned media would need to be separated into 
different fractions and extensive research on the exosomal fraction would need to be 
conducted in order to; firstly, identify the presence of E0771 secreted exosomes and 
secondly, to determine the exact proteomic composition of these exosomes and how 
their cargo is altered in response to glucose deprivation. 
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4.4. Effects of E0771 Conditioned Media on Cancer-Associated 
Fibroblast Metabolism 
Within the tumour stroma CAFs are large spindle-shaped mesenchymal cells with well-
defined fibronexi and stress fibres (De Wever et al., 2008). The identification of CAFs 
within the tumour microenvironment relies on the concomitant expression of several key 
protein markers such as alpha smooth muscle actin (α-SMA), platelet derived growth 
factor receptor α/β (PDGFR α/β), vimentin, and several others (Hinz et al., 2007). 
Furthermore, in several cases CAFs have very low to negative expression of epithelial 
cell markers such as E-cadherin and CD31. In particular, cancerous regions present in 
invasive ductal carcinoma of the breast display increased α-SMA+ expressing 
myofibroblasts with decreasing CD34+ fibrocytes (Catteau et al., 2013). The increased 
expression of α-SMA in the tumour stroma has been shown to contribute to cytoskeletal 
organization and to inhibit fibroblast migration, thereby increasing the contractile ability 
of CAFs (Ronnov-Jessen et al., 1996). Additionally, the abundant infiltration of α-SMA 
positive CAFs has been shown to occur in metastatic 4T1 and 410.4 mouse mammary 
carcinomas, but fails to occur in less aggressive 4T07 tumours (Avgustinova et al., 
2016). 
Based on this evidence, we aimed to firstly determine whether normal mouse embryonic 
fibroblasts (MEFs) could be “activated” into a cancer-associated fibroblast phenotype. As 
such we made use of Western blotting analysis and confocal microscopy to assess the 
expression levels of several CAF-associated mesenchymal protein markers, namely; α-
SMA, PDGFRα and vimentin as well as the epithelial protein marker, E-cadherin. We 
observed a significant increase in the expression of α-SMA in MEF cells treated with 
glucose deprived E0771 conditioned media when compared to both control and control 
conditioned media (Figure 3.14 and Figure 3.15a). A significant increase in vimentin 
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(Figure 3.14 and Figure 3.16a) expression was also seen in both untreated and 
glucose deprived E0771 conditioned media. These results are in agreement with 
literature where the recruitment of mesenchymal stem cells (MSCs) into prostate 
tumours has been shown to induce CAF activation, evident by the increased acquisition 
of both α-SMA and vimentin expression (Jung et al., 2013). Furthermore, the “activation” 
of CAFs is additionally associated with the decrease and/or loss of the epithelial marker 
E-cadherin. This was indeed observed in response to glucose deprived E0771 
conditioned media in our Western blot analysis of E-cadherin protein expression (Figure 
3.16b). We observed no statistical differences in the protein expression of PDGFRα 
across all of the treatment groups (Figure 3.15b). Although PDGFRα is a known protein 
marker of CAFs (Erez et al., 2010) the fact that we did not observe a statistically 
significant increase in protein expression in response to glucose deprived E0771 
conditioned media was slightly unexpected. However, as PDGFRα expression is also a 
marker of the capacity of cells to undergo EMT (Zhang et al., 2016, Yang et al., 2017), 
the non-significant increase we observed following both untreated E0771 and glucose 
deprived E0771 conditioned media treatment (Figure 3.15b) indicates that these cells 
have the capacity to undergo transition to a more mesenchymal phenotype. Therefore, 
when taken collectively our results suggest that MEF cells are indeed “activated” to a 
CAF phenotype in response to E0771 conditioned media and more so when these 
E0771 cancer cells have been starved of glucose for 12 hours (E0771-CM).  
Subsequent to the verification that MEF cells are able to “activate” a CAF phenotype 
when exposed to glucose deprived E0771 conditioned media, we set out to determine 
the effects that E0771 conditioned media has on the metabolic profile of “activated” 
CAFs. Our results show that glucose deprived E0771-CM lead to a significant increase 
in MTT reductive capacity of “activated” CAFs (Figure 3.17). This result was unexpected 
as it is thought that during the “reverse Warburg effect” the activation of CAFs by the 
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transfer of oxidative stress from cancer cells induces mitochondrial dysfunction in CAFs 
(Martinez-Outschoorn et al., 2010). However, our result may be explained by the fact 
that in response to induced stress, mitochondria initially undergo a respiratory burst in a 
compensatory attempt to promote cell survival, resulting in a rapid increase in MTT 
reduction (Pruett and Loftis, 1990). It is thus conceivable that we could have observed a 
decrease in MTT reductive capacity following a longer treatment time. 
Martinez-Outschoorn and colleagues (2010) demonstrated that, within a co-culture 
system, MCF-7 human breast cancer cells can induce oxidative stress in adjacent 
hTERT immortalized fibroblasts. Based on this, we aimed to assess whether conditioned 
media derived from glucose deprived E0771 cancer cells would elicit the same response 
and induce oxidative stress in “activated” MEFs. We observed a significant increase in 
the mean fluorescent intensity of both DCF (cytosolic H2O2) and MitoSOX (mitochondrial 
O2-) in MEF cells that were treated with glucose deprived E0771-CM alone (Figure 
3.18). Our results are thus in accordance with those obtained by Martinez-Outschoorn 
and colleagues (2010).  
Hypoxia-inducible factor α (HIF-1α) is an essential component in the cellular adaptive 
response to hypoxia. The stabilization of HIF-1α has been shown to occur in response to 
both hypoxic and non-hypoxic stimuli (Richard et al., 2000). Although reactive oxygen 
species (ROS), including H2O2 and O2-, have been associated with the induction of HIF-
1α (Jung et al., 2008), the mechanisms underlying the induction and stabilization of HIF-
1α by ROS remains to be fully elucidated; it has however been proposed that under 
conditions of limited oxygen supply, the stabilization of HIF-1α is linked to the oxygen 
sensor capacity of ROS (Richard et al., 2000, Görlach et al., 2001). In addition to the 
regulatory role of ROS in HIF-1α stabilization, under both hypoxic and non-hypoxic 
conditions, nutrient sensing by adenosine monophosphate-activated protein kinase 
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(AMPK) activity also plays a critical role in regulating HIF-1α transcriptional activity 
during hypoxic conditions in a variety of cancer types (Lee et al., 2003). Our Western 
blot analysis of HIF-1α protein expression showed a significant increase following 
treatment with both untreated E0771 and glucose deprived E0771 conditioned media, 
suggesting that the stabilization of HIF-1α in “activated” MEFs by epithelial cancer cells 
occurs independently of nutrient deprivation (Figure 3.19). A possible explanation for 
the increased expression of HIF-1α we observed in the untreated E0771 conditioned 
media treatment group could be as a result of the ability of mitochondrial ROS to 
stabilize HIF-1α (Comito et al., 2011), although we did not observe a statistically 
significant increase in either MitoSox (Figure 3.18b) or DCF (Figure 3.18a) in MEF cells 
following untreated E0771 conditioned media treatment, the increase in mitochondrial 
superoxide levels seen may have become significant following a longer treatment 
period.  
The activation of HIF-1α has several critical functions, which include the maintenance of 
cellular redox and energy homeostasis. Most notably in the context of this study, HIF-1α 
stabilization plays an essential role in the induction of autophagy in several cancer cell 
types and in MEFs (Tracy et al., 2007, Bellot et al., 2009). The removal of ROS-
transformed mitochondria by the process of autophagy (more specifically, mitophagy) 
during hypoxic and nutrient deprived conditions, has been shown to reduce intracellular 
oxidative stress and promote cell survival (Scherz-Shouval et al., 2007, Chen et al., 
2009). The mammalian Target of Rapamycin (mTOR) functions as a critical sensor of 
intracellular nutrient availability. As such mTOR serves as a potent negative regulator of 
autophagic activity and a decrease in its activity leads to the induction autophagy 
through the activation of Atg13 and Unc-51-like kinase (ULK1), two of the main initiators 
of phagophore formation (Lozy et al., 2012). We observed a significant decrease in both 
mTOR (Ser2448) phosphorylation and total mTOR protein expression (Figure 3.20) 
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following the treatment of MEF cells with both E0771 untreated conditioned media and 
E0771 conditioned media, suggestive of the induction of autophagy. The induction of 
autophagy by decreased mTOR activity is accompanied by the increased expression of 
the autophagic marker LC3 II (Kimura et al., 2009). As such, we assessed LC3 II 
expression in MEF cells following E0771 conditioned media treatment and observed no 
significant changes in LC3 II protein expression across all treatment groups (Figure 
3.21a), which may suggest that autophagic flux has not been increased in response to 
E0771 conditioned media treatment. This result was unexpected as it has been 
proposed previously that autophagy is induced in stromal cells in response to increased 
oxidative stress (Pavlides et al., 2012, Maes et al., 2013) to provide glycolytic 
intermediates resulting in the enhanced production of L-lactate. In order to obtain a 
better understanding of the role of autophagy in MEF cells following E0771 conditioned 
media treatment, we assessed the protein expression of the autophagy receptor 
p62/SQSTM1 (p62). A significant increase in p62 protein expression was seen in MEFs 
following treatment with both untreated E0771 and glucose deprived E0771 conditioned 
media (Figure 3.21b). p62 recognises and binds to proteins tagged by ubiquitin, 
targeting them for degradation (Komatsu et al., 2007), and during the process of 
autophagosome formation, p62 associates with LC3 II sequestered to the inner surface 
of the phagophore (Mizushima et al., 2008). Autophagosomal cargo is subsequently 
delivered to lysosomes (Rabinowitz et al., 2010) where the release of lysosomal 
digestive enzymes results in the degradation of p62 as well as sequestered cellular 
constituents. As such, the accumulation of p62 we observed following E0771-CM might 
indicate impaired autophagosomal clearance. As mentioned previously, p62 is also an 
adaptor protein which plays a role in various other pathways, including the ubiquitin 
proteasome system (UPS) (Babu et al., 2005). Based on this, the increase in p62 protein 
expression we observed, might be attributed to enhanced activity of the UPS system in 
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MEFs when treated with E0771 conditioned media. The UPS also plays a critical role in 
proteasomal degradation and has been shown to play a role in the regulation of 
metabolic genes (Maneix et al., 2016). It is conceivable that enhanced UPS activity may 
play a role in regulating glycolysis in our treatment conditions, and could serve as an 
additional source (i.e. amino acids) of metabolic intermediates. 
Additionally, HIF-1α results in increased glycolytic flux by activating the transcription of 
genes regulating glucose transporters and glycolysis (Iyer et al., 1998, Seagroves et al., 
2001, Lum et al., 2007). Based on this, we assessed glucose uptake in MEF cells 
following treatment with E0771-derived conditioned media by utilizing the fluorescent 
deoxyglucose analog, 2-NBDG. We observed a significant increase in glucose uptake in 
MEF cells that were treated with conditioned media derived from glucose deprived 
E0771 cancer cells (Figure 3.22). We have also shown that this increase in glucose 
uptake is in part mediated by the glucose transporter, GLUT4 (Figure 3.23). The 
increased translocation of GLUT4 to the plasma membrane in response to glucose 
deprived E0771 conditioned can be explained by the fact that in insulin-sensitive tissues, 
the translocation of both the GLUT3 and GLUT4 transporters is stimulated by the 
presence of the growth factor insulin-like growth factor 1 (IGF-1) (Bryant et al., 2002). 
The role of GLUT4 mediated glucose uptake in MEF cells in response to treatment with 
E0771-CM is further substantiated by our proteomics data as an increase in IGF-1 was 
observed in the conditioned media derived from glucose deprived E0771 cancer cells 
(Figure 3.12). Collectively, our data suggest that in response to conditioned media 
derived from glucose deprived E0771 breast cancer cells, ROS-induced increased HIF-
1α leads to an increase in IGF-1 mediated GLUT4 translocation, thus increasing glucose 
uptake in “activated” MEF cells.  
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Under normal cellular conditions the end product of glycolysis, pyruvate is converted to 
acetyl-CoA, by the enzyme pyruvate dehydrogenase (PDH). Acetyl-CoA then enters the 
tricarboxylic acid (TCA) cycle resulting in an increase in energy production via oxidative 
phosphorylation. However, HIF-1α stabilization during conditions of increased cellular 
stress leads to the inhibition of PDH with the accumulation of intracellular pyruvate. As 
the inhibition of PDH prevents the conversion of pyruvate to acetyl-CoA, it is converted 
to lactate, allowing for continuous flux through glycolysis (Kim et al., 2006, Papandreou 
et al., 2006). Based on the theory that the “reverse Warburg effect” is a prominent 
feature within the tumour microenvironment, HIF-1α mediated inhibition of PDH is 
recognized as being a central component of the “reverse Warburg effect”. The increased 
glycolytic flux induced in CAFs, therefore leads to the enhanced production of 
metabolites such as lactate, which may be shunted to and utilized by oxygen and 
nutrient deprived epithelial cancer cells. Our aim was to determine whether HIF-1α 
activation results in the inhibition of PDH in MEF cells following treatment with E0771 
conditioned media. Our results showed a significant increase in the amount of PDH in 
MEFs in response to treatment with glucose deprived E0771 conditioned media (Figure 
3.24). However, the assessment of PDH activity showed no significant differences 
following treatment with E0771 conditioned media (Figure 3.25). This result was 
unexpected, however, the increase in the amount of PDH we observed in MEF cells 
following treatment with glucose deprived E0771 conditioned media could be as a result 
of a compensatory mechanism in an attempt to overcome an increase in glycolytic flux. 
The fact that we did not see an accompanying increase in PDH activity suggests that 
HIF-1α may indeed be influencing PDH activity, where the indirect inhibition of PDH by 
HIF-1α occurs via the direct induction of pyruvate dehydrogenase kinase (PDK). 
Therefore it is plausible that the induction of PDK by HIF-1α, may be time dependent 
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and as a result, a decrease in PDH activity would only be seen following longer 
treatment periods. 
We also set out to determine whether the enhanced glucose uptake we observed in 
MEF cells treated with E0771 conditioned media increases glycolytic flux with 
subsequent lactate production in these cells. We observed a significant increase in L-
lactate concentrations in MEFs cells following treatment with either untreated E0771 
conditioned media or glucose deprived E0771 conditioned media. However, no 
significant differences in L-lactate concentrations were observed in MEF cells treated 
with glucose deprived E0771-CM in comparison to untreated E0771 conditioned media 
(Figure 3.26). This might suggest that the ability of E0771 cancer cells to enhance L-
lactate production occurs independently of glucose concentrations. Nutrient deprived / 
hypoxic cancer cells are assumed to enhance the “reverse Warburg effect” in CAFs in 
comparison to normoxic cancer cells which receive adequate nutrients. However, due to 
the metabolic plasticity of epithelial cancer cells, oxygenated cancer cells have equal 
propensity to undergo metabolic symbiosis in order to satisfy their bioenergetics 
demands (Kennedy et al., 2010). 
The adaptability of cancer cell metabolism favours continuous tumour growth during 
periods of fluctuating glucose and oxygen tension within the changing tumour 
microenvironment. The monocarboxylate transporters (MCT) -1 and -4 are critical role 
players in the metabolic adaptability of cancer cells, which mediate the transport of 
several monocarboxylic acids, such as pyruvate and L-lactate across the plasma 
membrane (Pavlides et al., 2009). The existence of what has been termed the stromal-
epithelial “lactate shuttle” within the tumour allows for the transfer of L-lactate, produced 
by stromal CAFs, to epithelial cancer cells; thus allowing for increased flux through 
oxidative phosphorylation in epithelial cancer cells (Whitaker-Menezes et al., 2011). An 
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increase in the expression of the monocarboxylate exporter MCT-4, could signify an 
increase in the export of L-lactate we observed in MEFs treated with E0771 conditioned 
media. We therefore, assessed MCT-1 and MCT-4 protein expression in MEFs following 
E0771 conditioned media treatment. We observed a significant decrease in the 
expression of MCT-1, responsible for lactate import (Figure 3.27a). This result further 
supports the notion that E0771 conditioned media induces an increase in endogenous L-
lactate production in MEFs. However, when MCT-4 protein expression was assessed we 
observed no significant changes across all treatment groups (Figure 3.27b). This 
suggests that the increased L-lactate production in MEFs treated with E0771 
conditioned media is not exported out of the cell. However, as MCT-1 and MCT-4 are 
not the only monocarboxylate transporters present in fibroblasts, it is conceivable that 
the enhanced L-lactate we observed could be exported out of MEFs via MCT-2. 
Furthermore, as MEFs were treated with E0771 conditioned media for 24 hours, this 
treatment time may have been sufficient to induce an increase in L-lactate production 
but not long enough to induce MCT-4 receptor expression.  
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4.5. The Effects of E0771 Conditioned Media on the Proteome 
Secreted from Mouse Embryonic Fibroblast Cells 
As previously described, proteomic analysis of secreted proteins provides invaluable 
insight into the potential mechanisms underlying the cell-cell communications governing 
metabolic reprogramming within the tumour microenvironment.  Therefore, in order to 
determine candidate proteins which could possibly be involved in promoting E0771 
breast cancer cell survival and migration, we again aimed to utilize a bioinformatics 
approach to assess the protein composition of conditioned media generated from MEF 
cells previously treated with E0771 conditioned media. Broad assessment of protein 
elements which were differentially regulated between groups revealed a total of 7 protein 
elements exclusively present in conditioned media generated from MEF cells treated 
with E0771 untreated conditioned media (MEF_EUM) and a total of 23 protein elements 
exclusively to the conditioned media generated from MEF cells treated with glucose 
deprived E0771 conditioned media (MEF_ECM). Additionally a total of 32 elements were 
observed exclusively in control MEF conditioned media (MEF_C). Furthermore, we 
observed a total of 9 elements to be common to both MEF_C and MEF_ECM, 17 
common elements to MEF_C and MEF_EUM, and a total of 24 protein elements were 
found to be present in all three conditions (Figure 3.28).  
Interestingly, when GO terms and protein lists for both MEF_UTCM and MEF_CM were 
submitted in REVIGO and DAVID and collapsed into biological processes, we noted that 
several biological processes were observed to be significantly downregulated in 
MEF_UTCM (Figure 3.29) but were upregulated in MEF_ECM (Figure 3.36). Of these 
biological processes, Wnt signalling, protein polyubiquitination, glycolysis, 
gluconeogenesis and cell-cell adhesion were observed to be differentially regulated 
between MEF_UTCM and MEF_ECM. These results suggest that glucose deprived 
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E0771 breast cancer cells elicit differential metabolic reprogramming of MEF cells, 
resulting in the secretion of a pro-metastatic and glycolytic proteome, thereby 
highlighting the capacity of nutrient deprived breast cancer cells to reprogram the tumour 
microenvironment to suit their metabolic demands; thus promoting cancer cell survival 
and metastasis.  
In addition to the scatterplots, REVIGO also allows for the visualization and assessment 
of interactive graphs, which provides further insight into the hierarchical interactions 
between biological processes. Of interest, we observed a highly significant interaction 
between the tumour necrosis factor-mediated and the positive regulation of canonical 
Wnt signalling pathways. Aberrant tumour necrosis factor α (TNFα) signalling has been 
shown to promote cell migration thereby enhancing the metastatic dissemination of 
cancer cells (Karin and Greten, 2005, Kitakata et al., 2002, Li et al., 2012). Additionally 
the production of TNFα by stromal cells contributes significantly to tumour progression 
and is associated with poor clinical outcomes (Balkwill, 2002). However, the 
mechanisms whereby TNFα exerts these pro-metastatic effects in the tumour 
microenvironment remains to be fully elucidated. One mechanism that has been 
described involves the activation of Akt by TNFα, leading to the stimulation of NF-κβ and 
the upregulation of Snail (Julien et al., 2007).  
The zinc-finger protein Snail is a critical transcriptional repressor of E-cadherin, therefore 
the induction of Snail plays a fundamental role in epithelial-to-mesenchymal transition 
(EMT) and subsequent promotion of metastasis (Wu and Zhou, 2010). As such, TNFα is 
recognized as a being a profound role player in EMT-induced cancer cell migration and 
metastasis via the induction of NF-κβ/Snail signalling (Wu et al., 2009). TNFα has also 
been shown to induce Wnt/β-catenin signalling through the suppression of GSK-3β 
activity (Oguma et al., 2008). The activation of the Wnt signalling pathway in cancer 
further contributes to the induction of EMT through the upregulation of Snail (Yook et al., 
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2006). Moreover, exosomes released from synovial fibroblasts have been shown to 
contain a membrane bound form of TNFα (Zhang et al., 2006). Based on the knowledge 
that both Wnt ligands and TNFα are secreted in exosomes, we therefore speculate that 
the upregulation of proteins involved in both Wnt and TNF-mediated signalling observed 
in MEF_ECM (Figure 3.37) serves as a potential signalling mechanism whereby CAFs 
can promote cancer metastasis.  
In order to corroborate this, we analysed the functional annotation clustering (FAC) data 
obtained in DAVID for potential proteins associated with exosomes. Again, we observed 
a significant upregulation in the proteins annexins (A1 and A2), heat shock protein (HSP 
90α), S100 calcium binding protein A11 (S100A11) and charged multivesicular body 
protein 4B (CHMP4B), all of which are known to be secreted in exosome-like vesicles or 
endosomes (Wang et al., 2012, Greening et al., 2016). The upregulation of these 
exosome associated proteins in MEF_ECM indicates that exosomes may indeed be 
critical mediators in cell-cell communications within the tumour microenvironment.  
In addition to the hierarchical interactions observed between TNF and Wnt signalling, we 
also noted significant interactions between the MAPK cascade, proteolysis, glycolysis 
and protein polyubiquitination (Figure 3.38). Abnormalities in the mitogen-activated 
protein kinase (MAPK) cascade play a critical role in cancer progression (Sui et al., 
2014). Classically, the MAPK signalling pathway consists of the c-jun N-terminal kinase 
(JNK), the extracellular-signal-regulated kinase (ERK) and p38 MAPK (Hommes et al., 
2003). Upon activation, the MAPK signalling pathway exerts several cellular responses 
ranging from proliferation to apoptotic cell death (Dhillion et al., 2007). Recently, it has 
been proposed that in response to genotoxic stress, p38 MAPK and JNK are critical role 
players in the crosstalk between apoptosis and autophagy (Sui et al., 2014). The 
molecular mechanisms underlying p38 MAPK induced autophagy remain to be fully 
elucidated, however, it is thought that the phosphorylation of glycogen synthase 3β 
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(GSK3β) by p38 MAPK signalling results in autophagy-mediated cell survival (Choi et 
al., 2012); whereas, JNK mediated autophagic induction occurs via the dissociation of 
Beclin-1 from Bcl-2/Bcl-xL (Zhou et al., 2011). Moreover, the activation of both 
PI3K/Akt/mTOR and Ras/MAPK signalling cascades are associated with more 
aggressive cancer phenotypes, and poor clinical outcomes (Calvisi et al., 2011). In 
recent years, the molecular mechanisms underlying the functional cross-talk between 
PI3K/Akt/mTOR and Ras/MAPK signalling in cancer has gained widespread interest as 
a potential therapeutic target. mTORC1 has been shown to play a critical role in 
PI3K/Akt/mTOR and Ras/MAPK crosstalk, as the inhibition of mTORC1 results in the 
activation of both MAPK signalling (Carracedo et al., 2008) and autophagy (Wong et al., 
2015). Regardless of the molecular mechanisms underlying the interaction between 
MAPK signalling and autophagy, it is clear that the induction of these signalling 
pathways have wide spread consequences for the survival and progression of cancer.  
In addition to the interaction between autophagy and MAPK signalling in the promotion 
of cancer cell survival, cellular homeostasis is maintained through the tight regulation of 
both autophagy and ubiquitin proteasome system (UPS) mediated protein degradation 
(Lilienbaum, 2013). The careful orchestration between these two cellular degradative 
pathways is mediated by the cytosolic adapter protein p62/SQSTM1 (p62) (Puissant et 
al., 2012). As previously described the interaction between LC3 II and p62 is critical for 
autophagic protein degradation (Pankiv et al., 2007), however, p62 also influences UPS-
mediated protein degradation as the ubiquitin binding domain of p62 allows for the 
binding of ubiquitinated lysine residues, thus facilitating the delivery of ubiquitinated 
proteins to the proteasome system for degradation (Matsumoto et al., 2011). 
These results might suggest that in the context of our study, treatment of MEF cells with 
conditioned media generated from glucose deprived E0771 breast cancer cells result in 
enhanced protein catabolism through the induction of the ubiquitin proteasome system 
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(UPS) and possibly MAPK mediated autophagy. Increased protein catabolism in MEF 
cells could lead to the production of glycolytic intermediates which may be utilized by 
E0771 breast cancer cells for survival. These results combined with the enhanced 
glucose uptake (Figure 3.22) and L-lactate production (Figure 3.26) we observed with 
the molecular analysis of MEF cells following treatment with glucose deprived E0771 
conditioned media are suggestive of the induction of the “reverse Warburg effect”. 
However, further analysis on the role of the ubiquitin proteasome system and MAPK-
mediated autophagy in the induction of the “reverse Warburg effect” still needs to be 
assessed. 
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4.6. Effects of MEF Conditioned Media on E0771 Breast Cancer 
Cell Metabolism and Migration 
Signalling via the PI3K/Akt pathway in cancer contributes significantly to the promotion 
of cancer cell survival and tumour progression. The activation of the PI3K/Akt signalling 
pathway through both integrin and chemokine signalling has been well characterized 
(Datta et al., 1997). As cancer-associated fibroblasts are known to enhance tumour 
desmoplasia, the increased expression of integrins and chemokines during ECM 
remodelling leads to enhanced PI3K/Akt signalling (Lu and Kang, 2010). Our proteomics 
analyses of conditioned media obtained from MEF cells which had been treated with 
glucose deprived E0771-CM (MEF-CM) showed a significant increase in collagen type 
IV alpha 1 chain (COL4A1) (Figure 3.41). COL4A1 is an essential mediator of focal 
adhesion signalling and results in the activation of PI3K by focal adhesion kinase (FAK) 
(Chen et al., 1994). Furthermore, we also observed an increase in IGF-1 (Figure 3.41), 
an additional activator of PI3K/Akt signalling in cancer. Enhanced PI3K/Akt signalling in 
cancer cells has a wide variety of effects, the most prominent, within the context of this 
study, being the sustained proliferative signalling of epithelial cancer cells (Stemke-Hale 
et al., 2008) and epithelial-to-mesenchymal induced cancer cell migration (Fu et al., 
2015). Based on this, we assessed the cell viability of glucose deprived E0771 breast 
cancer cells following treatment with both treated and untreated MEF conditioned media. 
A significant increase in mitochondrial reductive capacity was seen following both MEF 
untreated conditioned media (MEF-UTCM) and MEF conditioned media (MEF-CM) when 
compared to control conditioned media (control-CM) (Figure 3.43). This is suggestive of 
either increased cell proliferation or mitochondrial stress, leading to a respiratory burst. 
In the context of our study, enhanced cell proliferation is unlikely to be occurring as we 
have shown that 12 hours of glucose deprivation in E0771 murine breast cancer cells 
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leads to a switch in substrate utilization (Figure 3.1), with an increase in mitochondrial 
oxidative stress (Figure 3.6b). It is therefore, more likely that the increase in MTT 
reductive capacity we observed when glucose deprived E0771 cancer cells are treated 
with MEF conditioned media, is as a result of increased mitochondrial stress and not 
enhanced cell proliferation. Additionally, when cell death was assessed by means of flow 
cytometry, we observed no significant changes in either live cell or dead cell populations 
across all treatment groups (Figure 3.44). This suggests that the activation of PI3K 
signalling within the context of this study is not involved in the induction of apoptotic cell 
death or cell proliferation but rather favours the survival of glucose deprived E0771 
cancer cells. 
As mentioned previously, MCT-1 is a critical role player in the metabolic adaptability of 
cancer cells, allowing for the import of L-lactate, produced by CAFs, into epithelial 
cancer cells (Whitaker-Menezes et al., 2011). As the increased expression of MCT-1 in 
epithelial cancer cells will allow for the enhanced uptake of L-lactate, we employed 
Western blot analysis to determine changes in the protein expression of both MCT-1 (L-
lactate import) and MCT-4 (L-lactate export). A significant increase in protein expression 
of MCT-1 with a concomitant decrease in the expression of the exporter MCT-4 was 
observed in glucose deprived E0771 breast cancer cells that were subjected to MEF-CM 
treatment in comparison to control (Figure 3.45b). Additionally, we observed a 
significant 2-fold increase in L-lactate concentrations in E0771 cells subjected to MEF-
CM treatment in comparison to control (Figure 3.46). Taken together, this data allows us 
to infer to a degree that L-lactate imported into E0771 cancer cells contributes to the 
increased L-lactate concentrations we observed.  
The concept of metabolic symbiosis implies that enhanced L-lactate concentrations 
within the tumour microenvironment leads to the net flux of L-lactate into epithelial 
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cancer cells where the conversion of L-lactate to pyruvate leads to enhanced oxidative 
phosphorylation and energy production (Sotgia et al., 2012).  As such, ATP production 
was assessed in E0771 breast cancer cells following MEF conditioned media treatment. 
We observed a significant increase in ATP concentrations in E0771 breast cancer cells 
following MEF-CM treatment alone in comparison to both the control and control-CM 
groups (Figure 3.47), supporting the notion that metabolites derived from metabolically 
reprogrammed CAFs are utilized by epithelial cancer cells for energy production and 
subsequent enhanced cell survival. Based on this and the fact that cancer cells have the 
propensity to utilize oxidative phosphorylation as an additional energy source during 
periods of increased metabolic demand (“reverse Warburg effect”) (Ward et al., 2012), 
the enhanced ATP concentrations we observed following MEF-CM treatment may be 
indicative of an increase in the flux of metabolites through oxidative phosphorylation.  
Pyruvate dehydrogenase forms part of a multi-subunit complex, termed the pyruvate 
dehydrogenase complex (PDC), which catalyzes the irreversible rate-limiting 
decarboxylation of pyruvate to acetyl-CoA. The availability of pyruvate entering oxidative 
phosphorylation is therefore entirely dependent on the enzymatic activity of the PDC, 
and therefore represents a critical regulatory step in glucose metabolism (McFate et al., 
2008). Therefore, for this study we carried out a pyruvate dehydrogenase (PDH) 
enzymatic activity assay in conjunction with a protein profile assay as a determinant of 
the oxidative phosphorylation capacity of E0771 breast cancer cells subjected to 
treatment with MEF conditioned media. Our results showed no significant differences in 
either the protein profile of PDH (Figure 3.48) or the enzymatic activity of PDH (Figure 
3.49) in E0771 murine breast cancer cells across all treatment groups.  Although we did 
not observe an increase in PDH activity in response to MEF-CM treatment, we cannot 
conclusively state that the overall flux of oxidative phosphorylation remains unchanged. 
Due to the complex nature of cancer cell metabolism coupled with the propensity of 
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cancer cells to switch substrate utilization due to metabolic plasticity; it is therefore 
plausible that increased oxidative phosphorylation could still take place in E0771 breast 
cancer cells following treatment with MEF-CM, where TCA intermediates are generated 
and shunted into oxidative phosphorylation bypassing PDH. For instance, it is known 
that enhanced reductive carboxylation of glutamine-derived acetyl-CoA often occurs in 
cancer cells with diminished mitochondrial activity (Wise et al., 2011, Metallo et al., 
2012). Based on this, additional metabolic assessments on E0771 breast cancer cells 
treated with MEF conditioned media will need to be conducted in order to fully elucidate 
whether the ”reverse Warburg effect” is indeed playing a role in maintaining E0771 
breast cancer cell survival. 
Furthermore, increased expression of pyruvate dehydrogenase kinase -1 (PDK-1), a 
potent antagonizer of PDH, plays a critical role in mediating the metastatic potential (Du 
et al., 2015) and regulation of metabolic reprogramming (Battello et al., 2016) in breast 
cancer cells which preferentially disseminate to the liver. Dupuy and colleagues (2015) 
also demonstrated that PDK-1 is essential for the effective dissemination and formation 
of liver metastases, evident by a reduction in both metastatic lesion number and size in 
Balb/c mice receiving splenic injection of cells expressing PDK-1 targeted shRNA 
(shPDK1) in comparison to control shRNA (shLUC) expressing cells (Dupuy et al., 
2015). 
When this is considered, in conjunction with the increased clustering of proteins involved 
in cell migration and metastasis from our proteomic analysis of MEF_ECM (Figure 3.36 
and Figure 3.37), it becomes clearer and more likely that treatment of E0771 breast 
cancer cells with MEF_ECM is involved more prominently in enhancing the metastatic 
phenotype of these E0771 cells. As such, the next aim of this study was therefore to 
determine the effects of MEF conditioned media in mediating E0771 cell migration and 
progression to a metastatic phenotype. We therefore made use of a migration (scratch) 
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assay to monitor and assess the capacity and rate of E0771 cancer cell migration in 
response to treatment with MEF conditioned media.  
An interesting observation noted for both the untreated MEF conditioned media (MEF-
UTCM) and MEF-CM treated groups was a steep increase in the slopes of the 
generated curves between 12 and 18 hours of conditioned media treatment, signifying 
an increase in the migratory speed (rate of change) of E0771 breast cancer cells in 
response to treatment with MEF conditioned media. Therefore, in order to determine if 
the speed at which E0771 cells treated with MEF conditioned media migrate is 
significant when compared to control, separate linear regression lines were generated 
between each time point. Between 12 - 18 hour treatment points a significant increase in 
in the slope of the linear regression line (migratory speed) was observed in MEF-UTCM 
and MEF-CM treated E0771 cancer cells (Table 3.1). Collectively, these results are in 
accordance with those obtained by Hu and colleagues (2013) where an increase in the 
transverse migratory capacity of SGC-7901 gastric cancer cells was observed following 
24 hours of exposure to CAF conditioned media (Hu et al., 2013).  
During the process of metastatic dissemination, epithelial cancer cells are obligated to 
acquire the ability to invade through the basement membrane, disseminate through the 
circulatory system and then proliferate at distant metastatic sites (Egeblad et al., 2008, 
Fein and Egeblad, 2013). The ability of cancer cells to invade is dependent on their 
acquisition of a more migratory phenotype, characterized by an increase in 
mesenchymal cell markers, such as vimentin, α-SMA and PDGFRα and others (Wei et 
al., 2008, Lee et al., 2013, MacDonald et al., 2001). Therefore, in order to determine 
whether the enhanced speed of migration observed in E0771 breast cancer cells 
following treatment with MEF conditioned media, we employed Western blotting 
analyses for four key markers of epithelial-to-mesenchymal transition (EMT). Our results 
showed a significant increase in the mesenchymal markers α-SMA (Figure 3.54a) and 
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vimentin (Figure 3.55a) in E0771 breast cancer cells in response to MEF-CM treatment 
alone. In order to more accurately determine whether E0771 cancer cells have acquired 
a more migratory capacity, an increase in mesenchymal markers needs to be 
accompanied by a loss or decrease in epithelial cell markers. As E-cadherin constitutes 
the prominent cell-adhesion molecule responsible for maintaining tight epithelial cell-cell 
adhesion, the downregulation of E-cadherin in cancer is associated with EMT induction 
and enhanced tumour invasion (Von Burstin et al., 2009). Therefore, E-cadherin is often 
utilized as an essential marker of EMT in cancer cells. Our results showed a significant 
reduction in E-cadherin protein expression in E0771 breast cancer cells following 
treatment with MEF-UTCM as well as with MEF-CM in comparison to control (Figure 
3.55b). Collectively, this data suggests that treatment of E0771 breast cancer cells with 
MEF conditioned media does indeed result in the acquisition of a more mesenchymal 
phenotype. This is consistent with several studies where CAF-mediated EMT induction 
in PC3 cells results in the enhanced motility and the acquisition of a stem-like behaviour 
(Giannoni et al., 2011, Xiao et al., 2014, Guan et al., 2014, Lau et al., 2016). 
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4.7. Effects of MEF Conditioned Media on Doxorubicin resistance 
in E0771 Breast Cancer Cells 
Anthracyclines, such as doxorubicin, are considered as some of the most effective 
chemotherapeutic agents for the treatment of breast cancer (Barrett-Lee et al., 2009). 
Unfortunately, anthracyclines are also cytotoxic and affect a wide variety of physiological 
systems. Aside from the severe cumulative dose-dependent side effects, resistance of 
cancer cells to chemotherapeutic strategies (chemo-resistance) has become an ongoing 
complex issue faced by many cancer patients. Tumours may become resistant to a wide 
range of chemotherapies, during the process of acquiring resistance, this ultimately 
leads to an approximate 90% failure rate seen with the treatment of metastatic breast 
cancer (MBC) (Coley et al., 2008). Furthermore, the majority of patients diagnosed with 
breast cancer will at some point have a recurrence of the disease, resulting in a poorer 
clinical outcome. It is widely accepted that cancer cell response to chemotherapeutic 
agents, including doxorubicin, is strongly influenced by signals derived from stromal cells 
present within the tumour microenvironment (Velaei et al., 2016).  
In the past, the tumour microenvironment and the influence of stromal cells in advancing 
tumour progression and metastasis has been largely underestimated, as such research 
into understanding the influence of the tumour microenvironment in conferring 
chemotherapeutic resistance to epithelial cancer cells has gained increasing attention. 
The next part of this study, was therefore established in order to elucidate the effects 
that MEF-CM in combination with doxorubicin has on E0771 breast cancer cell 
metabolism and migration. We first set out to determine a lower, clinically relevant dose 
of doxorubicin which leads to significant cell death in the chemotherapy resistant E0771 
murine breast cancer cells (Figure 3.56). Our results demonstrate that 2.5 µM 
doxorubicin lead to a significant reduction in MTT reductive capacity of E0771 cancer 
cells. The combination of MEF-CM with doxorubicin treatment resulted in a significant 
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increase in the mitochondrial reductive capacity of E0771 breast cancer cells (Figure 
3.57). This result is similar to those obtained in the previous section where MEF-CM 
alone resulted in a significant increase in MTT reductive capacity of E0771 cells. As 
described previously, this increase in mitochondrial reductive capacity likely 
demonstrates a mitochondrial respiratory burst (van de Loosdrecht et al., 1994, 
Stephanenko and Dmitrenko, 2015) and not increased cell proliferation. Assessment of 
cell death by means of flow cytometry showed a significant increase in the dead cell 
population with a concomitant decrease in the live cell population of E0771 cells treated 
with MEF-CM and doxorubicin (Figure 3.58), suggesting that MEF-CM was able to 
overcome doxorubicin resistance in E0771 breast cancer cells. However, in order to 
accurately determine the mode of cell death that occurs in E0771 breast cancer cells in 
response to MEF-CM in addition to doxorubicin treatment, additional assays to assess 
autophagy, apoptosis and necrosis would need to be performed. 
In order to determine the role that doxorubicin plays in the induction of the “reverse 
Warburg effect” in E0771 cancer cells treated with MEF conditioned media, we again 
assessed the protein expression of the L-lactate transporters, MCT-1 and MCT-4. We 
observed a significant increase in the expression of the exporter MCT-4 following MEF-
CM treatment in combination with doxorubicin treatment when compared to the 
doxorubicin control group (Figure 3.59b). A significant increase in the concentration of 
L-lactate was observed in E0771 cancer cells treated with the combination of 
doxorubicin and MEF-CM (Figure 3.60), indicating that this L-lactate can be shunted into 
oxidative phosphorylation and utilized by E0771 breast cancer cells, contributing to the 
enhanced ATP production we observed (Figure 3.61).  
Doxorubicin is a weak basic chemotherapeutic agent which has an acid dissociation 
constant of 7.5 - 9.5, as such the cellular uptake of doxorubicin is significantly reduced in 
tumours where increased interstitial lactate results in a lowered pH (Gerweck et al., 
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2006, Mellor et al., 2011). Therefore, a further explanation for the increased expression 
of MCT-4 and significant increases in L-lactate we observed in E0771 breast cancer 
cells treated with MEF-CM in combination with doxorubicin, might be that the enhanced 
export of L-lactate out of E0771 cancer cells results in an increased acidification of the 
surrounding cellular environment, in an attempt to significantly reduce doxorubicin 
uptake.  
As described previously, PDH catalyzes the conversion of pyruvate to acetyl-CoA 
thereby governing the metabolic transition of glycolysis to oxidative phosphorylation 
(Golias et al., 2016). Our results showed a significant increase in the protein profile of 
PDH in E0771 cancer cells treated with MEF-CM in combination with doxorubicin in 
comparison to all other treatment groups (Figure 3.62), this result was promising with 
regards to the induction of the “reverse Warburg effect”, however, when we assessed 
PDH enzymatic activity in these cells, no significant differences were observed across all 
treatment groups in comparison to control (Figure 3.63). This suggests that although 
overall PDH protein expression is upregulated following 24 hours of MEF-CM plus 
doxorubicin treatment, the activation of PDH remains the same and therefore the 
enzymatic conversion rate of pyruvate to acetyl-CoA remains constant. When the non-
significant increase in L-lactate levels we observed is taken into account with an 
enhanced PDH expression, it becomes plausible that the induction of the “reverse 
Warburg effect” could be occurring in E0771 cancer cells treated with MEF-CM in 
conjunction with doxorubicin. However, additional metabolic assessment using 
isotopically labelled metabolic substrates (such as 13C-glucose) need to be performed in 
order to fully elucidate the contribution of the “reverse Warburg effect” to E0771 breast 
cancer metabolism, within the context of this study.  
The systemic use of chemotherapeutic agents for the treatment of cancer has been 
shown to effectively eradicate cancer cells, however, more and more commonly 
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increased resistance to chemotherapeutic agents and enhanced metastases has been 
reported (Li et al., 2015, Daenen et al., 2011). Based on this we set out to determine the 
combined effects of doxorubicin and MEF-CM treatment on E0771 breast cancer cell 
migration and the induction of EMT. Our results showed a significant reduction in the 
migratory capacity of E0771 breast cancer cells in response to the combined treatments 
of doxorubicin with MEF-UTCM across all time points (Figure 3.64), suggesting that 
fibroblasts that have not been activated to a CAF phenotype lead to a reduction in the 
metastatic capacity of epithelial breast cancer cells. Similar to the results obtained for 
the treatment of E0771 cells with MEF-CM alone (Figure 3.52), we noted a significant 
increase in the slopes of the generated curves between 12 and 18 hours of the 
combined treatment using MEF-CM and doxorubicin, again signifying an increase in the 
migratory speed (rate of change) of E0771 breast cancer cells. Similarly, separate linear 
regression lines were generated between each time point in order to determine if the 
speed at which E0771 cells migrate was significant when compared to doxorubicin alone 
(Table 3.3). Between 12 - 18 hour treatment points, a significant increase in in the slope 
of the linear regression line (migratory speed) was observed in Doxorubicin and MEF-
CM combination treated E0771 group. 
The induction of epithelial-to-mesenchymal (EMT) has been suggested to confer both 
chemoresistance and metastatic properties in breast cancer cells (Kurrey et al., 2009, 
Hollier et al., 2009). Furthermore, in addition to its’ therapeutic effects, doxorubicin has 
also been implicated in enhanced malignancy through the induction of EMT. Both β-
catenin and TGFβ-signalling are critical for the process of doxorubicin-induced EMT in a 
variety of human cancer types, including gastric and breast cancer (Han et al., 2013). 
Therefore, we assessed the protein expression levels of several key markers of EMT to 
determine the effects of doxorubicin in combination with MEF conditioned media on EMT 
induction. Our results showed a significant reduction in α-SMA and PDGFRα protein 
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expression (Figure 3.67) following doxorubicin treatment in combination with both MEF-
UTCM and MEF-CM in E0771 breast cancer cells. Additionally, we noted a significant 
increase in both vimentin and E-cadherin protein expression (Figure 3.68) following the 
combined treatments of doxorubicin with MEF-UTCM or MEF-CM. The significant 
reduction in PDGFRα expression we observed suggests an overall decrease in EMT in 
E0771 breast cancer cells, despite the increase in vimentin expression we observed. 
However, in doxorubicin resistance breast cancer cells, vimentin expression serves as a 
critical marker of metastatic capacity (Pan et al., 2012, Tezcan and Gündüz, 2014), 
evident by the fact that silencing of vimentin is associated with a drastic reduction in both 
metastasis and invasiveness (McInroy and Määttä, 2007). Based on this evidence, the 
increase in vimentin expression we observed, suggests that an increase in the 
metastatic ability of E0771 breast cancer cells occurs as a result of doxorubicin 
treatment alone and more so when combined with MEF conditioned media. Our results 
are consistent with several other studies which have demonstrated a significant increase 
in vimentin expression following long term doxorubicin treatment (Li et al., 2015).   
EMT is a dynamic and relatively fluid process, wherein the conversion of epithelial cells 
into a mesenchymal state is not necessarily an irreversible commitment (Zheng et al., 
2015). In tumours, the presence of cells which have converted fully to a mesenchymal 
state is rare, and most commonly quasi-mesenchymal phenotypes are observed, 
wherein partial EMT has occurred. Furthermore, recent evidence suggests that the equal 
co-expression of both epithelial (E) and mesenchymal (M) signatures, defined as an E/M 
state, is associated with increased plasticity, self-renewal and stemness (Grosse-Wilde 
et al., 2015) which indicates a more metastatic phenotype. As such it is conceivable that 
with the combination of doxorubicin and MEF-CM treatment, E0771 breast cancer cells 
undergo partial EMT, and therefore the increased co-expression of vimentin and E-
cadherin represents a quasi-mesenchymal state. 
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4.8. The Effects of Autophagic Manipulation in CAFs on the 
Migration Capacity of E0771 Breast Cancer Cells 
The autophagic process plays a critical role in maintaining cellular homeostasis and 
biogenesis during periods of nutrient deprivation / hypoxia (Pavlides et al., 2012). During 
tumourigenesis, autophagy provides a pro-survival advantage to cancer cells (Tόth et 
al., 2002). In the context of the tumour microenvironment, the induction of stromal 
autophagy in addition to enhanced nutrient import by cancer cells allows for the 
recycling of nutrients, thus supporting tumour growth and proliferation (Katheder et al., 
2017)   
Based on this knowledge, we used Atg5 as a molecular target to assess the role of 
autophagy in CAFs on the migratory capacity of E0771 breast cancer cells. Therefore, 
we made use of an endoribonuclease-prepared siRNA (esiRNA) against the murine Atg5 
gene to effectively silence Atg5 protein expression in MEFs. Prior to assessing the 
effects of conditioned media generated from Atg5 knockdown MEFs, we verified the 
silencing of Atg5 in MEF cells using Western blot analysis. Our results, show that we 
were able to achieve a silencing efficiency of 94% using 500 ng of Atg5 esiRNA for a 
period of 96 hours (Figure 3.69), we therefore made use of this concentration and time 
point for all subsequent transfections done to generate Atg5 knockdown MEF 
conditioned media (Atg5 MEF-CM).  
In order to determine whether autophagic manipulation in CAFs can counteract the 
survival effects we observed in E0771 breast cancer cells following treatment with MEF 
conditioned media (Figure 3.43 and Figure 3.44), we carried out MTT viability assays 
on E0771 cancer cells following treatment with Atg5 knockdown conditioned media 
(Atg5 MEF-CM). Our results show that Atg5 MEF-CM effectively reduces the MTT 
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reductive capacity of E0771 breast cancer cells when compared to untreated E0771 
cells (control) as well those that had been treated with mock-CM (no esiRNA). This 
suggests that the decrease in MTT reductive capacity, and therefore a decrease in cell 
viability, is as a direct result of Atg5 silencing in MEFs and not due to the transfection 
procedure itself. This result is a promising indication that the inhibition of autophagy in 
stromal CAFs could serves as a potential therapeutic target for the treatment of breast 
cancer. However, this avenue would need more extensive research, in order to elucidate 
whether the targeting of CAF autophagy could potentially sensitize epithelial breast 
cancer cells to the cytotoxic effects of chemotherapeutic drugs, like doxorubicin.  
The role of autophagy in cancer metastasis is another “double-edged sword” as during 
the initial stages of metastatic dissemination, autophagy inhibits invasion of cancer cells 
by restricting necrosis-induced inflammation and inducing cell death (DeNardo et al., 
2009, Mukhopadhyay et al., 2014). However, during advanced stages of metastasis, 
enhanced survival of ECM-detached cancer cells, autophagy serves as a pro-metastatic 
process protecting cancer cells from cellular stressors encountered at distant metastatic 
tumour sites (Han et al., 2008, Herrero-Martín et al., 2009). Furthermore, the production 
of pro-migratory and invasive factors through autophagy has been shown to promote 
Ras-driven invasion and migration of cancer cells (Lock et al., 2014).  
In addition to the pro-survival role that autophagy in CAFs has been proposed to play in 
cancer cell survival (Wang et al., 2017b), enhanced autophagy in surrounding stromal 
CAFs is thought to also promote metastatic dissemination of epithelial cancer cells. This 
is thought to occur as a result of the secretion of circulating chemokines and pro-
metastatic factors, including matrix metalloprotease-9 (MMP-9) and lysyl oxidase (LOX) 
(Erler et al., 2009). Additionally, Wang and colleagues recently demonstrated that 
conditioned media derived from isolated CAFs with enhanced autophagy not only 
enhanced survival, but also resulted in the promotion of EMT in triple negative breast 
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cancer cells when compared to conditioned media derived from normal fibroblasts 
(Wang et al., 2017a). However, it is currently not clear whether the processes of 
autophagy and EMT act in concert with each other to promote cancer cell invasion and 
metastasis or if EMT is independent of autophagy. Furthermore, the extent on which 
cancer cells rely on enhanced autophagy in stromal cells has yet to be fully elucidated. 
Therefore, in this section of the study, as proof of concept we set out to determine 
whether the manipulation of autophagy in MEFs could lead to altered EMT and 
migratory capacity of E0771 breast cancer cells. 
We observed a significant reduction in the migratory capacity of E0771 breast cancer 
cells following treatment with Atg5 MEF-CM (Figure 3.72), however, we also observed a 
similar reduction in E0771 migration with the treatment with both the mock-CM and 
eGFP-CM. Therefore, the results we observed are as a direct result of the 
electroporation and not an effect of Atg5 silencing in MEFs. The effects of 
electroporation on cell migration were made more evident when EMT was assessed by 
means of Western blotting, where a significant reduction in α-SMA, PDGFRα (Figure 
3.74) and vimentin (Figure 3.75a) protein expression was observed in E0771 cells that 
treated with conditioned media derived from MEF cells which had been electroporated 
without any esiRNA (mock-CM).  These results may be explained by the fact that 
electroporation involves the permeabilization of the plasma membrane with the use of a 
high energy electrical current in order to allow the entry of siRNA into the cell. While this 
had no effect on the viability it may have resulted in potent effects on cell-cell adhesion 
and cytoskeletal structure of MEF cells. Based on the significant clustering of proteins 
involved in cell-cell adhesion and migration we observed with the proteomics analysis of 
MEF conditioned media (see section 3.4) it is conceivable that electroporation of MEF 
cells could lead to significant alterations in the proteome of MEF conditioned media and 
thus could account for the significant loss in expression of the mesenchymal protein 
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markers, α-SMA, PDGFRα and vimentin that we observed in E0771 breast cancer cells 
following treatment with mock-CM. This is further corroborated by the fact that 
electroporation with voltages of 200 – 1000 V has previously been shown to result in a 
disruption of the actin cytoskeleton in 3T3 fibroblasts and also lead to alterations in cell 
adhesiveness of MDA-MB-231 breast cancer cells (Pehlivanova et al., 2012). Our 
transfection protocol made use of a single 1350 V pulse, as this falls past the extreme 
end of that used by Pehlivanova and colleagues, our results suggests that this could 
indeed have resulted in actin cytoskeleton reorganization in MEFs thereby affecting EMT 
in the E0771 breast cancer cells. 
Although we observed a significant reduction in α-SMA, PDGFRα and vimentin protein 
expression as a result of the electroporation process, we also noted that E0771 breast 
cancer cells that were treated with the Atg5 knockdown MEF conditioned media (MEF-
CM) showed a significant increase in all three mesenchymal markers, α-SMA, PDGFRα 
and vimentin (Figure 3.74 and Figure 3.75), when compared to the mock-CM treated 
control group. This suggests that the knockdown of Atg5 in MEFs rescues the loss of 
mesenchymal markers due to the electroporation process we observed in E0771 breast 
cancer cells. Although these results are suggestive of a mild recovery of a mesenchymal 
phenotype in E0771 breast cancer cells, we are unable to effectively conclude what the 
role of autophagic manipulation in CAFs has on the migratory capacity of E0771 breast 
cancer cells. In order to effectively determine this, these experiments would need to be 
repeated using a different transfection protocol which does not result in drastic 
alterations in cell-cell adhesion and migration processes of MEFs. Additionally, it would 
be of great interest to assess the proteome of conditioned media generated from 
electroporated MEFs in order to determine the specific alterations that occur in response 
to the electroporation procedure.  
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4.9. In vivo Tumour-Bearing C57BL/6 Mouse Model 
In vitro cancer models are extensively used to study the molecular mechanisms 
underlying cancer progression, chemoresistance and metastasis (Katt et al., 2016), and 
while these models provide invaluable insight for the development of novel 
chemotherapeutic strategies, they often fail to effectively represent the complexity of the 
3D tumour microenvironment. Furthermore, the influences of the stromal compartment of 
tumours have been largely underestimated and as such many pre-clinical models have 
resulted in the clinical failure of chemotherapeutic strategies (Singh et al., 2010). 
Therefore, in order to gain a better understanding into the systemic influences exerted 
on epithelial cancer cells and the effects that this has on tumour growth, 
chemoresistance and metastatic capacity, we employed a physiologically relevant in vivo 
tumour-bearing mouse model.  
Briefly, 40 eight week old female C57BL/6 mice were utilized for this section of the study.  
Mice were inoculated with syngeneic E0771 breast cancer cells into the right fourth 
mammary fat pad, and following the appearance of palpable tumours, mice received a 
cumulative dose of 12 mg/kg doxorubicin. We observed no significant differences in the 
body weights of mice across all treatment groups when compared to controls (Figure 
3.76). Additionally, doxorubicin administration had no effect on tumour growth over the 
course of the study (Figure 3.77). Our in vitro results indicate that the E0771 breast 
cancer cells are resistant to the cytotoxic effects of doxorubicin, as the viability of E0771 
cells is maintained (at approximately 80%) following concentrations which exceed 
clinically relevant concentrations (10.0 µM) of doxorubicin (Figure 3.56). Clinically the 
administration of doxorubicin involves doses which range between 15 and 90 mg/m2, 
which results in plasma concentrations ranging from 0.3 – 5 µM (Gewirtz, 1999). 
Therefore, as the dosage of doxorubicin we chose for the in vivo tumour-bearing mouse 
model was calculated to fall within the clinically relevant dosages of doxorubicin 
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administration (12 mg/kg is equivalent to 36 mg/m2 in mice) (Reagan-Shaw et al., 2007), 
the fact that we did not see any differences in the tumour volumes of mice treated with 
doxorubicin confirm the resistant nature of these cells.  These results were further 
supported when Kaplan-Meier survival analyses were performed, as no statistically 
significant differences were observed in the time taken to reach the desired tumour 
volume (Figure 3.78).  
Once tumours reached a desired volume of 400 mm3, mice were sacrificed and tumours 
as well as mammary fat pads were harvested and processed for further analysis. 
Histological assessment of mammary fat pads qualitatively showed no major 
ultrastructural changes between the groups (Figure 3.79 and Figure 3.80). Additionally, 
significant collagen deposition was observed surrounding blood vessel and between 
lobules in all groups (Figure 3.83 and Figure 3.84). However, a significant decrease in 
the intensity of collagen staining was observed in the mammary fat pads of tumour-
bearing mice that were treated with doxorubicin. This may have resulted from a slight 
difference in staining times between samples; however, the effects of doxorubicin on 
normal mammary tissue cannot be excluded, as it is widely accepted that doxorubicin 
has profound cytotoxic effects on normal tissue. 
Histologically, we observed three distinct regions of nuclear staining within tumour 
sections from tumour control and tumour + doxorubicin animals (Figure 3.81 and Figure 
3.82). In order to determine whether these regions can be associated with hypoxia / 
nutrient deprivation, immunofluorescent staining for the proliferation marker Ki67 was 
performed on tumour sections (Figure 3.87). Again in tumour sections from animals that 
had been treated with doxorubicin we observed distinctive regions of cell proliferation, 
where the outer region of tumour sections stained more intensely (indicated by an 
increase in the mean fluorescent intensity) than the inner region. Based on these results, 
we were able to conclude that the inner regions observed in our H&E stains occur as a 
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result of decreased cell proliferation, which is most likely associated with an oxygen / 
nutrient gradient that is established as tumour volume increases.  
Interestingly, we also observed significant fat cell infiltration in addition to the formation 
of new blood vessels (neo-angiogenesis) within tumour sites in both tumour control and 
tumour + doxorubicin animals (Figure 3.82). The infiltration of non-tumourigenic cells 
into the tumour site, highlight the importance of stromal cells within the tumour 
microenvironment. Additionally, when compared to the highly organized and well defined 
blood vessels seen in the mammary fat pads, we noted that newly formed blood vessels 
within the tumour are significantly larger and more chaotic, these results are not 
surprising as it is well-known that new vasculature within tumours are structurally and 
functionally abnormal in comparison to those observed in normal tissue (Nagy et al., 
2009). Furthermore, unlike that seen in normal tissue, tumour blood vessels have 
detached or absent pericytes (Inai et al., 2004) in some cases the diameter of the blood 
vessel is smaller and they exhibit increased permeability to large molecules (Izumi et al., 
2002, Winkler et al., 2004, Tong et al., 2004).  
Picosirius Red staining for fibrosis in tumours, similarly showed an increase in collagen 
deposition around newly formed blood vessels within tumours (Figure 3.85) as seen in 
mammary fat pads. However, we also noted an increase in collagen deposition within 
the tumour mass itself which was not surrounding any visible blood vessels (Figure 
3.86). In order to determine whether the increased fibrosis observed within the tumour 
mass occurred as a result of increased fibroblast infiltration, and subsequent CAF 
“activation”, into the tumour mass we performed immunofluorescent staining against 
both α-SMA and vimentin. While both tumour control and tumour + doxorubicin sections 
stained heavily for both α-SMA and vimentin (Figure 3.88), we noted several regions of 
increased co-localization in the tumour + doxorubicin group. These regions are 
suggestive of the presence of CAFs within the tumour mass. However, in order to 
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definitively state that these are CAF specific regions, additional imaging would need to 
be performed, wherein additional markers of CAFs are utilized. For instance, it would be 
of great benefit to perform a four colour stain where samples are stained for additional 
CAF markers namely; E-cadherin and PDGFRα, in addition to α-SMA and vimentin.  
As mentioned previously, tumours are recognized as being highly complex organs, and 
this highly structured environment plays a critical role in the survival and progression of 
cancerous epithelial cells within the tumour (Tanner and Gottesman, 2015). In recent 
years, research into the influence of the tumour microenvironment on epithelial cancer 
cells has become critical, as it has become increasingly evident that the interactions 
between stromal and epithelial cancer cells plays a role in tumour progression and 
metastasis. Additionally, the three dimensional (3D) nature of tumours results in 
differential effects on epithelial cancer cells that cannot be recapitulated using traditional 
two dimensional (2D) in vitro cell culture models (Yoshii et al., 2015). Therefore, in order 
to gain a better understanding of the influence of CAFs on epithelial cell invasion and 
thus their metastatic capacity, we employed the 3D branching morphogenesis assay 
using epithelial organoids isolated from both the mammary fat pads and tumours of 
C57BL/6 mice, and subjected isolated organoids to treatment with MEF conditioned 
media.   
Interestingly, we observed that the treatment of epithelial organoids isolated from control 
(Figure 3.89) and tumour-control (Figure 3.91) animals with MEF conditioned media, 
showed no significant differences in the degree of invasion of epithelial cells into 
Matrigel® compared to control media treated organoids. However, organoids that were 
isolated from animals which received the in vivo administration of doxorubicin, showed 
enhanced invasion and migratory capacity when subjected to MEF conditioned media 
treatment. This was observed in organoids isolated from both doxorubicin control 
(Figure 3.90) and tumour + doxorubicin (Figure 3.92) animals, suggesting that 
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doxorubicin results in the enhanced invasive capacity of primary mammary epithelial 
organoids regardless of whether these were isolated from normal tissue or from 
tumours. Additionally, we also noted that when tumour + doxorubicin isolated organoids 
were treated with MEF conditioned media, epithelial cells migrate quickly out of the 
central organoid “mass”, and detach from their leader edge (Figure 3.92). This result 
suggests that tumour epithelial organoids acquire an enhanced metastatic capacity 
when exposed to both doxorubicin and MEF-CM.  
In recent years, it has become increasingly evident that the in vivo administration of 
doxorubicin induces pro-metastatic changes within the microenvironment of primary 
breast tumours (Karagiannis et al., 2017). This has been attributed to what has been 
termed, the tumour microenvironment of metastasis (TMEM) which consists of the direct 
contact of an epithelial cancer cell with both an endothelial cell and a macrophage 
(Rohan et al., 2014). The interaction of these cells within the tumour microenvironment 
has been associated with enhanced metastasis in human breast cancers (Robinson et 
al., 2009), and chemotherapeutic agents, including doxorubicin, elicits TMEM-mediated 
pro-metastatic changes within the breast tumour microenvironment. Moreover, the 
clustering of pro-migratory proteins we observed with the proteomic analysis of MEF 
conditioned media, could further explain the enhanced migratory capacity of epithelial 
organoids we observed. We therefore propose that CAFs elicit pro-metastatic changes 
in the tumour microenvironment of mammary tumours though the secretion of pro-
migratory factors which result in similar effects to those mediated by TMEM. 
We further, set out to determine whether epithelial-to-mesenchymal transition (EMT) in 
tumours affects their metastatic capacity. Therefore, Western blot analysis of whole 
tumours and mammary fat pads was employed to assess the relative protein expression 
levels of α-SMA, PDGFRα, vimentin and E-cadherin. In tumours a significant reduction 
in the protein expression levels of both PDGFRα (Figure 3.94b) and vimentin (Figure 
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3.96a) was observed in tumour + doxorubicin mice. Additionally, this was associated 
with a significant increase in E-cadherin expression (Figure 3.96b). Collectively, these 
results suggest that in mammary tumours, doxorubicin results in decreased EMT, which 
would often be associated with decreased metastatic capacity of tumour cells. Despite 
this, the results we obtained for the 3D branching morphogenesis assay suggest an 
increase in epithelial cell migration. Conventionally, invasion and metastasis can be 
defined as the migration of single cells, groups of cells or as elongated strands of 
connected cancer cells (Leighton et al., 1960). With the dissemination of collective 
strands of epithelial cells, cell-cell adhesions remain intact (Friedl et al., 2012), and 
therefore would not be associated with the loss of E-cadherin, or the subsequent 
induction of EMT. Based on this, we speculate that the enhanced migratory capacity we 
observed in epithelial organoids isolated from tumour-bearing mice treated with 
doxorubicin occurs as a result of collective cell migration that is not associated with the 
induction of EMT. However, as the Western blot analysis was performed on tumour 
samples that were not subjected to MEF conditioned media treatment, we cannot rule 
out the induction of EMT in epithelial organoids as this may have occurred as a result of 
pro-migratory factors present in MEF conditioned media. Moreover, as whole tumours 
were utilized for Western blot analysis, the EMT results we obtained are representative 
of the tumour microenvironment as a whole; therefore it is possible that we may have 
observed an increase in EMT using Western blot analysis on isolated epithelial cells in 
addition to the whole tumour samples. 
Finally, to assess the effects of doxorubicin on the migratory capacity of non-
tumourigenic mammary tissue, we assessed markers of EMT using Western blot 
analysis. A significant decrease in the protein expression levels of α-SMA (Figure 3.93a) 
in the mammary fat pads harvested from tumour-bearing mice treated with doxorubicin 
when compared to both control and tumour control mice were observed. Additionally, 
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when compared to tumour control mice, only a significant reduction in both PDGFRα 
(Figure 3.93b) protein expression was observed in the mammary fat pads of tumour + 
doxorubicin mice. A significant increase in vimentin protein expression was seen in the 
mammary fat pads of tumour control mice when compared to control (no tumours) 
(Figure 3.95a), however, this decreased significantly with doxorubicin administration in 
tumour-bearing mice. Similarly, E-cadherin protein expression was significantly 
increased in tumour control animals when compared to control (Figure 3.95b), however, 
no significant difference was observed in the tumour + doxorubicin treated group when 
compared to both control and tumour control groups. Collectively, this data suggests that 
an increase in E/M phenotype is seen in the mammary fat pads of tumour control mice. 
However, treatment with doxorubicin causes this phenotype to return to that of control 
animals. Mammary tissue is comprised predominantly of adipocytes supported by 
connective tissue interspersed with stromal, endothelial cell and macrophages (Kim et 
al., 2013). As adipose tissue constitutes the most abundant stromal compartment of 
mammary tissue, the close proximity of primary breast tumours to adipocytes suggests 
that adipose tissue contributes significantly to the development and progression of 
breast cancer (Dumitrescu and Cotarla, 2005). The presence of mesenchymal stem cells 
(MSC) within the tumour microenvironment, derived either from bone marrow or from the 
breast tissue itself, have been described for their ability to promote tumour growth, 
angiogenesis and metastasis (Walter et al., 2009, Muehlberg  et al., 2009, Pinilla et al., 
2009). In fact, the recruitment of MSCs into the tumour microenvironment and their 
subsequent differentiation has been shown to give rise to CAFs (Zhao et al., 2010). 
Therefore, our results (Figure 3.93 and Figure 3.95) could likely reflect the propensity of 
normal mammary tissue to generate mesenchymal stem-like cells, which may 
disseminate to the tumour site and support tumour growth and metastasis.  Additionally, 
doxorubicin treatment could reverse the E/M phenotype seen in tumour-bearing mice. 
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Chapter 5: Final Conclusions 
The highly complex nature of the tumour microenvironment combined with the influences 
that surrounding stromal cells have on cancerous epithelial cells contribute significantly 
to tumour growth and progression. Although extensive progress over the last decade 
has been made in an attempt to elucidate the role of the tumour microenvironment in 
tumour progression, the molecular mechanisms underlying this interaction as well as the 
involvement of CAFs in epithelial cancer cell migration and metastasis remain largely 
underestimated. Therefore, in order to gain a better understanding of the stromal-
epithelial interactions within the tumour microenvironment we employed a well-defined in 
vitro model as well as a physiologically relevant in vivo tumour-bearing mouse model of 
breast cancer. We also utilized a bioinformatics approach in order to assess the 
secreted proteome from both epithelial cancer cells and “activated” fibroblasts to 
determine the molecular mechanisms underlying the contribution of each cell type to the 
metabolic reprogramming of the tumour microenvironment. 
We observed several differences in the ability of glucose deprived E0771 breast cancer 
cells to metabolically reprogram MEF cells, most notably differential effects in the 
secreted proteome of MEF cells was observed following treatment with glucose deprived 
E0771 conditioned media in comparison to control E0771 conditioned media. This likely 
reflects the propensity of epithelial cancer cells to selectively reprogram stromal cell 
metabolism depending on their bioenergetic demands, and thus highlights the plasticity 
of epithelial cancer cells and their ability to extensively manipulate the surrounding 
microenvironment for survival and subsequently their metastatic dissemination.  
This study provides convincing evidence which illustrates the important role that the 
induced metabolic reprogramming of stromal fibroblasts has on the survival of nutrient 
deprived breast cancer cells. Additionally, we show that nutrient deprivation of E0771 
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cancer cells results in the secretion of a differential proteome from MEF cells, resulting in 
enhanced proteolysis and glucose metabolism, and thereby increasing the production of 
metabolites, such as L-lactate, which can be utilized by nutrient deprived E0771 breast 
cancer cells for ATP production and cell survival. Furthermore, we also provide evidence 
that “activated” CAFs confer pro-metastatic abilities to E0771 breast cancer cells, via the 
induction of epithelial-to-mesenchymal transition (EMT) and induce an increased rate of 
migration. The results obtained from the tumour-bearing mouse model reflect the 
enhanced metastatic capacity conferred to by MEF conditioned media. It also 
highlighted the synergistic effects that pro-migratory factors secreted by “activated” 
CAFs and doxorubicin elicit on the enhanced migration and invasiveness of isolated 
primary epithelial organoids. Most importantly, as the majority of patients with metastatic 
breast cancer relapse and ultimately develop tumours which have become more 
resistant to chemotherapeutic agents like doxorubicin, our results contribute significantly 
to the development of new therapeutic strategies to overcome these obstacles. 
During the course of this study we experienced a few limitations. Most importantly, we 
were unable to determine the effects of autophagic manipulation in CAFs on the 
migratory capacity of epithelial breast cancer cells due to the potent effects that 
electroporation has on cell-cell adhesion and epithelial-to-mesenchymal transition 
(EMT). Therefore, the use of an alternative transfection protocol, such as the use 
lipofectamine 3000, which does not influence cell adhesion junctions and EMT, would be 
of great benefit in elucidating the role of stromal autophagy on the metastatic capacity of 
epithelial cancer cells. Although we assessed the protein profile as well as the enzymatic 
activity of pyruvate dehydrogenase (PDH) as an indicator of the ability of MEF and 
E0771 cells to undergo oxidative phosphorylation in response to conditioned media 
treatment, we were unable to definitively determine the oxidative phosphorylation 
capacity of these cells as metabolic intermediates may be shunted into the tricarboxylic 
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acid (TCA) cycle independently of PDH. Therefore, the use of more in depth metabolic 
analysis of both glycolysis and oxidative phosphorylation may have provided better 
insight into the metabolic reprogramming of MEFs and the subsequent pro-survival 
effects conferred to epithelial cancer cells.  
Based on the significant role that cancer-associated fibroblasts (CAFs) play in tumour 
progression, chemoresistance and metastasis, it is recommended that additional co-
culture models are performed, particularly ones utilizing a 3D approach, wherein 
epithelial cancer cells are cultured together with CAFs. The use of such a 3D co-culture 
model could provide insight into the effects that direct contact with stromal cells has on 
the survival and metastatic capacity of epithelial cancer cells. Furthermore, it is well 
established that standard 2D cell culture models greatly affect the phenotype of cells 
therefore the use of a 3D model could better recapitulate the in vivo tumour 
microenvironment and as such provide invaluable information into the effects of cell-cell 
adhesions on tumour growth and survival.   
In conclusion, we have demonstrated that “activated” mouse embryonic fibroblast (MEF) 
cells contribute significantly to the pro-survival and pro-metastatic abilities of glucose 
deprived E0771 breast cancer cells. Furthermore, this study has contributed significantly 
to the understanding of the molecular mechanisms underlying the stromal-epithelial 
interactions within the tumour microenvironment. However, extensive research still 
needs to be conducted in order to exploit these interactions for the development of novel 
therapeutic strategies for the treatment of metastatic breast cancer.   
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Figure 5.1: Summary of main findings. We have demonstrated that glucose deprived E0771 breast cancer 
cells successfully “activate” to a cancer-associated fibroblast (CAF) phenotype in normal mouse embryonic 
fibroblast (MEF) cells. This is most likely due to the release of exosomes which result in the acquisition of an 
enhanced mesenchymal phenotype. We have also demonstrated that treatment with MEF conditioned media 
elicits differential responses in vitro and in vivo. In vitro treatment of glucose deprived E0771 breast cancer cells 
with MEF conditioned media resulted in an enhanced metastatic capability that was dependent on epithelial-to-
mesenchymal transition. Whereas, in vivo MEF conditioned media promoted enhanced invasiveness of 
epithelial organoids which was independent of epithelial-to-mesenchymal transition induction. 
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7.1. Proteomics – List of Proteins 
7.1.1. Proteomics Analysis of E0771 conditioned media  
 
 
Group 
Accession 
Number 
Description 
Confidence 
score 
Anova (p) 
Fold 
Change 
E0771_C I3L145 
Sex hormone-binding 
globulin 
5.205962709 5.34E-05 11.57035277 
E0771_C P43652 Afamin 3.781422089 0.0001793 2.196765224 
E0771_C Q96D15 Reticulocalbin-3 13.30528088 0.000212 17.92971387 
E0771_C P04004 Vitronectin 17.98074799 0.0003757 2.706463703 
E0771_C Q06033 
Inter-alpha-trypsin inhibitor 
heavy chain H3 
35.41013703 0.000733 2.16369489 
E0771_C Q14118 Dystroglycan 23.47307826 0.0008326 3.080225771 
E0771_C Q8NDW8 
Tetratricopeptide repeat 
protein 21A 
2.268184612 0.0015768 3.329415209 
E0771_C P05543 Thyroxine-binding globulin 22.21085603 0.0017916 5.454819359 
E0771_C P02647 Apolipoprotein A-I 15.41758964 0.0024173 4.214960073 
E0771_C A0A087WSY9 
Thioredoxin reductase 1, 
cytoplasmic 
10.10739902 0.0034767 4.512266001 
E0771_C Q99497 Protein DJ-1 7.668671354 0.003866 2.204523717 
E0771_C P05452 Tetranectin 11.07079683 0.0050455 3.509300867 
E0771_C P02461 Collagen alpha-1(III) chain 68.80913822 0.0050637 5.070493532 
E0771_C Q92520 Protein FAM3C 4.448114427 0.0052545 4.886536663 
E0771_C Q8NF91 Nesprin-1 24.71886474 0.00594 2.231554617 
E0771_C Q16718 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 5 
1.385617891 0.0060123 6.897579225 
E0771_C P68871 Hemoglobin subunit beta 29.83783544 0.0061377 3.131500028 
E0771_C P02753 Retinol-binding protein 4 11.77082489 0.0065332 4.421631083 
E0771_C D6RF35 Vitamin D-binding protein 94.4880968 0.0094468 6.210660712 
E0771_C P51884 Lumican 24.51921047 0.0122448 2.625482934 
E0771_C Q06323 
Proteasome activator 
complex subunit 1 
36.37396179 0.0143785 2.365973585 
E0771_C P08697 Alpha-2-antiplasmin 19.56058745 0.0145895 4.528110877 
E0771_C E7ER44 Lactotransferrin 32.76727595 0.0231877 2.361678455 
E0771_C P69905 Hemoglobin subunit alpha 70.79701702 0.0240917 2.233877481 
E0771_C P09960 Leukotriene A-4 hydrolase 13.90659489 0.024128 2.016656464 
E0771_C P55072 
Transitional endoplasmic 
reticulum ATPase 
193.0158475 0.0243696 3.397644393 
E0771_C P02748 Complement component C9 9.250128838 0.0275597 2.598960383 
E0771_C Q6ZU64 
Cilia- and flagella-associated 
protein 65 
1.469533219 0.0290416 3.565396709 
Table 7.1: List of differentially expressed proteins in E0771 control conditioned media 
(E0771_C). 
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Group 
Accession 
Number 
Description 
Confidence 
score 
Anova (p) 
Fold 
Change 
E0771_GD P05019 Insulin-like growth factor I 27.18266803 4.00E-07 100.9117103 
E0771_GD Q92896 Golgi apparatus protein 1 13.85584627 2.79E-06 124.3286638 
E0771_GD P50454 Serpin H1 22.80631544 5.71E-06 22.26215147 
E0771_GD P78330 
Phosphoserine 
phosphatase 
17.47569586 9.16E-06 199.4467577 
E0771_GD P35527 
Keratin, type I cytoskeletal 
9 
2.275532567 9.57E-06 37.68567626 
E0771_GD P48506 
Glutamate--cysteine ligase 
catalytic subunit 
4.367829656 2.65E-05 48.36694635 
E0771_GD P14543 Nidogen-1 42.11164221 3.81E-05 8.904518968 
E0771_GD Q99536 
Synaptic vesicle 
membrane protein VAT-1 
homolog 
35.4234255 4.39E-05 31.52992635 
E0771_GD O43852 Calumenin 12.42646181 5.15E-05 84.9097467 
E0771_GD P25786 
Proteasome subunit alpha 
type-1 
35.74063221 9.61E-05 35.92075316 
E0771_GD P30101 
Protein disulfide-isomerase 
A3 
18.56128015 0.0001062 5.254872763 
E0771_GD P47755 
F-actin-capping protein 
subunit alpha-2 
11.84349912 0.0001155 125.7207973 
E0771_GD A0A075B7D9 
TATA-binding protein-
associated factor 2N 
2.723973745 0.0001225 17.96232547 
E0771_GD P07237 Protein disulfide-isomerase 54.8232496 0.0001311 6.60750763 
E0771_GD P05198 
Eukaryotic translation 
initiation factor 2 subunit 1 
16.39010559 0.0001396 57.05598229 
E0771_GD O43707 Alpha-actinin-4 150.87147 0.000145 11.2233816 
E0771_GD Q15404 Ras suppressor protein 1 16.22518375 0.0001466 31.96150798 
E0771_GD P11021 
78 kDa glucose-regulated 
protein 
163.6413764 0.0001506 11.3600147 
E0771_GD Q9HC38 
Glyoxalase domain-
containing protein 4 
2.240987264 0.0001539 201.137088 
E0771_GD A0A0A0MTS2 
Glucose-6-phosphate 
isomerase (Fragment) 
35.92159293 0.0001728 98.51070454 
E0771_GD P17174 
Aspartate 
aminotransferase, 
cytoplasmic 
21.27582497 0.0001729 51.0418461 
E0771_GD P35268 60S ribosomal protein L22 11.36012289 0.0001806 154.1847734 
E0771_GD P14625 Endoplasmin 58.01996899 0.0001895 45.3519957 
E0771_GD P08243 
Asparagine synthetase 
[glutamine-hydrolyzing] 
33.94811192 0.0001934 24.69495924 
E0771_GD P26196 
Probable ATP-dependent 
RNA helicase DDX6 
14.80218148 0.0002096 6.730056045 
E0771_GD P23526 Adenosylhomocysteinase 26.47191433 0.0002272 17.77492161 
E0771_GD P06733 Alpha-enolase 144.3654213 0.00023 21.96717627 
E0771_GD P61981 14-3-3 protein gamma 28.52762339 0.0002485 24.56096903 
E0771_GD P31946 14-3-3 protein beta/alpha 29.01540539 0.0002509 9.35160291 
E0771_GD Q96KP4 
Cytosolic non-specific 
dipeptidase 
15.23104494 0.0002727 14.87396388 
Table 7.2: List of differentially regulated proteins in glucose deprived E0771 conditioned 
media (E0771_GD) 
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E0771_GD K7ESG5 
Proteasome activator 
complex subunit 3 
15.28695245 0.0002831 19.93834724 
E0771_GD A0A0A0MT01 Gelsolin 61.7798389 0.0002904 4.326626433 
E0771_GD P16989 Y-box-binding protein 3 20.35567549 0.0002918 38.86421734 
E0771_GD Q15393 
Splicing factor 3B subunit 
3 
27.57274331 0.0003076 77.96245178 
E0771_GD P31939 
Bifunctional purine 
biosynthesis protein PURH 
14.30122551 0.000311 5.502952087 
E0771_GD P60900 
Proteasome subunit alpha 
type-6 
23.75948401 0.0003199 21.83285015 
E0771_GD P34932 
Heat shock 70 kDa protein 
4 
119.9358079 0.0003464 18.43800541 
E0771_GD O15511 
Actin-related protein 2/3 
complex subunit 5 
11.53761872 0.0003529 102.9519305 
E0771_GD Q9Y333 
snRNA-associated Sm-like 
protein LSm2 
9.608326012 0.0003582 17.79172191 
E0771_GD P22626 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
58.26867651 0.0003676 38.44655884 
E0771_GD P11142 
Heat shock cognate 71 
kDa protein 
419.5409654 0.0003722 18.94990834 
E0771_GD P14550 
Alcohol dehydrogenase 
[NADP(+)] 
25.4247084 0.0003807 32.97295381 
E0771_GD P40925 
Malate dehydrogenase, 
cytoplasmic 
19.59996273 0.000409 21.77753032 
E0771_GD J3KTL2 
Serine/arginine-rich-
splicing factor 1 
22.64515346 0.0004264 39.31116722 
E0771_GD Q04917 14-3-3 protein eta 27.68847628 0.0005319 526.4568285 
E0771_GD P13797 Plastin-3 54.92559414 0.0005333 6.615250793 
E0771_GD Q01995 Transgelin 26.09286228 0.0005475 11.14295467 
E0771_GD P20290 Transcription factor BTF3 4.072192706 0.000552 20.07061817 
E0771_GD P26038 Moesin 123.0576281 0.0005636 23.66602474 
E0771_GD H0YL52 
Tropomyosin alpha-1 chain 
(Fragment) 
86.19312822 0.0005665 19.95933505 
E0771_GD P36955 
Pigment epithelium-
derived factor 
42.25616633 0.0005666 4.288011783 
E0771_GD P60981 Destrin 19.11083247 0.0006551 51.67840279 
E0771_GD Q9Y266 
Nuclear migration protein 
nudC 
21.17417674 0.0006648 31.76922728 
E0771_GD P63104 14-3-3 protein zeta/delta 51.81710983 0.0007014 9.926934748 
E0771_GD P12081 
Histidine--tRNA ligase, 
cytoplasmic 
18.0798167 0.0007155 64.41617409 
E0771_GD P62258 14-3-3 protein epsilon 89.45852815 0.0007341 17.55090253 
E0771_GD J3QQX2 
Rho GDP-dissociation 
inhibitor 1 
24.35314005 0.0007552 36.16010318 
E0771_GD P25398 40S ribosomal protein S12 2.426077818 0.0008165 50.11784675 
E0771_GD Q00577 
Transcriptional activator 
protein Pur-alpha 
4.315667173 0.0008398 20.68473769 
E0771_GD P62495 
Eukaryotic peptide chain 
release factor subunit 1 
15.87442813 0.0008428 17.21459969 
E0771_GD P22392 
Nucleoside diphosphate 
kinase B 
77.94623192 0.0008681 17.72287615 
E0771_GD P49721 
Proteasome subunit beta 
type-2 
29.7717515 0.000869 5.249568663 
E0771_GD P12814 Alpha-actinin-1 135.9385131 0.0008773 8.236881737 
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E0771_GD P15121 Aldose reductase 3.156545481 0.0009088 10.02671543 
E0771_GD Q15056 
Eukaryotic translation 
initiation factor 4H 
13.01107154 0.0009515 49.09596288 
E0771_GD P61160 Actin-related protein 2 5.068111751 0.0010003 9.732465305 
E0771_GD E9PAV3 
Nascent polypeptide-
associated complex 
subunit alpha, muscle-
specific form 
44.57516428 0.0010148 11.37474143 
E0771_GD P28838 Cytosol aminopeptidase 13.25727622 0.0010156 41.66120379 
E0771_GD P26447 Protein S100-A4 10.80759821 0.0010209 13.03488612 
E0771_GD P00338 
L-lactate dehydrogenase A 
chain 
60.81994037 0.0010325 22.39194496 
E0771_GD Q9Y617 
Phosphoserine 
aminotransferase 
19.11834003 0.0010523 26.95235973 
E0771_GD P30050 60S ribosomal protein L12 60.48927603 0.0010684 12.10680745 
E0771_GD Q09666 
Neuroblast differentiation-
associated protein AHNAK 
105.5206309 0.001118 7.385812706 
E0771_GD Q5T3N1 Annexin (Fragment) 22.29151562 0.0011323 7.148271985 
E0771_GD O75436 
Vacuolar protein sorting-
associated protein 26A 
3.023696422 0.0011345 48.06475372 
E0771_GD P05388 
60S acidic ribosomal 
protein P0 
38.48232022 0.0011409 13.47304982 
E0771_GD P25788 
Proteasome subunit alpha 
type-3 
23.07187084 0.0011546 13.07494708 
E0771_GD Q9H444 
Charged multivesicular 
body protein 4b 
14.22018781 0.0012056 113.893564 
E0771_GD P24534 Elongation factor 1-beta 17.24048202 0.0012171 54.06454884 
E0771_GD Q8NEV1 
Casein kinase II subunit 
alpha 3 
14.00826212 0.001254 57.59737427 
E0771_GD P20618 
Proteasome subunit beta 
type-1 
17.66082493 0.001292 28.13805107 
E0771_GD P61088 
Ubiquitin-conjugating 
enzyme E2 N 
35.41492654 0.0012957 13.65754205 
E0771_GD P18206 Vinculin 142.6392357 0.001301 6.6939887 
E0771_GD P09417 Dihydropteridine reductase 17.62223854 0.001322 30.8429989 
E0771_GD P61086 
Ubiquitin-conjugating 
enzyme E2 K 
17.32208458 0.0013324 32.07035282 
E0771_GD F8WCF6 
Actin-related protein 2/3 
complex subunit 4 
24.29611519 0.0013614 44.49991079 
E0771_GD P07900 
Heat shock protein HSP 
90-alpha 
213.9144792 0.0013713 12.84012893 
E0771_GD P43490 
Nicotinamide 
phosphoribosyltransferase 
13.7263839 0.001376 12.8982451 
E0771_GD A0A0C4DFV9 Protein SET 34.04941749 0.0013861 16.89099393 
E0771_GD Q5HYB6 
Epididymis luminal protein 
189 
73.36451715 0.0013926 29.32104725 
E0771_GD P61604 
10 kDa heat shock protein, 
mitochondrial 
19.98617907 0.0013965 44.13686282 
E0771_GD P60709 Actin, cytoplasmic 1 249.1469143 0.0014048 5.343437634 
E0771_GD P15090 
Fatty acid-binding protein, 
adipocyte 
14.23845041 0.0014528 19.04684404 
E0771_GD P56537 
Eukaryotic translation 
initiation factor 6 
18.6117551 0.0014588 90.80153572 
E0771_GD P30086 Phosphatidylethanolamine- 14.02810625 0.0014752 10.05761132 
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binding protein 1 
E0771_GD P18669 
Phosphoglycerate mutase 
1 
131.5371954 0.0015324 13.86821352 
E0771_GD P28070 
Proteasome subunit beta 
type-4 
18.07024651 0.0015696 52.30637204 
E0771_GD O14818 
Proteasome subunit alpha 
type-7 
28.06374998 0.0015888 43.13663362 
E0771_GD P35241 Radixin 70.44512818 0.0016249 110.6631766 
E0771_GD D6RBL5 Annexin 63.98054264 0.0016527 20.13347112 
E0771_GD P30041 Peroxiredoxin-6 19.54424544 0.001717 16.63084012 
E0771_GD P16949 Stathmin 20.95897788 0.0017462 9.512590349 
E0771_GD P50395 
Rab GDP dissociation 
inhibitor beta 
51.21330209 0.0017658 11.88023666 
E0771_GD P49720 
Proteasome subunit beta 
type-3 
35.61487044 0.0017795 7.351094514 
E0771_GD Q9UNZ2 NSFL1 cofactor p47 16.14487173 0.0018055 43.06861523 
E0771_GD P35052 Glypican-1 31.3686554 0.0018074 4.648628876 
E0771_GD P31153 
S-adenosylmethionine 
synthase isoform type-2 
26.88696816 0.0018299 7.492477447 
E0771_GD A0A087WTT1 
Polyadenylate-binding 
protein 
44.50320919 0.001865 6.55602266 
E0771_GD E7EQR4 Ezrin 65.28155066 0.001934 15.65419309 
E0771_GD F5H018 
GTP-binding nuclear 
protein Ran (Fragment) 
16.71268999 0.0019795 5.067810675 
E0771_GD A0A0A0MSI0 
Peroxiredoxin-1 
(Fragment) 
40.56018373 0.0020625 20.43352992 
E0771_GD O75368 
SH3 domain-binding 
glutamic acid-rich-like 
protein 
2.414711319 0.0021171 40.9104179 
E0771_GD P11047 Laminin subunit gamma-1 34.91880231 0.0022402 5.448408607 
E0771_GD P62857 40S ribosomal protein S28 15.30735046 0.0022646 16.27778204 
E0771_GD P62942 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A 
19.99314866 0.0022744 15.57283435 
E0771_GD P12004 
Proliferating cell nuclear 
antigen 
28.42660156 0.0023071 8.193243287 
E0771_GD P07355 Annexin A2 111.8606583 0.0023201 14.67871844 
E0771_GD Q9Y3F4 
Serine-threonine kinase 
receptor-associated 
protein 
8.465085033 0.0023689 9.633715604 
E0771_GD P54136 
Arginine--tRNA ligase, 
cytoplasmic 
29.7001631 0.0024244 14.1914355 
E0771_GD A0A1C7CYX9 
Dihydropyrimidinase-
related protein 2 
61.55114303 0.002467 32.04000096 
E0771_GD O00303 
Eukaryotic translation 
initiation factor 3 subunit F 
16.56597614 0.0024879 10.79219191 
E0771_GD F8W1I6 Dynactin subunit 2 13.93919298 0.0024891 13.94591096 
E0771_GD P60174 
Triosephosphate 
isomerase 
88.16869552 0.0025154 7.241575821 
E0771_GD P26641 Elongation factor 1-gamma 47.86005903 0.00253 15.45695806 
E0771_GD P13667 
Protein disulfide-isomerase 
A4 
35.21866854 0.0025649 13.25902836 
E0771_GD P00491 
Purine nucleoside 
phosphorylase 
4.985312953 0.002639 36.49561633 
Stellenbosch University  https://scholar.sun.ac.za
308 
 
E0771_GD P08572 Collagen alpha-2(IV) chain 4.552047911 0.0026574 18.20379026 
E0771_GD Q6P452 Annexin 31.13235259 0.0027218 6.705898436 
E0771_GD P63244 
Receptor of activated 
protein C kinase 1 
11.76338043 0.0027324 10.02347918 
E0771_GD Q9HB71 Calcyclin-binding protein 21.38135904 0.0027361 13.35003289 
E0771_GD O14737 
Programmed cell death 
protein 5 
19.20361583 0.0027507 37.26724714 
E0771_GD B4DXW1 Actin-related protein 3 41.0734679 0.0028313 3.989451697 
E0771_GD P50990 
T-complex protein 1 
subunit theta 
32.51208573 0.0028378 11.22403974 
E0771_GD P54577 
Tyrosine--tRNA ligase, 
cytoplasmic 
14.98249373 0.0029068 95.00745671 
E0771_GD P27797 Calreticulin 3.630604717 0.0030247 6.171153844 
E0771_GD P23528 Cofilin-1 48.95576562 0.0032264 8.856963346 
E0771_GD X6RJP6 Transgelin-2 (Fragment) 59.22518039 0.0032284 8.199977373 
E0771_GD P60660 Myosin light polypeptide 6 33.57707942 0.0033157 8.614175117 
E0771_GD P13929 Beta-enolase 74.2433916 0.0033193 14.40020733 
E0771_GD P17987 
T-complex protein 1 
subunit alpha 
23.61830161 0.0034827 8.354177175 
E0771_GD Q15084 
Protein disulfide-isomerase 
A6 
32.87948727 0.0035249 9.821288795 
E0771_GD P12955 Xaa-Pro dipeptidase 11.38883424 0.0035489 6.63436214 
E0771_GD P08865 40S ribosomal protein SA 51.57748296 0.0035746 4.147811317 
E0771_GD Q99471 Prefoldin subunit 5 14.78491305 0.00369 11.12798189 
E0771_GD P08238 
Heat shock protein HSP 
90-beta 
326.6901234 0.0037918 8.246171054 
E0771_GD P51858 
Hepatoma-derived growth 
factor 
32.06325485 0.0038253 4.774944941 
E0771_GD P46108 Adapter molecule crk 9.509125916 0.0039168 25.33114856 
E0771_GD P62937 
Peptidyl-prolyl cis-trans 
isomerase A 
81.88757395 0.0039775 7.93440443 
E0771_GD P04075 
Fructose-bisphosphate 
aldolase A 
68.55165946 0.0040727 7.362172059 
E0771_GD E9PGT1 Translin 25.61779411 0.0041932 40.5495951 
E0771_GD P07737 Profilin-1 23.04368405 0.0044326 5.710632245 
E0771_GD O15212 Prefoldin subunit 6 18.2558432 0.0046145 30.82969036 
E0771_GD E9PF17 Versican core protein 20.14070083 0.0048299 9.399178079 
E0771_GD P42167 
Lamina-associated 
polypeptide 2 
19.29821901 0.0049617 50.73426189 
E0771_GD Q96C86 m7GpppX diphosphatase 2.035682075 0.0050653 3.310530542 
E0771_GD Q5PY61 Polyubiquitin-C 33.00610944 0.0053567 11.05634782 
E0771_GD P30520 
Adenylosuccinate 
synthetase isozyme 2 
2.07675278 0.0056083 10.57552564 
E0771_GD Q9Y262 
Eukaryotic translation 
initiation factor 3 subunit L 
15.28873387 0.0056966 168.0510296 
E0771_GD O00148 
ATP-dependent RNA 
helicase DDX39A 
21.5750899 0.00573 10.3588676 
E0771_GD Q3BDU5 Prelamin-A/C 117.4170305 0.0057681 12.36559143 
E0771_GD P31150 
Rab GDP dissociation 
inhibitor alpha 
30.46551202 0.0058626 10.74325911 
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E0771_GD P37837 Transaldolase 16.93206375 0.0059913 6.864507858 
E0771_GD P12429 Annexin A3 15.65324113 0.0060379 718.7246173 
E0771_GD R4GMT0 Alpha-centractin 8.747653768 0.0061034 5.349816694 
E0771_GD P40926 
Malate dehydrogenase, 
mitochondrial 
23.53498419 0.0062363 12.67831485 
E0771_GD P28066 
Proteasome subunit alpha 
type-5 
39.12310879 0.0062656 13.03324322 
E0771_GD Q92626 Peroxidasin homolog 18.32735215 0.0063618 10.44706722 
E0771_GD P84077 ADP-ribosylation factor 1 51.07551082 0.0063821 13.26285689 
E0771_GD P54727 
UV excision repair protein 
RAD23 homolog B 
18.62965095 0.0063837 2.790122965 
E0771_GD P12268 
Inosine-5'-monophosphate 
dehydrogenase 2 
18.30885909 0.0065278 24.31346318 
E0771_GD P23284 
Peptidyl-prolyl cis-trans 
isomerase B 
40.49443876 0.0066615 7.157678277 
E0771_GD Q9Y265 RuvB-like 1 30.02748556 0.006671 13.08236372 
E0771_GD K7ES31 
Eukaryotic translation 
initiation factor 3 subunit K 
4.697122713 0.0068126 12.71679842 
E0771_GD P47989 
Xanthine 
dehydrogenase/oxidase 
3.342303305 0.0069782 6.608001147 
E0771_GD P68032 
Actin, alpha cardiac 
muscle 1 
111.3026141 0.0072859 10.51306663 
E0771_GD P13639 Elongation factor 2 176.6888796 0.007471 8.311274646 
E0771_GD Q02809 
Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 1 
3.005564943 0.0078867 3.731769855 
E0771_GD P06748 Nucleophosmin 79.61927002 0.0080428 8.090073104 
E0771_GD Q6UVK1 
Chondroitin sulfate 
proteoglycan 4 
4.674650553 0.0083273 138.1705557 
E0771_GD E7EM57 
Glucose-6-phosphate 1-
dehydrogenase 
(Fragment) 
24.38034691 0.0085039 6.689857273 
E0771_GD O15144 
Actin-related protein 2/3 
complex subunit 2 
8.988264466 0.0092017 2.682215798 
E0771_GD P04406 
Glyceraldehyde-3-
phosphate dehydrogenase 
13.71045553 0.0092146 6.633323351 
E0771_GD P45877 
Peptidyl-prolyl cis-trans 
isomerase C 
14.01299334 0.0095438 2.844549735 
E0771_GD B4DNK4 Pyruvate kinase 143.4995821 0.0095721 4.048009313 
E0771_GD P54578 
Ubiquitin carboxyl-terminal 
hydrolase 14 
11.63630836 0.0096358 11.81433337 
E0771_GD Q92743 Serine protease HTRA1 30.18318982 0.0097863 3.601502734 
E0771_GD P49368 
T-complex protein 1 
subunit gamma 
36.63937881 0.0102291 8.51266966 
E0771_GD Q14847 
LIM and SH3 domain 
protein 1 
15.01765103 0.0102912 21.77965629 
E0771_GD Q8NFI4 Putative protein FAM10A5 5.004166077 0.0105949 2.905479756 
E0771_GD Q96E39 
RNA binding motif protein, 
X-linked-like-1 
16.29530805 0.0113433 11.07678801 
E0771_GD P21810 Biglycan 81.33259475 0.011553 2.291050985 
E0771_GD Q92688 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member B 
4.430843064 0.0119703 9.046775964 
E0771_GD Q15046 Lysine--tRNA ligase 13.50486486 0.0123956 15.6381417 
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E0771_GD P17931 Galectin-3 17.6179048 0.0125497 6.064707764 
E0771_GD Q9BS26 
Endoplasmic reticulum 
resident protein 44 
18.63773741 0.0126871 8.040439191 
E0771_GD Q8NC51 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
30.73792272 0.0129015 11.0169867 
E0771_GD G3V213 
Adenylate kinase 2, 
isoform CRA_a 
14.87611305 0.0134286 409.3987188 
E0771_GD P63000 
Ras-related C3 botulinum 
toxin substrate 1 
4.004296155 0.0138767 7.942737962 
E0771_GD P61221 
ATP-binding cassette sub-
family E member 1 
38.61225812 0.0142311 9.623481034 
E0771_GD P19338 Nucleolin 56.83687246 0.0142443 12.83643062 
E0771_GD P31948 
Stress-induced-
phosphoprotein 1 
33.01403816 0.0142532 15.9651215 
E0771_GD Q15257 
Serine/threonine-protein 
phosphatase 2A activator 
9.40876143 0.0143895 923.1228835 
E0771_GD P00390 
Glutathione reductase, 
mitochondrial 
13.16686601 0.0143962 304.4120026 
E0771_GD Q00839 
Heterogeneous nuclear 
ribonucleoprotein U 
10.96310806 0.0144464 8.776007587 
E0771_GD Q9NUQ9 Protein FAM49B 16.27709457 0.0147385 16.12807098 
E0771_GD E9PK01 
Elongation factor 1-delta 
(Fragment) 
10.34346365 0.0148448 15.85849785 
E0771_GD Q5SZU1 
D-3-phosphoglycerate 
dehydrogenase 
20.39647605 0.0159053 8.578555236 
E0771_GD A0A0G2JL54 Complement C4-B 23.30479865 0.0161831 3.274646021 
E0771_GD P25787 
Proteasome subunit alpha 
type-2 
29.98958476 0.0169424 9.90208828 
E0771_GD P09382 Galectin-1 31.27442255 0.0175186 2.967614746 
E0771_GD P09012 
U1 small nuclear 
ribonucleoprotein A 
11.79659915 0.017725 254.160116 
E0771_GD O75822 
Eukaryotic translation 
initiation factor 3 subunit J 
1.857363001 0.0183003 124.8261837 
E0771_GD P62805 Histone H4 40.2800152 0.0184892 2.728730422 
E0771_GD Q9BXX0 EMILIN-2 13.97977926 0.0188567 10.88501761 
E0771_GD P68036 
Ubiquitin-conjugating 
enzyme E2 L3 
15.39378171 0.0192643 9.800277814 
E0771_GD J3KP15 
Serine/arginine-rich-
splicing factor 2 
(Fragment) 
10.96662803 0.0194526 30.77341944 
E0771_GD D6RAH7 
Ubiquitin-conjugating 
enzyme E2 D3 
11.07867708 0.0195856 30.83260776 
E0771_GD F8W6I7 
Heterogeneous nuclear 
ribonucleoprotein A1 
14.80474899 0.0198982 11.24102904 
E0771_GD P61978 
Heterogeneous nuclear 
ribonucleoprotein K 
45.81466189 0.0207411 3.625346631 
E0771_GD P13928 Annexin A8 23.40497842 0.0210746 2.848626695 
E0771_GD P05387 
60S acidic ribosomal 
protein P2 
21.39648349 0.0225001 36.84159485 
E0771_GD P55327 Tumor protein D52 12.69666249 0.0231827 30.52443045 
E0771_GD P13645 
Keratin, type I cytoskeletal 
10 
22.11270389 0.0235383 6.327520074 
E0771_GD Q9UKY7 Protein CDV3 homolog 8.645760564 0.0248908 254.8258074 
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E0771_GD J3KQ32 Obg-like ATPase 1 2.057474481 0.0254672 26.45053206 
E0771_GD E7ETZ0 Calmodulin 18.41873969 0.0270125 12.78815221 
E0771_GD P22314 
Ubiquitin-like modifier-
activating enzyme 1 
10.08000373 0.0285251 4.357973535 
E0771_GD O00622 Protein CYR61 10.8300273 0.0305074 2.811365881 
E0771_GD Q14974 Importin subunit beta-1 13.91818923 0.0306267 3.66264864 
E0771_GD P14678 
Small nuclear 
ribonucleoprotein-
associated proteins B and 
B' 
4.102182284 0.0323491 34.66788912 
E0771_GD Q04760 Lactoylglutathione lyase 19.0899903 0.0330204 6.850529196 
E0771_GD P68104 Elongation factor 1-alpha 1 104.7595316 0.0367757 3.169286028 
E0771_GD Q9P258 Protein RCC2 13.61000298 0.0373669 45.35112037 
E0771_GD B0YIW6 Archain 1, isoform CRA_a 12.03770228 0.0387714 2.614687833 
E0771_GD Q99832 
T-complex protein 1 
subunit eta 
1.733462994 0.0392465 3.783963018 
E0771_GD P08670 Vimentin 187.4989487 0.0420206 2.896464371 
E0771_GD P63241 
Eukaryotic translation 
initiation factor 5A-1 
32.73388319 0.0452708 2.813513233 
E0771_GD P00558 Phosphoglycerate kinase 1 90.93888147 0.046696 3.129548188 
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7.1.2. Proteomics Analysis of MEF conditioned media  
 
 
Group 
Accession 
Number 
Description 
Confidence 
score 
Anova (p) 
Fold 
Change 
MEF_C P14174 
Macrophage migration 
inhibitory factor 
12.77878926 2.85E-06 7.564200324 
MEF_C P00747 Plasminogen 20.45311285 4.56E-05 21.69418352 
MEF_C P09429 High mobility group protein B1 21.06562199 7.60E-05 10.73004674 
MEF_C P00558 Phosphoglycerate kinase 1 90.93888147 9.77E-05 3.79384269 
MEF_C Q86VP6 
Cullin-associated NEDD8-
dissociated protein 1 
4.759442803 0.0001404 11.60533532 
MEF_C P22314 
Ubiquitin-like modifier-
activating enzyme 1 
10.08000373 0.0004287 4.374880395 
MEF_C B0YIW6 Archain 1, isoform CRA_a 12.03770228 0.000506 3.556512783 
MEF_C P62937 
Peptidyl-prolyl cis-trans 
isomerase A 
81.88757395 0.0006568 3.306751805 
MEF_C P09382 Galectin-1 31.27442255 0.0007813 4.150264026 
MEF_C E9PIA8 
Palmitoyl-protein thioesterase 
1 (Fragment) 
17.29199112 0.000959 3.051644669 
MEF_C B4DNK4 Pyruvate kinase 143.4995821 0.0010078 3.959793987 
MEF_C Q06323 
Proteasome activator complex 
subunit 1 
36.37396179 0.0012721 3.290128673 
MEF_C Q14974 Importin subunit beta-1 13.91818923 0.0013138 3.670455458 
MEF_C Q01995 Transgelin 26.09286228 0.0018977 3.076369832 
MEF_C P04075 
Fructose-bisphosphate 
aldolase A 
68.55165946 0.0032034 3.242566541 
MEF_C P07737 Profilin-1 23.04368405 0.0032754 3.015715679 
MEF_C P12004 
Proliferating cell nuclear 
antigen 
28.42660156 0.0036523 3.607955032 
MEF_C Q12841 Follistatin-related protein 1 61.8950355 0.0046812 4.395455115 
MEF_C E9PK01 
Elongation factor 1-delta 
(Fragment) 
10.34346365 0.0048529 5.422384798 
MEF_C P60174 Triosephosphate isomerase 88.16869552 0.0057625 3.354651694 
MEF_C Q8NFI4 Putative protein FAM10A5 5.004166077 0.0071957 2.115886625 
MEF_C Q07954 
Prolow-density lipoprotein 
receptor-related protein 1 
1.822362664 0.0101923 2.111399629 
MEF_C Q14847 LIM and SH3 domain protein 1 15.01765103 0.0118117 36.49210367 
MEF_C P05387 
60S acidic ribosomal protein 
P2 
21.39648349 0.0133154 4.256357453 
MEF_C Q15637 Splicing factor 1 4.921340739 0.0158422 6.400020015 
MEF_C P27797 Calreticulin 3.630604717 0.0212682 2.963129109 
MEF_C P23142 Fibulin-1 24.3109702 0.0385416 2.002286373 
MEF_C P40926 
Malate dehydrogenase, 
mitochondrial 
23.53498419 0.0470423 3.132641773 
MEF_C P63000 
Ras-related C3 botulinum 
toxin substrate 1 
4.004296155 0.0474118 2.405405586 
 
Table 7.3: List of differentially regulated proteins in MEF control conditioned media (MEF_C) 
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Group 
Accession 
Number 
Description 
Confidence 
score 
Anova (p) 
Fold 
Change 
MEF_EUM P07339 Cathepsin D 24.70351857 3.91E-07 20.20902204 
MEF_EUM E9PBF6 Lamin-B1 3.040874728 7.31E-07 12.05598322 
MEF_EUM Q99497 Protein DJ-1 7.668671354 1.46E-06 4.37208887 
MEF_EUM Q8IUX7 Alpha-2-HS-glycoprotein 52.37726794 5.56E-05 34.33673973 
MEF_EUM P22692 
Adipocyte enhancer-binding 
protein 1 
27.75316991 5.65E-05 12.72143831 
MEF_EUM D6RF35 
Insulin-like growth factor-
binding protein 4 
31.20025893 5.86E-05 46.44737396 
MEF_EUM E7ER44 Vitamin D-binding protein 94.4880968 0.0003304 12.78641855 
MEF_EUM Q6ZU64 Lactotransferrin 32.76727595 0.0004445 2.772133956 
MEF_EUM F5GY55 
Cilia- and flagella-
associated protein 65 
1.469533219 0.0006223 5.57361659 
MEF_EUM Q14118 
DNA damage-binding 
protein 1 
41.21515873 0.001816 2.557396391 
MEF_EUM Q15149 Dystroglycan 23.47307826 0.0018748 2.682154846 
MEF_EUM P02765 Plectin 46.10077906 0.0026239 3.128565474 
MEF_EUM Q02790 
Peptidyl-prolyl cis-trans 
isomerase FKBP4 
4.377302955 0.0036246 3.912809212 
MEF_EUM H0YMZ1 Transthyretin 10.33210583 0.0065524 25.06316252 
MEF_EUM P02766 
Proteasome subunit alpha 
type (Fragment) 
20.19146079 0.006681 4.21324574 
MEF_EUM J3KMX3 Alpha-fetoprotein 28.10762696 0.0075399 2.728096788 
MEF_EUM P43652 Afamin 3.781422089 0.0095422 2.307227725 
MEF_EUM Q92520 Protein FAM3C 4.448114427 0.0114107 3.109329026 
MEF_EUM P07602 Prosaposin 23.39733244 0.0129487 5.766958707 
MEF_EUM P05452 Tetranectin 11.07079683 0.018398 2.318315941 
MEF_EUM P01008 Antithrombin-III 36.55639853 0.02029 2.002620074 
MEF_EUM P08697 Alpha-2-antiplasmin 19.56058745 0.0261311 3.366791859 
MEF_EUM P02461 Collagen alpha-1(III) chain 68.80913822 0.0308634 3.597210887 
MEF_EUM P20929 Nebulin 3.546539557 0.0340621 5.927327888 
 
 
 
 
 
 
 
 
 
Table 7.4: List of differentially regulated proteins in MEF untreated conditioned media 
(MEF_UTCM) 
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Group 
Accession 
Number 
Description 
Confidence 
score 
Anova (p) 
Fold 
Change 
MEF_ECM P09486 SPARC 99.15823693 9.46E-09 3.605443198 
MEF_ECM P06865 
Beta-hexosaminidase subunit 
alpha 
4.592586031 2.28E-07 18.47288292 
MEF_ECM O15144 
Actin-related protein 2/3 
complex subunit 2 
8.988264466 2.84E-07 21.84305318 
MEF_ECM P35052 Glypican-1 31.3686554 3.13E-07 181.9229737 
MEF_ECM Q02809 
Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 1 
3.005564943 3.44E-07 6.013931359 
MEF_ECM P05019 Insulin-like growth factor I 27.18266803 9.34E-07 32.94904762 
MEF_ECM P12268 
Inosine-5'-monophosphate 
dehydrogenase 2 
18.30885909 1.04E-06 93.76989051 
MEF_ECM P45877 
Peptidyl-prolyl cis-trans 
isomerase C 
14.01299334 5.54E-06 16.97948783 
MEF_ECM Q15113 
Procollagen C-endopeptidase 
enhancer 1 
32.96217797 6.60E-06 13.16524648 
MEF_ECM Q8NBP7 
Proprotein convertase 
subtilisin/kexin type 9 
13.81429275 1.21E-05 39.86114126 
MEF_ECM Q9Y265 RuvB-like 1 30.02748556 1.23E-05 29.28067993 
MEF_ECM P61221 
ATP-binding cassette sub-
family E member 1 
38.61225812 1.50E-05 7.070787786 
MEF_ECM O00154 
Cytosolic acyl coenzyme A 
thioester hydrolase 
13.66437377 1.55E-05 71.27723437 
MEF_ECM P50990 
T-complex protein 1 subunit 
theta 
32.51208573 2.23E-05 9.779899159 
MEF_ECM P20618 
Proteasome subunit beta 
type-1 
17.66082493 2.69E-05 37.11879069 
MEF_ECM O75436 
Vacuolar protein sorting-
associated protein 26A 
3.023696422 3.08E-05 71.36600412 
MEF_ECM P07355 Annexin A2 111.8606583 3.22E-05 39.61265247 
MEF_ECM A0A075B7D9 
TATA-binding protein-
associated factor 2N 
2.723973745 4.10E-05 10.10915742 
MEF_ECM P11047 Laminin subunit gamma-1 34.91880231 4.95E-05 11.3209345 
MEF_ECM P17931 Galectin-3 17.6179048 5.56E-05 6.572031651 
MEF_ECM D6RBL5 Annexin 63.98054264 7.03E-05 44.6026168 
MEF_ECM P54136 
Arginine--tRNA ligase, 
cytoplasmic 
29.7001631 8.37E-05 11.50800378 
MEF_ECM F8WCF6 
Actin-related protein 2/3 
complex subunit 4 
24.29611519 9.27E-05 53.39536859 
MEF_ECM A0A0C4DFV9 Protein SET 34.04941749 9.68E-05 8.27237306 
MEF_ECM P49368 
T-complex protein 1 subunit 
gamma 
36.63937881 0.0001137 10.23846865 
MEF_ECM P11021 
78 kDa glucose-regulated 
protein 
163.6413764 0.0001178 6.521059166 
MEF_ECM E7EM57 
Glucose-6-phosphate 1-
dehydrogenase (Fragment) 
24.38034691 0.000118 19.54911756 
MEF_ECM Q9UNZ2 NSFL1 cofactor p47 16.14487173 0.0001266 13.71943513 
MEF_ECM Q9Y266 
Nuclear migration protein 
nudC 
21.17417674 0.0001303 22.07304387 
MEF_ECM Q92743 Serine protease HTRA1 30.18318982 0.0001499 7.896707029 
MEF_ECM Q02818 Nucleobindin-1 83.37053992 0.0001571 7.448348442 
Table 7.5: List of differentially regulated proteins in MEF treated conditioned media 
(MEF_CM) 
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MEF_ECM P07900 
Heat shock protein HSP 90-
alpha 
213.9144792 0.0001649 5.185647396 
MEF_ECM P19338 Nucleolin 56.83687246 0.0001808 26.43263861 
MEF_ECM P23284 
Peptidyl-prolyl cis-trans 
isomerase B 
40.49443876 0.0001905 14.43957878 
MEF_ECM P63244 
Receptor of activated protein 
C kinase 1 
11.76338043 0.0002138 9.609555685 
MEF_ECM A0A0A0MTS2 
Glucose-6-phosphate 
isomerase (Fragment) 
35.92159293 0.0002273 45.39718663 
MEF_ECM Q8NEV1 
Casein kinase II subunit 
alpha 3 
14.00826212 0.0002505 44.72304 
MEF_ECM P48506 
Glutamate--cysteine ligase 
catalytic subunit 
4.367829656 0.0002528 24.99311748 
MEF_ECM P31948 
Stress-induced-
phosphoprotein 1 
33.01403816 0.000257 43.03005038 
MEF_ECM P61088 
Ubiquitin-conjugating enzyme 
E2 N 
35.41492654 0.0002731 6.177626818 
MEF_ECM O00303 
Eukaryotic translation 
initiation factor 3 subunit F 
16.56597614 0.0002868 11.22867526 
MEF_ECM P08238 
Heat shock protein HSP 90-
beta 
326.6901234 0.0002957 5.283039516 
MEF_ECM P68032 Actin, alpha cardiac muscle 1 111.3026141 0.0002976 4.975532316 
MEF_ECM P13929 Beta-enolase 74.2433916 0.000302 12.11008746 
MEF_ECM P28070 
Proteasome subunit beta 
type-4 
18.07024651 0.0003225 40.8216952 
MEF_ECM P50991 
T-complex protein 1 subunit 
delta 
25.39158072 0.0003534 27.68682388 
MEF_ECM P23246 
Splicing factor, proline- and 
glutamine-rich 
5.789375976 0.0003942 5.486943163 
MEF_ECM P00390 
Glutathione reductase, 
mitochondrial 
13.16686601 0.0003975 60.96463606 
MEF_ECM K7ESG5 
Proteasome activator 
complex subunit 3 
15.28695245 0.000414 6.894054314 
MEF_ECM P17987 
T-complex protein 1 subunit 
alpha 
23.61830161 0.0004293 6.789096659 
MEF_ECM Q6P452 Annexin 31.13235259 0.0004486 8.805750573 
MEF_ECM Q15046 Lysine--tRNA ligase 13.50486486 0.0004842 22.18081367 
MEF_ECM P28838 Cytosol aminopeptidase 13.25727622 0.0005221 10.01769177 
MEF_ECM P11142 
Heat shock cognate 71 kDa 
protein 
419.5409654 0.0005287 5.708618564 
MEF_ECM P15090 
Fatty acid-binding protein, 
adipocyte 
14.23845041 0.0005699 23.51281093 
MEF_ECM P62857 40S ribosomal protein S28 15.30735046 0.0005862 5.333414866 
MEF_ECM P22626 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
58.26867651 0.000605 7.116743277 
MEF_ECM Q15393 Splicing factor 3B subunit 3 27.57274331 0.0006479 34.1105804 
MEF_ECM P20290 Transcription factor BTF3 4.072192706 0.0006482 7.895818755 
MEF_ECM P61086 
Ubiquitin-conjugating enzyme 
E2 K 
17.32208458 0.0006581 15.24428797 
MEF_ECM P34932 Heat shock 70 kDa protein 4 119.9358079 0.0006744 9.225842753 
MEF_ECM B4DXW1 Actin-related protein 3 41.0734679 0.0006822 2.990269952 
MEF_ECM Q9P258 Protein RCC2 13.61000298 0.0007529 477.0052906 
MEF_ECM P60981 Destrin 19.11083247 0.000763 10.78770483 
MEF_ECM P36955 
Pigment epithelium-derived 
factor 
42.25616633 0.0008088 2.684722162 
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MEF_ECM P00338 
L-lactate dehydrogenase A 
chain 
60.81994037 0.0008264 12.55381661 
MEF_ECM P68036 
Ubiquitin-conjugating enzyme 
E2 L3 
15.39378171 0.0009029 6.091791719 
MEF_ECM Q96KP4 
Cytosolic non-specific 
dipeptidase 
15.23104494 0.0009628 5.796643656 
MEF_ECM Q9Y333 
U6 snRNA-associated Sm-
like protein LSm2 
9.608326012 0.0009741 6.589097474 
MEF_ECM P30041 Peroxiredoxin-6 19.54424544 0.0010085 8.040433576 
MEF_ECM P12814 Alpha-actinin-1 135.9385131 0.0010117 5.564014072 
MEF_ECM Q00577 
Transcriptional activator 
protein Pur-alpha 
4.315667173 0.0010272 25.3897925 
MEF_ECM P60842 
Eukaryotic initiation factor 
4A-I 
36.85229005 0.0010298 5.053309115 
MEF_ECM P25787 
Proteasome subunit alpha 
type-2 
29.98958476 0.0010503 18.15917369 
MEF_ECM O14818 
Proteasome subunit alpha 
type-7 
28.06374998 0.0010516 21.17066879 
MEF_ECM P17174 
Aspartate aminotransferase, 
cytoplasmic 
21.27582497 0.0011038 16.27978407 
MEF_ECM J3QQX2 
Rho GDP-dissociation 
inhibitor 1 
24.35314005 0.0011468 9.166165824 
MEF_ECM P40925 
Malate dehydrogenase, 
cytoplasmic 
19.59996273 0.0011878 5.805742005 
MEF_ECM P50454 Serpin H1 22.80631544 0.0012022 6.836089806 
MEF_ECM P23526 Adenosylhomocysteinase 26.47191433 0.0012051 9.230900531 
MEF_ECM Q9HB40 
Retinoid-inducible serine 
carboxypeptidase 
15.80621185 0.0013997 8.034601757 
MEF_ECM P12429 Annexin A3 15.65324113 0.0014836 14.81975507 
MEF_ECM E7EQR4 Ezrin 65.28155066 0.0015004 6.943780963 
MEF_ECM R4GMT0 Alpha-centractin 8.747653768 0.0015288 7.09259762 
MEF_ECM P13928 Annexin A8 23.40497842 0.0015312 7.155816712 
MEF_ECM F8VQ14 
T-complex protein 1 subunit 
beta 
18.31020378 0.0015754 8.290674209 
MEF_ECM P35241 Radixin 70.44512818 0.0016782 17.70868518 
MEF_ECM Q9HB71 Calcyclin-binding protein 21.38135904 0.0020453 14.21027596 
MEF_ECM P60900 
Proteasome subunit alpha 
type-6 
23.75948401 0.0020861 11.03239509 
MEF_ECM A0A1C7CYX9 
Dihydropyrimidinase-related 
protein 2 
61.55114303 0.0024641 13.996752 
MEF_ECM O14737 
Programmed cell death 
protein 5 
19.20361583 0.0024778 17.95434479 
MEF_ECM O43852 Calumenin 12.42646181 0.0024931 26.83904677 
MEF_ECM E9PAV3 
Nascent polypeptide-
associated complex subunit 
alpha, muscle-specific form 
44.57516428 0.0025044 4.495296949 
MEF_ECM J3KQ32 Obg-like ATPase 1 2.057474481 0.0025091 19.00549393 
MEF_ECM P14625 Endoplasmin 58.01996899 0.0025136 11.61822017 
MEF_ECM P43490 
Nicotinamide 
phosphoribosyltransferase 
13.7263839 0.0025198 12.32924574 
MEF_ECM P28066 
Proteasome subunit alpha 
type-5 
39.12310879 0.0025762 11.45178936 
MEF_ECM P55327 Tumor protein D52 12.69666249 0.0026762 15.31758237 
MEF_ECM P15121 Aldose reductase 3.156545481 0.002699 5.973819171 
Stellenbosch University  https://scholar.sun.ac.za
317 
 
MEF_ECM P78330 Phosphoserine phosphatase 17.47569586 0.0030526 102.1512124 
MEF_ECM P13667 
Protein disulfide-isomerase 
A4 
35.21866854 0.0030877 5.531724164 
MEF_ECM P35527 Keratin, type I cytoskeletal 9 2.275532567 0.003188 8.283451964 
MEF_ECM Q15257 
Serine/threonine-protein 
phosphatase 2A activator 
9.40876143 0.00337 396.205298 
MEF_ECM P06748 Nucleophosmin 79.61927002 0.0033762 10.86986247 
MEF_ECM Q99536 
Synaptic vesicle membrane 
protein VAT-1 homolog 
35.4234255 0.0035306 4.887990838 
MEF_ECM P30520 
Adenylosuccinate synthetase 
isozyme 2 
2.07675278 0.0035407 4.334989747 
MEF_ECM A0A0G2JL54 Complement C4-B 23.30479865 0.0036636 6.919384844 
MEF_ECM Q14563 Semaphorin-3A 35.67553254 0.0037111 6.695348738 
MEF_ECM P09417 Dihydropteridine reductase 17.62223854 0.0038692 9.482017172 
MEF_ECM P25786 
Proteasome subunit alpha 
type-1 
35.74063221 0.0041639 18.81838379 
MEF_ECM P12110 Collagen alpha-2(VI) chain 23.5741394 0.0044072 6.374719566 
MEF_ECM Q92896 Golgi apparatus protein 1 13.85584627 0.0044345 39.28319961 
MEF_ECM P60709 Actin, cytoplasmic 1 249.1469143 0.004766 2.461971433 
MEF_ECM P62258 14-3-3 protein epsilon 89.45852815 0.0050134 8.159645689 
MEF_ECM E9PGT1 Translin 25.61779411 0.0051955 12.68110738 
MEF_ECM P18669 Phosphoglycerate mutase 1 131.5371954 0.00532 4.761661215 
MEF_ECM P16035 Metalloproteinase inhibitor 2 60.53373099 0.0055238 2.474458381 
MEF_ECM Q9Y262 
Eukaryotic translation 
initiation factor 3 subunit L 
15.28873387 0.0057268 277.6428121 
MEF_ECM P26641 Elongation factor 1-gamma 47.86005903 0.0058307 8.535410383 
MEF_ECM P47989 
Xanthine 
dehydrogenase/oxidase 
3.342303305 0.005861 2.718817663 
MEF_ECM O43707 
>sp|O43707|ACTN4_HUMAN 
Alpha-actinin-4 
150.87147 0.0058805 5.577634365 
MEF_ECM P22392 
Nucleoside diphosphate 
kinase B 
77.94623192 0.0059457 6.15089058 
MEF_ECM P13639 Elongation factor 2 176.6888796 0.0061044 3.69656157 
MEF_ECM Q08752 
Peptidyl-prolyl cis-trans 
isomerase D 
18.80003183 0.0062396 5.773316813 
MEF_ECM P25398 40S ribosomal protein S12 2.426077818 0.0065573 7.94089657 
MEF_ECM P84077 ADP-ribosylation factor 1 51.07551082 0.0066131 8.417716449 
MEF_ECM P12081 
Histidine--tRNA ligase, 
cytoplasmic 
18.0798167 0.006852 20.3827 
MEF_ECM Q92626 Peroxidasin homolog 18.32735215 0.0069114 23.39501459 
MEF_ECM P46108 Adapter molecule crk 9.509125916 0.0074471 12.56253001 
MEF_ECM P06733 Alpha-enolase 144.3654213 0.0076636 6.40860101 
MEF_ECM F8W1I6 Dynactin subunit 2 13.93919298 0.0077509 5.177639163 
MEF_ECM P51858 
Hepatoma-derived growth 
factor 
32.06325485 0.0080764 3.035724985 
MEF_ECM Q3BDU5 Prelamin-A/C 117.4170305 0.0081776 11.21609294 
MEF_ECM Q99471 Prefoldin subunit 5 14.78491305 0.0085546 4.412037791 
MEF_ECM P49721 
Proteasome subunit beta 
type-2 
29.7717515 0.0086381 4.21711785 
MEF_ECM Q15404 Ras suppressor protein 1 16.22518375 0.0096962 9.438348293 
MEF_ECM P61160 Actin-related protein 2 5.068111751 0.0099821 4.600273498 
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MEF_ECM O75822 
Eukaryotic translation 
initiation factor 3 subunit J 
1.857363001 0.0101962 24.84973395 
MEF_ECM P16989 Y-box-binding protein 3 20.35567549 0.0103461 4.280511776 
MEF_ECM P47755 
F-actin-capping protein 
subunit alpha-2 
11.84349912 0.0105393 22.17359515 
MEF_ECM P31153 
S-adenosylmethionine 
synthase isoform type-2 
26.88696816 0.0107121 4.093519293 
MEF_ECM P42167 
Lamina-associated 
polypeptide 2, isoforms 
beta/gamma 
19.29821901 0.0108101 9.411338879 
MEF_ECM P24534 Elongation factor 1-beta 17.24048202 0.0108399 5.20226479 
MEF_ECM P30086 
Phosphatidylethanolamine-
binding protein 1 
14.02810625 0.0114798 3.52084203 
MEF_ECM P31150 
Rab GDP dissociation 
inhibitor alpha 
30.46551202 0.0116165 4.548028555 
MEF_ECM O75368 
SH3 domain-binding glutamic 
acid-rich-like protein 
2.414711319 0.0116792 11.49590187 
MEF_ECM P12955 Xaa-Pro dipeptidase 11.38883424 0.0118667 15.11063735 
MEF_ECM P16949 Stathmin 20.95897788 0.0125873 2.599283939 
MEF_ECM Q99832 
T-complex protein 1 subunit 
eta 
1.733462994 0.0127299 12.90157742 
MEF_ECM Q16181 Septin-7 18.59617012 0.0139076 14.40931327 
MEF_ECM J3KTL2 
Serine/arginine-rich-splicing 
factor 1 
22.64515346 0.0139504 17.36692056 
MEF_ECM P35268 60S ribosomal protein L22 11.36012289 0.013986 33.55002354 
MEF_ECM Q92688 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member B 
4.430843064 0.0151632 10.38968587 
MEF_ECM P14550 
>sp|P14550|AK1A1_HUMAN 
Alcohol dehydrogenase 
[NADP(+)] 
25.4247084 0.0151806 5.263829452 
MEF_ECM J3KR44 Ubiquitin thioesterase 16.17578218 0.0152034 4.294969352 
MEF_ECM P61978 
Heterogeneous nuclear 
ribonucleoprotein K 
45.81466189 0.0164366 7.223612415 
MEF_ECM A0A087WTT1 Polyadenylate-binding protein 44.50320919 0.0167812 6.833016817 
MEF_ECM P31949 Protein S100-A11 19.43224453 0.0171565 4.968403585 
MEF_ECM O15212 Prefoldin subunit 6 18.2558432 0.0171665 10.18382323 
MEF_ECM Q5SZU1 
D-3-phosphoglycerate 
dehydrogenase 
20.39647605 0.0171969 16.490005 
MEF_ECM P08670 Vimentin 187.4989487 0.0173837 4.210940104 
MEF_ECM P68104 Elongation factor 1-alpha 1 104.7595316 0.0180475 3.215160776 
MEF_ECM P00491 
Purine nucleoside 
phosphorylase 
4.985312953 0.0185877 9.172146463 
MEF_ECM Q9BXX0 EMILIN-2 13.97977926 0.0190658 5.583255667 
MEF_ECM P08243 
Asparagine synthetase 
[glutamine-hydrolyzing] 
33.94811192 0.0191626 9.809759358 
MEF_ECM F8W6I7 
Heterogeneous nuclear 
ribonucleoprotein A1 
14.80474899 0.0195646 5.951677308 
MEF_ECM Q5HYB6 
Epididymis luminal protein 
189 
73.36451715 0.0205258 4.879795231 
MEF_ECM A0A0U1RRM4 
Polypyrimidine tract-binding 
protein 1 
4.17401055 0.0205955 2.948856719 
MEF_ECM Q04917 14-3-3 protein eta 27.68847628 0.0224323 10.7151933 
MEF_ECM Q96E39 RNA binding motif protein, X- 16.29530805 0.0225953 7.410021956 
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linked-like-1 
MEF_ECM Q15056 
Eukaryotic translation 
initiation factor 4H 
13.01107154 0.0228567 6.88219021 
MEF_ECM P54578 
Ubiquitin carboxyl-terminal 
hydrolase 14 
11.63630836 0.0235592 4.295532361 
MEF_ECM Q9NUQ9 Protein FAM49B 16.27709457 0.0260215 6.518540441 
MEF_ECM P23528 Cofilin-1 48.95576562 0.0269823 2.524999932 
MEF_ECM Q5T3N1 Annexin (Fragment) 22.29151562 0.0276463 4.333201774 
MEF_ECM P07237 Protein disulfide-isomerase 54.8232496 0.0281085 3.300320292 
MEF_ECM P05388 
60S acidic ribosomal protein 
P0 
38.48232022 0.0288343 3.517194072 
MEF_ECM P04264 Keratin, type II cytoskeletal 1 41.43977023 0.0296036 3.786299894 
MEF_ECM J3KP15 
Serine/arginine-rich-splicing 
factor 2 (Fragment) 
10.96662803 0.0299526 40.04680892 
MEF_ECM Q9UKY7 Protein CDV3 homolog 8.645760564 0.0301626 11.68680738 
MEF_ECM P49720 
Proteasome subunit beta 
type-3 
35.61487044 0.0309348 4.473751899 
MEF_ECM H0YL52 
Tropomyosin alpha-1 chain 
(Fragment) 
86.19312822 0.0357489 3.074466096 
MEF_ECM P13797 Plastin-3 54.92559414 0.0369476 2.937397332 
MEF_ECM Q15084 
Protein disulfide-isomerase 
A6 
32.87948727 0.0380449 3.457893932 
MEF_ECM P08572 Collagen alpha-2(IV) chain 4.552047911 0.0391399 22.48815316 
MEF_ECM P63241 
Eukaryotic translation 
initiation factor 5A-1 
32.73388319 0.0400551 4.060502477 
MEF_ECM P62277 40S ribosomal protein S13 11.71976658 0.0406664 449.7241649 
MEF_ECM Q9H444 
Charged multivesicular body 
protein 4b 
14.22018781 0.044152 3.814376892 
MEF_ECM P61981 14-3-3 protein gamma 28.52762339 0.0446285 5.296363815 
MEF_ECM P56537 
Eukaryotic translation 
initiation factor 6 
18.6117551 0.0448056 6.275252457 
MEF_ECM Q04760 Lactoylglutathione lyase 19.0899903 0.0454793 4.007332552 
MEF_ECM Q9UK55 
Protein Z-dependent 
protease inhibitor 
11.22333628 0.0481182 3.44906279 
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7.2. Flow Cytometry 
 
7.2.1. Assessment of mitochondrial superoxide levels in E0771 
murine breast cancer cells following glucose deprivation 
 
Figure 7.1: Representative flow cytometry histograms of E0771 breast cancer cells assessing 
mitochondrial O2- levels following glucose deprivation. E0771 cells were incubated in 25 mM 
glucose containing DMEM (Control), or glucose free (0 mM) DMEM for 4, 8 and 12 hours. 
Mitochondrial oxidative stress was assessed by means of flow cytometry using MitoSox. 
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7.2.2. Assessment of mitochondrial superoxide levels in MEF cells 
following treatment with E0771 conditioned media 
Figure 7.2: Representative flow cytometry histograms of MEF cells assessing mitochondrial 
O2- levels following treatment with E0771 conditioned media. MEF cells were subjected to (1) 
Control, (2) Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-
UTCM) and (4) glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Oxidative stress 
was assessed by means of flow cytometry following staining with MitoSox. 
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7.2.3. Assessment of cytoplasmic hydrogen peroxide levels in E0771 
murine breast cancer cells following glucose deprivation 
 
Figure 7.3: Representative flow cytometry histograms of E0771 breast cancer cells assessing 
cytoplasmic H2O2 levels following glucose deprivation. E0771 cells were incubated in 25 mM 
glucose containing DMEM (Control), or glucose free (0 mM) DMEM for 4, 8 and 12 hours. 
Mitochondrial oxidative stress was assessed by means of flow cytometry using DCF. 
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7.2.4. Assessment of cytoplasmic hydrogen peroxide levels in MEF 
cells following treatment with E0771 conditioned media  
 
Figure 7.4: Representative flow cytometry histograms of MEF cells assessing cytoplasmic H2O2 
levels following E0771 conditioned media treatment. MEF cells were subjected to (1) Control, (2) 
Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-UTCM) and (4) 
glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. Oxidative stress was assessed by 
means of flow cytometry following staining with either DCF. 
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7.2.5. Assessment of glucose uptake in MEF cells following treatment 
with E0771 conditioned media  
Figure 7.5: Representative flow cytometry histograms of MEF cells assessing cytoplasmic 
H2O2 levels following E0771 conditioned media treatment. MEF cells were subjected to (1) 
Control, (2) Control conditioned media (Control-CM), (3) E0771 untreated conditioned media (E0771-
UTCM) and (4) glucose deprived E0771 conditioned media (E0771-CM) for 24 hours. 
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7.2.6. Assessment of cell death in E0771 breast cancer cells following 
treatment with MEF conditioned media  
 
Figure 7.6: Representative flow cytometry plots of E0771 breast cancer cells assessing cell 
death following MEF conditioned media treatment. Subsequent to 12 hours of glucose deprivation 
(0 mM glucose DMEM), E0771 cells were subjected to (1) Control, (2) Control conditioned media 
(Control-CM), (3) Untreated MEF conditioned media (MEF-UTCM) and (4) E0771 treated MEF 
conditioned media (MEF-CM) for 24 hours. 
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7.2.7. Assessment of cell death in E0771 breast cancer cells following 
treatment with Doxorubicin and MEF conditioned media 
Figure 7.7: Representative flow cytometry plots of E0771 breast cancer cells assessing cell 
death following Doxorubicin and MEF conditioned media treatment. Subsequent to 12 hours of 
glucose deprivation (0 mM glucose DMEM), E0771 cells were subjected to (1) Doxorubicin, (2) 
Doxorubicin + Control conditioned media, (3) Doxorubicin + Untreated MEF conditioned media (Dox + 
MEF-UTCM) and (3) Doxorubicin + E0771 treated MEF conditioned media (Dox + MEF-CM) for 24 
hours. 
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